CRC_8796_FM.qxd
6/22/2007
11:27
Page i
Second Edition
Antisense Drug Technology
Principles, Strategies, and Appli...
206 downloads
2887 Views
7MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
CRC_8796_FM.qxd
6/22/2007
11:27
Page i
Second Edition
Antisense Drug Technology
Principles, Strategies, and Applications
CRC_8796_FM.qxd
6/22/2007
11:27
Page ii
CRC_8796_FM.qxd
6/22/2007
11:27
Page iii
Second Edition
Antisense Drug Technology
Principles, Strategies, and Applications
Edited by
Stanley T. Crooke
Boca Raton London New York
CRC Press is an imprint of the Taylor & Francis Group, an informa business
CRC_8796_FM.qxd
6/22/2007
11:27
Page iv
CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2008 by Taylor & Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-10: 0-8493-8796-5 (Hardcover) International Standard Book Number-13: 978-0-8493-8796-8 (Hardcover) This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright.com (http:// www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. Library of Congress Cataloging-in-Publication Data Antisense drug technology : principles, strategies, and applications / editor Stanley T. Crooke. -- 2nd ed. p. ; cm. Includes bibliographical references and index. ISBN-13: 978-0-8493-8796-8 (alk. paper) ISBN-10: 0-8493-8796-5 (alk. paper) 1. Antisense nucleic acids--Therapeutic use. I. Crooke, Stanley T. [DNLM: 1. Oligonucleotides, Antisense--therapeutic use. QU 57 A6324 2006] I. Title. RM666.A564A567 2006 615’.31--dc22 Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com and the CRC Press Web site at http://www.crcpress.com
2006101712
CRC_8796_FM.qxd
6/22/2007
11:27
Page v
Contents Preface ..............................................................................................................................................ix Acknowledgments............................................................................................................................xi The Editor......................................................................................................................................xiii Contributors....................................................................................................................................xv Part I Introduction ........................................................................................................................................1 Chapter 1 Mechanisms of Antisense Drug Action, an Introduction...................................................................3 Stanley T. Crooke, Timothy Vickers, Walt Lima, and Hongjiang Wu Chapter 2 The RNase H Mechanism ................................................................................................................47 Walt Lima, Hongjiang Wu, and Stanley T. Crooke Chapter 3 Small RNA Silencing Pathways.......................................................................................................75 Alla Sigova and Phillip D. Zamore Chapter 4 Splice Switching Oligonucleotides as Potential Therapeutics.........................................................89 Peter Sazani, Maria A. Graziewicz, and Ryszard Kole Part II The Basics of Oligonucleotide-Based Therapeutics ......................................................................115 Chapter 5 Basic Principles of Antisense Drug Discovery ..............................................................................117 Susan M. Freier and Andrew T. Watt Chapter 6 The Medicinal Chemistry of Oligonucleotides..............................................................................143 Eric E. Swayze and Balkrishen Bhat Chapter 7 Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs ...........................183 Arthur A. Levin, Rosie Z. Yu, and Richard S. Geary Chapter 8 Routes and Formulations for Delivery of Antisense Oligonucleotides .........................................217 Gregory E. Hardee, Lloyd G. Tillman, and Richard S. Geary Chapter 9 Liposomal Formulations for Nucleic Acid Delivery......................................................................237 Ian MacLachlan v
CRC_8796_FM.qxd
vi
6/22/2007
11:27
Page vi
CONTENTS
Part III A Hybridization-Based Drugs: Basic Properties 2⬘-O-Methoxyethyl Oligonucleotides ..................271 Chapter 10 Pharmacological Properties of 2⬘-O-Methoxyethyl-Modified Oligonucleotides ..........................273 C. Frank Bennett Chapter 11 Pharmacokinetic/Pharmacodynamic Properties of Phosphorothioate 2⬘-O-(2-Methoxyethyl)Modified Antisense Oligonucleotides in Animals and Man .........................................................305 Richard S. Geary, Rosie Z. Yu, Andrew Siwkowski, and Arthur A. Levin Chapter 12 Toxicologic Properties of 2⬘-O-Methoxyethyl Chimeric Antisense Inhibitors in Animals and Man .......................................................................................................................327 Scott P. Henry, Tae-Won Kim, Kimberly Kramer-Stickland, Thomas A. Zanardi, Robert A. Fey, and Arthur A. Levin Chapter 13 An Overview of the Clinical Safety Experience of First- and Second-Generation Antisense Oligonucleotides............................................................................................................365 T. Jesse Kwoh Chapter 14 Manufacturing and Analytical Processes for 2⬘-O-(2-Methoxyethyl)-Modified Oligonucleotides.............................................................................................................................401 Daniel C. Capaldi and Anthony N. Scozzari Part III B Hybridization-Based Drugs: Basic Properties Duplex RNA Drugs ..............................................435 Chapter 15 Utilizing Chemistry to Harness RNA Interference Pathways for Therapeutics: Chemically Modified siRNAs and Antagomirs .............................................................................437 Muthiah Manoharan and Kallanthottathil G. Rajeev Chapter 16 Discovery and Development of RNAi Therapeutics......................................................................465 Antonin R. de Fougerolles and John M. Maraganore Part IV Other Chemical Classes of Drugs ..................................................................................................485 Chapter 17 Optimization of Second-Generation Antisense Drugs: Going Beyond Generation 2.0 ................487 Brett P. Monia, Rosie Z. Yu, Walt Lima, and Andrew Siwkowski Chapter 18 Modulating Gene Function with Peptide Nucleic Acids (PNA)....................................................507 Peter E. Nielsen
CRC_8796_FM.qxd
6/22/2007
CONTENTS
11:27
Page vii
vii
Chapter 19 Locked Nucleic Acid......................................................................................................................519 Troels Koch and Henrik Ørum Chapter 20 Morpholinos ...................................................................................................................................565 Patrick L. Iversen Part V Therapeutic Applications ...............................................................................................................583 Chapter 21 Potential Therapeutic Applications of Antisense Oligonucleotides in Ophthalmology ................585 Lisa R. Grillone and Scott P. Henry Chapter 22 Cardiovascular Therapeutic Applications ......................................................................................601 Rosanne Crooke, Brenda Baker, and Mark Wedel Chapter 23 Developing Antisense Drugs for Metabolic Diseases: A Novel Therapeutic Approach ...............641 Sanjay Bhanot Chapter 24 Inflammatory Diseases...................................................................................................................665 Susan A. Gregory and James G. Karras Chapter 25 Antisense Oligonucleotides for the Treatment of Cancer..............................................................699 Boris A. Hadaschik and Martin E. Gleave Chapter 26 Targeting Neurological Disorders with Antisense Oligonucleotides.............................................721 Richard A. Smith and Timothy M. Miller Chapter 27 Mechanisms and Therapeutic Applications of Immune Modulatory Oligodeoxynucleotide and Oligoribonucleotide Ligands for Toll-Like Receptors ............................................................747 Jörg Vollmer and Arthur M. Krieg Chapter 28 Aptamer Opportunities and Challenges .........................................................................................773 Charles Wilson Index...............................................................................................................................................801
CRC_8796_FM.qxd
6/22/2007
11:27
Page viii
CRC_8796_FM.qxd
6/22/2007
11:27
Page ix
Preface At the conclusion of the preface for the first edition of this publication, I wrote: The chapters in this volume, recent publications, and recent symposia, such as the meeting sponsored by Nature Biotechnology, provide compelling answers to the questions about the technology. In the aggregate, the data provide ample justification for cautious optimism. It is clearly a remarkably valuable tool to dissect pharmacological processes and confirm the roles of various genes. Perhaps more importantly, even the first-generation compounds— the phosphorothioates—may have sufficient properties to be of use as drugs for selected indications, and new generations of antisense drugs may broaden the therapeutic utility of drugs based on antisense technology. Nevertheless, it is important to remember that we are less than a decade into the aggressive creation and evaluation of antisense technology. And we are attempting to create an entirely new branch of pharmacology: new chemical class, oligonucleotides; a new receptor, RNA; a new drug–receptor binding motif, hybridization; and new postreceptor binding mechanisms. Thus there are still many more questions than answers. Arguably, then, we are at the end of the beginning of this technology. There is a great deal more to do before we understand the true value and limits of antisense, but we are buoyed by the progress to date and look forward to the challenges ahead.
So where do we stand today? This volume speaks to logarithmic progress in oligonucleotide-based therapeutics and, in particular, antisense therapeutics. Advances in every area from medicinal chemistry to clinical evaluations are remarkable, especially when one considers the modest investment that has been made relative to the investments in other new platform opportunities such as monoclorial antibodies or gene therapy. Nevertheless, despite logarithmic progress in advancing and understanding the technology, the process of converting the technology to therapeutically important, commercially successful, and systemically administered new medicines has encountered several substantial disappointments. Although macugen, an aptamer, was approved for the local treatment of age-related macular edema (see Chapter 22), two first-generation antisense drugs administered systemically failed to achieve positive phase 3 studies. The new drug application (NDA) for a third drug, Genasense, was rejected by the Food and Drug Administration (FDA) and a new NDA for use of the drug in chronic lymphocytic leukemia was also rejected. How should we interpret these disappointments with regard to the value of the technology as a whole and in the context of the extraordinary progress that has been reported? This volume provides detailed answers to that enormously complex question. Affinitak, a first-generation antisense inhibitor of protein kinase C (PkC) was added to either carboplatinum and taxol or gemcitibine and cisplatinum and its effects on survival in patients with stage III/IV nonsqamous cell carcinoma of the lung (NSCCL) were evaluated. It resulted in no statistically significant survival benefit. Although we were unable to measure drug levels in tumors in the phase 3 studies, based on our experience with other first- and second-generation antisense drugs, we believe it is likely that there was sufficient drug in the tumors to produce a pharmalogic effect. So perhaps, PkC is not a significant contributor to the maintenance of the malignant phenotype in these patients. Perhaps we underdosed; we certainly didn’t achieve a maximal tolerated dose. Perhaps the disease was so advanced that patients could not benefit. That a new drug added to a two-drug regimen for NSCCL failed to bring benefit is not too surprising as most drugs have failed in this setting. Nevertheless, Affinitak failed and it was a setback for acceptance of the technology. The failure of Affinitak is discussed in some detail in Chapter 26. Because initial phase 2 results obtained in randomized double-blind placebo-controlled clinical trials were quite positive, the failure of Alicaforsen in the treatment of patients with Crohn’s disease is perhaps more disappointing and puzzling. It was also surprising because after a dose of 2 mg/kg three times weekly for one month in a phase 2 trial, we reported reductions of ICAM-1, the Alicaforsen target, in the bowels of patients with Crohn’s disease. In fact, in two phase 3 studies we used doses substantially greater than 2 mg/kg, so it is likely that the drug was dosed adequately. Our ix
CRC_8796_FM.qxd
x
6/22/2007
11:27
Page x
PREFACE
best guess is that ICAM-1 is not critical in maintenance of Crohn’s disease in the patients we studied. Interestingly, as discussed in Chapter 25, the enema formulation of the drugs has demonstrated good efficacy in patients with ulcerative colitis. However, it is gratifying that in studies on Affinitak and Alicaforsen and now many other firstgeneration antisense drugs, we did not encounter severe dose-limiting toxicities. Even in the presence of very toxic chemotherapeutic regimes, in very sick patients, Affinitak’s contribution to toxicity was modest (see Chapters 14 and 26 for review). The third first-generation antisense drug to undergo phase 3 evaluations, an NDA, Genasense, was submitted for approval by the FDA for the treatment of malignant melanoma and was rejected. More recently, an NDA for the treatment of chronic lymphocytic leukemia was submitted. Despite the fact that the trial met its primary endpoint, the oncology advisory panel recommended the NDA be denied. Are there general lessons about antisense technology to be derived from these disappointments? Yes. First and most important, the experiences with these drugs and the many other first-generation antisense drugs demonstrate that even first-generation antisense drugs are reasonably well tolerated. Even Genasense, the most immunotoxic of the first-generation antisense drugs, was adequately tolerated when administered at relatively high doses in the presence of very cytotoxic chemotherapeutic regimens. Second, it is clear that antisense drugs with improved potency, better pharmacokinetic properties, and improved therapeutic index are needed. Of course, that was obvious in 1989 when we began the work on the technology, the evaluation of first-generation drugs, and the creation of second-generation drugs. Importantly, as Part 3 of the volume demonstrates, 2⬘ methoxyethyl chimeras represent a dramatic advance and are performing well. Other new chemistries and mechanisms of action offer the promise of even greater advances (Part 4 of this volume). Third, obviously drugs fail and often we really do not understand why. After more than 100 years of experience with small molecule drug discovery, 9 out of the 10 small molecules that begin development fail. So, it should not be surprising that representatives of a new class of drugs also fail. After all, they are subject to the same challenges and issues that all drugs face in phase 3 trials and in the regulatory process. What is important is amply demonstrated by this volume. Our understanding of the technology has advanced at a remarkable pace. New mechanisms and new opportunities for antisense drugs and other oligonucleotide-based drugs are being identified at an exciting pace. Second-generation antisense drugs are dramatically better, work in vitro, in vivo, and in clinical trials. And the technology is poised to continue logarithmic growth. Therefore, the tasks that remain are to finish the first leg of the journey. Developing a new platform for drug development is much more than a marathon. We must continue to aggressively, but prudently pursue the great opportunity that is presented by the technology and which is now firmly in our grasp. Stanley T. Crooke Isis Pharmaceuticals, Inc.
CRC_8796_FM.qxd
6/22/2007
11:27
Page xi
Acknowledgments Editing a multiauthor volume is a bit like managing the United Nations. The editor has no authority and must depend on the goodwill and commitment of the authors of the chapters and his ability to twist the occasional arm. In the preparation of this volume, I was fortunate to have outstanding authors who met their commitments. I want to thank all the authors for their scholarly contributions and their commitment to meet the deadlines I imposed. I hope the reader will agree that all the chapters offer excellent value and are more than simply reviews. Rather, individually and in the aggregate, I believe that they constitute a compilation of the information available about this complex topic today and are integrated in a fashion that supports the development of a perspective on the future and an informed agenda with which to continue to advance the science. I want to thank Donna Parrett, who not only was responsible for preparing the two chapters in which I was involved, but was also coordinating the assembly of the book while completing all her other responsibilities. Thanks, Donna. I also want to thank those who will read the book. I appreciate your interest and look forward to the many contributions to the field that will be supported by the knowledge summarized in this volume.
xi
CRC_8796_FM.qxd
6/22/2007
11:27
Page xii
CRC_8796_FM.qxd
6/22/2007
11:27
Page xiii
The Editor Stanley T. Crooke is founder, chairman, and chief executive officer of Isis Pharmaceuticals. Isis is a development-stage biopharmaceutical company that is focused on a new paradigm in drug discovery, antisense oligonucleotides. Since Dr. Crooke and his colleagues founded Isis in 1989, the company has grown rapidly, completing its initial public offering in May 1991, and has reported broad progress in antisense technology and its rapid conversion to therapeutic product opportunities. Isis was the first company to commercialize an antisense drug and has achieved a number of important corporate collaborative relationships. In 2006, Dr. Crooke was named in Nature Biotechnology as one of biotech’s influential individuals. Dr. Crooke is currently a member Northern Arizona University Arts and Sciences Advisory Council, Flagstaff, Arizona and San Diego State University BioScience Center Scientific Advisory Board. He is a member of the Current Drugs Advisory Board; the Editorial Advisory Board of Journal of Drug Targeting and Antisense Research and Development; and the Editorial Board of Gene Therapy and Molecular Biology. He is also editor-in-chief of Current Opinion in Anticancer Drugs and section editor for Biologicals and Immunologicals for Expert Opinion on Investigational Drugs. Prior to founding Isis, Dr. Crooke was president of Research and Development for SmithKline Beckman Corporation (SKB). He also coordinated the research and development activities of SKB including its instruments, diagnostics, animal health, and clinical laboratory businesses. Before joining SKB, Dr. Crooke helped establish the anticancer drug discovery and development program at Bristol Myers, which succeeded in bringing to market a significant number of drugs. During his career, Dr. Crooke has supervised the development of 19 drugs currently on the market and others in development. In addition to his involvement in the pharmaceutical industry, Dr. Crooke also maintains active academic positions. He is an adjunct professor at San Diego State University, and has won a number of teaching awards. He has authored over 440 publications and has edited 20 books. Dr. Crooke is active in molecular and cellular biology and pharmacology of antisense oligonucleotides. Dr. Crooke received his BS in Pharmacy from Butler University, Indianapolis, Indiana, and his MD and PhD from Baylor College of Medicine, Houston, Texas.
xiii
CRC_8796_FM.qxd
6/22/2007
11:27
Page xiv
CRC_8796_FM.qxd
6/22/2007
11:27
Page xv
Contributors Brenda Baker Isis Pharmaceuticals, Inc. Carlsbad, California
Maria A. Graziewicz Ercole Biotech Inc. Chapel Hill, North Carolina
C. Frank Bennett Isis Pharmaceuticals, Inc. Carlsbad, California
Susan A. Gregory Isis Pharmaceuticals, Inc. Carlsbad, California
Sanjay Bhanot Isis Pharmaceuticals, Inc. Carlsbad, California
Lisa R. Grillone Aerie Pharmaceuticals, Inc. Research Triangle Park, North Carolina
Balkrishen Bhat Isis Pharmaceuticals, Inc. Carlsbad, California
Boris A. Hadaschik The Prostate Centre Vancouver General Hospital Vancouver, British Columbia, Canada
Daniel C. Capaldi Isis Pharmaceuticals, Inc. Carlsbad, California Rosanne Crooke Isis Pharmaceuticals, Inc. Carlsbad, California Stanley T. Crooke Isis Pharmaceuticals, Inc. Carlsbad, California Antonin R. de Fougerolles Alnylam Pharmaceuticals Cambridge, Massachusetts Robert A. Fey Isis Pharmaceuticals, Inc. Carlsbad, California Susan M. Freier Isis Pharmaceuticals, Inc. Carlsbad, California Richard S. Geary Isis Pharmaceuticals, Inc. Carlsbad, California Martin E. Gleave Department of Urologic Sciences Vancouver General Hospital Vancouver, British Columbia, Canada
Gregory E. Hardee Isis Pharmaceuticals, Inc. Carlsbad, California Scott P. Henry Isis Pharmaceuticals, Inc. Carlsbad, California Patrick L. Iversen AVI BioPharma, Inc. Corvallis, Oregon James G. Karras Isis Pharmaceuticals, Inc. Carlsbad, California Tae-Won Kim Isis Pharmaceuticals, Inc. Carlsbad, California Troels Koch Santaris Pharma Hørsholm, Denmark Ryszard Kole University of North Carolina Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Kimberly Kramer-Stickland Biogen IDEC San Diego, California xv
CRC_8796_FM.qxd
6/22/2007
11:27
Page xvi
xvi
CONTRIBUTORS
Arthur M. Krieg Coley Pharmaceutical Group, Inc. Wellesley, Massachusetts
Peter Sazani Ercole Biotech Inc. Chapel Hill, North Carolina
T. Jesse Kwoh Isis Pharmaceuticals, Inc. Carlsbad, California
Anthony N. Scozzari Isis Pharmaceuticals, Inc. Carlsbad, California
Arthur A. Levin Isis Pharmaceuticals, Inc. Carlsbad, California
Alla Sigova Department of Biochemistry and Molecular Pharmacology University of Massachusetts Medical School Worcester, Massachusetts
Walt Lima Isis Pharmaceuticals, Inc. Carlsbad, California Ian MacLachlan Protiva Biotherapeutics Inc. Burnaby, British Columbia, Canada Muthiah Manoharan Alnylam Pharmaceuticals Cambridge, Massachusetts John M. Maraganore Alnylam Pharmaceuticals Cambridge, Massachusetts Timothy M. Miller Department of Neurosciences University of California San Diego, California Brett P. Monia Isis Pharmaceuticals, Inc. Carlsbad, California
Andrew Siwkowski Isis Pharmaceuticals, Inc. Carlsbad, California Richard A. Smith Center for Neurologic Study La Jolla, California Eric E. Swayze Isis Pharmaceuticals, Inc. Carlsbad, California Lloyd G. Tillman Isis Pharmaceuticals, Inc. Carlsbad, California Timothy Vickers Isis Pharmaceuticals, Inc. Carlsbad, California Jörg Vollmer Coley Pharmaceutical, GmbH Langenfeld, Germany
Peter E. Nielsen The Panum Institute University of Copenhagen Copenhagen, Denmark
Andrew T. Watt Isis Pharmaceuticals, Inc. Carlsbad, California
Henrik Ørum Santaris Pharma Hørsholm, Denmark
Mark Wedel Isis Pharmaceuticals, Inc. Carlsbad, California
Kallanthottathil G. Rajeev Alnylam Pharmaceuticals, Inc. Cambridge, Massachusetts
Charles Wilson Archemix Corp Cambridge, Massachusetts
CRC_8796_FM.qxd
6/22/2007
11:27
Page xvii
CONTRIBUTORS
Hongjiang Wu Isis Pharmaceuticals, Inc. Carlsbad, California Rosie Z. Yu Isis Pharmaceuticals, Inc. Carlsbad, California
xvii
Phillip D. Zamore Department of Biochemistry and Molecular Pharmacology University of Massachusetts Medical School Worcester, Massachusetts Thomas A. Zanardi Isis Pharmaceuticals, Inc. Carlsbad, California
CRC_8796_FM.qxd
6/22/2007
11:27
Page xviii
CRC_8796_S001.qxd
4/23/2007
09:24 AM
Page 1
PART
I
Introduction
CRC_8796_S001.qxd
4/23/2007
09:24 AM
Page 2
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 3
CHAPTER
1
Mechanisms of Antisense Drug Action, an Introduction Stanley T. Crooke, Timothy Vickers, Walt Lima, and Hongjiang Wu
CONTENTS 1.1
1.2
1.3
1.4
Introduction...............................................................................................................................5 1.1.1 The Opportunity ...........................................................................................................5 1.1.2 The Challenge...............................................................................................................5 1.1.3 Phases of Antisense Drug Action .................................................................................7 RNA Intermediary Metabolism ................................................................................................7 1.2.1 Coding RNAs................................................................................................................7 1.2.2 Noncoding RNAs..........................................................................................................9 1.2.2.1 Antisense Transcripts ....................................................................................9 1.2.2.2 Small Noncoding RNAs..............................................................................10 1.2.2.3 Other Noncoding RNAs ..............................................................................12 Factors that Influence the Selectivity of Antisense Drugs .....................................................12 1.3.1 Affinity........................................................................................................................12 1.3.2 Specificity for Nucleic Acid Sequences .....................................................................13 1.3.3 Protein Binding to Target RNA ..................................................................................14 1.3.4 Facilitated Hybridization ............................................................................................14 1.3.5 Levels of Target RNA.................................................................................................15 1.3.6 Terminating Mechanism .............................................................................................15 1.3.7 Posttranscriptional Modifications of RNA .................................................................15 1.3.8 Screening Processes Used to Identify Antisense Inhibitors .......................................16 1.3.9 Therapeutic Specificity (Therapeutic Index)..............................................................19 Occupancy-Only-Mediated Mechanisms ...............................................................................19 1.4.1 Modulation of Splicing...............................................................................................19 1.4.1.1 Can Antisense Drugs Be Used to Alter Splicing in Vitro and in Vivo? ....................................................................................20 1.4.1.2 How Is the Activity of Antisense Drugs Affected by the Strength of the Splicing Signal? .................................................................21 1.4.1.3 Does the Position of the Antisense Drug at a Splice Site Affect the Activity of the Antisense Drug?..........................................24 1.4.1.4 Do the Characteristics of Introns or Exons Affect the Activities of Antisense Agents? .................................................24 3
CRC_8796_ch001.qxd
5/24/2007
4
21:54
Page 4
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
1.4.1.5
Can Antisense Agents Designed to Bind Exonic Enhancer or Silencer Sequences Affect Splicing? ......................................25 1.4.1.6 Does Chemical Class Influence Activity?...................................................25 1.4.2 Translation Arrest .......................................................................................................25 1.4.2.1 Is It Feasible to Arrest Translation with Antisense Drugs? ........................25 1.4.2.2 What Are the Optimal Sites in Target RNAs to Induce Translation Arrest? ..........................................................................25 1.4.2.3 What Is the Influence of Chemical Class on Activity?...............................26 1.4.2.4 How Robust Is Translation Arrest? .............................................................26 1.4.3 Disruption of Necessary RNA Structure ....................................................................26 1.5 Occupancy-Activated Destabilization ....................................................................................26 1.5.1 5 Capping ..................................................................................................................27 1.5.2 Inhibition of 3-Polyadenylation ................................................................................27 1.5.3 Other Mechanisms......................................................................................................27 1.5.4 RNase H......................................................................................................................27 1.5.4.1 Do Antisense Drugs That Use the RNase H Mechanism Work?...................................................................................28 1.5.4.2 What Sites in Target RNAs Are Accessible to RNase H–Based Antisense Drugs? .........................................................................28 1.5.4.3 Can Information about the Enzymology of RNase H1 Be Used to Improve the Performance of RNase H–Based Drugs?..............................................................................30 1.5.4.4 How Robust a Mechanism Is RNase H?.....................................................30 1.5.5 Double-Strand RNase (siRNA) ..................................................................................31 1.5.5.1 siRNA and RNase H Mechanisms Are Similar ..........................................32 1.5.5.2 RISC-Mediated Pathways ...........................................................................33 1.5.5.3 RISC-Mediated Pathways Are Promiscuous with Regard to Hybridization-Based Off-Target Effects.....................................34 1.5.5.4 siRNAs May Induce Transcriptional Repression........................................35 1.5.5.5 siRNAs Have Displayed Activities in Vivo That Are Similar to Those Displayed by RNase H Antisense Drugs—But There Are Also Substantial Differences................................................................................36 1.5.5.6 Structural Features and Medicinal Chemistry of siRNAs ..................................................................................36 1.5.5.7 Unique Challenges of Duplex RNA Drugs.................................................37 1.5.6 Covalent Modifications of Target Nucleic Acids .......................................................38 1.5.7 Oligonucleotide-Induced Cleavage of Target RNA....................................................38 1.5.8 RNase L–Mediated Cleavage .....................................................................................38 1.6 Micro-RNAs ...........................................................................................................................39 1.7 Conclusions and Future Perspectives .....................................................................................39 Acknowledgments ............................................................................................................................40 References ........................................................................................................................................40
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 5
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
5
1.1 INTRODUCTION 1.1.1
The Opportunity
The antisense concept derives from an understanding of nucleic acid structure and function and depends on Watson–Crick hybridization [1]. Thus, arguably, the demonstration that nucleic acid hybridization is feasible [2] and the advances in situ hybridization and diagnostic probe technology [3] lay the most basic elements of the foundation supporting the antisense concept. The first clear enunciation of the concept of antisense oligonucleotides as therapeutic agents was in the work of Zamecnik and Stephenson [4] in 1978. In this publication, these authors reported the synthesis of a 13 nucleotide long oligodeoxyribonucleotide, which was complementary to a sequence in the respiratory syncytial virus genome. They suggested that this oligonucleotide could be stabilized by 3- and 5-terminal modifications and showed evidence of antiviral activity. More important, they discussed possible sites for binding in ribonucleic acid (RNA) and potential mechanisms of action of oligonucleotides. The opportunity suggested by the antisense concept was seductive for a number of reasons. First, it suggested that it might be possible to create gene-selective reagents and drugs. The perceived value of such selectivity has increased as the molecular biology of the cell has become better understood and it has become apparent that most genes are arrayed within multigene families. The concept also suggested the possibility of the rational design of reagents and drugs based on well-understood principles: Watson–Crick hybridization rules. Again, the perceived value of such an approach has increased since the ability to dissect molecular biological processes at ever greater detail has evolved and the productivity of drug discovery exercises using traditional approaches has declined. The demonstration of broad distribution to multiple organs, multiple routes of administration, and excellent therapeutic index of second-generation antisense drugs as well as their potential applicability to a very broad array of diseases have further enhanced the perceived value of the technology. Finally, advances in understanding noncoding RNAs, RNA structure, function, and metabolism have broadened the potential targets and pathways to be exploited, adding further to the perceived value of the platform. In short, the more that has been understood about the RNA world and the performance of the hybridization-based drugs, the broader and more exciting the overall opportunity seems. 1.1.2
The Challenge
The development of antisense technology is, in effect, the creation of a new pharmacology. The receptor for antisense drugs is a specific sequence of nucleotides in a target RNA. Thus, a key step in the development of the platform was the understanding of the structure, functions, and intermediary metabolism of RNA from a pharmacological perspective. Advances in understanding all these aspects of RNA and advances in identifying novel RNA species have contributed to the evolution of antisense technology. Prior to the late 1980s and early 1990s, essentially no medicinal chemistry had been performed on oligonucleotides. In fact, the phosphorothioate modification, which has proven to be a versatile and useful backbone modification, was first synthesized to stabilize polyribonucleotides used to induce interferon [5] and the methylphosphonates were discovered as a part of an effort to evaluate the effects of chemical modifications on hybridization [6]. However, since the early 1990s, extraordinary progress in creating and evaluating modifications of oligonucleotides has been reported (for review, see [7,8]). The pharmacophore, a dinucleotide, and a few of the many hundreds of modifications made and tested are all shown in Figure 1.1. In our laboratories at Isis, we have had the opportunity to evaluate and compare hundreds of modified oligonucleotides in various animal models. Thus, there is today a substantial chemical toolbox and an extraordinarily rich database that extends from synthesis to hybridization and nuclease stability to all the characteristics of interest with regard to drug properties for these modifications.
Figure 1.1
N
O
O N
O
R
N
N
O
H
O
R
R O O PS O O Base
O
O
O Base
R
N
O
H
H
LNA
O O
O Base
R
O
O Base
OCH3
O
ENA
O
Base
O R Phosphodiester
O
O Base
O
O
O
NH
N
NH
N
O
O
PNA
O
Base
Base
OCH3
OCH3 O O O PS O O Base
O
2′-OMOE
O R O PO O O Base
O
O
The pharmacophore and representative oligonucleotide modifications.
G-Clamp
O
O O PS O
O N
O
O Base
OCH3
O Base
O O PS O
O
2′-OMe O Base
2′-F
O
O
N
O
O
O P
F
H2 C
O
N
O
R
O Base
R
Morpholino
Base
R
O Base
O
Methylenemethylimino
Phophoramidate O Base
R
O Base
O PO O
HN
O
O
O Base
Phosphorothioate
O Base
O O PS O
O
H3 C N O
F O O PS O O Base
O
6
Phenoxazine
O
H
R
O
O R O PS O O Base
O N
N
NH 2
21:54
N
O
O
O Base
R
O N
O O PS O
O
N
OH (NH 2 )
O
H3 C
5/24/2007
O
5-Propynyl-
H3 C
5-Methyl-C
CRC_8796_ch001.qxd Page 6
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 7
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
7
As progress in creating the chemical toolbox was effected, these chemicals were used to induce drug effects expected to begin with binding to the target RNA. Once an antisense drug binds to its target sequence, it may induce a variety of events that lead to destruction or inactivation of the RNA. We have referred to these as terminating mechanisms. Again, the progress in understanding terminating mechanisms has been gratifying and will be the subject of this chapter. Of course, contemporaneously, the properties of various types of antisense drugs had to be defined. These properties include ease of synthesis, analytical characteristics, stability, pharmacokinetics, toxicological properties, formulations, and routes of delivery. Remarkable progress has been achieved for many different types of oligonucleotide analogs providing the basis for rational selection of oligonucleotides, formulations, doses, schedules, and the design of preclinical and clinical trials (for review, see [9] and this volume). 1.1.3
Phases of Antisense Drug Action
At the most conceptual level, the effects of hybridization-based drugs can be divided into three phases: pre- or nonhybridization, hybridization, and posthybridization. Because the typical cellular level of target m-RNAs is less than 100 copies per cell, the interaction with target RNA results in de minimis reduction of the total antisense drug concentration. Consequentially, nonhybridization interactions, principally with cellular and extracellular proteins, account for the pharmacokinetics and non-pharmacologically-based toxicological properties of antisense drugs. As our understanding has become more sophisticated, ever larger numbers of subtle variations in these properties due to variations in sequence have been identified. Nevertheless, most pharmacokinetic and toxicologic observations are qualitatively and quantitatively consistent across all members of a chemical class, i.e., class-generic behaviors are observed. Thanks to the extraordinary advances reported, we now understand these properties in detail for several classes of antisense drugs and are beginning to dissect them down to the level of specific interactions between oligonucleotides and proteins that result in specific properties (for review, see [10–14] and this volume). Equally impressive progress has been reported with regard to understanding the posthybridization or terminating mechanisms. In fact, today, for some mechanisms we have sufficient understanding to use the mechanistic information to design improved antisense drugs. The progress in understanding the mechanisms of action of antisense drugs has previously been reviewed [15] and is the subject of this chapter. Rather remarkably, however, very little progress has been reported in understanding how hybridization to a specific target RNA occurs in cells. Although the evidence that antisense agents can specifically hybridize to many specific RNA species and cause reduction of the target RNA is overwhelming in cells and animals, little is understood either about the process by which hybridization takes place or the kinetics of intracellular hybridization in cells. Conceptually, it would seem challenging for antisense drugs to identify and bind to the few copies of their cognate sequences in the midst of substantially greater concentrations of potentially competitive nucleic acid sequences in the cells. This remains an area in which there are inadequate explanations for the observed phenomena and where future research should focus.
1.2 RNA INTERMEDIARY METABOLISM 1.2.1
Coding RNAs
Most oligonucleotides are designed to modulate the information transfer from the gene to protein—in essence, to alter the intermediary metabolism of RNA. Figure 1.2 summarizes these processes. RNA intermediary metabolism is initiated with transcription. The transcription initiation complex contains proteins that recognize specific deoxyribonucleic acid (DNA) sequences and
CRC_8796_ch001.qxd
5/24/2007
21:54
8
Page 8
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION Transcriptional arrest
Transcription
CAP Capping/ polyadenylation
AAAA
CAP
Splicing
AAAA Nucleus
CAP
AAAA
Transport CAP
Effects on catabolism of RNA
CAP AAAA
Degradation CAP Translation
Effects on anabolism of mRNA
AAAA
Translational arrest
Protein
Figure 1.2
RNA intermediary metabolism. Steps in the transcription and processing for a pre-mRNA are shown. The thick lines represent exons. The thin lines represent noncoding regions including the 5 and 3 UTRs and introns. Potential sites for intervention are defined by arrows.
locally denature double-stranded DNA, thus allowing a member of the RNA polymerase family to transcribe one strand of the DNA (the antisense strand) into a sense pre-messenger RNA (pre-mRNA) molecule. Usually during transcription, the 5 end of the pre-mRNA is capped by adding a methyl-guanosine, and most often by methylation of one or two adjacent sugar residues. This enhances the stability of the pre-mRNA and may play a role in a number of key RNA processing events [16]. Between the 5 cap and the site at which translation is initiated is usually a stretch of nucleotides referred to as the 5 untranslated region (5-UTR). This area may play a key role in regulating messenger RNA (mRNA) half-life and transitional efficiency [17]. Similarly, the 3 end of the pre-mRNA usually has a stretch of several hundred nucleotides beyond the translation termination signal. This area often plays an important role in determining mRNA half-life. Moreover, posttranscriptionally, most pre-mRNA species are polyadenylated. Polyadenylation stabilizes the RNA, is important in transport of mature mRNA out of the nucleus, and may play important roles in the cytoplasm as well [18,19]. Because eukaryotic genes usually contain intervening sequences (introns), most pre-mRNA species must have these sequences excised and the mature RNA spliced together. Splicing reactions are complex, highly regulated, and involve specific sequences, small-molecular-weight RNA species, and numerous proteins. Alternative splicing processes are often used to produce different mature mRNAs and, thus, different proteins. Even though introns have been considered waste, important sequences are conserved, and intronic sequences can play important roles including coding for proteins, antisense transcripts, and noncoding RNAs [20]. Mature mRNA is exported to the cytoplasm and engages in translation. mRNA half-lives vary from a few minutes to many hours, and appear to be highly regulated. Each step shown in the pathway is a composite of numerous steps and is theoretically amenable to intervention with oligonucleotides. The pathway is fully defined for virtually no mRNA, and available information is insufficient to determine the rate-limiting steps in the intermediary metabolism of any mRNA species. Alternative splicing is an important biological process, has been implicated in a large number of diseases and has been the subject of intervention with antisense drugs. In a typical multiexon
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 9
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
9
RNA, the splicing pattern may be altered in many ways. Although the splicing of most exons is constitutive, the splicing of some exons is inducible and is highly cell- and tissue-context-dependent (for review, see [16]). Although a key determinant of the rate and extent of splicing is the strength of the splicing site consensus sequences, intronic, and exonic sequences that may enhance or inhibit splicing of a particular exon play important roles. As will be discussed, interventions with antisense drugs designed to encourage a particular splicing pattern have been successful. Sites at which success has been observed include splice sites and exonic sequences. 1.2.2
Noncoding RNAs
In the past few years, the prevalence and importance of noncoding RNAs have become much more apparent. Although there are numerous types of noncoding RNAs, two classes, antisense transcripts and micro-RNAs, may be particularly important with regard to antisense therapeutics.
1.2.2.1 Antisense Transcripts Antisense transcripts were identified in eukaryotic cells some time ago, but the extent of antisense transcripts and the breadth of roles they may play have been appreciated only recently (for review, see [21]). Antisense transcripts may code for a variety of proteins or may be noncoding [22]. Noncoding antisense transcripts appear to regulate gene expression at a variety of points in the information transfer process from transcription to translation [21,22]. Of equal importance, however, is the actual production of double-stranded RNA (dsRNA) through binding of an antisense transcript to its sense transcript. Eukaryotic cells contain a variety of enzymatic pathways to process dsRNAs [23,24] and they can induce a number of important processes including posttranscriptional gene silencing [25]. Antisense transcripts can arise from transcription of both strands of a gene. Alternatively in many cases, transcription of two closely positioned genes coding for different proteins and reading in the opposite orientation can lead to an “antisense” transcript for the genes [26]. Importantly, recent studies suggest that 5–10% of the human genome may have antisense transcripts [27,28]. Thus, antisense transcripts may be the result of at least two processes and play important roles in regulating gene function and phenotype via a variety of mechanisms [29]. Given the prevalence and roles of natural antisense manuscripts, it seems likely that they have an effect on the activities of antisense drugs. Clearly, if an antisense transcript were to hybridize to a portion of a target RNA, that portion would be less accessible to an antisense drug, irrespective of chemistry or mechanism of action. Also, any influence of an antisense transcript on the regulation of intermediary metabolism of a targeted RNA could influence the effects induced by an antisense drug designed to bind to that RNA. To date, there has been no report of studies designed to directly assess the effect of antisense transcripts on the activities of antisense drugs. However, at Isis we have created antisense drugs to more than 4000 genes and have never failed to find active drugs to any RNA target based on screening processes that evaluate the effects of scores of antisense drugs designed to bind to multiple sites within the RNA. Nor has it proven unusually difficult to identify antisense drugs designed to bind to the 3 untranslated region (3-UTR) of targeted RNAs, a site to which many antisense transcripts bind (for review, see [9,30]). As most antisense transcripts are reported to be poly A minus and localized to the nucleus, it may be that some of the potential effects of antisense transcripts on antisense drug activity are avoided when antisense drugs are designed to target mature RNAs and can work in both the nucleus and cytosol. However, many antisense drugs are designed to bind to sites that are excised before the RNA exits the nucleus and have been shown to be active; so drug effects in the cytoplasm cannot fully explain the failure to identify RNA sequences that may be inaccessible because of binding to antisense RNA. Clearly, much more work needs to be done in this area with focused experiments that can directly address the impacts of antisense transcripts on the activities of antisense drugs.
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 10
10
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
1.2.2.2 Small Noncoding RNAs The recent discovery of small noncoding RNAs has stimulated one of the most exciting new areas of research in cell biology. Small noncoding RNAs are RNA species that do not code for proteins, but are involved in a host of vital cellular processes. These tiny RNAs add a new layer of regulation of gene function, are involved in processing multiple classes of RNA, respond to viral infections, represent novel RNA targets for antisense drugs, present novel cellular pathways to exploit as new mechanisms for antisense drugs, and in due course may be found to be accountable for some of the limitations and off-target effects of antisense drugs. This group of RNAs is comprised of C or D box containing small RNAs (C/D RNAs), micro-RNAs and small interfering RNA (siRNAs) (for review, see [31]). C/D RNAs are metabolically stable 60–300 nucleotide RNAs that reside in the nucleus and localize to the nucleolus or Cajal bodies and are involved in site-specific methylation of RNAs. They are crucial to processing of preribosomal RNAs as well as pre-mRNAs. Most are transcribed from introns of genes and are processed from the host-gene intron. They contain specific C-box or D-box sequences located near their 5 or 3 termini, respectively. Micro-RNAs are 19–23 nucleotide RNA species. It is estimated that as many as 3% of genes in the mammalian genome have complementary micro-RNAs. Micro-RNAs may form perfect duplexes with their targets, in which case they lead to cleavage in the center of the duplex; or imperfect duplexes, in which case they may lead to translation arrest or cleavage of the targeted RNA. Although micro-RNAs and siRNAs were originally thought to be quite different and result in different cellular responses, in fact the characteristics and behaviors of these RNAs appear to be very similar. Figure 1.3 summarizes the characteristics of the small noncoding RNAs discovered to date.
5′ D/D′
3′
3′
5′
CH3
5 bp Small nucleolar RNAs (snoRNAs)
18S, 5.8S, 28S rRNAs
3′
5′
U6
Other RNAs ? (mRNA ?)
3′ 5′ Perfect DNA duplex
RNA degradation (RNA interference) Figure 1.3
Small Cajal-body-specific RNAs (scaRNAs)
U1, U2, U4, U5
5′
3′ 5′
3′ Irregular RNA duplex
Chromatin modifications
Nonproductive translation
C/D RNA modifications guide and miRNAs. Sequences complementary to the cognate RNA target are depicted in thick lines. (Top) For C/D RNAs, the nucleotide triggered for 2-O-methylation is denoted by a box. It is always paired to the fifth nucleotide upstream from the D (or D) box. The different RNA targets of C/D snoRNAs and scaRNAs are shown. (Bottom) For miRNAs, depending on the degree of complementary with their target, they can trigger RNA cleavage in the middle of the duplex (RNA interference) or nonproductive translation of the target mRNA by an unknown mechanism. miRNA can also promote RNA-directed DNA methylation.
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 11
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
11
Micro-RNAs can be transcribed from the sense or antisense strands of DNA. They can be located in introns, exons, or intragenic regions. Thus, they may use the transcriptional machinery of annotated genes or they may derive from independent transcriptional units (for review, see [32]). Irrespective of gene location or orientation, the initial transcript, the pre-mir, is typically kilobases long and is processed in the nucleus to a pre-mir, an approximately 70-nucleotide species by an RNase III called drosha. The pre-mir is exported to the cytoplasm and cleaved to the approximately 20-nucleotide mir by another RNase III dicer (for review, see [33]). The mir can then be loaded into the RNA-induced silencing complex (RISC) complex in which it may hybridize perfectly or imperfectly with target RNAs. Perfect hybridization leads to degradation by the RISC complex. Imperfect hybridization may lead to translation arrest or degradation of the RNA after localization in processing bodies [34]. Each of these steps is significantly more complex than described and a more detailed description is beyond the scope of this review, but the pathways are shown in simplified form in Figure 1.4. In addition to these complex pathways, it is now apparent that microRNAs or RASi RNAs may, if their sequences are complementary to repetitive DNA sequences, activate the RNA-induced transcriptional silencing (RITS) complex and lead to gene inactivation and heterochromatin formation (for reviews, see [35–37]). Furthermore, these processes can lead to
miRNA - siRNA Biogenesis dsRNA Cell membrane
RLC TRBP
Dicer
siRNA Ago2
RLC
Exportin 5
TRBP
Dicer
Pre-mir Drosha
mRNA
Mature mir RISC
Ago 1/2/3/4
DGCR8
?
Ago
Dcp
P body
40s 60s
Pre-mir DNA Nucleus
mRNA
Cytoplasm
Figure 1.4 The micro-RNA and siRNA pathways. Large precursor RNAs (pre-mirs) are transcribed. They are processed by human RNase III (Drosha) in the nucleus to pre-mirs. Pre-mirs are exported from the nucleus by exporten. In the cytoplasm pre-mi processing bodies are processed by a complex, the RISC loading complex (RLC), of proteins including the RNase III, dicer, and thyroid hormone receptor-binding protein (TRBP). Mature mirs load RISC and eIF2c2 cleaves the target RNA. This may enter processing bodies (p-bodies). Alternatively, the RISC complex can arrest translation. Exogenous RNAs may also enter the pathways.
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 12
12
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
“spreading” and the silencing of additional genes located near the repetitive DNA. Finally, it has been shown that RNA sufficient to induce gene silencing can be processed in the nucleus by transcription of inverted DNA repeats or by cleavage of longer RNA precursors. The potential impacts of small RNAs on antisense therapeutics are manifold and several will be discussed in more detail in later sections of this review and in subsequent chapters. Most directly and obviously micro- and siRNAs reinforce the opportunity suggested in 1998 that RNA-like antisense drugs that activate double-strand RNases could be therapeutically valuable [38]. The direct application of duplex oligoribonuleotides to exploit the RNA interference (RNAi) pathway has been the subject of a great deal of work and is but one means of exploiting double-strand RNases [39]. Perhaps even more important is the identification of multiple new pathways by which regulatory RNAs are produced and used. Each arm of each of these pathways presents unique opportunities and risks. Each protein and each RNA involved presents a potential site for the interaction of antisense drugs that could lead to off-target effects. Micro-RNAs are themselves attractive targets for antisense drugs as demonstrated by several recent publications (for review, see [40]). Again, this area is one that deserves a great deal of attention. It is gratifying to see substantial progress already.
1.2.2.3 Other Noncoding RNAs There are, of course, many other noncoding RNAs, including ribosomal RNA, small-molecular weight nuclear, nuclear, and nucleolar RNAs (for review, see [41]) and RASi RNAs [37]. Although a review of these RNA species is beyond the scope of this chapter, each class of RNA could influence the effects of antisense drug if they were to bind to partially complementary sequences accrued and may represent interesting target opportunities as well.
1.3 FACTORS THAT INFLUENCE THE SELECTIVITY OF ANTISENSE DRUGS 1.3.1
Affinity
The affinity of oligonucleotides for their receptor sequences results from hybridization interactions. The two major contributors to the free energy of binding are hydrogen bonding (usually Watson–Crick base pairing) and base stacking in the double helix that is formed. Affinity is affected by ionic strength, where in general the higher the ionic strength, the higher the affinity of charged oligonucleotides for polynucleotides. As affinity results from hydrogen bond formation between bases and stacking occurs between coplanar bases, affinity increases as the length of the oligonucleotide receptor complex increases. Thus, the affinity per nucleotide unit and the number of hybridizing nucleotide pairs are crucial determinants of overall affinity. Affinity also varies as a function of the sequence in the duplex. Nearest-neighbor rules support the prediction of the free energy of binding for DNA–DNA and RNA–RNA hybrids with relatively high precision [42,43]. A common misconception is that DNA–RNA duplexes are more stable than DNA–DNA duplexes. In fact, the relative stability of these duplexes varies as a function of the sequence. RNA–RNA duplexes are typically the most stable [9]. As with other drug–receptor interactions, activity requires a minimum level of affinity. For many targets and types of oligonucleotides, the minimum length of an oligonucleotide may be 12–14 nucleotides. Although theoretical affinities for oligonucleotide single-strand nucleic acid interactions are very large, in practice, affinity constants are substantially lower. Several factors contribute to the differences between theoretical and realized affinities. Undoubtedly, the most important factor is that RNA can adopt a variety of secondary structures (for review, see [44]). In addition to secondary structure, RNA can adopt tertiary structures. Tertiary structures result from the interactions of secondary structures in an RNA molecule with other secondary structural elements or single-stranded regions [45].
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 13
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
13
A third factor that can potentially reduce the affinity of an oligonucleotide for its RNA receptor is that oligonucleotides can form secondary and tertiary structures themselves. To avoid duplex formation, oligonucleotides that contain self-complementary regions are usually not employed. However, other structures that were not well understood or expected have been described. Tetrameric complexes formed by oligonucleotides with multiple guanosines [46–49] and other base sequences [50] can be highly stable, clearly would prevent an antisense interaction, and have a number of biological effects that have confounded interpretation of experiments. Since RNA and oligonucleotide structures are affected by ionic milieu and nonproductive interactions with proteins and polycations, the in vivo situation is, of course, considerably more complicated. Relatively little is understood about the interplay among all these factors and their effects on the true affinities of oligonucleotides for potential RNA targets. Advances in the medicinal chemistry of antisense drugs have resulted in numerous classes of these agents that display substantially enhanced affinity (for review, see [51]). Conceptually, increased affinity should result in increased potency. Indeed, this has been observed in both in vitro and in vivo test systems (e.g., see [52]). However, in our experience, the increase in potency has typically not been as substantial as predicted based on affinity considerations. This has prompted us to begin to search for potential cellular factors that may influence hybridization. A second potential effect of increasing affinity should be that greater numbers of sites within an RNA molecule might be accessible to antisense drugs. Indeed, that has been our experience. For example, we have compared the activities of lower- and higher-affinity antisense drugs that work via an RNase H (RNase H enzymes are double-strand RNA-binding proteins that cleave RNA in an RNA–DNA duplex) mechanism against a number of cellular targets. In addition to the expected increase in potency, many more sites within the RNA were accessible to the higher-affinity class of antisense drugs for all the transcripts studied. 1.3.2
Specificity for Nucleic Acid Sequences
Specificity derives from the selectivity of Watson–Crick or other types of base pairing. The decrease in affinity associated with a mismatched base pair varies as a function of the specific mismatch, the position of the mismatch in a region of complementarity, and the sequence surrounding the mismatch. In a typical interaction between complementary 18-mers, the G37 or change in the Gibbs free energy of binding induced by a single mismatch varies from 0.2 to 4.0 kcal/ mol/modification at 100 mM NaCl. Thus, a single base mismatch could result in a change in affinity of approximately 500-fold [53]. Modifications of oligonucleotides may alter specificity. At the genomic level, any sequence of 17 residues is expected to occur only once [54]. Assuming a random distribution of sequences in RNA, any sequence of 13 residues is expected to occur once in the cellular RNA population and, if the nonrandom nature of mammalian RNA sequence is taken into account, an 11-mer or perhaps smaller oligonucleotide could identify and bind to a unique sequence [55]. To exploit fully the theoretical potential for specificity of an oligonucleotide in a therapeutic context, it is necessary to manipulate the length of the oligonucleotide and its concentration at target. The results of such an exercise have been reported [56]. In this study, phosphorothioate oligodeoxynucleotides were designed to target the normal or codon 12-point mutation of Ha-ras mRNA. Predictions from hybridization experiments suggested that approximately a fivefold specificity for mutant compared to normal Ha-ras RNA was possible. By optimizing oligonucleotide length and the extracellular concentration of the oligonucleotide, nearly theoretical specificity was achieved in cells in tissue culture. Other factors can also be used to enhance specificity. RNA secondary and tertiary structure assures that not all sequences are equally accessible. Design of oligonucleotides to interact with sequences involved in the maintenance of RNA structure can theoretically enhance specificity and, if the structure is essential to the stability or function of the RNA, potency. Furthermore, many RNA
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 14
14
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
and DNA sequences interact with proteins, again assuring far more diversity in response to an oligonucleotide and, therefore, greater specificity than might be predicted solely on the basis of differences in nucleic acid sequence. 1.3.3
Protein Binding to Target RNA
Although understanding RNA structure provides crucial information that enhances the identification of optimal binding sites for antisense drugs, it is not sufficient for a number of reasons, including the fact that RNAs bind multiple proteins at multiple sites (for review, see [57]). Obviously, any protein interaction with a target RNA may adversely affect the ability of the antisense drug to interact with the desired sites in the RNA. Despite the progress in understanding factors that influence antisense drug activity, virtually nothing is known about the competition between antisense drugs and proteins that bind to RNA. This is undoubtedly one of the reasons that algorithms designed to select optimal binding sites in RNA based on predicting internal RNA structures have failed to provide significant benefit, as discussed in a later section. 1.3.4
Facilitated Hybridization
Precisely how an antisense drug binds to its cognate site in a target RNA in cells is unknown. However, given the enormous excess of partially complementary sites relative the very few copies of individual mRNAs with the fully complementary binding site, it seems unlikely that the process is as simple as hybridization reactions in which appropriate concentrations of two reactants are mixed in a test tube. This has prompted us to consider the possibility that intracellular hybridization to cognate sites is somehow facilitated. Several proteins have been shown to promote RNA annealing or hybridization [57]. A protein found in messenger ribonucleoprotein particles (mRNP), a member of the Y-box family of proteins P50 (YB-1), has been reported to be involved in a number of DNA repair and replication processes and to promote hybridization of RNA (and DNA) [58]. This protein was reported to enhance RNA hybridization by up to a thousandfold. Its activity was dependent on the ratio of protein to RNA, the length of the RNA, and ionic strength. It did not require adenosine triphosophate (ATP) hydrolysis. It also enhanced hybridization of DNA. The promiscuity of this protein suggests that it can participate in facilitating the hybridization of antisense drugs of various chemistries to target RNAs. Its localization to the polysomes, m-RNPs, and in the nucleus makes it an excellent candidate to facilitate the hybridization of antisense drugs in all cellular compartments. Although the detailed mechanism is not yet understood, it has been proposed that YB-1 works stoichiometrically by melting interfering structures and increasing the local effective concentrations of the two hybridizing strands. As all the proteins in this family have clusters of positively charged amino acids, it is thought that they may serve to neutralize the charge–charge repulsion of the two nucleic acids strands as well. Other proteins display similar properties. For example, the major proteins of the heterogeneous nuclear ribonucleoprotein complexes (hnRNP A1, C1, and U) exhibit annealing activities [59]. More recently, the RISC has been shown to facilitate hybridization of RNA strands in the RISC complex by as much as 400 fold [60]. Thus, there is ample and growing evidence that facilitated hybridization occurs in cells. How might facilitated hybridization affect the activity of antisense drugs? First, it may be the case that the facilitation of hybridization by RISC is simply the first demonstration of the phenomenon and that all interactions of antisense drugs with their cognate sequences are facilitated. It is possible that the substantial differences in potency of antisense drugs designed to bind to different sites in target RNAs could be a function of RNA structure, proteins that are bound, and the ability of the site to participate in facilitated hybridization. Finally, as chemistries diverge substantially from natural nucleic acid structures, e.g., peptide nucleic acids, they may be less able to participate in facilitated hybridization and this might explain the limited activities displayed by some chemical
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 15
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
15
classes. It may also impose true structural limitations on the divergence from natural nucleic acid structures that can be tolerated in antisense drugs. At present, the proposition that facilitated hybridization is important in determining the effectiveness of antisense drugs is largely conjectural. However, this area has benefited from virtually no research and now that the tools are available, progress in this important area should be forthcoming. 1.3.5
Levels of Target RNA
Although it is theoretically possible that the concentration, transcriptional rate, or stability of a target RNA may influence the effectiveness of antisense drugs, at least for antisense drugs that work via the RNase H mechanism, it has been experimentally determined that RNA concentration and transcription rate do not affect their performance [61]. In this study the level of RNA transcribed from either an exogenous or induced endogenous gene was varied from 1 to 400 copies per cell and shown to have no effect on the potency or efficacy of antisense drugs transfected into either A549 or HeLa cells. Nor did transcription rate have any effect. Less direct evidence also derives from our broad experience in screening for antisense drug activity. As a general rule, within a specific chemical and mechanistic class of antisense drugs, the maximum potency and efficacy achieved against each RNA target is roughly comparable. Inasmuch as we have identified antisense drugs to approximately 4000 genes, if RNA concentration, transcriptional rate, or RNA stability significantly influenced antisense drug performance it seems likely that greater variability in these parameters would have been observed (for review, see Chapter 5 in this volume). Why do these factors not affect the activities of antisense drugs? Consider the basic equation that defines drug action: D F & DR → Effect where D is the drug concentration, R the receptor concentration, and DR the drug–receptor complex. Given the low concentrations of pre- and m-RNAs in cells and the high intracellular concentrations of antisense drugs achieved, the receptor concentration can be eliminated and drug effect should be dependant only on drug concentration. Transcriptional rate should have no effect because receptor concentrations are irrelevant. Similarly, m-RNA decay rate should have no effect. 1.3.6
Terminating Mechanism
The first step in the induction of pharmacodymic effects by an antisense drug is hybridization to its cognate sequence or receptor. What happens after binding is also of great importance. Terminating mechanisms can be divided into occupancy only and occupancy-induced degradation classes. Inhibiting RNA function by occupying selected sites in the target RNA has been demonstrated and includes processes such as translation arrest and inhibition of splicing or induction of alternative splicing. Occupancy-induced destabilization of RNA involves the recruitment of nucleases that degrade the target RNA and can include RNases H and double-strand RNases such as those involved in siRNA activities. The “robustness” of the terminating mechanism can be qualitatively characterized using several parameters. These include the ease of identification of active antisense drugs, the ratio of active to inactive sites in target RNAs, and the potency and efficacy of drugs that use the mechanism both in vitro and in vivo. We now have enough experience to compare the robustness of various mechanisms in vitro. For comparisons of robustness in vivo, we have less data, but some trends are emerging. These topics will be considered in some detail in later sections of this review. 1.3.7
Posttranscriptional Modifications of RNA
Although RNAs are subject to far fewer postsynthesis modifications than proteins, posttranscriptional modifications that could influence the activities of antisense drugs do occur.
CRC_8796_ch001.qxd
16
5/24/2007
21:54
Page 16
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Posttranscriptional modifications of RNA include 2-0 methyl modifications of the ribose, conversion of uridine to pseudouridine and RNA editing (for review, see [62–64]). However, only RNA editing has been shown to modify the sequences of pre- and mature m-RNAs. RNA editing is effected by the deamination of either adenosine to inosine or cytosine to uridine. In both cases, the sequence of the RNA is modified from that originally transcribed from the gene. RNA editing has been shown to play significant roles by introducing new codons that may initiate translation, prematurely stop translation, alter splicing, or influence other steps in the metabolism and utilization of RNAs (for review, see [64,65]). Given how frequently RNA editing occurs and its substantial importance to normal and pathophysiological process, it seems likely that the processes should influence the activities of antisense drugs. Clearly, the introduction of a mismatch in the center of a 2 gap in a second-generation antisense drug should dramatically reduce activity that would be dependant on RNase H1. It is also possible that editing of siRNA duplexes by adenosine deaminase and editing of single-strand oligoribonucleotides by cytosine deaminase could take place even though they would not be ideal substrates for the enzymes. If that were to happen, of course, off-target effects could ensue. To date, however, no systematic studies of the potential impacts of RNA editing on the activities of antisense drugs have been reported. Although it is unlikely that RNA editing could profoundly influence the activities of many antisense drugs, it is possible that a thorough evaluation of this possibility could help explain some anomalous behaviors observed occasionally with specific antisense drugs. 1.3.8
Screening Processes Used to Identify Antisense Inhibitors
In drug discovery, it is axiomatic that the more thorough the search to identify an optimal drug, the better the drug. Antisense drug discovery technology provides additional incentives for thorough screening. First, the design, synthesis, and testing of potential antisense inhibitors is straightforward, rapid, and automatable. Second, a wide array of potential chemical modifications is now available. Third, substantial experience with multiple terminating mechanisms can inform screening processes. Fourth, because all the drugs from a particular chemical class behave similarly, there is great value in databases that can be created from information about the performance of hundreds to thousands of representatives of each chemical class. Fifth, it is now apparent that it is possible to identify problematic sequence motifs such as immunostimulatory consensus sequences, and thus avoid them. At Isis, the screening process begins with the sequence of the target RNA. That sequence is input and algorithms design antisense inhibitors to 40–80 different sites within the RNA excluding known problematic motifs and sequences that may lead to internal structures in the antisense agents. These are then screened at active concentrations in cells. Multiple active antisense inhibitors are then studied in detailed dose–response curves in vitro. For targets of substantial interest, at this stage we often screen antisense inhibitors to as many as several hundred additional sites. Then typically, 5–6 potential antisense drugs are taken into rodents. In fact, we typically evaluate several antisense inhibitors in monkeys (Figure 1.5). Thus, compared to earlier times, the antisense drugs designed today at Isis begin better because of the medicinal chemistry and basic research done earlier and the number of problematic motifs excluded. The final selection of the lead drug for detailed study then benefits from the number of potential drugs evaluated in vitro and in vivo providing better data-driven choices. As can be observed in Figure 1.6, just screening multiple sites in each target RNA greatly enhances the likelihood of enhanced performance by antisense drugs. Consider, for example, the likelihood of success with antisense oligonucleotide 1 (ASO1) or ASO2 compared to some of the less active antisense inhibitors. Moreover, as this screen was performed with higher-affinity more potent second-generation antisense drugs, the ratio of sensitive versus insensitive sites is very high and much higher than observed with most other chemistries or mechanisms of action. Furthermore, each RNA is different. Thus, in our experience algorithms designed [66,67] to identify optimal sites in target RNAs have simply not performed adequately to reduce the need for detailed in vitro screening (see Chapter 5 for more detailed discussion).
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 17
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
17
150
FAK mRNA (relative units)
125
100
75
50
25
0
Figure 1.5
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Oligonucleotide
Routine screening process to identify optimal antisense drugs (2006). The sequence of the target RNA is used to identify potential antisense inhibitors. On the basis of earlier research, many potentially problematic sequences are excluded. The process is enhanced by evaluating multiple candidates in several species. Avoid mouse immunostimulatory motifs
Avoid mouse toxic motifs Oligo design
Avoid human immunostimulatory motifs
Avoid C strings
Avoid toxicity Mouse lean screens/ pharmacology screens
Avoid proinflammatory activity Avoid toxicity
Monkey screens (human candidate) Avoid kidney toxicity
Figure 1.6
Avoid proinflammatory activity
Results of an initial screen of 2-MOE chimeric antisense inhibitors designed to inhibit superoxide dismutase 1. Each inhibitor was transfected into A549 cells at 100 nM and the effects on SOD1 RNA levels evaluated 24 h after treatment of the cells.
Do these generalizations apply to drugs other than 2 methoxy-ethyl (2-MOE) chimeras that work via an RNase H mechanism? Yes. For example, consider Figure 1.7, which compares the activities of phosphorothioate oligodeoxynucleotides and 2-MOE chimeras. Or consider the experience gained comparing siRNAs to second-generation antisense inhibitors. The activities of siRNAs are influenced
Figure 1.7
5′-UTR 3300 nt
ASO 1
3′-UTR
Intron Targeting ASOs
Comparison of antisense inhibition of p125 FAK by first- and second-generation antisense drugs. A549 cells were treated with 400 nM of each of the antisense drugs. Twenty-four hours after transfection, the level of p125 FAK messenger RNA was assessed by real-time polymerase chain reaction (RT-PCR). The black bars represent the level of p125 FAK RNA with 20 mer phosphorothioate oligonucleotides. The grey bars represent the levels of p125 FAK RNA in cells treated with a 20 mer 2-MOE chimeric second-generation antisense drugs. Both classes of drugs activate human RNase H1.
0
20
40
ASO 2
Negative control oligos
18
60
Untreated control
21:54
80
100
120
140
5/24/2007
% Control expression
CRC_8796_ch001.qxd Page 18
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 19
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
19
by target structure just as RNase H–based antisense drugs [68]. In fact a thorough and direct comparison of the performance of second-generation antisense inhibitors to siRNA showed very comparable ratios of sensitive to insensitive sites and considerable overlap in active sites [69]. Single-strand antisense RNAs behave similarly as well [70]. For less robust mechanisms such as translation arrest or inhibition of splicing, the need to identify an optimal inhibitor is even greater. 1.3.9
Therapeutic Specificity (Therapeutic Index)
Clearly, in a therapeutic context, the ability of an oligonucleotide to bind selectively to specific sequences in nucleic acid targets is an important factor in determining its therapeutic index. However, oligonucleotide analogs can interact with other cellular components, and these interactions can have significant effects on the therapeutic index of oligonucleotides. The factors that determine the significance of nonnucleic interactions of oligonucleotides on the therapeutic index include the affinities for nonnucleic acid sites versus nucleic acids, the numbers of different nonnucleic acid binding sites, the concentrations of each of the binding sites, the biological importance of various binding sites, and kinetic factors. These are, of course, conceptually equivalent to the factors that affect the therapeutic index of drugs of all classes, but very little is understood about these potential interactions [71–73]. Chemical classes of oligonucleotides differ in their tendency to interact with various nonnucleic acid targets. For example, phosphorothioates tend to bind to a wide range of proteins with relatively low affinity [15]. Nevertheless, detailed in vitro and in vivo toxicological studies have shown that these interactions probably reduce the therapeutic index of phosphorothioates less than perhaps was expected [7,72]. We believe that this is because the phosphorothioates bind with very low affinity to a large number of proteins and their potential toxic effects are consequently “buffered.” As previously discussed, improvements in the performance of antisense drugs effected by advances in chemistry, design, mechanisms of action, and screening processes have all been shown to profoundly influence the therapeutic specificity of antisense drugs. 1.4 OCCUPANCY-ONLY-MEDIATED MECHANISMS Classic competitive antagonists are thought to alter biological processes because they bind to receptors, preventing natural agonists from binding and inducing normal biological processes. Binding of oligonucleotides to specific sequences may inhibit the interaction of the RNA with proteins, other nucleic acids, or other factors required for essential steps in the intermediary metabolism of the RNA or its utilization by the cell. 1.4.1
Modulation of Splicing
A key step in the intermediary metabolism of most mRNA molecules is the excision of introns. These “splicing” reactions are sequence-specific and require the concerted action of spliceosomes. Consequently, oligonucleotides that bind to sequences required for splicing may prevent binding of necessary factors or physically prevent the required cleavage reactions. This then would result in inhibition of the production of the mature mRNA. In the past several years, substantial progress has been reported in the discovery of antisense drugs that inhibit splicing and result in alternative splicing. Not surprisingly, the first compelling demonstration that antisense drugs could affect splicing was the restoration of correct splicing in thalesemic pre-mRNA in a cell-free system [74]. Since that observation, a variety of chemically modified antisense drugs have been shown to alter splicing in vitro and in vivo. Obviously, to induce alternative splicing, antisense drugs that do not induce degradation of the target RNA must be used, so fully modified 2-methoxy, 2-MOE, peptide nucleic acid (PNA), morpholino, and fully modified locked nucleic acid (LNA) analogs have been studied (for review, see [75]).
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 20
20
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Although the inhibition of splicing is interesting, alternative splicing is perhaps more exciting because in this setting it is possible to use an antisense drug to induce the production of an alternative protein; in effect to produce “agonist-like” activities. Both the inhibition of splicing and the induction of alternative splicing have been reported for a number of genes in vitro and a few in vivo (for review, see Chapter 4 in this volume). However, alteration of splicing has proven to be very difficult for many genes and no obvious explanation for difference in susceptibility has emerged. Because the use of antisense drugs to alter splicing is reviewed in detail in a subsequent chapter, in this chapter I will address a number of questions concerning the mechanism: 1. Can antisense drugs be used to alter splicing in vitro and in vivo? 2. How is the activity of antisense drugs affected by the a. Strength of splicing signal b. Splicing element to which the drugs binds c. Position of the drug vis-à-vis the splicing element d. Characteristics of the intron or exon e. Presence of exonic enhancers or silencers f. Chemical class or the antisense drug 3. Is it possible to design antisense drugs that affect exonic enhancer or silencer function? 4. Is efficacy influenced by cell or tissue context? 5. How robust a mechanism is alteration of splicing?
1.4.1.1 Can Antisense Drugs Be Used to Alter Splicing in Vitro and in Vivo? Today, there is no question that appropriately designed antisense drugs can alter splicing. The evidence for this is, of course, broader and more compelling in vitro, but there are now also multiple well-documented examples of antisense drugs altering splicing in vivo.
Alteration of Dystrophin Splicing One of the better-characterized examples of alteration in splicing induced by antisense drugs is the exon skipping induced in dystrophin RNA. Dystrophin is an essential protein for the normal function of skeletal and cardiac muscle. The gene for dystrophin is subject to mutations that result in early termination of the protein or frame shift mutations that can result in a dysfunctional protein. When shortened dystrophin is produced, the protein is partially effective and milder muscular dystrophy is observed. As the pre-mRNA for dystrophin has a large number of introns, the goal has been to induce exon skipping, thereby avoiding the frame shift mutations that result in a shortened form of the protein. A number of laboratories have reported that 2 methoxy and morpholino oligomers induced altered splicing in vitro and in vivo [76–80]. Indeed, in dystrophic mice, induction of alternative splicing with a morpholino antisense drug resulted in improved muscle performance.
B-Cell Lymphoma/Leukemia Cell x (Bc1-x) The Bc1-x gene can result in the production of either a long or short form of the protein and this is effected by use of an alternative splice site. Bc1-x long inhibits apoptosis while Bc1-x short induces apoptosis. 2-MOE antisense agents were shown to induce the production of Bc1-x short in malignant cells and this resulted in apoptosis [81,82].
Alteration of Splicing in -Globin RNA The Kole Laboratory has developed a transgenic mouse that expresses green fluorescent protein and has a -globin intron with an aberrant splice site. When the aberrant splice is blocked, normal splicing ensues and green fluorescent protein is produced and easily detectable in mouse tissues.
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 21
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
21
These investigators used this model to demonstrate that 2-MOE and 4-Lysine PNA antisense agents could potently induce alternative splicing of the transgene while morpholinos were less potent [83].
MyD88 MyD88 is an adapter protein through which proinflammatory cytokines signal. In a very thorough study, the authors demonstrated that 2-MOE antisense agents could alter splicing of MyD88 in vitro and in several tissues in vivo [84]. This was associated with reduced interleukin 1 beta (IL-1) signaling in vitro and in vivo.
1.4.1.2 How Is the Activity of Antisense Drugs Affected by the Strength of the Splicing Signal? Both 5 and 3 splicing signals are degenerate in mammalian cells and numerous factors influence the relative efficiency of splicing of different introns. Some of these factors include the strength of the 5 and 3 splice sites, the characteristics of the polypyrimidine tract, the size of the intron, the guanosine cytosine (GC) content of the intron, the presence of exonic enhancers and silencers, and the affinity of the two exonic sequences adjacent to the intron for each other (for review see [85]). To some extent, it may be simpler to define the strength of the 5 splice site than other sites. Based only on the sequence of the 5 splice sites itself, 5 splice sites have been divided into strong, intermediate, and weak. The strength of the splice site correlated with the complementarity to the terminus of uridine-rich RNA 1a (U1a RNA) [86]. Only for the weak 5 splice sites did factors other than the sequence of the splice site play a role. In contrast, the efficiency of 3 splice sites appears to be related to the strength of the splice signal, the GC content of the intron, the position and strength of the polypyrimidine tract, and the presence of exonic regulatory elements. Even considering all these factors, the correlations with predicted rates of splicing are only modest [87]. Thus, it is clear that attempting to evaluate the effects of the efficiency of a particular splicing event on the activity of antisense drugs is likely to be challenging. Indeed, that has proven to be the case. To begin to address the effects of splice-site strength on the activities of antisense inhibitors, some years ago we [88] constructed a luciferase receptor gene with -globin or adenovirus introns. Mutating the weaker splice signals in the -globin construct progressively toward the stronger adenovirus signals progressively increased the extent of splicing. Inhibition of splicing was greater when the weaker splice sites were targeted. On the basis of these studies, we suggested that introns with weaker splicing signals might be more sensitive to antisense inhibition. In a thorough examination of multiple introns in dystrophin pre-mRNA, the effects of one hundred and fourteen (114) 2 methoxy antisense inhibitors designed to bind to different sites and induce skipping of many different exons were evaluated [76]. Although there was substantial variability in the ease with which different splicing of events were inhibited, very little correlation between the strength of splice sites and activity was observed. Antisense agents designed to bind to 3 splice sites and branch points were reported to be ineffective. A detailed analysis of antisense agents designed to cause skipping of exon 23 in the dystrophin pre-mRNA also showed that the 5 splice site, but not the 3 splice, was sensitive to the effects of these agents [77]. In contrast, in other pre-mRNA targets, antisense agents designed to bind to either 5 or 3 splice sites were effective [83,84]. On the basis of all the results available then, it appears that alteration in splicing can be achieved by binding to either 5 or 3 splice sites, but there is great variability in the results. In fact, in unpublished studies focused on eIF-4E and survivin, in which we have thoroughly evaluated 5 and 3 splice sites, again, activities were observed at both splice sites. Figure 1.8 exemplifies our experience. In this study, 20-nucleotide full 2-MOE antisense agents were designed to bind to various regions of the 5 and 3 splice junctions in various pre-mRNA, cells were treated, and the induction of splice-variant RNA species evaluated. For MCL-1, inhibitors of both the 5 and 3 splice sites were effective, with the 5 splice site being slightly more susceptible. In contrast, for
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 22
22
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION Acceptor
Donor
Intron
Exon
0
Intron
0
5′ Splice site ASOs
3′ Splice site ASOs
utc
MCL-1
mMyd88
hMyd88
ERalpha exon4
IL4
Syk
Figure 1.8
Effect of 2 MOE ASOs on RNA splicing. A schematic representation of targeting strategy. A series of 5 ASOs were designed to the acceptor or donor site of the exon targeted for skipping. Number indicates ASO start site relative to the intro/exon junction. All ASOs are 20 nucleotides in length and have 2 MOE ASOs targeted to exon splice sites at a single concentration of 200 nM for 4 h using Lipofectin Reagent. ASO was removed and fresh media added to cells. Following overnight incubation, cells were harvested and total RNA purified using RNeasy mini columns (Qiagen). Standard RT-PCR analysis of mRNA was preformed using PCR primers complementary to exonic sequence bracketing the targeted exon. Of total RNA, 5 g were reverse-transcribed in the presence of oligo(dT) using SuperScript II reverse transcriptase according to the manufacturer’s protocol (Invitrogen Life technologies). Following a 1-h incubation at 42°C, the cDNA was diluted by the addition of 80 l of water. Three microliters of the diluted cDNA were combined with 15 l of HotStarTaq mix (Qiagen) and 2.5 l each of 10 uM forward and reverse PCR primer in a final volume of 30 l. The PCR was cycled 30 s at 94°C, 30 s at 72°C, and 2 min at 60°C with 35 repetitions. Products were visualized by electrophoresis on 2% agarose gels stained with ethidium bromide.
splicing in mouse and human, MyD88, only the 3 splice site was susceptible. For the other targets, both 5 and 3splice sites were sensitive with slight differences in sensitivity between the two sites. So both the 5 and 3 splice sites are amenable to the effects of antisense drugs. Is there then a pattern of sensitivity with regard to the strength of the splicing signal? If there is, it is certainly neither obvious nor universal. One of the problems, of course, is deciding how strong a splice signal is. Using the classification of 5 splice sites proposed by Roca et al. [86], no pattern in responsiveness as a function of splice signal is evident in published data, nor in unpublished information at
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 23
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
23
Isis involving many targets. Although it is even more difficult to assign a “strength” value for 3 splice sites, certainly no pattern emerges [89]. What about more complex approaches to assignment of “strength” to splice sites? A good example derives from studies on estrogen receptor (ER). ER has 8 exons. Skipping of each of the exons has been observed naturally, as has skipping of several exons simultaneously [90]. Because all the splice sites are relatively homologous to consensus sites, a statistical evaluation of sequences 60 nucleotides upstream and downstream of the splice sites was used to assess relative “strength.” Relative strengths of splice signals were then compared to the frequency with which an intron was skipped naturally. Although the correlation was very limited, the study suggested that something abut the intron–exon junctions around exon 4 encouraged more alternative splicing. We evaluated the ability to alter splicing of three introns in ER (Figure 1.9). In this experiment, we evaluated five 2-MOE inhibitors positioned around the 5 and 3 splice sites of these exons. Figure 1.9 shows that for the frequently alternatively spliced exon 4 that had an intermediate “strength” of splice signal, potent inhibitors were found. In contrast, exon 7 is also frequently alternatively spliced as is shown in Figure 1.9, but no inhibitors were found.
Acceptor
(a)
Donor
Intron
Intron
Exon
0
0
5′ Splice site ASOs
(b) utc
3′ Splice site ASOs 0
0
ER-alpha exon7
ER-alpha exon5
ER-alpha exon4
Figure 1.9
Effects of 2 MOE ASOs on estrogen receptor alpha RNA splicing. (a) Schematic representation of targeting strategy. A series of 5 ASOs was targeted to the acceptor or donor site of the exon targeted for skipping. Numbering indicates ASO start site relative to the intron/exon junction. All ASOs are 20 nucleotides in length and have 2 MOE sugar modifications with phosphorothioate linkages at all positions. (b) MCF-7 cells were treated with 2 MOE ASOs targeted to exon splice sites at a single concentration of 200 nM for 4 h using Lipofectin Reagent. ASO was removed and fresh media added to cells. Following overnight incubation, cells were harvested and total RNA purified; then standard RT-PCR analysis of mRNA was preformed using PCR primers complementary to exonic sequence bracketing the targeted exon as detailed above.
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 24
24
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Exon 5 is also frequently alternatively spliced, has a high “strength score” and no inhibitors were identified. On the basis of all the data, we can therefore conclude the following: ●
● ●
The ability to alter splicing of different introns by antisense drugs is variable and no obvious rules have emerged. Both 5 and 3 splice sites are amenable to effects of antisense drugs. There is no correlation between strength of splice sites or propensity to undergo alternative splicing, and the effectiveness of antisense modulation of splicing is apparent.
1.4.1.3 Does the Position of the Antisense Drug at a Splice Site Affect the Activity of the Antisense Drug? The answer to this question is unequivocally yes. This conclusion is supported by an evaluation of published data and exemplified by the data shown in Figure 1.8. Although effectiveness appears to vary as a function of the position of the 20-nucleotide antisense agents vis-à-vis the splice junctions for all targets, the only generalization supported by the observations is that agents that bind to or are adjacent to the junction and extend some distance into the intron or exon tend to be more effective than those that do not include the splice junction.
1.4.1.4 Do the Characteristics of Introns or Exons Affect the Activities of Antisense Agents? Given the wide variation in responsiveness of introns to alteration of splicing by antisense drugs and the lack of obvious explanations for this provided by in the characteristics of the splice site, it is obvious that other intronic or exonic characteristics must contribute [89,90]. However, no generalizations are feasible based on available data. For example, we evaluated the three ER exons shown in Table 1.1 for the presence of several putative exonic splicing enhancers (ESEs). At the 5 and 3 ends of the exons to which the splice antisense agents would have bound, all three exons were endowed with a number of putative ESEs, yet there was no obvious difference that could explain the ease of induction of skipping of exon 4 versus the other exons. Of course, it may be that the putative ESEs are, in fact, not functional or that antisense binding to the SF2 ESE is somehow unique. Nevertheless, based on evidence available today, the identification of ESEs within the binding site of antisense agents designed to bind to splice junctions results in no obvious guidance with regard to the design of the drugs.
Table 1.1
Predicted Exonic Enhancer Sequences in Estrogen Receptor 5 ESE sites
3 ESE sites
Target
SF2/ASF Thr 1.956
SC35 Thr 2.383
SRp40 Thr 2.67
SRp55 Thr 2.676
SF2/ASF Thr 1.956
SC35 Thr 2.383
SRp40 Thr 2.67
SRp55 Thr 2.676
ER-alpha E4 ER-alpha E5 ER-alpha E7 mMyD88 hMyD88 Syk MCL-1 IL-4
3.233 N N 2.786 2.786 4.018 N 2.922
2.893 N 3.321 3.867 3.299 3.850 N N
3.009 2.995 N N 3.830 2.863 2.762 N
Na 3.405 N 2.858 3.366 N 3.831 N
2.506 N 4.065 3.122 4.115 3.407 N 3.411
N 3.721 2.476 3.186 3.186 4.956 2.572 2.711
3.455 N 3.526 3.176 3.280 3.585 N 2.692
N N 4.087 N N 2.908 N 3.831
Note: ESEfinder was used to locate putative exonic splicing enhancers within or overlapping the first or last 20 bases of each exon. Scores are given for ESEs with values above the threshold for each sequence element. The thresholds are values above which a score for a given sequence is considered to be significant (high-score motif). Where more than one ESE was found for given sequence element, only the highest score has been given. a ESE absent [89].
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 25
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
25
1.4.1.5 Can Antisense Agents Designed to Bind Exonic Enhancer or Silencer Sequences Affect Splicing? The answer to the question is yes. Perhaps the most thorough study reported to date examined the effects of a number of 2-MOE antisense agents that targeted exonic regulatory sequences in the pre-mRNA of the spinal motor neuron 2 (SMN2) gene [91]. Several agents were shown to either induce or inhibit exon inclusion.
1.4.1.6 Does Chemical Class Influence Activity? Both in vitro and in vivo, the answer to this question is yes. Analyses of in vitro data are more robust both because there are more data and because differences in pharmacokinetic and toxicologic properties are less likely to influence the results. Activities have been observed for fully modified 2 methoxy, 2-MOEs, 4-Lysine and 8-Lysine PNAs, and morpholinos. As a general rule, in vitro potencies correlated with relative affinities for RNA: PNA2-MOEmorpholinos2 methoxy [76–84]. Only modest experience has been reported in vivo. Nevertheless, 2 methoxy, 2-MOEs, morpholinos, and Lysine PNAs have been shown to be active [76–84]. Direct comparisons have again suggested that affinity for target RNA is the critical determinant although differences in pharmacokinetics complicate the analyses. 1.4.2
Translation Arrest
Translation arrest is defined as the inhibition of translation secondary to binding (and not inducing cleavage) of an antisense drug to a target RNA in a fashion that inhibits the translation of the message into protein. Because polysomes are capable of “melting” structures in RNA, inhibitors of translation have typically interacted with the 5-UTR, or the translation initiation codon, or an internal ribosome entry (IRE) sequence (for review, see [7,15]). However, antisense inhibitors designed to bind to sites in coding sequences have also been shown to be active. Here again, meaningful progress has been reported and significant questions remain to be answered.
1.4.2.1 Is It Feasible to Arrest Translation with Antisense Drugs? Yes. Translation arrest can be induced by a variety of chemical classes of antisense drugs in vitro and in vivo. Well-documented examples include inhibition of intercellular adhesion molecule 1 (ICAM-1) [92], Hepatitis C virus (HCV) [93–95], and c-Myc [96]. In vivo activities have been reported for targets such as HCV and c-Myc [94–96]. Morpholino antisense drugs designed to inhibit translation have also been studied in the clinic and these results are reviewed in Chapter 20.
1.4.2.2 What Are the Optimal Sites in Target RNAs to Induce Translation Arrest? The 5-UTRs of m-RNAs vary in length from a few nucleotides to hundreds, beginning with a 5 cap [92]. Many m-RNAs also contain internal IREs, thus multiple potential sites outside the coding region may be affected. Several studies have attempted to identify optimal sites in target RNAs for translation arrest. For example, in a study on Hepatitis C viral core protein production in hepatocytes, a 2-MOE antisense agent designed to the translation initiation codon did not inhibit protein production while another antisense drug designed to bind to a loop in the 5-UTR was effective [97]. In a more detailed study, multiple 2 methoxy antisense agents were designed to bind a variety of sites in the 5-UTR and the coding region of the core protein. The effects were evaluated in a cell free protein synthesis assay and in hepatocytes [93]. Binding to several sites in the UTR, the translation initiation codon and in the open reading frame resulted in inhibition of core protein synthesis, but the most effective inhibitors were all located near the translation initiation site. In fact, effectiveness declined dramatically as the binding sites were shifted a few nucleotides into the coding sequence from the translation initiation codon.
CRC_8796_ch001.qxd
26
5/24/2007
21:54
Page 26
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
In contrast, for mammalian m-RNAs, most studies have suggested that binding in the 5-UTR tends to be more effective. For example, the inhibition of the translation of ICAM-1 was effected by binding antisense agents to the 5 cap [91]. In this interesting study, the level of ICAM-1 RNA actually increased in the cytoplasm and was associated with subpolysome functions rather than polysomes, suggesting that entry into the polysome cycle was inhibited by binding the antisense drug to the 5 cap. Also of interest was the observation that binding to the area of the m-RNA adjacent to the cap had no effect on the splicing of the first intron.
1.4.2.3 What Is the Influence of Chemical Class on Activity? Very little work has been reported with regard to this question, but two studies [92,93,98] have evaluated the effects of various fully 2-modified oligonucleotides. Although the correlation is not perfect, if the results from studies with the relatively unstable 2 fluoro (2 F) analog are excluded, there is a trend toward increasing potency with increasing affinity for target RNA.
1.4.2.4 How Robust Is Translation Arrest? Given the amount of work reported on translation arrest, a definitive conclusion about the robustness of the mechanism versus cleavage-moving mechanisms is not possible. However, it is clear that significantly less sequence space is available to antisense agents designed to inhibit translation splicing and the ratio of actives to inactives is lower than for cleavage-based mechanisms. However, in the one study that directly compared translation arrest to RNase H–based target RNA cleavage, potencies were roughly equivalent in vitro [92]. 1.4.3
Disruption of Necessary RNA Structure
RNA adopts a variety of three-dimensional structures induced by intramolecular hybridization, the most common of which is the stem loop. These structures play crucial roles in a variety of functions. They are used to provide additional stability for RNA and as recognition motifs for a number of proteins, nucleic acids, and ribonucleoproteins that participate in the intermediary metabolism and activities of RNA species. Thus, given the potential general utility of the mechanism, it is surprising that occupancy-based disruption of RNA structure has not been more extensively exploited. As an example, we designed a series of oligonucleotides that bind to the important stem-loop present in all RNA species in human immunodeficiency virus (HIV), the transactivating region (TAR) element. We synthesized a number of oligonucleotides designed to disrupt TAR, and showed that several indeed did bind to TAR, disrupt the structure, and inhibit TAR-mediated production of a reporter gene [99,100]. Furthermore, general rules useful in disrupting stem-loop structures were developed [101]. Although designed to induce relatively nonspecific cytotoxic effects, two other examples are noteworthy. Oligonucleotides designed to bind to a 17-nucleotide loop in Xenopus 28 S RNA required for ribosome stability and protein synthesis inhibited protein synthesis when injected into Xenopus oocytes [102]. Similarly, oligonucleotides designed to bind to highly conserved sequences in 5.8 S RNA inhibited protein synthesis in rabbit reticulocyte and wheat germ systems [103].
1.5 OCCUPANCY-ACTIVATED DESTABILIZATION RNA molecules regulate their own metabolism. A number of structural features of RNA are known to influence stability, various processing events, subcellular distribution, and transport. It is likely that as RNA intermediary metabolism is better understood, many other regulatory features and mechanisms will be identified.
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 27
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
1.5.1
27
5 Capping
A key early step in RNA processing is 5 capping (Figure 1.2). This stabilizes pre-mRNA and is important for the stability of mature mRNA. It also is important in binding to the nuclear matrix and transport of mRNA out of the nucleus. Since the structure of the cap is unique and understood, it presents an interesting target. Several oligonucleotides that bind near the cap site have been shown to be active, presumably by inhibiting the binding of proteins required to cap the RNA. For example, the synthesis of Simian virus 40 (SV40) T-antigen was reported to be most sensitive to an oligonucleotide linked to poly-L-lysine that targeted the 5-cap site of RNA [102,104]. However, again, in no published study has this putative mechanism been rigorously demonstrated. In fact, in no published study have the oligonucleotides been shown to bind to the sequences for which they were designed. In studies in our laboratory, we have designed oligonucleotides to bind to 5 cap structures and identified reagents to cleave the unique 5 cap structure [105]. These studies demonstrated that 5-cap-targeted oligonucleotides were capable of inhibiting the binding of the translation initiation factor eIF-4. 1.5.2
Inhibition of 3-Polyadenylation
In the 3-UTR of pre-mRNA molecules, there are sequences that result in the posttranscriptional addition of long (hundreds of nucleotides) tracts of polyadenylate. Polyadenylation stabilizes mRNA and may play other roles in the intermediary metabolism of RNA species. Theoretically, interactions in the 3-terminal region of pre-mRNA could inhibit polyadenylation and destabilize the RNA species. Although there are a number of oligonucleotides that interact in the 3-UTR and display antisense activities [106], to date, only one study has reported evidence for alterations in polyadenylation. In this study [106], fully modified 2-MOE antisense regents caused polyadenylation to be redirected, increasing RNA stability and enhanced protein synthesis. This study certainly merits attention and follow up because the mechanism offers the potential to create antisense agents that selectively increase expression of a protein. 1.5.3
Other Mechanisms
In addition to 5 capping and 3 adenylation, there are clearly other sequences in the 5- and 3-UTRs of mRNA that affect the stability, localization, and translatability of the molecules. Again, there are a number of antisense drugs that may work by interfering with these processes, but no studies that confirm these possibilities have been reported. 1.5.4
RNase H
Without question, the RNase H mechanism has proven to be the most robust mechanism identified and characterized to date. The experience with first- and second-generation RNase H–based antisense drugs in vitro and in vivo exceeds by many fold the total experience with drugs of all other mechanisms. Several thousand humans have been treated with first- and second-generation RNase H–based antisense drugs. Again, this experience dwarfs the combined experience with antisense drugs designed to work through other mechanisms (for review, see 9; Chapters 2, 3, and 4; and Part 4 of this volume), and this mechanism is reviewed in considerable detail in Chapter 2 of this volume. In this chapter, I will address a number of questions about the RNase H mechanism and consider future experiments. The RNases H cleave RNA only in RNA–DNA duplexes. In human cells, two RNases H have been identified, cloned, and expressed (for review, see [107,108] and Chapter 2 in this volume). We have characterized the enzymological properties of human RNase H1 and to a lesser extent those of human RNase H2 (for review see chapter 2 of this volume). We have demonstrated that the antisense effects
CRC_8796_ch001.qxd
28
5/24/2007
21:54
Page 28
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
of DNA-like antisense drugs in cells and animals are due strictly to the activities of RNase H1, even though RNase H2 is substantially more abundant. We have demonstrated that RNase H2 is not involved in the effects of DNA-like antisense drugs because it is inaccessible to the oligonucleotide RNA duplexes formed, probably because it is bound to chromatin (Chapter 2, this volume and [107–109]).
1.5.4.1 Do Antisense Drugs That Use the RNase H Mechanism Work? Yes. In vitro, in vivo, and in humans RNase H–based antisense drugs have produced impressive pharmacological effects in a wide range of cells and tissues when given by a wide range of routes of administration (for review, see [9] and this volume). In fact, in studies in our laboratories on more than 4000 genes, we have never failed to identify multiple potent and selective RNase H–based actives for any target.
1.5.4.2 What Sites in Target RNAs Are Accessible to RNase H–Based Antisense Drugs? Figure 1.7 shows results form an in vitro screen for RNase H–based active sites. Obviously, sites throughout the pre-mRNA are accessible to RNase H1–based antisense drugs. Despite the vast experience in designing and testing RNase H–based antisense drugs, no rules or guides have emerged that enable selection of optimal sites in target RNAs to which to bind to. Thus, we continue to screen against a large number of sites throughout the target RNA as shown in Figure 1.7. That no rules for site selection have emerged despite the enormous experience confirms that the interaction of oligonucleotides with target RNA and the recruitment and activation of RNase H1 are complex processes governed by many factors that are inadequately understood. The demonstration that sites in pre-mRNA and mature mRNA appear to be equally amenable to the effects of RNase H–based antisense drugs is consistent with the observations that human RNase H1 is present in the nucleus, cytosol, and mitochondria (for review, see [15,108,109] and Chapters 2 and 10 in this volume). As we have demonstrated that recruitment of RNase H1 to the antisense drug–RNA duplex is limiting [109], it is likely that in addition to the access of the antisense drug to a site in a target RNA, the access and relative activity of human RNase H1 at the site of drug binding to the duplex is critical. Human RNase H1 consists of an RNA-binding domain, a spacer region, and a catalytic domain (Figure 1.10) (for review, see [110,111] and Chapter 2 in this volume). Two Lysines and a tryptophan in the RNA-binding domain position the enzyme at the first DNA/RNA nucleotide and the catalytic domain cleaves approximately one helical turn from the binding site. The enzyme displays little sequence preference, but within a particular site the enzyme displays preferred cleavage sites. Thus, for any site to be affected by human RNase H1, a binding site and a site with appropriate characteristics to support cleavage must be separated by one helical turn from the RNA binding site. Therefore, a number of sites that might be accessible to antisense drugs might not be optimal sites for RNase H1 resulting in variations in potency. The use of second-generation antisense drugs exaggerates the potential effects of site selection as shown in Figure 1.11. Consequently, the substantial variations in potency from site to site are easily explained. Until much more is known about the influence of sequence on protein binding and subtle changes in RNA structure, it is very unlikely that more sophisticated rules for site selection will be developed, i.e., screening to identify optimal sites will remain essential. Perhaps a more interesting question is why so many sites are amenable to RNase H1–mediated cleavage. The answer to this question awaits much more research. We know that RNase H1 is active as a monomer in contrast to RNase H2, which is only active in a complex of several proteins. We also know that RNase H1 is present in multiprotein complexes, but do not know the identity of any of the RNase H1–associated proteins. Perhaps the associated proteins facilitate access and the induction of the appropriate RNA conformation to support activity.
3
4
5
Nucleus
RNase H
DNA
Nucleus
RNase III
mRNA
Helicase
RISC
3
4
Antisense strand
5
Cytoplasm
Figure 1.10 Schematic showing a simplified view of RNase H and siRNA mechanisms. The left panel shows a single-stranded DNA-like antisense oligonucleotide entering a cell, interacting with its target RNA in the cytoplasm or nucleus of a cell, and then recruiting RNase H1. The right panel shows an siRNA duplex entering a cell, the duplex entering the siRNA pathway, the sense strand being removed, and the RISC complex cleaving the target RNA.
DNA
mRNA
2
2
1
21:54
RNase H
1
Cell membrane
Sense strand
siRNA antisense mechanism
5/24/2007
Cytoplasm
Cell membrane
Antisense strand
RNase H antisense mechanism
CRC_8796_ch001.qxd Page 29
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION 29
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 30
30
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
RNA-BD
Cat
5′ 3′
mRNA ASO
Figure 1.11 Schematic of potential interactions of human RNase H1 with a 2-MOE- chimeric antisense drug mRNA duplex. Because RNase H1 is unable to cleave RNA opposed to a 2-MOE modified nucleotide and because subtle conformational changes due to sequence differences result in preferred cleavage sites, the extent of cleavage can vary substantially from site to site in a target RNA.
1.5.4.3 Can Information about the Enzymology of RNase H1 Be Used to Improve the Performance of RNase H–Based Drugs? Yes. This topic is dealt with in considerably more detail in Chapter 2 of this volume. Suffice it to say, we have shown that by extending the RNase H gap and introducing modifications at the junctions of the MOE wings and the gap, we can improve potency [110,112]. For example, we have shown that a gap-widened version of a 2-MOE chimeric antisense inhibitor of phosphatase and tensin homolog deleted on chromosome ten (PTEN) was significantly more potent in reducing liver PTEN RNA than the parent second-generation antisense drug when administered to mice [111]. Although the extent to which the potency may be increased varies, several of these “generation 2.2” analogs are progressing toward clinical trials.
1.5.4.4 How Robust a Mechanism Is RNase H? The RNase H mechanism is remarkably robust. At Isis alone, RNase H–based inhibitors to as many as 4000 genes have been identified. With second-generation antisense inhibitors, the active to inactive ratio in vitro is typically 1 or greater. Thorough studies comparing second-generation RNase H–based inhibitors to siRNA in vitro have demonstrated that the two approaches result in approximately the same hit rates and similar potencies at most sites [69]. However, for scientists without ready access to 2-MOE chimeric antisense agents, siRNA is probably a more efficient and easier-to-use approach for in vitro gene functionalization (e.g., see [113]). The fact that there is considerable overlap in active sites in target RNAs for 2-MOE second-generation antisense inhibitors and siRNA (Figure 1.12) suggests that access to human RNase H1 and to the RISC complex in the cytoplasm to target RNAs must be similar. More important, there is substantial experience with RNase H–based first- and second-generation antisense drugs in animals and in man. Second-generation 2-MOE antisense inhibitors have proven to be potent and versatile gene-selective inhibitors in vivo. As their pharmacokinetic and toxicological properties are well defined, the design of appropriate controls and interpretation of the results of in vivo experiments are relatively straightforward (for review, see [10–12,114] and Part 3 of this volume). Moreover, they can be administered by multiple routes [115]. Finally, they display important activities in clinical trials (for review, see Part 3 of this volume). Another important consideration with regard to the “robustness” of an antisense mechanism is how well in vitro results obtained with agents that work via the mechanism in question correlate with in vivo observations. We have had the opportunity to address this question in a number of ways and in several species, but the most complete data set compares the potencies of RNase H–based antisense drugs in reducing target RNAs in vitro to their potencies with regard to reducing target RNA levels in the liver of mice treated systemically with the drugs. One interesting means to evaluate this is to systematically adjust the potency of antisense drugs either by introducing mismatches or by introducing chemical modifications, then comparing the rank order potency in vitro versus in vivo. For example, the potency of first-generation RNase H–based
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 31
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
RNA-BD Cat 5′ 3′
31
mRNA ASO
Fast
or
I
RNA-BD Cat
5′ MOE 3′
II 5′ MOE 3′
mRNA MOE
ASO
Fast
RNA-BD Cat
mRNA MOE
Slow
ASO
Figure 1.12 Schematic showing the RNA binding, spacer, and catalytic domains of human RNase H1 and their interactions with an mRNA antisense drug duplex.
inhibitors to c-Raf kinase was varied by introducing mismatches; then the rank order potency in vitro was compared to that observed for reducing c-Raf kinase in RNA levels in mouse livers. There was a one-to-one correlation [116]. These observations have been repeated many times with other targets and other sets of antisense agents. Further, we compared the activities of 129 RNase H–based antisense drugs targeted to 63 different genes in vitro to their relative potencies in reducing the same target RNA in mouse livers after systemic administration. The correlation was highly statistically significant ( p 0.001). Thus, the RNase H mechanism has proven to be extraordinarily robust in vitro and in vivo, and as growing data suggest, in the clinic. In fact, the robustness of the mechanism is even more remarkable on reflection. We know that only RNase H1 is involved in this mechanism. We have shown that although it is expressed ubiquitously, the concentration of RNase H1 in cells is very low [117]. Moreover, phosphorothioate antisense drugs are highly effective competitive antagonists to human RNase H1 [118]. Despite this, for many targets, RNase H–based antisense drugs can reduce the levels of target RNAs by as much as 90%. Why is not the top part of the dose–response curve lost if phosphorothioate-modified oligonucleotides are such effective inhibitors of human RNase H1? We do not know, but we hypothesize that human RNase H1 is located in a multiprotein complex. Perhaps it is protected from inhibition until it binds to a duplex substrate. We also surmise that for most target RNAs, turnover of the enzyme is not terribly important because of the limited number of copies of most RNAs in cells. These questions should be the focus of future research in addition to continuing to use the understanding about human RNase H to guide the development of antisense drugs that form RNA antisense duplexes that are more attractive substrates for human RNase H1. 1.5.5
Double-Strand RNase (siRNA)
In 1998, using stabilized single-strand and duplex oligoribonucleotides, we reported that dsRNases in cells and tissues could degrade RNA–RNA-like duplexes [38]. We also showed that nuclear and cytoplasmic homogenates could degrade RNA–RNA-like duplexes and partially purified the enzyme involved. Subsequently, such activities in mammalian cells were shown to be mediated, at least in part, by the siRNA pathway [70]. The identification of the siRNA pathway in mammalian cells has led to the emergence of the use of siRNAs for gene functionalization, target validation, and therapeutic purposes, and to the elaboration of exciting new areas of cell biology. Chapters 3, 15, and 16 of this volume provide detailed reviews of the
CRC_8796_ch001.qxd
32
5/24/2007
21:54
Page 32
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
pathways and progress in the development of siRNA therapeutics. In this chapter, our goals are to the following: Mechanistically compare and contrast the siRNA mechanism to the RNase H–based mechanism. Consider some of the unique opportunities and challenges presented by the siRNA pathway with regard to the therapeutic potential of siRNAs. Consider some of the challenges of using duplex RNAs as therapeutics and potential solutions to these issues.
● ●
●
1.5.5.1 siRNA and RNase H Mechanisms Are Similar The goal of both RNase H–based and siRNA antisense inhibitors is to bind to target RNAs via Watson and Crick hybridization and recruit a cellular nuclease that will degrade the targeted RNA (Figure 1.13). Antisense drugs designed to work via the RNase H mechanism are single-stranded and must have a DNA-like portion that serves as the antisense strand of the duplex that becomes a substrate for RNase H1. As RNase H1 is present in both the nucleus and cytosol, it is possible for these antisense agents to work in both cellular compartments and on sites in the RNA that are excised in the nucleus or are present in the mature m-RNA. siRNA activities are typically effected with duplex RNAs. The simplest way to think of the sense strand is that it meets the basic definition of a drug delivery device: it is used to enhance the stability of the drug, the antisense strand, and the delivery of the antisense strand to the site of
120
90
60
30
0
19 57 197 314 421 494 671 757 817 891 952 1106 1169 1262 1342 1418 1504 1541 1694 1792 1855 2020 2098 2180 2268 2347 2403 2523 2598 2703 2765 2806 2844 2950 3037 3088
Relative mRNA expression (qRT/PCR)
150
Target site start position Figure 1.13 Phosphatase and tensin homolog deleted on chromosome ten (PTEN) oligonucleotide screen. A series of 36 chimeric RNase H–dependent oligonucleotides and a series of corresponding siRNA duplexes were administered to T24 cells in the presence of Lipofectin Reagent. Sixteen hours later, total RNA was harvested and PTEN mRNA levels assessed by qRT/PCR as detailed in Materials and Methods. Results are the percent PTEN mRNA relative to untreated control. Solid bars: chimeric RNase H–dependent oligonucleotides; striped bars: siRNAs.
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 33
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
33
action, RISC. Unfortunately, it is not yet an optimal drug delivery device because it is not pharmacologically inert and is metabolized to potentially pharmacologically active metabolites. Once the sense strand is removed, the antisense strand is used by the RISC complex to degrade the target RNA. It has been suggested that RISC is localized in the cytoplasm, so siRNA drugs are assumed to work in the cytoplasm. Thus, in both cases, hybridization-based drugs are designed to exploit normal cellular processes to effect cleavage of target RNA. Thanks to the extraordinary progress in understanding the RISC mediated pathways, we know more about the cellular functions and pathways with which siRNAs may interact than RNase H–based antisense drugs, but obviously RNase H has cellular functions and participates in pathways including those involved in de novo and repair DNA synthesis and probably others (for review, see Chapter 2). Similarities between RNase H–based and RISC-based mechanisms extend beyond both simply being RNA cleavage mechanisms. As was discussed previously, both require access to RNA and display similar patterns of sites of activities in target RNAs [119–121]. Both are influenced similarly by RNA structure [119–121]. The variations between the potencies for the most sensitive versus least sensitive sites in RNA are roughly comparable [119]. In fact, eIF2c2, the RISC effector, is an RNase H–type enzyme and generates cleavage products with 5 phosphates and 3 hydroxyls [122,123]. Both mechanisms are quite robust in vitro despite the fact that human RNase H1 and eIF2c2 are present in low amounts in cells. Finally, oligonucleotides that employ both mechanisms can be chemically modified with similar modifications, albeit at different positions and with somewhat different results (for review, see [124–129] and Chapter 15 of this volume). There are also important differences between the RNase H and RISC-based mechanisms.
1.5.5.2 RISC-Mediated Pathways One of the most important differences between the RNase H–based mechanism and the RISCbased mechanism is that pathways can be induced by activation of RISC or other pathways that may be induced by double-strand RNA molecules are remarkably more diverse that those associated with RNase H. In fact, the siRNA-associated pathways are extraordinarily complex and our understanding of the pathways evolves almost monthly as new data are reported. These pathways will be reviewed in much more detail in Chapter 3 and other chapters of this volume. The purpose of this discussion is to highlight therapeutic issues and opportunities related to the diverse siRNA pathways and the pleitropic effects that they may mediate. In contrast to RNase H, RISC-mediated pathways are designed to differentially respond to siRNAs that are fully or partially complementary to target RNA and to induce different outcomes (Figure 1.14). Fully complementary siRNAs are thought to induce an initial cleavage by eIF2c2, then subsequent degradation of the target RNA in cytoplasmic bodies. Partially complementary siRNAs may induce target RNA degradation or translation arrest. Thus, cellular responses to siRNAs are much more promiscuous with regard to hybridization and more versatile than those to RNase H–based antisense drugs, offering interesting opportunities and substantial challenges. From a gene functionalization perspective, the potential to affect multiple RNA targets is highly problematic, but the potential to affect the level of synthesis of unintended proteins is even more problematic because of analytical limitations in measuring proteins. From a therapeutic perspective, the potential to induce multiple hybridization-based effects through at least two different mechanisms is a cause of substantial concern and will require very careful experimentation and controls to (1) define the mechanism by which pharmacological effects are induced and (2) ensure the safety of each siRNA drug candidate. Moreover, since such effects may be very species-specific (if not cell- and tissue-context dependent), they influence considerations about the design of preclinical toxicological evaluation.
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 34
34
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Programmed RISC
Programmed GW182 RISC
Full complement
eIF2C2
eIF2C2
5′
mRNA
guide
Partial complement
or
? Programmed RISC
Programmed RISC eIF2C1 eIF2C3
Programmed RISC
GW182
eIF2C1/2/3/4 eIF2C2
eIF2C4
Guide or
Guide
Guide or
5′ ?
Arrest
Degrade
Programmed RISC
Programmed RISC
eIF2C1/2/3/4
eIF2C1/2/3/4
Programmed GW182 RISC
GW182
Dcp1
eIF2C2
5′ Exosome
5′
5'
Dcp2
Deaden.
Helicase ?
XRN1
Ski2 / 3 / 8
Ribosome Cytoplasmic bodies Figure 1.14 RISC Pathway Programmed RISC contains guide (antisense) strand bound to the slicer enzyme eIF2c2. Guide strand exhibiting full complementarity (siRNA) or partial complementarity (miRNA) hybridize to target mRNA and the glycine/tryptophan-rich GW182 RNA-binding protein localizes programmed RISC to cytoplasmic bodies [168]. eIF2c2 of programmed RISC containing siRNA guide strand cleaves target mRNA. eIF2c2 nicked mRNA is further degraded by the 5 → 3 exonuclease XRN1 and 3 → 5 exonuclease of the exosome in cytoplasmic bodies [169]. Exosome cofactors SKI2, 3, and 8 of yeast have also been shown to be important for the degradation of the nicked mRNA [169]. Target mRNA bound to programmed RISC containing miRNA guide strand is degraded in the cytoplasmic bodies by deadenolases and the decapping enzymes DCP1 and 2 [170,171]. Alternatively, target mRNA bound to programmed RISC containing miRNA guide strand promotes ribosomal drop-off, resulting in translational arrest [172].
1.5.5.3 RISC-Mediated Pathways Are Promiscuous with Regard to Hybridization-Based Off-Target Effects Although effects on target RNAs that have sequences that are partially complementary to the desired target are observed on occasion with RNase H–based antisense drugs, this has proven to be a very modest issue. In fact, the dominant cause of off-target effects of RNase H–based antisense drugs is interactions with proteins. In contrast, siRNA-mediated systems have evolved to be promiscuous at the level of RNA sequence. This is a unique and potentially very difficult problem with which to contend. In fact, as suggested by Figure 1.14, the RISC complex tolerates a large number of mismatches outside the seed region and still results in translation arrest and/or target RNA cleavage. This is dramatically different from RNase H, which may tolerate a mismatch or two at the 5 or 3 termini, but is intolerant of mismatches of any sort in the cleavage area (for review, see Chapter 2 in this volume). Nevertheless, specific effects for many siRNAs have been reported; there are probably qualitycontrol processes that limit the number of off-target effects. But there are now several reports that
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 35
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
35
demonstrate that hybridization-based off-target effects are common with siRNAs. Two papers published by the same group [130,131] exemplify the challenges related to the promiscuity of siRNAs and the problems of developing an exciting new scientific idea. Despite the common wisdom that all pharmacological agents result in unintended effects and scores of publications dealing with offtarget effects of other hybridization-based drugs, this group initially drew the following conclusion: “These results indicate that siRNA is a highly specific tool for targeted gene knockdown, establishing siRNA mediated gene silencing as a reliable approach to large scale gene functionalization and target validation” [130,131]. One year later, using similar methods but more thorough investigations, the same authors reported very substantial off-target effects that occurred at concentrations near those at which the target RNA was reduced [132]. Such hybridization-based off-target effects have also been reported by other laboratories [133–135]. In one study, RNAs with 3-UTR sequences complementary to the seven-nucleotide seed region of the antisense strand of siRNA (a large number) were affected [133,135]. This problem is exacerbated by the potential for true nonspecific effects that may not be related to promiscuous hybridization but rather other mechanisms such as induction of interferon [134]. Furthermore, a screen of randomly selected siRNAs showed that a number of siRNAs could result in reduced viability of HeLa cells transfected with 10 nM of the siRNAs. The toxicity appeared to correlate with the presence of a four-base-pair motif [136]. The mechanisms that might underlie the cellular toxicity were not identified. That the problems of specificity associated with promiscuous hybridization may not be insurmountable is suggested by one publication in which modifications at position 2 of a siRNA reduced off-target effects [137]. It is also important to remember that the sense strand is capable of hybridization-based effects as well as the antisense strand. Contending with the potential of promiscuous hybridizationbased effects of two stabilized strands will be particularly challenging. However, as siRNAs are modified to enhance nuclease stability and in vivo pharmacokinetics, those modifications are likely to increase protein binding, exacerbating the non-hybridization-based off-target effects. In short, a great deal of very careful pharmacological work is required to minimize these problems. Specifically, we must develop appropriate chemistries and designs to reduce the promiscuity of hybridization-based effects while minimizing non-hybridization-based effects. We must be able to measure both strands in vivo and create sense strands that are relatively rapidly degraded so as to avoid the potential pharmacological effect of the sense strand. Alternatively, the use of stabilized single-strand antisense oligonucleotides may be of value here.
1.5.5.4 siRNAs May Induce Transcriptional Repression siRNAs can induce heterochromatin and gene silencing, i.e., a heritable repression of gene transcription, in all species including humans (for review, see [35,138]). siRNAs may be generated in the nucleus by the action of the RNA-dependent RNA polymerase on single-stranded RNA or by transcription of inverted DNA repeats [35]. These siRNAs can interact with the RITS complex. Activation of RITS can directly methylate DNA or induce methylation of histones, which can methylate DNA [138]. This then leads to the formation of heterochromatin, silencing of the targeted gene, and in some cases spreading of silencing to contiguous genes [139–144]. Exogenous siRNAs complementary to promoter regions of both an integrated reporter gene and an endogenous gene in human cells have also been reported to be capable of transcriptional gene silencing [144]. The transcriptional silencing activity required transport of the siRNA to the nucleus, suggesting that it interacts with the RITS complex in the nucleus. However, RISC and siRNA have now been reported to be present in the nucleus [145], so the effects might have been mediated via nuclear loading RISC and transfer to RITS. What are the implications of transcriptional gene silencing, heterochromatin formation, and spreading for the therapeutic uses of siRNAs and RISC activation? Although it is theoretically possible to avoid promoter sequences, it is also possible that the RITS complex is imprecise in its
CRC_8796_ch001.qxd
36
5/24/2007
21:54
Page 36
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
interactions with nucleic acid sequences. If RITS were to be activated by therapeutic siRNAs, in theory alteration in the genome could result. If the RITS complex displays limited promoter sequence fidelity or if spreading occurs, substantial, entirely unexpected genomic effects could ensue. Thus, until more is understood it seems sensible to attempt to avoid activation of the RITS pathway if possible.
1.5.5.5 siRNAs Have Displayed Activities in Vivo That Are Similar to Those Displayed by RNase H Antisense Drugs—But There Are Also Substantial Differences Gratifying progress has been reported in demonstrating that siRNAs can be active in vivo. However, much remains to be learned before it is clear that siRNAs have properties that will support systemic applications for therapeutic purposes. Unmodified siRNAs designed to reduce TNF superfamily 6 (FAS) message and protein levels were administered to mice via hydrodynamic vein injections. Doses of 2–2.3 mg/kg were administered at 0 h, 8 h, and 24 h; then liver effects were evaluated. Fas RNA and protein were reduced for multiple days after the injections and the mice were protected from ligand-induced hepatitis [146]. These remarkable results may be partially explained by the hydrodynamic injection method. However, it has clearly been shown that unmodified siRNAs are rapidly cleared from blood via glomular filtration and are relatively rapidly degraded in plasma and tissues [147]. Thus, the effects and their prolonged duration are difficult to reconcile with the known pharmacokinetic properties of these chemicals, unless once RISC is loaded, the complex is stable and provides effects for prolonged periods of time. This same group also reported that siRNA bound to a fusion protein that included the fab fragment of an HIV-1 envelope antibody could accumulate in B16 melanoma tumors and reduce tumor growth [148]. Other groups have reported reduction of target RNAs in the livers of mice after delivering unmodified and modified siRNA in liposomes and in the livers of monkeys [149,150]. While these are encouraging results, substantial experience with liposome-formulated oligonucleotides has demonstrated significant limitations including the need to give the drugs by intravenous infusion and significant toxicities. A more important and relevant study was conducted in mice treated with siRNA containing 2 methoxy and partial phosphorothioate modifications and 3 sense conjugated cholesterol. This siRNA was targeted to apoB100 and produced significant reductions in apoB100 and reductions in cholesterol [151]. This work is important because it demonstrates that a chemically modified siRNA duplex can be delivered systemically without liposome formulation and produce effects. However, we have shown multiple times that cholesterol-conjugated oligonucleotides are highly hepatotoxic [152,153]. In conclusion, there is ample evidence of progress toward being able to use siRNAs systemically for therapeutic purposes. However, a great deal of work needs to be accomplished before such approaches can be considered ready for clinical development, in contrast to second-generation RNase H–based antisense drugs.
1.5.5.6 Structural Features and Medicinal Chemistry of siRNAs That it is possible to exploit the RISC pathway using agents that differ substantially from the 21-base-pair duplexes originally shown to be active [154] is now clear. One of our principal areas of focus is to develop stable single-strand RNA-like antisense drugs that can exploit both RISC and non-RISC mechanisms. Our demonstration in 1998 that single-strand stabilized RNA-like antisense agents were active in cells [38] and the demonstration that single-strand antisense RNA activates RISC [70,155,156] are quite exciting. In our laboratories, we have confirmed that chemically modified single-strand antisense oligoribonuleotides can reduce target RNAs and, at least in part, their effects are mediated by the RISC pathway (Balkrishen Bhat unpublished results). These results are perhaps more remarkable than might appear at first blush since we know that even extensively modified single-strand antisense oligoribonuleotides are still relatively unstable. Thus, as more is
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 37
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
37
learned about the medicinal chemistry of single-strand oligoribonuleotides, significant improvements in potency should be achievable. This could be quite important if some of the potential limitations of duplex RNA drugs about which we are concerned prove to be difficult to overcome. It is also possible to vary the length and structures of siRNA duplexes and influence the activities of siRNAs. In addition to variations in the ends (blunt versus overhangs), other factors such as GC content, bias toward low internal stability at the 3 terminus of the sense strand, and lack of inverted repeats increase siRNA activities in vitro [157]. siRNAs that were 25–31 nucleotides long and were substrates for dicer-mediated cleavage were also found to be more potent than 21 mers [158]. Additionally, substantial progress in defining potential chemical modifications that might be useful and identifying sites in siRNAs that can be modified without dramatic loss of activity have been reported [124–129,151]. Thus, it seems feasible to introduce a variety of modifications that may improve the drug properties of both single-strand antisense oligoribonuleotides and siRNA. The structure–activity relationships are being worked out for both classes of molecules and they appear to be different. More work is required to identify the modifications and positions to be modified that provide the best properties for systemic applications for therapeutic purposes for both classes of molecules.
1.5.5.7 Unique Challenges of Duplex RNA Drugs In the discovery and development of new drugs, many factors must be considered in addition to the observations of desired pharmacological effects at achievable doses. siRNA duplexes pose drug development challenges that are unique and different from those encountered with single-strand oligonucleotides.
Physical Chemical Properties siRNA duplexes are substantially different from single-strand oligonucleotides. Obviously, they are at least twice the molecular weight of single-strand antisense drugs. This is nontrivial since single-strand antisense drugs have molecular weights of 6000–7000 Daltons, the increase to perhaps greater than 14,000 Daltons should dramatically affect pharmacokinetic and toxicologic properties. It would also substantially increase the cost of manufacturing such drugs. Perhaps more important is the change in the interactions with water. Single-strand oligonucleotides are amphipathic, with the phosphates being very water-soluble and the bases hydrophobic. In a duplex, the phosphate backbones are presented to water and water is somewhat excluded from the more hydrophobic internal portion of the duplex. All these changes mean that extrapolation from the behavior of single-strand oligonucleotides to the behavior of duplexes is not possible.
Manufacturing Large-scale manufacturing of single-strand antisense drugs is well in hand and the advances made over the past 15 years can be employed in the manufacture of the sense and antisense strands of the duplex. The challenge will be to hybridize on large scale and to prove that there is no residual single-strand contamination.
The Sense Strand The sense strand is a drug delivery device. However, it is pharmacologically active. It may bind to unintended transcripts. It may be an immunostimulant. It may bind to a variety of proteins. As the sense strand is modified to enhance the pharmacokinetic properties of the duplex, these properties will likely become more prominent. Certainly, assays will need to be developed to follow the fate of the sense strand and to evaluate the potential effects of this pharmacologically and metabolically active drug delivery device.
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 38
38
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Immune Stimulation Oligonucleotides are immunostimulatory. The immunostimulatory properties of oligonucleotides are affected by dose length, sequence, chemical modifications, internal structure, and other factors (for review, see [9] and Chapters 1, 3, 13, and 27 of this volume). For single-strand antisense drugs, it is now possible to reduce the potential for immunostimulation. It is also possible to optimize to enhance immunostimulatory (see Chapter 27 of this volume). As a general rule, any propensity toward internal structure enhances the immunostimulatory potential of oligonucleotides. Thus, conceptually, duplex RNA might be expected to be at least as immunostimulatory and perhaps much more immunostimulatory than single-strand oligonucleotides once they are sufficiently stable and distribute to a variety of organs. In fact, siRNAs have been shown to be immunostimulatory. They have been shown to induce interferon in mammalian cells [159]. Unmodified siRNAs 23 nucleotide and longer induced interferon, up-regulated the dsRNA receptor and toll-like receptor 2 in a celltype-specific mamer [157]. In addition, dsRNAs may induce innate immunity [87]. Finally, both single strands when liberated from the duplex have the potential to be immunostimulants. Does the potential to induce a wide variety of immunological responses secondary to duplex properties and motifs, single-strand properties and motifs, and a variety of mechanisms pose an insurmountable problem? Probably not. However, it requires careful attention and lessons learned from studies on single-strand antisense drugs should be considered carefully. For example, ensuring that pharmacological observations are truly the result of siRNAs effects on the target RNA and not confounded by immunological effects is crucial and has been the subject of an enormous effort with regard to RNase H antisense-based drugs. For single-strand antisense drugs, we know that the rodent is particularly sensitive to these effects. We know that there are problematic sequence motifs that are species-specific. We know that chemical modifications can alter immunological properties of these drugs. We know that liposome encapsulation may worsen these effects (for review, see [7]). These lessons should be considered as pharmacological effects are reported and decisions to develop siRNA drugs are made. 1.5.6
Covalent Modifications of Target Nucleic Acids
One area of research that was a significant focus for a number of years was the synthesis of oligonucleotides conjugated to alkylating moleties species designed to alkylate the target RNA and result in disablement and degradation, or either of these. Despite all the early excitement and work, this approach has to a large extent been abandoned. This is primarily because there was no evidence that such approaches resulted in drugs as effective as those that were RNase H–based and because of concerns about toxicity (for review, see [15]). 1.5.7
Oligonucleotide-Induced Cleavage of Target RNA
Another approach that has been the subject of very substantial investment was the creation of either oligonucleotides that were conjugated to RNA cleavage reagents or synthetic ribozymes. Although work continues in these areas (for review, see [15]), little progress has been reported in recent years. It now appears that it is pharmacologically more attractive and feasible to create antisense drugs that recruit either RNase H1 or dsRNases such as the RISC complex than to create oligonucleotides that can effect RNA cleavage themselves. 1.5.8
RNase L–Mediated Cleavage
RNase L or 2-5 adenylate–dependent nuclease is an enzyme that cleaves RNA that contains at least a trimer of 2-5 linked adenylic acid at the 5 terminus of a target RNA (for review, see [160]). The enzyme is ubiquitous but exists in inactive form until activated by interferon. The enzyme has multiple anykrin motifs that suppress the activity of the enzyme until 2-5 is bound [124,161]. Failure in the regulation of RNase L or truncation of the enzyme is associated with disease. It is
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 39
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
39
therefore quite important to consider RNase L as a potential confounding mechanism for any dsRNA that could activate the interferon pathway. It is also a potential mechanism that could be exploited to induce antisense effects [160]. The challenge to exploitng RNase L as a mechanism has been the synthesis of stable oligonucleotide analogs that contain a 2-5 moiety. To some extent, this has been accomplished. One set of modifications included full 2 methoxy modifications of the oligonucleotide coupled to 5 and 3 phosphorothioate modifications and a 5 thiophosphate [162]. This molecule displayed improved activity against respiratory syncytial virus infection in monkeys after intranasal administration. Other modifications have also been reported. In short, the 2-5 adenyllic RNase or RNase L mechanism remains a potentially attractive mechanism. Very little work on this mechanism has been reported and it probably deserves more substantial efforts in the future. 1.6 MICRO-RNAs As previously discussed, micro-RNAs represent a new level of transcriptional and translational control and a very exciting area of research (for review, see [163]). They also present interesting targets for antisense-based therapeutics. Fully modified 2 methoxy antisense drugs designed to bind to several micro-RNAs were administered to mice and shown to produce substantial changes in m-RNA levels in a large number of RNA species [164]. Mir-122 inhibition with 2-MOE-based antisense drugs substantially reduced serum cholesterol, hepatic fatty acid oxidation, and hepatic synthesis of cholesterol [164,165] demonstrating that alteration of mir function could result in potentially interesting therapeutic effects. More recently, an initial structure activity relationship (SAR) study identified potential approaches to enhance the activities of antisense agents that target mirs [166]. The opportunity to target mirs with antisense drugs opens a number of exciting avenues because the mirs are thought to be involved in relatively large-scale phenotypic shifts including differentiation and dedifferentiation phenomena. Given the number of potential roles of these RNAs in normal and pathophysiologic processes and the relative ease with which they can be targeted with antisense drugs, the therapeutic potential seems quite high. However, careful selection of diseases to be targeted and exploration of the effects on phenotype will be essential given the breadth of potential effects. Furthermore, as components of the micro-RNA pathway are important to the maintenance of a normal phenotype, effects on micro-RNA pathways by single-strand antisense agents or siRNAs could have toxicities. In fact, overexpression of siRNAs has been shown to be toxic to animals possibly secondary to effects on exportin [167]. Therefore, this is an exciting new opportunity that requires prudent but aggressive research. 1.7 CONCLUSIONS AND FUTURE PERSPECTIVES In the 5 years since the publication of the first volume of this series, remarkable progress has been reported. RNase H–based antisense drugs have progressed across a broad front and the information gained about the mechanism is being used to improve their performance. New opportunities such as the use of dsRNases including siRNA and micro-RNAs have emerged and been the subjects of exciting progress. Perhaps equally important, concepts such as transcriptional control though triplex formation, and ribozymes have been thoroughly evaluated and demonstrated to offer too little value using current approaches to warrant further investment. Several areas deserve continued aggressive research. We need to continue to evaluate secondgeneration RNase H–based antisense drugs in the clinic and in animals to better define their strengths and limitations, particularly with regard to chronic administration. We need to continue to use the information on the RNase H mechanism to improve the performance of RNase H–based drugs and determine if generation 2.2 antisense drugs do indeed do perform better than second-generation drugs in the clinic.
CRC_8796_ch001.qxd
40
5/24/2007
21:54
Page 40
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
We must continue to invest in understanding the RISC mediated pathways and determine which limbs of the pathway we can safely exploit. We must then create agents that can be specific enough to activate the desired limbs of the RISC pathways only. We must determine if surmounting the challenges posed by duplex RNA drugs is feasible and evaluate the potential of single-strand RNA-based drugs. Splicing is now an even more interesting process to alter as we know it is feasible and have the tools to exploit if. However, we must develop a better understanding of splicing processes so that we can improve the robustness of the mechanism. RNase L represents a mechanism that deserves more investment. At present, it is difficult to know if it offers any advantage over other cleavage mechanisms. We should generate the data to support an informed decision about the value of this mechanism. Finally, micro-RNAs represent an exciting opportunity, but the roles of micro-RNAs, the pathways involved, and risks associated with large phenotypic shifts should be adequately understood before proceeding with the development of anti-mer therapeutics. ACKNOWLEDGMENTS We thank Dr. Frank Bennett, Dr. David Ecker, and Dr. Brenda Baker for critical review and helpful comments; as also Tracy Reigle for preparing the figures and Donna Parrett for excellent typographical assistance. REFERENCES 1. Watson, J., Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature, 1953. 171: 737–738. 2. Gillespie, D. and S. Spiegelman, A quantitative assay for DNA-RNA hybrids with DNA immobilized on a membrane. J. Mol. Biol., 1965. 12(3): 829–842. 3. Thompson, J.D. and D. Gillespie, Current concepts in quantitative molecular hybridization. Clin. Biochem., 1990. 23(4): 261–266. 4. Zamecnik, P.C. and M.L. Stephenson, Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proceedings of the National Academy of Science USA, 1978. 75(1): 280–284. 5. De Clercq, E., F. Eckstein, and T.C. Merigan, Interferon induction increased through chemical modification of synthetic polyribonucleotide. Science, 1969. 165: 1137–1140. 6. Barrett, J.C., P.S. Miller, and P.O. Ts’o, Inhibitory effect of complex formation with oligodeoxyribonucleotide ethyl phosphotriesters on transfer ribonucleic acid aminoacylation. Biochemistry, 1974. 13(24): 4897–4906. 7. Crooke, S.T., Basic Principles of antisense technologies, in Antisense Drug Technology: Basic Principles, Strategies, and Applications, S.T. Crooke, ed., 2001, Marcel Dekker, Inc.: New York, pp. 1–28. 8. Cook, P.D., Medicinal chemistry of antisense oligonucleotides, in Antisense Drug Technology: Basic Principles, Strategies, and Applications, S.T. Crooke, ed., 2001, Marcel Dekker, Inc.: New York, pp. 29–56. 9. Crooke, S.T., ed., Antisense Drug Technology: Basic Principles, Strategies, and Applications, 2001, Marcel Dekker, Inc.: New York. 10. Geary, R.S. et al., Pharmacokinetic properties in animals, in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, ed., 2001, Marcel Dekker, Inc.: New York, pp. 119–154. 11. Crooke, R.M. and M.J. Graham, Suborgan pharmacokinetics, in Antisense Drug Technology: Basic Principles, Strategies, and Applications, S.T. Crooke, ed., 2001, Marcel Dekker, Inc.: New York, pp. 155–182. 12. Yu, R.Z. et al., Pharmacokinetic properties in humans, in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, ed., 2001, Marcel Dekker, Inc.: New York, pp. 183–200. 13. Levin, A.A. et al., Toxicity of antisense oligonucleotides, in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, ed., 2001, Marcel Dekker, Inc.: New York, pp. 201–267.
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 41
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
41
14. Dorr, F.A., J.G. Glover, and T.J. Kwoh, Clinical safety of phosphorothioate oligodeoxynucleotides, in Antisense Drug Technology: Basic Principles, Strategies, and Applications, S.T. Crooke, ed., 2001, Marcel Dekker, Inc.: New York, pp. 269–290. 15. Crooke, S.T., Molecular mechanisms of action of antisense drugs. Biochem. Biophys. Acta, 1999. 1489(1): 31–44. 16. Mizumoto, K. and Y. Kaziro, Messenger RNA capping enzymes from eukaryotic cells. Prog. Nucleic Acid Res. Mol. Biol., 1987. 34: 1–28. 17. Ross, J., Messenger RNA turnover in eukaryotic cells. Mol. Biol. Med., 1988. 5(1): 1–14. 18. Friedman, D.I., M.J. Imperiale, and S.L. Adhya, RNA 3 end formation in the control of gene expression. Annu. Rev. Genet., 1987. 21: 453–88. 19. Manley, J.L., Polyadenylation of mRNA precursors. Biochem. Biophys. Acta, 1988. 950: 1–12. 20. Black, D., Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem., 2003. 72: 291–336. 21. Kumar, M. and G.G. Carmichael, Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. Microbiol. Mol. Biol. Rev., 1998. 62(4): 1415–1434. 22. Vanhee-Brossollet, C. and C. Vaquero, Do natural antisense transcripts make sense in eukaryotes? Gene, 1998. 211(1): 1–9. 23. Zamore, P.D., Ancient pathways programmed by small RNAs. Science, 2002. 296: 1265–1269. 24. Bass, B.L., RNA editing and hypermutation by adenosine deamination. Trends Biochem. Sci., 1997. 22(5): 157–162. 25. Zamore, P.D. et al., RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell, 2000. 101: 25–33. 26. Dahary, D., O. Elroy-Stein, and R. Sorek, Naturally occurring antisense: transcriptional leakage or real overlap? Genome Res., 2005. 15(3): 364–368. 27. Yelin, R., Widespread occurence of antisense transcription in the human genome. Nat. Biotechnol., 2003. 21: 379–386. 28. Kiyosawa, H. et al., Antisense transcripts with FANTOM2 clone set and their implications for gene regulation. Genome Res., 2003. 13(6B): 1324–1334. 29. Kiyosawa, H. et al., Disclosing hidden transcripts: mouse natural sense-antisense transcripts tend to be poly(A) negative and nuclear localized. Genome Res., 2005. 15(4): 463–474. 30. Freier, S.M., Methods of selecting sites in RNA for antisense targeting, in Antisense Drug Technology: Basic Principles, Strategies, and Applications, S.T. Crooke, ed., 2001, Marcel Dekker, Inc.: New York, pp. 107–118. 31. Royo, H. et al., Small non-coding RNAs and genomic imprinting. Cytogenet. Genome Res., 2006. 113(1–4): 99–108. 32. Sevignani, C. et al., Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm. Genome, 2006. 17(3): 189–202. 33. Pillai, R.S., MicroRNA function: multiple mechanisms for a tiny RNA? RNA, 2005. 11(12): 1753–1761. 34. Brengues, M., D. Teixeira, and R. Parker, Movement of eukaryotic mRNAs between polysomes and cytoplasmic processing bodies. Science, 2005. 310(5747): 486–489. 35. Matzke, M. and J. Birchler, RNAi mediated pathways in the nucleus. Nat. Rev., 2005. RNA Collection: 7–18. 36. Buhler, M., A. Verdel, and D. Moazed, Tethering RITS to a nascent transcript initiates RNAi- and heterochromatin-dependent gene silencing. Cell, 2006. 125(5): 873–886. 37. Vagin, V.V. et al., A distinct small RNA pathway silences selfish genetic elements in the germline. Science, 2006. 313(5785): 320–324. 38. Wu, H. et al., Identification and partial purification of human double strand RNase activity: a novel terminating mechanism for oligoribonucleotide antisense drugs. J. Biol. Chem., 1998. 273(5): 2532–2542. 39. Dykxhoorn, D.M., C.D. Novina, and P. Sharp, Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol., 2003. 4: 457–467. 40. Weiler, J., J. Hunziker, and J. Hall, Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther., 2005. 13: 496–502. 41. R.F. Gesteland and J.F. Atkins, eds., RNA World, 1993, Cold Spring Harbor Laboratory Press: Plainview. 42. Breslauer, K.J. et al., Predicting DNA duplex stability from the base sequence. Proceedings of the National Academy of Science USA, 1986. 83(11): 3746–3750.
CRC_8796_ch001.qxd
42
5/24/2007
21:54
Page 42
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION 43. Freier, S.M. et al., Improved free-energy parameters for predictions of RNA duplex stability. Proceedings of the National Academy of Science USA, 1986. 83(24): 9373–9377. 44. Chastain, M. and I. Tinoco, RNA structure as related to antisense drugs, in Antisense Reseach and Applications, 1993, CRC Press: Boca Raton, FL, p. 55. 45. Ecker, D., Strategies for invasion of RNA secondary structure, in Antisense Research Applications, S. T. Crooke and B. Lebleu, eds., 1993, CRC Press: Boca Raton, FL. pp. 378–400. 46. Tuerk, C. and L. Gold, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990. 249(4968): 505–510. 47. Wyatt, J.R., Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envlope-mediated cell fusion. Proceedings of the National Academy of Science USA, 1994. 91(4): 1356–1360. 48. Wang, K.Y. et al., A DNA aptamer which binds to and inhibits thrombin exhibits a new structural motif for DNA. Biochemistry, 1993. 32(8): 1899–1904. 49. Leroy, J.L. et al., Acid multimers of oligodeoxycytidine strands: stoichiometry, base-pair characterization, and proton exchange properties. Biochemistry, 1993. 32(23): 6019–6031. 50. Gehring, K., J.L. Leroy, and M. Gueron, A tetrameric DNA structure with protonated cytosine.cytosine base pairs. Nature, 1993. 363(6429): 561–565. 51. Crooke, S.T., Antisense Research and Applications, S.T. Crooke and B. Lebleu, eds., 1993, CRC Press: Boca Raton, FL. 52. Bennett, C.F. and T.P. Condon, Use of antisense oligonucleotides to modify inflammatory processes, in Antisense Research and Application, A Handbook of Experimental Pharmacology, S.T. Crooke, ed., 1998, Springer-Verlag: New York, pp. 371–393. 53. Freier S.M., W. Lima, Y.S. Sanghvi, T. Vickers, M. Zounes, P.D. Cook, and D.J. Ecker, Thermodynamics of antisense oligonucleotide hybridization, in GeneRegulation: Biology of Antisense RNA and DNA, R.P. Erickson, and J. G. Izant, eds., 1992, Raven Press: New York, pp. 95–107. 54. Thein, S.L. and R.B. Wallace, The use of synthetic oligonucleotides as specific hybridization probes in the diagnosis of genetic disorders, in Human Genetic Diseases: A Practical Approach, K.E. Davies, ed. 1986, IRL Press: Oxford, pp. 33–50. 55. Helene, C., Control of gene expression by triple-helix-forming oligonucleotides: the antigene strategy, in Antisense Research and Applications, S.T. Crooke and B. Lebleu, eds., 1993, CRC Press: Boca Raton, FL, pp. 375–385. 56. Monia, B.P. et al., Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem., 1992. 267(28): 19,954–19,962. 57. Saunders, L.R. and G.N. Barber, The dsRNA binding protein family: critical roles, diverse cellular functions. Faseb J., 2003. 17(9): 961–983. 58. Skabkin, M.A. et al., The major messenger ribonucleoprotein particle protein p50 (YB-1) promotes nucleic acid strand annealing. J. Biol. Chem., 2001. 276(48): 44,841–44,847. 59. Pontius, B.W. and P. Berg, Rapid assembly and disassembly of complementary DNA strands through an equilibrium intermediate state mediated by A1 hnRNP protein. J. Biol. Chem., 1992. 267(20): 13,815–13,818. 60. Wunsche, W. and G. Sczakiel, The activity of siRNA in mammalian cells is related to the kinetics of siRNA-target recognition in vitro: mechanistic implications. J. Mol. Biol., 2005. 345(2): 203–209. 61. Miraglia, L. et al., Variations in mRNA content have no effect on the potency of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev., 2000. 10(6): 453–461. 62. Samuel, C.E., RNA editing minireview series. J. Biol. Chem., 2003. 278(3): 1389–1390. 63. Maas, S., A. Rich, and K. Nishikura, A-to-I RNA editing: recent news and residual mysteries. J. Biol. Chem., 2003. 278(3): 1391–1394. 64. Blanc, V. and N.O. Davidson, C-to-U RNA editing: mechanisms leading to genetic diversity. J. Biol. Chem., 2003. 278(3): 1395–1398. 65. Smith, H.C., J.M. Gott, and M.R. Hanson, A guide to RNA editing. RNA, 1997. 3(10): 1105–1123. 66. Giddings, M.C. et al., Artificial neural network prediction of antisense oligodeoxynucleotide activity. Nucleic Acids Res., 2002. 30(19): 4295–4304. 67. Chalk, A.M. and E.L. Sonnhammer, Computational antisense oligo prediction with a neural network model. Bioinformatics, 2002. 18(12): 1567–1575.
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 43
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
43
68. Far, R.K. et al., Technical improvements in the computational target search for antisense oligonucleotides. Oligonucleotides, 2005. 15(3): 223–233. 69. Vickers, T.A. et al., Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem., 2003. 278(9): 7108–7118. 70. Holen, T. et al., Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway. Nucleic Acids Res., 2003. 31(9): 2401–2407. 71. Crooke, R.M., In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti-Cancer Drug Design, 1991. 6: 609–646. 72. Crooke, S.T., Oligonucleotide therapeutics, in Burger’s Medicinal Chemistry and Drug Discovery, Vol. 1, M.E. Wolff, ed., 1995, Wiley: New York, 863–900. 73. Crooke, S.T., Progress in antisense therapeutics. Hematol. Pathol., 1995. 9(2): 59–72. 74. Dominski, Z. and R. Kole, Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proceedings of the National Academy of Science USA, 1993. 90(18): 8673–8677. 75. Sazani, P. and R. Kole, Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J. Clin. Invest., 2003. 112(4): 481–486. 76. Aartsma-Rus, A. et al., Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides, 2005. 15(4): 284–97. 77. Mann, C.J. et al., Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J. Gene. Med., 2002. 4(6): 644–654. 78. Alter, J. et al., Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med., 2006. 12(2): 175–177. 79. Gebski, B.L. et al., Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum. Mol. Genet., 2003. 12(15): 1801–1811. 80. Williams, J.H. et al., Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers. Mol. Ther., 2006. 14(1): 88–96. 81. Taylor, J.K. et al., Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol., 1999. 17(11): 1097–1100. 82. Mercatante, D.R., J.L. Mohler, and R. Kole, Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J. Biol. Chem., 2002. 277(51): 49,374–49,382. 83. Sazani, P. et al., Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol., 2002. 20(12): 1228–1233. 84. Vickers, T.A. et al., Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2-O-methoxyethyl-modified oligonucleotide. J. Immunol., 2006. 176(6): 3652–3661. 85. Garcia-Blanco, M.A., A.P. Baraniak, and E.L. Lasda, Alternative splicing in disease and therapy. Nat. Biotechnol., 2004. 22(5): 535–546. 86. Roca, X., R. Sachidanandam, and A.R. Krainer, Determinants of the inherent strength of human 5 splice sites. RNA, 2005. 11(5): 683–698. 87. Wang, L. et al., Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J. Clin. Invest., 2002. 110(8): 1175–1184. 88. Hodges, D. and S.T. Crooke, Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides. Mol. Pharmacol., 1995. 48(5): 905–918. 89. Cartegni, L. et al., ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res., 2003. 31(13): 3568–3571. 90. Ferro, P. et al., Alternative splicing of the human estrogen receptor alpha primary transcript: mechanisms of exon skipping. Int. J. Mol. Med., 2003. 12(3): 355–363. 91. Hua, Y. et al., Enhancement of alternative exon 7 inclusion in SMN2 by antisense 2MOE oligonucleotides targeting the exon. PLoS Bio., 2007. 5(4): 73. 92. Baker, B.F. et al., 2-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem., 1997. 272(18): 11,994–12,000.
CRC_8796_ch001.qxd
44
5/24/2007
21:54
Page 44
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
93. Alt, M. et al., Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation. Eur. J. Clin. Invest., 1999. 29(10): 868–876. 94. Brown-Driver, V. et al., Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides. Antisense Nucleic Acid Drug Dev., 1999. 9(2): 145–154. 95. Azad, R.F. et al., Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother., 1993. 37(9): 1945–1954. 96. Arora, V. et al., c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity. J. Pharmacol. Exp. Ther., 2000. 292(3): 921–928. 97. Zhang, H. et al., Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob. Agents Chemother., 1999. 43(2): 347–353. 98. Hanecak, R. et al., Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J. Virol., 1996. 70(8): 5203–5212. 99. Brown, E.A., et al., Secondary structure of the 5 nontranslated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res., 1992. 20: 5041–5045. 100. Vickers, T. et al., Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element. Nucleic Acids Res., 1991. 19(12): 3359–3368. 101. Ecker, D.J. et al., Pseudo-half-knot formation with RNA. Science, 1992. 257(5072): 958–961. 102. Saxena, S.K. and E.J. Ackerman, Microinjected oligonucleotides complementary to the alpha-sarcin loop of 28 S RNA abolish protein synthesis in Xenopus oocytes. J. Biol. Chem., 1990. 265(6): 3263–3269. 103. Walker, K., S.A. Elela, and R.N. Nazar, Inhibition of protein synthesis by anti-5.8 S rRNA oligodeoxyribonucleotides. J. Biol. Chem., 1990. 265(5): 2428–2430. 104. Westermann, P., B. Gross, and G. Hoinkis, Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides. Biomed. Biochim. Acta., 1989. 48(1): 85–93. 105. Baker, B.F., L. Miraglia, and C.H. Hagedorn, Modulation of eukaryotic initiation factor-4E binding to 5-capped oligoribonucleotides by modified anti-sense oligonucleotides. J. Biol. Chem., 1992. 267(16): 11,495–11,499. 106. Vickers, T.A. et al., Fully modified 2-MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res., 2001. 29: 1293–1299. 107. Crooke, S.T., Antisense strategies. Curr. Mol. Med., 2004. 4: 465–487. 108. Lima, W.F., H. Wu, and S.T. Crooke, Human RNases H, in Methods in Enzymology, A.W. Nicholson, ed., 2001, Academic Press: San Diego, pp. 430–440. 109. Wu, H. et al., Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem., 2004. 279(17): 17,181–17,189. 110. Lima, W.F. et al., Human RNAse H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol. Pharmacol. (in press). 111. Lima, W.F. et al., The postional influence of the helical geometry of the heteroduplex substrate on human RNase H1 catalysis. Mol. Pharmacol. (in press). 112. Wu, H., W.F. Lima, and S.T. Crooke, Investigating the structure of human RNase H1 by site-directed mutagenesis. J. Biol. Chem., 2001. 276(26): 23,547–23,553. 113. Grunweller, A. et al., Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res., 2003. 31(12): 3185–3193. 114. Dean, N.M. et al., Pharmacology of 2-O-(2-methoxy)ethyl modified antisense oligonucleotides, in Antisense Drug Technology: Principles, Strategies, and Applications, S.T. Crooke, ed., 2001, Marcel Dekker Inc.: New York, pp. 319–338. 115. Hardee, G.E., S.P. Weinbach, and L.G. Tilman, New routes and novel formulations for delivery of antisense oligonucleotides, in Antisense Drug Technology: Basic Principles, Strategies, and Applications, S.T. Crooke, ed., 2001, Marcel Dekker, Inc.: New York, pp. 795–832. 116. Monia, B.P. and N.M. Dean, Pharmacological activity of antisense oligonucleotides in animal models of disease, in Antisense Research and Application, S.T. Crooke, ed., 1998, Springer-Verlag: Berlin Heidelberg, pp. 427–443. 117. Wu, H., W.F. Lima, and S.T. Crooke, Molecular cloning and expression of cDNA for human RNase H. Antisense Nucleic Acid Drug Dev., 1998. 8(1): 53–61.
CRC_8796_ch001.qxd
5/24/2007
21:54
Page 45
MECHANISMS OF ANTISENSE DRUG ACTION, AN INTRODUCTION
45
118. Wu, H., W.F. Lima, and S.T. Crooke, Properties of cloned and expressed human RNase H1. J. Biol. Chem., 1999. 274(40): 28,270–28,278. 119. Siwkowski, A.M. et al., Effects of altering antisense oligonucleotide composition on distribution, metabolism, RNase H activity, and potency in mice. In preparation. 120. Overhoff, M. et al., Local RNA target structure influences siRNA efficacy: a systematic global analysis. J. Mol. Biol., 2005. 348(4): 871–881. 121. Kretschmer-Kazemi Far, R. and G. Sczakiel, The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res., 2003. 31(15): 4417–4424. 122. Liu, J. et al., Argonaute2 is the catalytic engine of mammalian RNAi. Science, 2004. 305(5689): 1437–1441. 123. Haley, B. and P.D. Zamore, Kinetic analysis of the RNAi enzyme complex. Nat. Struct. Mol. Biol., 2004. 11(7): 599–606. 124. Hall, A.H. et al., RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res., 2004. 32(20): 5991–6000. 125. Prakash, T.P. et al., RNA interference by 2,5-linked nucleic acid duplexes in mammalian cells. Bioorg. Med. Chem. Lett., 2006. 16(12): 3238–3240. 126. Kraynack, B.A. and B.F. Baker, Small interfering RNAs containing full 2-O-methylribonucleotidemodified sense strands display Argonaute2/eIF2C2-dependent activity. RNA, 2006. 12(1): 163–176. 127. Dande, P. et al., Improving RNA interference in mammalian cells by 4-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2-O-alkyl modifications. J. Med. Chem., 2006. 49(5): 1624–1634. 128. Prakash, T.P. et al., Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem., 2005. 48(13): 4247–4253. 129. Chiu, Y.L. and T.M. Rana, siRNA function in RNAi: a chemical modification analysis. RNA, 2003. 9(9): 1034–1048. 130. Semizarov, D. et al., Specificity of short interfering RNA determined through gene expression signatures. Proceedings of the National Academy of Science USA, 2003. 100(11): 6347–6352. 131. Semizarov, D., P. Kroeger, and S. Fesik, siRNA-mediated gene silencing: a global genome view. Nucleic Acids Res., 2004. 32(13): 3836–3845. 132. Lin, X. et al., siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res., 2005. 33(14): 4527–4535. 133. Birmingham, A. et al., 3 UTR seed matches, but not overall identity, are associated with RNAi offtargets. Nat. Meth., 2006. 3(3): 199–204. 134. Jackson, A.L. et al., Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol., 2003. 21(6): 635–637. 135. Scacheri, P.C. et al., Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proceedings of the National Academy of Science USA, 2004. 101(7): 1892–1897. 136. Fedorov, Y. et al., Off-target effects by siRNA can induce toxic phenotype. RNA, 2006. 12: 1–9. 137. Jackson, A.L. et al., Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA, 2006. 12: 1197–1205. 138. Lippman, Z. and R. Martienssen, The role of RNA interference in heterochromatic silencing. Nature, 2004. 431(7006): 364–370. 139. Noma, K. et al., RITS acts in cis to promote RNA interference-mediated transcriptional and post-transcriptional silencing. Nat. Genet., 2004. 36(11): 1174–1180. 140. Cam, H.P. et al., Comprehensive analysis of heterochromatin- and RNAi-mediated epigenetic control of the fission yeast genome. Nat. Genet., 2005. 37(8): 809–819. 141. Schramke, V. et al., RNA-interference-directed chromatin modification coupled to RNA polymerase II transcription. Nature., 2005. 435(7046): 1275–1279. 142. Sugiyama, T. et al., RNA-dependent RNA polymerase is an essential component of a self-enforcing loop coupling heterochromatin assembly to siRNA production. Proceedings of the National Academy of Science USA, 2005. 102(1): 152–157. 143. Volpe, T.A. et al., Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science, 2002. 297(5588): 1833–1837.
CRC_8796_ch001.qxd
46
5/24/2007
21:54
Page 46
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
144. Morris, K.V. et al., Small interfering RNA-induced transcriptional gene silencing in human cells. Science, 2004. 305(5688): 1289–1292. 145. Robb, G.B. et al., Specific and potent RNAi in the nucleus of human cells. Nat. Struct. Mol. Biol., 2005. 12(2): 1–4. 146. Song, E. et al., RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med., 2003. 347–351. 147. Allerson, C.R., N. Sioufi, R. Jarres, T.P. Prakash, N. Naik, A. Berdeja, L. Wanders, R. Griffey, E.E. Swayze, and B. Bhat, Fully 2-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem., 2005 (in press). 148. Song, E. et al., Antibody mediated in vivo delivery of small interf RNAs via cell-surface receptors. Nat. Biotechnol., 2005. 23(6): 709–717. 149. Morrissey, D.V. et al., Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol., 2005. 23(8): 1002–1007. 150. Zimmermann, T.S. et al., RNAi-mediated gene silencing in non-human primates. Nature, 2006. 441(7089): 111–114. 151. Soutschek, J. et al., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 2004. 432(7014): 173–178. 152. Crooke, S.T. et al., Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther., 1996. 277(2): 923–937. 153. Henry, S.P. et al., Toxicological properties of several novel oligonucleotide analogs in mice. AntiCancer Drug Des., 1997. 12(1): 1–14. 154. Elbashir, S.M. et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001. 411: 494–498. 155. Martinez, J. et al., Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell, 2002. 110: 563–574. 156. Xu, Y. et al., Functional comparison of single- and double-stranded siRNAs in mammaliam cells. Biochem. Biophys. Res. Comm., 2004. 316: 680–687. 157. Reynolds, A. et al., Rational siRNA design for RNA interference. Nat. Biotechnol., 2004. 22(3): 326–30. 158. Kim, D.-H. et al., Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol., 2005. 23(2): 222–226. 159. Bridge, A.J. et al., Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet., 2003. 34(3): 263–264. 160. Torrence, P.F. et al., Develpoment of 2,5 oligonucleotides as potential therapeutic agents. Curr. Med. Chem., 1994. 1: 176–191. 161. Nakanishi, M. et al., Functional characterization of 2,5-linked oligoadenylate binding determinant of human RNase L. J. Biol. Chem., 2005. 280(50): 41,694–41,699. 162. Leaman, D.W. et al., Targeted therapy of respiratory synctial virus in African green monkeys by intranasally administered 2-5A antisense. Virology, 2002. 292: 70–77. 163. Kim, V.N. and J.W. Nam, Genomics of microRNA. Trends Genet., 2006. 22(3): p. 165–73. 164. Krutzfeldt, J. et al., Silencing of microRNAs in vivo with ‘antagomirs.’ Nature, 2005. 438(7068): 685–689. 165. Esau, C. et al., miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab., 2006. 3(2): p. 87–98. 166. Davis, S. et al., Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res., 2006. 34(8): 2294–2304. 167. Grimm, D. et al., Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 2006. 441(7092): 537–541. 168. Jakymiw, A. et al., Disruption of GW bodies impairs mammalian RNA interference. Nat. Cell Biol., 2005. 12: 1267–1274. 169. Orban, T.I. and E. Izaurralde, Decay of mRNAs targeted by RISC requires XRN1, the Ski complex, and the exosome. RNA, 2005. 11(4): 459–469. 170. Liu, J. et al., MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat. Cell Biol., 2005. 7(7): 719–723. 171. Wu, L., J. Fan, and J. Belasco, MicroRNAs direct rapid deadenylation of mRNA. Proceedings of the National Academy of Science USA, 2006. 11: 4034–4039. 172. Petersen, C. et al., Short RNAs repress translation after initiation in mammalian cells. Mol. Cell., 2006. 4: 533–542.
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 47
CHAPTER
2
The RNase H Mechanism Walt Lima, Hongjiang Wu, and Stanley T. Crooke
CONTENTS 2.1
Introduction.............................................................................................................................47 2.1.1 ASO Terminating Mechanisms ..................................................................................47 2.1.2 RNase H Enzymes......................................................................................................48 2.1.3 Human RNases H .......................................................................................................48 2.2 Human RNase H1...................................................................................................................49 2.2.1 Biochemical Properties...............................................................................................49 2.2.2 Structure and Enzymology .........................................................................................49 2.2.2.1 RNA-Binding Domain ................................................................................50 2.2.2.2 Catalytic Domain.........................................................................................52 2.2.3 Biological Roles .........................................................................................................55 2.2.4 Genomics and Regulation...........................................................................................56 2.3 Human RNase H2...................................................................................................................56 2.3.1 Structure and Enzymology .........................................................................................56 2.3.2 Biological Roles .........................................................................................................61 2.3.3 Genomics and Regulation...........................................................................................63 2.4 The Roles of the Human RNases H in the Effects of DNA-Like ASOs................................63 2.5 The Effects of Chimeric ASOs on Human RNase H1 Activity .............................................65 2.6 Implications for Antisense Therapeutics ................................................................................70 References ........................................................................................................................................71
2.1 INTRODUCTION 2.1.1
ASO Terminating Mechanisms
Antisense oligonucleotides (ASOs) are designed to modulate the information transfer from gene to protein—in essence to alter mRNA intermediary metabolism. mRNA intermediary metabolism is extremely complex beginning with transcription and concluding with degradation usually after translation. Each step is complex and in dynamic equilibrium with competing pathways. Although great progress has been made in understanding these processes, much remains unknown, and we
47
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
48
Page 48
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
have only begun to understand the potential impacts of ASOs on these processes and the factors that influence the outcomes. Once ASOs bind to a target RNA, they may induce pharmacological effects by one of two mechanisms: occupancy or occupancy-mediated destabilization [1–3]. Occupancy only mediated mechanisms include alteration of splicing, inhibiting of translation, and the disruption of required RNA structure and miRNA-induced gene silencing. Occupancy-mediated destabilization includes degradation of the target RNA by single- and double-stranded RNases. RNases H are enzymes that cleave the target RNA when bound in a DNA–RNA duplex. In addition, there are double-strand RNases that recognize RNA–RNA duplexes and cleave the target RNA. For example, the RISC endonuclease Argonaute2 combined with the antisense strand of siRNA, cleaves target mRNA at the sequence complementary to the siRNA [4,5]. This enzyme may also be involved in the activity of single-strand RNA-like ASOs. Thanks to the substantial progress reported in understanding the human RNases H, their roles in the effects of DNA-like ASOs, and the factors that influence the activities of DNA-like ASOs; today, we have the intellectual framework for the design of optimized RNase H-active ASOs. In this report, we shall review the progress in this area and discuss the implications of the observations on the design of more potent ASO therapeutics. 2.1.2
RNase H Enzymes
The RNases H hydrolyze RNA in RNA–DNA hybrids [6]. RNase H belongs to a nucleotidyl transferase super family, which includes transposase, retroviral integrase, Holliday junction resolvase, and the RISC nuclease Argonaute2. Proteins with RNase H activity have been isolated from numerous organisms ranging from viruses to mammalian cells and tissues [7–12]. Although RNase H isotypes vary substantially in molecular weight and associated functions, the nuclease properties of the enzymes are similar. All RNase H enzymes, for example, function as endonucleases exhibiting limited sequence specificity, require divalent cations (e.g., Mn2⫹ and Mg2⫹), and generate products with 5⬘-phosphate and 5⬘-hydroxyl termini [8]. In prokaryotes, three classes of RNase H enzymes, RNase H1, H2, and H3, have been identified. RNase H2 and H3 share significant sequence homology, whereas RNase H3 and RNase H1 share similar divalent cation preference and cleavage properties. Of the three classes, RNase H2 appears to be the most ubiquitous [13]. To date no organism has been shown to express active forms of all three classes of RNase H. The best characterized of the prokaryotic enzymes is Escherichia coli RNase H1 [14–18]. This enzyme is believed to be involved in DNA replication [19]. The key amino acids involved in metal binding, substrate binding, and catalysis have been identified and are highly conserved in the RNase H1 family [14,20–22]. Furthermore, the enzyme–substrate interaction has been determined based on the X-ray cocrystal structure for Bacillus halodurans RNase H1 and the heteroduplex substrate [23]. RNase H has also been shown to be involved in viral replication. RNase H domains have been identified in viral reverse transcriptases, and these typically share homology with E. coli RNase H1 [20]. The RNase H portion of the enzyme has been shown to cleave the viral RNA strand producing RNA primers for second-strand DNA synthesis, thereby converting the viral RNA into double-strand DNA [24]. Two classes of RNase H enzymes have been identified in mammalian cells [7,9–12]. They were reported to differ with respect to cofactor requirements and activity. For example, RNase H type 1 has been shown to be activated by both Mg2⫹ and Mn2⫹, and was active in the presence of sulfhydryl reagents, whereas RNase H type 2 was shown to be activated by only Mg2⫹ and inhibited by Mg2⫹ and sulfhydryl reagents [12]. 2.1.3
Human RNases H
Both human RNase H genes have been cloned and expressed [21–22,25]. RNase H1 is a 286 amino acid (aa) protein with a calculated mass of 32 kDa [22]. The enzyme is encoded by a single
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 49
THE RNase H MECHANISM
49
gene that is at least 10 kb in length and is expressed ubiquitously in human cells and tissues. The amino acid sequence of human RNase H1 displays strong homology with RNase H1 from yeast, chicken, E.coli, and mouse [22]. The human RNase H2 enzyme is a 299 aa protein with a calculated mass of 33.4 kDa and has also been shown to be ubiquitously expressed in human cells and tissues ([25]; H. Wu, unpublished data). Human RNase H2 shares strong amino acid sequence homology with RNase H2 from Caenorhabditis elegans, yeast, and E. coli [25].
2.2 HUMAN RNase H1 2.2.1
Biochemical Properties
Human RNase H1 has been cloned, expressed, and purified to electrophoretic homogeneity. The enzyme is active as a single polypeptide and retains activity after it is denatured and refolded [22,26]. The activity of RNase H1 is Mg2⫹-dependent and inhibited by Mn2⫹. Human RNase H1 was also inhibited by increasing ionic strength with optimal activity for both KCl and NaCl observed at 10–20 mM [22,26]. The enzyme exhibited a bell-shaped response to divalent cations and pH, with the optimum conditions for catalysis observed to be 1 mM Mg2⫹ and pH 7–8 [22,26]. The protein was shown to be reversibly denatured under the influence of temperature and destabilizing agents such as urea. Renaturation of human RNase H1 was observed to be highly cooperative and did not require divalent cations. Furthermore, RNase H1 displayed no tendency to form intermolecular disulfides or to form homomultimers. Human RNase H1 was shown to bind selectively to “A-form” duplexes with 10–20-fold greater affinity than that observed for E. coli RNase H1 [22,26]. Finally, human RNase H1 displays a strong positional preference for cleavage, that is, the enzyme cleaves between 8 and 12 nucleotides from the 5⬘-RNA–3⬘-DNA terminus of the duplex [26]. One biochemical property that has been used to classify RNase H enzymes is the sensitivity to sulfhydryl alkylating reagents such as N-ethylmaleimide (NEM) [12,14,22,27]. In general, RNase H1 enzymes are inhibited by NEM and both the E.coli and human enzymes share this property. In the case of E. coli RNase H1, NEM alkylation of C13 and C133 was responsible for the observed loss in enzymatic activity [14]. Alkylation of the cysteines was predicted to sterically interfere with substrate binding, as the E.coli enzyme was shown to be active under both reduced and oxidized conditions and the cysteine residues were not required for endonuclease activity [14]. A similar NEM alkylation pattern was observed for human RNase H1 with alkylation of the conserved C148 (C13 in the E. coli enzyme) resulting in the observed loss in activity (Figure 2.1) [28]. In addition, NEM alkylation of human RNase H1 had no effect on the binding affinity of the enzyme for the substrate. Given that C148 is positioned close to the catalytic site of the enzyme and the phosphate backbone of the substrate, NEM alkylation likely interferes with proper positioning of the enzyme on the substrate. Human RNase H1 is active only under reduced conditions [28]. Site-directed mutagenesis of human RNase H1 indicated that the conserved C148 and adjacent C147 residues were responsible for the observed redox-dependent activity of the enzyme (Figure 2.1) [28]. Tryptic digestion of the enzyme and analysis of the fragments by HPLC-ESI-FITCR mass spectrometry revealed a unique disulfide bond between the vicinal C147 and C148 residues under oxidized conditions [28]. Oxidation of the enzyme had no effect on the binding affinity of the enzyme for the substrate suggesting that the oxidized enzyme exhibited a conformation that could no longer catalyze the hydrolysis of the RNA. 2.2.2
Structure and Enzymology
The structure of human RNase H1 consists of three domains: a 73-aa region homologous with the RNA-binding domain (RNA-BD) of yeast RNase H1 at the amino-terminus of the protein, the conserved catalytic domain at the carboxy-terminus of the protein, and a 62-aa spacer region that
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 50
50
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION E186 W43 K59-K60
RNA-binding
1
Figure 2.1
C18
C46
D145
Spacer
73
K226-K227 K236 D210 K231
Catalytic
135 C147-C148 C191
286
Schematic showing the structure of human RNase H1. Enzyme consists of three domains. The 73-aa RNA-BD at the amino-terminus of the protein contains the tryptophan and lysine residues involved substrate binding at, respectively, positions 43, 59, and 60 as well as two cysteines at positions 18 and 46. The 62-aa spacer region is positioned between the RNA-BD and the catalytic domain. The 151-aa catalytic domain at the carboxy-terminus of the enzyme contains the glutamic and aspartic acid residues of the catalytic triad at positions 145, 186, and 210; the basic substrate-binding residues at positions 226, 227, 231, and 236; and the cysteines of the redox switch at positions 147 and 148.
separates the RNA-BD from the catalytic domain (Figure 2.1) [29–31]. The roles of each of the regions and a number of the specific amino acids were determined by site-directed mutagenesis of both the enzyme and substrate [26,29,32–35]. Although the specific role of the spacer region remains unclear, this region was shown to be required for the activity [29,36].
2.2.2.1 RNA-Binding Domain The RNA-BD of human RNase H1 is conserved in other eukaryotic RNases H1 [22,31]. The nuclear magnetic resonance (NMR) structure of the RNA-BD of Saccharomyces cerevisiae RNase H1 consists of a three-stranded antiparallel -sheet sandwiched between two -helices and shares strong structural similarities with the N-terminal domain of the ribosomal RNA-binding protein L9 [31,37]. Two highly conserved lysine residues are located within the third -strand. In addition, a highly conserved tryptophan at position 22 was shown to project outwards. A solvent exposed aromatic amino acid at this position was also observed in the L9 protein and has been shown to be important for binding to 23S ribosomal RNA [37]. In a 46 aa peptide corresponding to the RNA-BD of S. cerevisiae RNase H1, the conserved lysine residues have been shown to be important for binding to the heteroduplex substrate [30]. Site-directed mutagenesis of human RNase H1 showed that the conserved lysine residues at positions 59 and 60 were involved in binding to the heteroduplex substrate (Figure 2.1) [36]. Alanine substitution of the Lys59 (K59A) and Lys60 (K60A) resulted in a twofold reduction in the binding affinity for the substrate compared with the wild-type enzyme. Alanine substitution of the conserved tryptophan residue (W43A), in contrast, had no effect on the binding affinity for the substrate but exhibited a significantly lower Km and kcat values compared with the wild-type enzyme (Table 2.1) [36]. The lower Km and kcat values for the mutant enzyme are indicative of nonproductive binding interactions between the enzyme and the substrate suggesting that the tryptophan is important for properly positioning the enzyme on the heteroduplex for catalysis. Importantly, human RNase H1 has been shown to exhibit a strong positional preference for cleavage cleaving the heteroduplex substrate 7–12 nucleotides from the 3⬘-DNA/5⬘-RNA terminus (Figure 2.2) [26]. Under single turnover conditions, the positional preference for cleavage was more pronounced suggesting that given a single interaction between human RNase H1 and the heteroduplex, the majority of the RNase H1 proteins bound to the heteroduplex in such a manner so as to cleave the substrate 7–10 nucleotides from the 5⬘-RNA [36]. Mutants in which W43 and K59–K60 of the RNA-BD were substituted with alanine, showed a loss of the positional preference for cleavage (Figure 2.2) [36]. Together these data suggest that the W43, K59, and K60
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 51
THE RNase H MECHANISM
51
Table 2.1 Initial Cleavage Rates for Wild-Type and Mutant Human RNase H1 Proteins Human Enzyme RNase RNase RNase RNase
H1 H1[K59,60A] H1[W43A] H1[W43/K59.60A]
kcat (min⫺1)
Km (nM) 601 1264 129 1084
⫾ ⫾ ⫾ ⫾
42 88 4 96
1.46 1.00 0.04 1.19
⫾ ⫾ ⫾ ⫾
0.05 0.08 0.001 0.11
kcat/Km (M⫺1/min) (2.4 ⫾ 0.04) (7.9 ⫾ 0.6) (3.0 ⫾ 0.2) (8.8 ⫾ 0.1)
⫻ ⫻ ⫻ ⫻
6
10 105 105 105
Kd (nM) 665 1121 412 1556
⫾ ⫾ ⫾ ⫾
13 136 67 119
Note: The kcat, Km, and Kd values were determined as previously described [36]. The kcat, Km, and Kd values are an average of n ⱖ 2 slopes of Lineweaver–Burk and/or Augustisson analysis with estimated errors of CV ⬍ 10%. (A)
r(GGGCGCCGUCGGUGUGG) d(CCCGCGGCAGCCACACC) (B)
r(GGGCGCCGUCGGUGUGG) d(CCCGCGGCAGCCACACC) Figure 2.2
Comparison of cleavage patterns for human and E. coli RNases H1. Digestion of the heteroduplex was performed as previously described [29]. The RNA sequence (5⬘ → 3⬘) is shown above the DNA sequence. The arrows indicate the sites of enzymatic digestion, and the size of the arrows reflects the relative cleavage intensities. (A) Cleavage pattern for human RNase H1. (B) Cleavage pattern for E. coli RNase.
residues constitute an extended nucleic-binding surface for the RNA-BD of the human RNase H1 with the lysine residues forming electrostatic interactions with the phosphate backbone and the solvent-exposed tryptophan forming either stacking interactions or hydrogen bonds with the heterocycle bases of the substrates [36]. In addition, these data suggest that the interaction between the RNA-BD and the substrate takes place at the 3⬘-DNA/5⬘-RNA pole of the heteroduplex (Figure 2.3). Structure–activity relationships at the 3⬘-DNA/5⬘-RNA terminus of the heteroduplex substrate have also been performed. These studies include modifications at the 3⬘, 2⬘, and heterocycle base of the terminal 3⬘-nucleotide in the DNA strand as well as modifications at the 5⬘ and 2⬘ of the terminal 5⬘-nucleotide in the RNA strand [36]. Heteroduplex substrates containing a 3⬘-phosphate at the 3⬘-terminus of the DNA strand or 5⬘-phosphate at the 5⬘-terminus of the RNA strand had no effect on either the cleavage pattern or rate of cleavage compared with the substrate containing hydroxyl groups at the 3⬘-DNA/5⬘-RNA terminus [36]. In contrast, a single ribonucleotide or 2⬘-methoxyethyl (MOE) substitution at the 3⬘-terminus of the DNA strand, with or without a 3⬘-phosphate, resulted in the ablation of the 5⬘-most cleavage site (Figure 2.3). A similar ablation of the 5⬘-most cleavage site was observed for a heteroduplex substrate in which a mismatched base pair was positioned at the 3⬘-DNA/5⬘-RNA terminus [36]. Similarly, heteroduplex substrates in which the DNA strand was successively truncated at the 3⬘-terminus resulted in a concomitant ablation of the 5⬘-most cleavage with a constant 7 base pair separation between the 3⬘-terminus of the DNA and 5⬘-most cleavage site [36]. Conversely, no shift in the cleavage pattern was observed for heteroduplex substrates in which the DNA strand was successively truncated at the 5⬘-terminus. The structure–activity relationships for the 3⬘-DNA/5⬘-RNA terminus of the heteroduplex are consistent with the site-directed mutagenesis of the RNA-BD in which stable base pairing at the 3⬘-DNA/5⬘-RNA terminus would be important for intercalation of the
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 52
52
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION (A)
Spacer RNABD
Cat
5′ 3′
7 base pairs
(B)
Spacer RNABD
Cat
5′ 3′
7 base pairs Figure 2.3
Schematic illustrating the relationship between the position of the RNA-binding domain and the catalytic domain of human RNase H1 on the heteroduplex substrate. (A) Each observed cleavage site on the RNA is coupled to a specific binding interaction between the RNA-binding domain and the 3⬘-DNA/5⬘-RNA pole of the heteroduplex substrate. The distance between the heteroduplex/RNAbinding domain interaction and the catalytic site is ⬃7 base pairs. (B) Crossed-out box represents either an RNA/RNA, 2⬘-MOE/RNA or mismatched base pair at the 3⬘-DNA/5⬘-RNA terminus of the heteroduplex. The alteration in helical geometry or steric interference by the 2⬘-substitutents disrupts the binding interaction between the RNA-binding domain and the heteroduplex resulting in the observed ablation of catalytic activity at the 5⬘-most cleavage site on the RNA.
W43 residue, and the interstrand phosphate distance across the minor groove within this region would be critical for the interaction with K59 and K60 [36]. Taken together these data suggest that the RNA-BD of human RNase H1 binds to the first stable 3⬘-DNA/5⬘-RNA base pair in the heteroduplex substrate and positions the catalytic domain approximately one helical turn 5⬘ on the RNA (Figure 2.3).
2.2.2.2 Catalytic Domain The catalytic domain of human RNase H1 is highly conserved relative to other RNase H1 proteins [15–17,29,38]. The glutamic acid and two aspartic acid residues of the catalytic site, as well as the histidine and aspartic acid residues of the proposed second divalent cation-binding site of the E. coli enzyme are conserved in human RNase H1 (Figure 2.1) [15–17,38]. In addition, the lysine residues within the highly basic -helical substrate-binding region of E. coli RNase H1 are also conserved in the human enzyme (Figure 2.1). The substitution of the conserved catalytic amino acids Asp-145, Glu-186, and Asp-210 of human RNase H1 with respectively, Asn, Gln, and Asn resulted in the complete ablation of the catalytic activity [29]. Furthermore, the ablation of cleavage activity observed for the catalytic site mutations did not appear to be due to a loss in the binding affinity for the heteroduplex substrate, as these substitutions had no effect on the binding affinity of the mutant proteins for the heteroduplex substrate. Alanine substitution of as few as two lysine residues in the basic substrate-binding region of the catalytic domain (e.g., lysines at positions 226, 227, 231, and 236)
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
THE RNase H MECHANISM
Page 53
53
ablated the activity of human RNase H1 [29]. Again, the basic substrate-binding mutants exhibited binding affinities for the substrate comparable to the wild-type enzyme, suggesting that other regions of the human enzyme may be contributing to the overall binding interaction and that the lysine residues may play a more critical role in properly positioning the enzyme on the substrate for cleavage. In fact, the binding affinity for the deletion mutant of human RNase H1 in which the RNA-BD was deleted was fivefold lower compared with the wild-type enzyme [29]. In addition, the catalytic rate for the mutant enzyme without the RNA-BD was twofold faster than the kcat observed for the wild-type enzyme [29]. The deletion mutant demonstrates that the RNA-binding domain increases the affinity for substrate and reduces catalytic efficiency. Structure–activity relationships at the catalytic site of the heteroduplex substrate have also been determined [35]. In this study, modified nucleotides were introduced into the oligodeoxyribonucleotides at the human RNase H1-preferred cleavage sites on the heteroduplex. The modifications consisted of nucleotides exhibiting RNA-like northern, DNA-like southern, and eastern-biased sugars with and without 2⬘-substitutents. In addition, varying degrees of conformational flexibility were introduced into the heteroduplex substrate by incorporating base modifications which -stack with adjacent nucleotides but do not form hydrogen bonds, abasic deoxynucleotides, internucleotide hydrocarbon linkers ranging from three to five residues, and ganciclovir substitution of the deoxyribose. Heteroduplexes containing modifications exhibiting strong northern (e.g., 2⬘-fluorothymidine and 2-thiouridine) or southern (e.g., 2⬘-methylthiothymidine) conformational biases with and without bulky 2⬘-subtituents showed significantly slower site-specific cleavage rates for the ribonucleotide opposing the modification as well as the adjacent ribonucleotides. The nucleotide modifications predicted to mimic the sugar pucker of the deoxyribonucleotide of an RNA/DNA heteroduplex (e.g., heteroduplexes containing the 2⬘-ara-fluoropyrimidines and pseudouridine modifications) exhibited cleavage rates comparable to the rates observed for the unmodified substrate [35]. The 2⬘-ara-fluoro modification has been shown by NMR to form the eastern O4⬘-endo sugar conformation similar to DNA when hybridized to RNA [39]. In addition, the size and position of the 2⬘-ara-substituent, that is, the fluorine is directed upward and away from the minor groove, is predicted not to sterically interfere with the enzyme. These modified heteroduplexes, which suggest variations in minor groove width as a function of sugar conformation, appear to obviate the proper positioning of the enzyme on the heteroduplex substrate. Modifications imparting the greatest degree of conformational flexibility were the poorest substrates, resulting in dramatically slower cleavage rates for the ribonucleotide opposing the modification and the surrounding ribonucleotides. Specifically, heteroduplex substrates containing highly flexible hydrocarbon linkers were among the poorest substrates for RNase H1 activity [35]. The site-specific rates for the ribonucleotide opposing the hydrocarbon linkers as well as the surrounding 3⬘- and 5⬘-ribonucleotides were either significantly reduced or ablated resulting in initial cleavage rates (V0), approximately twofold slower than the unmodified substrate. Heteroduplex substrates containing ganciclovir-, abasic-, and tetrahydrofuran-modified deoxyribonucleotides were also poor substrates for human RNase H1, although the site-specific cleavage rates for these heteroduplexes were slightly faster than the rates observed for the heteroduplexes containing the hydrocarbon linkers [35]. In contrast, the base modifications that -stack with adjacent nucleotides, but do not form hydrogen bonds with the bases of the RNA strand (e.g., 2-fluoro-6-methylbenzoimidazole, 4-methylbenzoimidazole, and 2,4-difluorotoluyl deoxyribonucleotides), better supported human RNase H1 activity. Comparable initial cleavage rates and site-specific cleavage rates were observed for these heteroduplexes compared with the unmodified substrate [35]. Although conformational flexibility of the deoxyribose was preferred, flexibility in the phosphate backbone of the DNA strand inhibited human RNase H1 activity. These data suggest that proper positioning of the phosphate groups
CRC_8796_ch002.qxd
6/20/2007
54
9:30 PM
Page 54
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
of the deoxyribonucleotide, presumably for electrostatic contact with the enzyme, is essential for human RNase H1 catalysis. The cleavage rates observed for the -stacking deoxyribonucleotides suggest that stable base stacking independent of hydrogen bond formation between the bases at the catalytic site appeared to offer sufficient rigidity to the phosphate backbone. Taken together these data suggest that sugar conformation, minor groove width, and the relative positions of the intra- and internucleotide phosphates are critical determinants in the selective recognition of the heteroduplex substrate by human RNase H1. In addition, the structure–activity relationships at the catalytic site of the heteroduplex substrate suggest that the preferred properties for the modified oligodeoxyribonucleotide include (1) a conformationally flexible sugar producing an O4⬘-endo pucker when hybridized to RNA; (2) no sterically bulky 2⬘-substituents; and (3) a conformationally rigid phosphate backbone. Clearly, the 2⬘-ara-fluoro-, pseudouridine-, and -stacking-modified deoxyribonucleotides exhibit many of these qualities. The recent X-ray crystal structure of RNase H from B. halodurans bound to the RNA/DNA heteroduplex substrate offers further insights into the observed effects of modified nucleotides on human RNase H1 catalysis [23]. Specifically, the catalytic domain of the enzyme was shown to interact with both the RNA and DNA strands of the heteroduplex substrate including the phosphates of the RNA strand on either sides of the scissile phosphate; the three 2⬘-hydroxyls upstream; and three 2⬘-hydroxyls downstream of the scissile phosphate; the heterocycle bases of both strands upstream of the scissile phosphate; and the DNA backbone upstream of the cleavage site via a phosphate-binding pocket (Figure 2.4). In all, the binding interactions between the enzyme and substrate comprise six base pairs of the heteroduplex substrate. The catalytic domain of human RNase H1 shares strong sequence homology with the catalytic domain of the B. halodurans RNase H, suggesting that human RNase H1 likely interacts in a similar manner with the heteroduplex substrate. Considering the scope of the interactions, modified nucleotides within the DNA strand of the heteroduplex can affect catalysis in a number of different ways. For example, the modified nucleotides could have a direct effect on catalysis if the modifications were positioned at sites on the substrate that interact directly with the enzyme (e.g., modified internucleotide linkages positioned at the phosphate-binding pocket of the enzyme) (Figure 2.4). In addition, modified nucleotides that influence the local substrate structure would have a local effect on catalysis when positioned adjacent to the nucleotides that directly interact with the enzyme (e.g., hydrophobic base modifications) (Figure 2.4). Finally, modified nucleotides that exert a long-range influence on substrate structure would exhibit a distributive or transmission effect on catalysis (e.g., northern- or southern-biased 2⬘-modifications positioned outside the footprint of the enzyme) (Figure 2.4).
3′
5′
5′
3′ PO-binding pocket Figure 2.4
Model for the interaction of RNase H1 with the heteroduplex substrate. The putative enzyme/nucleotide interactions for cleavage at ribonucleotide 7. The arrow indicates the position of the scissile phosphate. Heteroduplex is shown with the RNA strand (upper) oriented from 5⬘ to 3⬘ and the ASO (lower) from 3⬘ to 5⬘. The dark gray and light gray structures indicate the interactions between the enzyme and, respectively, the sugars of the nucleotides and heterocycle bases. The black filled circles represent the enzyme/phosphate interactions.
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 55
THE RNase H MECHANISM
2.2.3
55
Biological Roles
Human RNase H1 is ubiquitously expressed in the cell, residing in both the nucleus and cytoplasm [40]. Important insights into the biological roles of mammalian RNase H1 have recently been provided by an RNase H1 knockout mouse [41]. The knockout was embryonically lethal and failed to produce mitochondrial DNA resulting in defective mitochondria and massive apoptosis. Both the mouse and human enzyme have a putative mitochondrial localization signal (MLS). Thus, the authors concluded that the enzyme is likely involved in Okazaki fragment processing in the mitochondria. The biochemical and enzymological data are consistent with the proposed biological role of the enzyme. The enzyme is believed to participate in the generation and/or removal of RNA primers during lagging strand DNA synthesis. These RNA primers form chimeric structures consisting of a 7–14 ribonucleotide region at the 5⬘-terminus and contiguous stretches of DNA extending in the 3⬘-direction (Figure 2.5) [42]. On the basis of the positional preference for cleavage exhibited by human RNase H1, cleavage of the chimeric structure would occur at or near the RNA–DNA junction, effectively removing the RNA primer (Figure 2.5). Alternatively, human RNase H1 cleavage of the RNA/DNA heteroduplex formed during DNA replication would produce the observed 7–14 ribonucleotide primers for lagging strand DNA synthesis. The human RNase H1 activity observed for Okazaki-like substrates was consistent with the proposed biological role for the enzyme [43]. The Okazaki-like substrates consisted of an oligodeoxyribonucleotide annealed to a complementary RNA/DNA chimeric oligonucleotide containing 10 and 15 ribonucleotides at the 5⬘-pole and, respectively, 10 and 5 contiguous deoxyribonucleotides extending 3⬘. The Okazaki-like substrates ablated the 3⬘-most cleavage sites and exhibited enhanced cleavage rates for the remaining cleavage sites. In other words, the successive ablation of the 3⬘-most cleavage sites produced new preferred cleavage sites [43]. Furthermore, given that the short RNA primers are interspersed within long stretches of dsDNA, the model for the interaction between the enzyme and the heteroduplex substrate correlates well with biological role for the enzyme. First, the strong positional preference for cleavage is consistent with the length of the RNA primers. Second, human RNase H1 binds the RNA/DNA heteroduplex ⬃50-fold tighter than dsDNA suggesting that the enzyme would not be trapped in nonproductive interactions within the large field of dsDNA [26]. Third, the limited sequence discrimination exhibited by the enzyme would be beneficial given that the RNA primers comprise mixed sequences. Finally, given that high concentrations of proteins and their cofactors such as manganese superoxide dismutase (SOD2) are required to regulate the highly oxidative environment of the mitochondria, human RNase H1 may have evolved a sensitivity to manganese as well as a redox switch to regulate the activity of the enzyme within this environment.
RNA primer
Lagging strand
5′ Okazaki fragment
RNA primer 5′
Okazaki fragment
Okazaki fragment
Leading DNA strand Figure 2.5
Schematic illustrating the position of human RNase H1 cleavage during lagging strand DNA synthesis. Upper and lower lines represent, respectively, the lagging and leading DNA strands. Lagging strand contains the 7–12 nucleotide RNA primers interdispersed between 200 and 300 nucleotide long Okazaki fragments. Arrows indicate the predicted human RNase H1 cleavage sites based on the positional preference for cleavage exhibited by the enzyme, that is, 7–12 nucleotides from the 5⬘-terminus of the RNA. Human RNase H1 cleavage is predicted to occur at or near the junction between the RNA primer and the Okazaki fragment.
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 56
56
2.2.4
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Genomics and Regulation
Human RNase H1 is encoded by a single gene on chromosome 2p25 [22]. The gene spans 13 kb and contains seven introns with the shortest being 333 base pairs and the longest being 4480 base pairs. There are also multiple pseudogenes in chromosomes 1 and 17. Although expressed at low levels, the enzyme is broadly expressed in cells and tissues [22]. In all cells and tissues, we observed a 1.2 kb band that corresponds to the mature message and a 5 kb band that may be an alternatively or incompletely processed message or a transcript from one of the pseudogenes. The promoter region has numerous potential regulatory elements, but to date, we have seen no evidence of transcriptional regulation of the gene (Wu, unpublished data). Obviously, much more work is required before firm conclusions can be drawn about transcriptional regulation or alternative pre-mRNA processing.
2.3 HUMAN RNase H2 Although human RNase H2 has been cloned and expressed by a number of laboratories [25], much less is known about the properties of this enzyme. This is due primarily to the fact that human RNase H2 is inactive as a monomer. Human RNase H2 is also inactive in the gel renaturation assay so there is no assay with which to study the enzyme in situ. Consistent with these observations, recombinant RNase H2 from yeast was also shown to be inactive as a single polypeptide [44]. In fact, affinity purification identified two yeast proteins Ydr279p and Ylr54p associated with RNase H2, which restored RNase H2 activity in a reconstitution assay [44]. 2.3.1
Structure and Enzymology
Human RNase H2 is a 33 Kd protein that is homologous to E. coli RNase H2 (23% amino acid identity). On the basis of the crystal structure and mutational analyses of archaeal RNase H2, human RNase H2 has highly conserved RNA binding and catalytic domains [45,46]. Of the type 2 enzymes, prokaryote RNases HII are the best characterized. The three-dimensional structure has been determined and the key catalytic amino acids identified [47]. Although type 1 and 2 enzymes exhibit very low-sequence homology, the tertiary structures of these enzymes are similar [45]. In fact, the catalytic- and substrate-binding amino acids of type 1 and 2 enzymes are conserved [47]. The prokaryote type 1 and 2 enzymes were also shown to generate similar patterns based on short heteroduplexes [48]. Finally, prokaryotic RNases HI and HII were shown to differ with respect to cofactor requirements. Specifically, RNase H1 can be activated with both Mg2⫹ and Mn2⫹, whereas RNase H2 is active only in the presence of Mn2⫹ [48]. Given that cloned, expressed, and purified human RNase H2 is inactive in the gel renaturation or solution-based assays, we have developed an assay that, for the first time, supports preliminary characterization of the enzymology of human RNase H2 (Wu, unpublished data). To achieve this, we reasoned that the enzyme may require one or more protein cofactors for activity or that refolding of the enzyme could be ineffective. Thus, we prepared highly purified polyclonal antibodies to both human RNase H1 and RNase H2 and used them to immunoprecipitate both native enzymes in protein complexes from cells. We immunoprecipitated the overexpressed cloned enzymes and analyzed the activity of both the native and overexpressed proteins either by the trichloroacetic acid (TCA) precipitation or gel electrophoresis assays. For the overexpression of human RNase H2, a strain of adenovirus containing the full-length H2 cDNA insert was developed (Figure 2.6A). Figure 2.6B shows the Western blot for overexpressed human RNase H2 in Hela and A549 cells. Furthermore, the virally encoded human RNase H2 protein comigrated with the RNase H2 protein from uninfected cells confirming that the overexpressed protein was full length (data not shown). Peak expressions were observed 36–48 h after
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 57
THE RNase H MECHANISM
57
(A)
Full-length human RNase H2 cDNA Met1
Inserted cDNAs
FL_H2
Met27
FL_H1
MLS Full-length human RNase H1 cDNA Met27
NT 26 animo acid minus H1 cDNA
Virus shuttle vector: pACCMVpLpA(-)LoxP-ssp
Adv arm CMV promoter − MCS Adv arm (B) Size standard
Native Hela lysate
H2 virus infection
A549 cells Time (h)
0
12
24
36
Hela cells 48
0
12
24
48
Size standard 50 kDa
50 kDa RNase H2
36 kDa
36 kDa 30 kDa
30 kDa H2 Ab immobilized on Agarose Gel
Figure 2.6
36
Western blot with anti-RNase H2 Ab
Development of adenoviruses overexpressing human RNases H. (A) Human RNase H constructs in adenovirus shuttle vectors. Full-length (FL) and N-terminal 26 amino acid (putative mitochondria localization signal, MLS) minus RNase H1, and full-length RNase H2 cDNAs were amplified by PCR and cloned into EcoRI and XhoI sites in the multiple cloning site (MCS) downstream from the CMV promoter in the adenovirus shuttle vector, pACCCMVpLpA(-)Loxp-ssp (core facility of University of Michigan). (B) Western blot analysis of protein lysates from Hela or A549 cells infected with fulllength H2 virus (200 pfu/cell). The cells were harvested at different time points (0, 12, 24, 36, and 48 h) after virus infection. The protein concentrations of the cell lysates were measured. The lysates were subjected to 4–20% gradient SDS-PAGE (20 g/lane) and Western blot analysis with antiRNase H2 antibody (right panel). Immunoprecipitation was performed using uninfected Hela cell lysate with purified H2 Ab which was covalently immobilized to agorose beads. The eluted samples were subjected to western blot analysis with the H2 Ab (left panel).
infection. Human RNase H2 was also overexpressed in T24, MCF7, and HepG2 cells (data not shown). The overexpression of human RNase H1 was performed as previously reported [1]. Because RNase H1 contains a 26 aa putative MLS at the N-terminus of the protein, the 26-aa deletion mutant adenovirus was also developed to evaluate the role of this signal peptide in the subcellular localization of RNase H1. To compliment the overexpression experiments, potent selective DNA-like ASOs and small interference RNAs (siRNA) were identified to reduce cellular RNase H2 [49,50]. A screen of ASOs targeting the mRNA of human RNase H2 revealed ISIS 194186, which was located at nucleotides 1008 to 989 in the 3⬘ UTR of the RNA (accession number AY 363912) as the most potent ASO (Table 2.2). The most potent siRNA for RNase H2 was si-21956 and located at nucleotides 667–686 in the coding region. Both the ASOs and siRNAs targeting human RNase H2 mRNA reduced RNase H2 mRNA and protein levels in a dose-dependent manner and the effects were specific to RNase H2 (Figure 2.7). The duration of effect was greater than 48 h (data not shown). The two RNase H enzymes display different cleavage patterns in the substrate (Figure 2.8). Human RNase H1 preferentially cleaves the heteroduplex 6–7 nucleotides from the 5⬘-RNA/3⬘-DNA terminus of the duplex while RNase H2 preferentially cleaves 11–12 bases from this terminus. Further, the cleavage pattern observed for immunoprecipitated human RNase H1 was identical to that observed with cloned and purified RNase H1 [40]. In fact, there was excellent correlation between the human RNase H1 activities observed for the recombinant protein, the gel renaturation assay, and the immunoprecipitation (IP) assay. Specifically, RNase H1 immunoprecipitated from human cells exhibited similar cleavage site specificity and basic properties such as sensitivity to divalent cations as those observed for both the recombinant protein and gel renaturation
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 58
58
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION Table 2.2 ASOs and siRNAs against Human RNase H2 ISIS # 21955 21956 21957 21958 21959 21960 21961 21962 194186
Antisense oligonucleotides O
O B
O O P O -S O
2′-MOE O O
B DNA
O P O -S O
Si21955 si21956 si21957 si21958 si21959 si21960 si21961 si21962
Small interference RNA (siRNA)
Sequences
% Inhibition
CAGTTTCTCCACGAATTGCC TTTTGTCTTGGGATCATTGG AGCTGAACCGGACAAACTGG CCTCTTTCTCCAGGATGGTC ACTCCAGGCCGCGTTCCAGG CCTACGTGTGGTTCTCCTTA GCACACTCCCACCTTGCTTC CAAAAGGAAGTAGCTGGACC CCTACGTGTGGTTCTCCTTA
33.3 63.1 68.1 38.0 81.2 91.7 6.1 36.0
GGCAAUUCGUGGAGAAACUGC CCAAUGAUCCCAAGACAAAAG CCAGUUUGUCCGGUUCAGCUG GACCAUCCUGGAGAAAGAGGC CCUGGAACGCGGCCUGGAGUC UAAGGAGAACCACACGUAGGG GAAGCAAGGUGGGAGUGUGCU GGUCCAGCUACUUCCUUUUGG
19.2 87.6 42.4 45.8 53.8 9.9 15.2 0
Note: Bold text in the ASO sequences represent 2⬘-MOE nucleotides and plain text represent deoxynucleotides. All ASOs contained phosphorothioate linkages throughout the molecules. To the left of the table is the structure of 2⬘-MOE and 2⬘-deoxynucleotides with a phosphorothioate linkage between them. % inhibition: reduction of RNase H2 mRNA level in A549 with ASO (200 nM) or siRNA (100 nM) treatment for 24 h compared to control oligonucleotide or siRNA treatment, detected by Northern blot with 32Plabeled RNase H2 cDNA probe. ISIS194186 shares the same sequence as ISIS21960 (the most potent ASO for RNase H2 in the study), but with only five (instead of six) 2⬘-MOE nucleotides in both wings of the oligonucleotide. For siRNAs, all nucleotides are ribonucleotides and the internucleotide linkages are phosphates. Only the sense strands are shown.
Hela cells
(A) Treatment
Control
Concentration (nM)
0 120 10
ASO194186 25
60 120
Hela cells
A549 cells Control
ASO194186
0 120 10 25
60 120
Control
si21956
0 120 10 25
60 120
A549 cells Control 0
si21956
120 10 25 60 120
RNase H2 (1.4 kb) G3PDH
(B) RNase H2 (~37 kDa) 100% ------------------- <25%
Figure 2.7
100% ------------------- <10%
100% ------------------- <20%
100% ---------------- <10%
ASO ISIS194186 or si21956 reduces RNase H2 mRNA and protein levels in Hela and A549 cell lines. Cells were treated with different amounts of ASO or siRNA for 24 h and total RNA and cell lysates were prepared. (A) RNA was subjected to 1.2% agarase/formaldehyde gel (5 g total RNA/lane) and Northern blot analysis with 32P-labeled human RNase H2 or a G3PDH cDNA probe. (B) 20 g proteins of cell lysate were used for Western blot with anti human RNase H2 Ab.
3 8 24 60
∗
∗ ∗
0 1 3
8 24 60
G−5′
G
G
C
G
C
C
G
U
C
G
G
U
G
U
G
G−3′
RNA sequence
0
10
20
30
40
G G
C
G
C C* G
U C* G*
G
U
G
U
Substrate RAS RNA sequence (5′−3′)
G
G
RNase H2
RNase H1
G
9:30 PM
Relative percentage digestion
Different digestion patterns of human RNase H1 and H2. The 17-mer RAS RNA/DNA substrate was prepared and subjected to digestion by the H1 or H2 Ab immunoprecipitated (IP) samples from Hela cells for different time periods at 37oC. The digested duplexes were subjected to denaturing polyacrylamide gel analysis. (Left) Cleavage of 17-mer RAS duplex. The asterisks indicate the major differences in cleavage sites between RNase H1 and H2. (Right) The relative extent of digestions at each position of the substrate was calculated with the phosphor-imager and the relative percentages of digestion are compared between RNase H1 and H2. The sequence of the target RNA is shown to the right of the gel image and as the abscissa of the graph that quantitates the site-specific cleavage ratio.
1
H2
6/20/2007
Figure 2.8
Time (min) 0
H1
CRC_8796_ch002.qxd Page 59
THE RNase H MECHANISM 59
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 60
60
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
assay [26,28,29,40]. These data also confirm the specificity of the IP assay because different cleavage patterns were observed for the immunoprecititation of human RNase H2 and RNase H1 (Figure 2.8 and Figure 2.13). Finally, these results differ from the cleavage specificities observed for prokaryotic RNases H2 in which similar cleavage patterns were observed for both the type 1 and 2 enzymes [48]. The metal requirements between RNases H2 from human and prokaryotes also differed. Specifically, human RNase H2 is active in the presence of Mg2⫹ and Mn2⫹ whereas the prokaryote RNase H2 was active only in the presence of Mn2⫹ (Wu, unpublished). Figure 2.9 demonstrates that overexpression of the enzymes resulted in greater activity in the Hela cell extracts. The extent of the increase in RNase H1 activity was comparable to the change in the enzyme protein level as shown in the Western blot after H1 Ab IP (Figure 2.9A), while approximately the twofold increase of H2 activity was much less than the change in the level of the protein (six- to eightfold) (Figure 2.9B). In contrast, when the cells were pretreated with H2 siRNA, the H2 activity extracted from cells was significantly reduced (⬃67%) and the extent of the reduction correlated well with the reduction of the H2 protein (Figure 2.9C). Our data suggest that RNase H2 may be part of a multiprotein complex that plays a key role in regulating its activity. For example, the failure to increase activity as greatly as the amount of RNase H2 overexpressed in the cell suggests that other proteins in the putative complex may be rate limiting (Figure 2.9B). In fact, Jeong et al. [44] have shown that S. cerevisiae RNase H2 is in a complex containing at least two other proteins and that these proteins are required for activity. We believe this is likely the case in mammalian cells as well.
(A)
(B) Control FL_H1 Virus virus
Loxp
40 30 20 10 0 0
5
10
Time (min)
Control H1 virus I.R. (nM/min) 1.6± 0.29 12.52± 0.43
Percentage digestion (%)
H1 virus
50
Percentage digestion (%)
60
60
Percentage digestion (%)
RNase H2
RNase H2
RNase H1
Figure 2.9
Control H2 siRNA siRNA treated treated cells cells
(C) Control FL_H2 Virus virus
H2 virus 50
Loxp
40 30 20 10 0
0
5
10
Time (min)
Control H2 virus I.R. (nM/min) 4.59±0.65 7.59 ± 2.66
30 Control siRNA H Ab IP
25
H2 siRNA treatment H2 Ab
20 15 10 5 0 0
5
10
Time (min)
Control siRNA H2 siRNA I.R. (nM/min) 3.02±0.30 0.98 ± 0.24
RNase H Ab immunoprecipitation (IP)-coupled TCA assay. Hela cells were either infected with human RNase H1, H2, control virus (200 pfu/cell) or treated with 100 nM H2, control siRNA in 10 cm plate in quadruplicate for 24 h before harvest. Cell lysates were prepared and protein concentrations measured. A 0.7 mg protein lysate was used for H1 Ab IP (15 g H1 Ab/mg protein lysate) or 0.35 mg per tube for H2 Ab IP (30 g H2 Ab/mg protein). One set of the IP samples was eluted in 2x SDS loading buffer (Invitrogen Inc., San Diego) and subjected to SDS-PAGE and Western blot with H1 or H2 Abs. The other three sets of IP samples were used in the enzyme activity assay with 50 nM of a 17-mer RNA/DNA duplex as the substrate. The RNA/DNA duplex was hybridized and then digested with the IP samples for different lengths of time at 37oC. The digested duplexes were subjected to TCA precipitation and the radioactivity in supernatants was determined for the digested RNA fragments by scintillation counting. The experiments were performed in triplicate. The bars show the standard errors of the mean. The initial rates were calculated and presented under the graph. Comparison of the effects of pretreatment of cells with control or full-length RNase H1 viruses (A), cells infected with control or H2 viruses (B), and cells transfected with control or RNase H2 siRNAs (C).
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 61
THE RNase H MECHANISM
61
Thus it is now possible to compare both human enzymes in comparable assays with IP validation that indeed each activity represents the enzyme assumed. Results from the assay demonstrate that the enzymes display different cleavage patterns. Obviously much more work is required with multiple substrates before drawing definitive conclusions about substrate requirements and cleavage patterns for human RNase H2. 2.3.2
Biological Roles
Little is known regarding the biological role of human RNase H2. Our IP data suggest that (1) the majority of the human RNase H2 activity was found in the nuclease; and (2) human RNase H2 may be part of a multiprotein complex that plays a key role in regulating its activity. To test this hypothesis, we evaluated the subcellular localization of human RNase H2 by fluorescence microscopy (Figure 2.10). As a control we also evaluated the subcellular localization of human RNase H1. In uninfected Hela cells, human RNase H2 is localized primarily in the nucleus. For human RNase H1, endogenous enzyme is present in very low levels and mainly in nucleus (Figure 2.10A). RNase H1 was difficult to identify in the cytosol by immunofluorescence, but faint cytoplasmic fluorescence was observed. In cells infected with adenoviral vectors overexpressing RNase H2, again the enzyme was localized primarily in the nucleus. Overexpression of fulllength RNase H1 resulted in extensive nuclear staining and staining of the cytoplasm. Because the N-terminal 26 aa of human RNase H1 contains a putative MLS, we constructed the 26-aa deletion (A)
(B) NR IgG
Anti-H1 Ab
(C) Anti-H1 Ab
Infected with virus 1 H1 rol _H 6(−) ont C 2 FL
us vir
Size standard
50 kDa
Uninfected Hela cell
Anti-H2 Ab
Uninfected Hela cell
Anti-H1 Ab
FL_H1 virus infected Hela cell
RNase H1
36 kDa
infected Hela cell
30 kDa
Mitotracker red Purified H1 Ab
Uninfected Hela cell
26(−)H1 virus infected Hela cell
Anti-H2 Ab
Anti-H1 Ab
FL_H2 virus infected Hela cell
FL_H1 virus infected Hela cell
Figure 2.10
FL_H1 virus infected Hela cell
26(−)H1 virus infected Hela cell
Anti-H1 Ab mitotracker red merge
FL_H1 virus infected Hela cell
26(−)H1 virus infected Hela cell
(See color insert following page 270.) Immunofluoresence staining of human RNases H with purified anti-H1 or H2 antibody. Normal rabbit IgG (NR IgG) was used as control. (A) Human RNase H1 and H2 immunostaining of normal (uninfected) or virus infected Hela cells. (B) RNase H1 staining of Hela cells infected with H1 virus and costaining with mitochondrial-specific stain. (C) Expression of human full length (FL) and N-terminal 26 amino acid (⫺26) minus RNase H1 in Hela cells. Hela cells were infected with FL or ⫺26 minus RNase H1 virus or control virus (LoxP) for 24 h. The cell lysates were prepared and subjected to immunoprecipitation with RNase H1 Ab. The immunoprecipitated samples were then used to the Western blot with same H1 Ab.
CRC_8796_ch002.qxd
6/20/2007
62
9:30 PM
Page 62
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
mutant and evaluated its subcellular localization (Figure 2.10C). Clearly, the deletion mutant is localized strictly to the nucleus confirming that the mitochondrial signaling sequence plays a role in the subcellular localization of the full-length enzyme. To evaluate this in more detail, we compared the immunoflourescense of full-length and 26-aa minus RNase H1 enzymes with a mitochondrial-specific staining with mitotracker red (Figure 2.10B). This clearly shows that the full-length enzyme is localized to the nucleus and colocalized with the mitochondrial stain while the 26-aa minus protein is localized strictly to the nucleus, which is consistent with the mouse [41]. In addition, these results suggest that the first 26 aa of the enzyme is indeed an MLS. Inasmuch as human RNase H2 has been thought to be involved in nuclear DNA synthesis, one possibility is that it is bound to chromatin. In these experiments, we cross-linked various proteins to chromatin in Hela cells as described in Figure 2.11. We compared the rates of in vivo cross-linking for human RNase H2 to chromatin to rates of cross-linking of proteins known to be integral members of chromatin and to chromatin-associated proteins. Figure 2.11 shows that RNase H2 readily cross-linked to chromatin at about the same rate as histone H4 or topoisomerase. The two well-known DNA-interacting transcription factors, CREB and NFB are also shown by this cross-linking method. In contrast, RNase H1 did not cross-link at any reproducible level at any time. These observations add support for the concept that RNase H2 is involved in nuclear DNA synthesis, while RNase H1 is involved in mitochondrial DNA synthesis. They also suggest that because RNase H2 is chromatin associated, it cannot participate in the antisense effects of DNA-like ASOs while RNase H1 can. Of course, our data do not exclude the possibility that other cellular interactions may limit the accessibility of RNase H2 to ASO–RNA duplexes, but since the putative RNase
(A)
Size Hela Std. (KDa) lysate MW
(B)
0
Cross-link time (min) 2 4 8 16 32
Abs for Western blot
RNase H2 in chromatin
Histone H3
10
Histone H4
100
DNA Topoisomerase I
36
RNase H2
36
RNase H1
% RNase H2
RNase H2 in Chromatin
17
100 75 50 25 0 0
2 4 8 16 Cross-linking time (min)
32
Histone H4 in chromatin
CREB
65
NFκB
% Histon H4
45
Histone H4 in nulear 100 75 50 25 0
0
2 4 8 16 Cross-linking time (min)
32
Figure 2.11 RNase H2 is associated with chromatin. (A) Formaldehyde cross-linking with the time course of 2, 4, 8, 18, and 32 min was performed in Hela cells preincubated with 3H-thymidine and the DNA/protein complexes. The complexes were boiled for 20 min in SDS loading buffer and the samples with the equivelent DNA concentrations (⬃80 g and 11,000 cpm of 3H/lane or 20 g/lane for histone H3 and H4 analysis) were subjected to SDS-PAGE. The Hela cell lysate (50 g) was loaded as the control. The Western blots were then performed with a variety of Abs. (B) Correlation of the crosslinking time with extent of protein (RNase H2, Fen 1, and histone H4) binding to DNA. The Western blots for RNase H2, Flap endonuclease-1 (Fen 1), and histone H4 were analyzed by image scanning from multiple (ⱖ3 times) cross-linking experiments. The extent of the three proteins binding to DNA was correlated to the cross-linking times. The bars represent standard error of the mean of multiple experiments.
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 63
THE RNase H MECHANISM
63
H2 protein complex is fully capable of degrading substrates in lysates, they do demonstrate that the protein complex does not preclude activity. Moreover, virtually all the nuclear RNase H2 cross-linked to chromatin, so certainly the bulk of the enzyme is likely complexed to chromatin. 2.3.3
Genomics and Regulation
The RNase H2 gene spans ⬃7 kb and has seven introns, the shortest of which is 89 base pairs and the longest 2678 base pairs (Wu, unpublished data). It is located at p13.2 on chromosome 19. In contrast to RNase H1, a single RNA at ⬃1.4 kb is detected with appropriate probes on Northern blots. In contrast to RNase H1, human RNase H2 appears to be transcriptionally regulated. Its expression appears to vary as a function of the cell cycle, being present in greater quantities during S phase (Sharkey and Crooke, unpublished).
2.4 THE ROLES OF THE HUMAN RNases H IN THE EFFECTS OF DNA-LIKE ASOs Although it has been assumed that DNA-like ASOs cause target RNA reduction by binding to the target RNA and creating a DNA/RNA duplex that serves as a substrate for RNase H, definitive proof that this mechanism is responsible for the observed effects in mammalian cells and animals has been lacking [1,3]. In cell-free systems, the addition of E. coli RNase H or human RNase H1 to DNA–RNA duplexes results in degradation of the target RNA [26,39,51]. The ability of DNA-like ASOs to cause a reduction in target RNAs in cells has been demonstrated many times as well [3]. Moreover, changes in the structure of DNA-like ASOs that resulted in loss of the ability of the duplex to serve as a substrate for RNase H in cell-free systems have been reported to result in a loss of target RNA reduction in cells treated with the modified ASOs [3,52,53]. Additionally Giles et al. [54] used reverse ligation polymerase chain reaction (PCR) to identify cleavage products from bcr-abl mRNA in cells treated with a DNA-like ASO. Nevertheless, none of these studies directly demonstrate that DNA-like ASOs reduce target RNA by activating RNase H, nor has the specific RNase H that is responsible been identified. To address this issue, we have overexpressed both human RNase H1 and RNase H2 in several cell lines and mouse liver. Specifically, Hela and A549 cells were infected with either the control (LoxP) or H2 insert containing adenovirus (Figure 2.6) [40]. We have also reduced the levels of each enzyme by using DNA-like ASOs and siRNA designed to reduce each of the enzymes (Figure 2.7) [40]. We have then explored the effects of these manipulations on the potencies of a number of well-characterized DNA-like ASOs to several different target RNAs [55–58]. In every case, increasing the level and activity of human RNase H1 increased the potency of the ASOs, while increasing the level and activity of RNase H2 had no effect on the IC50 values for several DNA-like ASOs to different targets [40]. Moreover, overexpression of human RNase H1 in mouse liver but not RNase H2 increased the potency of a DNA-like ASO targeting Fas after intravenous administration [40]. Further, reducing the level and activity of RNase H1 reduced the potencies of the ASOs, while reducing RNase H2 had no effect [40]. To further confirm that reduction of RNase H2 did not cause a loss of ASO potency, we performed the experiment shown in Figure 2.12. In this experiment, the total siRNA concentration was held constant at 25 nM and the ratio of RNase H1 siRNA to RNase H2 siRNA was varied. The 25 nM siRNA to human RNase H2 had no effect on the potency of the c-Raf ASO. As the ratio of siRNA to RNase H1 versus RNase H2 was increased, there was a progressive loss of potency for the c-Raf ASO. These data represent the first direct demonstration of the involvement of an RNase H in the activity of DNA-like ASOs and that RNase H1, not RNase H2, is responsible for most of the activity.
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
% Reduction of cRaf mRNA
64
Page 64
100 90 80 70 60 50 40 30 20 10 0
Control H1 (0 nM)/H2 (25 nM) H1 (6.25 nM)/H2 (18.75 nM) H1 (12.5 nM)/H2 (12.5 nM) H1 (18.75 nM)/H2 (6.25 nM) H1 (25 nM)/H2 (0 nM)
0
0.5 1 1.5 2 Log anti-cRaf ASO concentration (nM) IC50 (nM) Control H1 (0 nM)/H2 (25 nM) H1 (6.25 nM)/H2 (18.75 nM) H1 (12.5 nM)/H2 (12.5 nM) H1 (18.75 nM)/H2 (6.25 nM) H1 (25 nM)/H2 (0 nM)
8.02 8.30 12.42 15.74 17.91 21.48
Figure 2.12 The effects of various ratios of RNase H1 and H2 siRNAs on the potency of anti-cRaf ASO (ISIS 13650). Cells were first transfected with various concentrations of RNase H2 siRNA as indicated for 10 h before the cells were split into 96 well cell culture plates (6000 cells/well) and incubated for 10–14 h. The cells were transfected with various concentrations of ISIS 13650 for 24 h before harvest. Total RNAs were prepared and the cellular cRaf and RNase H2 mRNA levels were determined with RT-PCR in which the reverse transcription and PCR amplification of cRaf and RNase H2 mRNAs were performed in the 96 well format. The total concentration of siRNA was maintained at 25 nM and the ratio of H1 siRNA to H2 siRNA was varied from 0 to 1. The vertical bars represent the standard errors of the mean of three replicates of a representative experiment.
We have shown that in intact cells, RNase H2 appears to play no role in degradation of RNAs targeted by DNA-like ASOs. Nevertheless, IP experiments showed that the presumed RNase H2 protein complex is fully capable of degrading RNA in DNA-like ASO/RNA duplexes and that the pattern of degradation induced by RNase H2 differed from that of RNase H1 (Figure 2.8). Thus, a reasonable hypothesis was that in intact cells human RNase H2 is unavailable to participate in degradation of RNA in DNA-like ASO–RNA duplexes. To evaluate this in more detail, we prepared nuclear extracts and exposed RNA/DNA duplexes to them. In these experiments, we used a different sequence from that used in Figure 2.8 to further confirm the differences in sites of cleavage. Figure 2.13A shows the cleavage of the RNA in the duplex substrate by the nuclear homogenates. The nuclear homogenates immunoprecipitated with the RNase H2 antibody cleaved the heteroduplex at the 11th and 12th ribonucleotide from the 5⬘-terminus of the RNA (Figure 2.13B). Conversely, nuclear homogenates immunoprecipitated with human RNase H1 and H2 antibodies cleaved at ribonucleotides 6 and 7 (Figure 2.13C). When the extract was repeatedly immunoprecipitated with the RNase H2 antibody, the supernatant displayed the human RNase H1 cleavage pattern, predominantly cleaving at ribonucleotides 6 and 7 (Figure 2.13D). The supernatant repeatedly immunoprecipitated with human RNase H1 antibody, displayed the human RNase H2 cleavage pattern, predominantly cleaving at ribonucleotides 11 and 12 (Figure 2.13E). Thus both enzymes are present and active in the nuclear extracts. Again in this experiment using a different substrate, the enzymes displayed different cleavage patterns consistent with the observations shown in Figure 2.8. This result also emphasizes the relative lack of influence of sequence on cleavage with either enzyme. To confirm the results in Figure 2.13 and to quantitate the relative contributions of each of the RNases H in the nuclear homogenates, we preformed two
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 65
THE RNase H MECHANISM
65
(A) Time (min)
RNase H2 specific
RNase H1 specific
0
(B)
5 25 125
0
5 25 125
(C) 0
(D)
5 25 125
0
5 25 125
(E) 0
5 25 125
C U C G A A A C G G A A G A A C G G U A
RNase H1 RNase H2 specific specific
Substrate: Figure 2.13
32 P-AUGGCAAGAAGGCAAAGCUC
TACCGTTCTTCCGTTTCGAG
3’ 5’
Hela cell nuclear extract contains RNase H activity. The 100 nM 20-mer RNA/DNA duplex substrate was prepared and subjected to digestion by Hela cell nuclear extracts (10 g total protein), the H1 or H2 Ab IP samples and the extracts depleted of each RNase H with the Abs for different time periods at 37oC. The digested duplexes were subjected to denaturing polyacrylamide gel analysis. The asterisks indicate the major differences in cleavage sites between RNase H1 and H2. The sequence of the RNA/DNA duplex is shown at the bottom of the figure.
experiments. In the first experiment, (Figure 2.14A), we pretreated cells with the siRNA specific for RNase H1 or RNase H2, and a control siRNA, then prepared cellular homogenates, and determined the initial rate of degradation of RNA in the duplex substrate. Pretreatment of cells with an siRNA to RNase H2 reduced cellular RNase H2 by ⬃60% (data not shown) and reduced the initial rate of cleavage of the substrate by ⬃60%. Treatment of the cells with the siRNA to RNase H1 reduced RNase H1 by ⬃60% (data not shown), but had only a small effect on the initial rate of cleavage in the homogenate (Figure 2.14A). This result is consistent with the results from experiments in which nuclear lysates were immunoprecipitated with antibodies against human RNase H1 and RNase H2 and the extent of reduction of the intact substrate was much lower in the RNase H2-depleted supernatant (Figure 2.13D) than the supernatant in which the RNase H1 was depleted (Figure 2.13E). Taken together, these data suggest that RNase H2 activity is more abundant than RNase H1 activity in cells. In the second experiment (Figure 2.14B), we prepared nuclear extracts, then removed the RNases H with the antibodies, and measured the initial rates of cleavage. Again, depletion of RNase H2 resulted in a much greater reduction of the initial rate than did depletion of RNase H1. Depletion of both RNases H resulted in loss of nearly all of the cleavage activities in the lysate. These data also suggest that in cellular homogenates, the bulk of enzyme activity is a result of RNase H2 (Figure 2.13A). Finally, the fact that IP of both enzymes resulted in almost total loss of activity, suggests that under the conditions of the assay, the two enzymes account for most of the activity. 2.5 THE EFFECTS OF CHIMERIC ASOs ON HUMAN RNase H1 ACTIVITY First-generation phosphorothioate oligodeoxynucleotides have been shown to induce pharmacological effects in vivo and to reduce target RNA in humans [59]. However, they display significant
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 66
66
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION (A)
50
Percent cleavage (%)
45 40
Control siRNA
35 30
H1 siRNA
25 20
H2 siRNA
15 10 5 0 0
I.R. (nM/min) (B)
20 Time (min) Control 1.21 ± 0.05
40 H1 siRNA 1.1±0.09
50 45
Percent cleavage (%)
H2 siRNA 0.46±0.07
IgG Ab strip
40 35
H1 Ab strip
30 25
H2 Ab strip
20 15
H1 Ab &H2 Ab strip
10 5 0 0
20
40
Time (min)
I.R. (nM/min)
IgG strip 1.21±0.05
H1 Ab strip 0.87±0.08
H2 Ab strip H1&H2 strip 0.32±0.05 0.042± 0.021
Figure 2.14 RNase H activity of the cell lysates or supernatants after immunoprecipitation. The enzyme activity was measured with TCA precipitation. 2–5 g proteins were used in the assay with 150 nM RNA/DNA substrate. The experiments were performed in triplicate. The bars show the standard errors of the mean. The initial rates were calculated and presented under the graph. (A) The lysate enzyme activities of Hela cells pretreated with 100 nM RNase H1, H2 or control siRNA for 24 h. (B) The activities of the supernatants after the cell lysates were depleted (immunoprecipitated) with RNase H1 and/or H2 antibody or rabbit IgG. The initial rates are shown as means ⫾ standard error of the mean from at least three separate experiments.
limitations including limited potency and the need to be given intravenously every other day. Second-generation chimeric ASOs consisting of a deoxyribonucleotide region to support RNase H activity flanked by modified nucleotides (e.g., 2⬘-MOE nucleotides) are the products of more than a decade of medicinal chemistry research of antisense oligonucleotides in which more than 1000 modifications were evaluated (for review, see Ref. [3]). 2⬘-MOE chimeric ASOs have been shown to be 10- to 40-fold more potent, safer, and extend elimination half-lives in all species including man from 14 to 30 days (for review, see Ref. [3]). To provide a more precise understanding of the effects of MOE nucleotides on both the overall rate of cleavage and the precise positions of cleavage induced by human RNase H1, we prepared a series of chimeric ASOs in which the deoxyribonucleotides of the ASO were successively substituted
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 67
THE RNase H MECHANISM
67
(A)
2
V0 (nM/min)
with MOE residues at the 3⬘- and 5⬘-poles of the ASO [43]. Successive MOE substitution at the 3⬘-terminus of the ASO resulted in a concomitant ablation of the 5⬘-most cleavage site in the oligoribonucleotide, whereas MOE substitution at the 5⬘-terminus of the ASO resulted in a concomitant ablation of the 3⬘-most cleavage site [43]. As a result, the chimeric substrates produced fewer human RNase H1 cleavage sites and slower overall cleavage rates (Figure 2.15). In fact, a twofold reduction in the initial cleavage rate was observed for chimeric substrates containing as few as two to three MOE substitutions. To examine the effects of MOE substitutions positioned at both the 5⬘- and 3⬘-poles of the ASO on human RNase H1 activity, several ASO sequences were prepared in which the deoxyribonucleotide region was positioned centrally (5-10-5) or toward the 3⬘-pole of the ASO (2-10-8) [43]. All of the unmodified heteroduplex substrates tested exhibited the preferred position for cleavage 7–12 ribonucleotides from the 5⬘-terminus of the RNA. The cleavage sites for the 5-10-5 heteroduplexes were shifted 3⬘ on the RNA compared with the unmodified substrates. A further shift 3⬘ in the RNA was observed for the cleavage sites of the 2-10-8 heteroduplexes. Importantly, the chimeric ASO that shifted the positions of cleavage away from the preferred sites exhibited slower overall cleavage rates [43]. In a control experiment, unmodified substrates were prepared in which the oligodeoxyribonucleotide sequences matched the DNA regions of the 5-10-5 and 2-10-8 chimeric substrates. In all cases the unmodified substrates exhibited significantly faster cleavage rates compared with the chimeric substrates suggesting that the slower cleavage rates observed for the chimeric substrates was due to the MOE substitutions and not the length or sequence of the deoxyribonucleotide region [43]. These results clearly demonstrate that MOE substitutions in the ASO inhibit human RNase H1 activity. Several factors appear to contribute to the reduction in human RNase H1 activity. First,
1
0 U
19-1 18-2 17-3 16-4 15-5 14-6 13-7 12-8 11-9 10-10 9-11 8-12 7-13 6-14
Heteroduplex
V0 (nM/min)
(B) 1.5
1.0
0.5
0.0
U
1-19 2-18 3-17 4-16 5-15 6-14 7-13 8-12 9-11 10-10
Heteroduplex Figure 2.15 Initial cleavage rates for chimeric MOE heteroduplex substrates. (A) Successive substitution of 1–14 MOE-modified nucleotides at the 3⬘-pole of the ASO. (B) Successive substitution of 1–10 MOE-modified nucleotides at the 5⬘-pole of the ASO. Initial cleavage rates (V0) were determined as previously described [26]. The vertical bars represent the standard errors of the mean of three replicates of a representative experiment.
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
68
Page 68
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
chimeric heteroduplexes redirected the position of cleavage outside the positional preference for cleavage. Second, the influence of the MOE residues on human RNase H1 activity was directional (Figure 2.15). The observed differences in activity between chimeric heteroduplexes containing MOE residues at the 5⬘-pole versus 3⬘-pole of the ASO is likely the result of the binding directionality of the enzyme, in which the 3⬘-pole MOE substitutions would be positioned at the RNA-binding domain and the 5⬘-pole MOE substitutions would be positioned adjacent to the catalytic domain of the enzyme (Figure 2.16). Given that the RNA-binding domain of human RNase H1 has been shown to be important for properly positioning the enzyme on the heteroduplex for catalysis [36], 3⬘-pole MOE substitutions likely interfere with the binding of the enzyme to this portion of the substrate, effectively redirecting the enzyme to the RNA/DNA region of the chimeric heteroduplex (Figure 2.15A and Figure 2.16). Consistent with this model, 5⬘-pole MOE substitutions would interfere with the catalytic domain of the enzyme, resulting in the observed progressive ablation of human RNase H1 cleavage sites without the concomitant production of new preferred cleavage sites and slower overall cleavage rates (Figure 2.15B and Figure 2.16). Third, the reduction in human RNase H1 activity observed for the chimeric heteroduplexes appeared to be primarily due to the MOE substitutions as comparable cleavage rates were observed for the unmodified heteroduplexes containing the 10 and 20 deoxyribonucleotides without flanking MOE residues. In addition, the MOE residues appeared to effect the cleavage activity of the adjacent deoxyribonucleotide regions as a 4–5 base-pair separation from the 5⬘-most cleavage site on the RNA and the nearest MOE at the 3⬘-pole of the ASO and a 2 base-pair separation between the 3⬘-most cleavage site on the RNA and the nearest MOE at the 5⬘-pole of the ASO was observed. The influence of the MOE substitutions on human RNase H1 activity is consistent with the solution structure of a chimeric heteroduplex containing deoxyribonucleotides flanked on both ends
(A)
3′-MOE
RNA-BD
cat
5′ 3′
(B)
5′-MOE
RNA-BD
cat
5′ 3′ Figure 2.16 Model for the interaction of RNase H1 with the heteroduplex substrate containing MOE modifications at the 3⬘- and 5⬘-poles of the ASO. The light gray and dark gray lines represent, respectively, the sense oligoribonucleotide oriented 5⬘ → 3⬘ and chimeric ASO 3⬘ → 5⬘. The light gray and dark gray boxes represent, respectively, MOE residues at the 3⬘- and 5⬘-poles of the ASO. The binding interaction for human RNase H1 is shown with the RNA-binding domain (RNA-BD) of the enzyme positioned 5⬘ to the catalytic domain (Cat) on the oligoribonucleotide. Each observed cleavage site on the RNA is coupled to a specific binding interaction between the RNA-BD and the 3⬘-DNA/5⬘-RNA pole of the heteroduplex substrate. (A) Alteration in helical geometry or steric interference by the MOE substitutions at the 3⬘-pole of the ASO disrupts the binding interaction between the RNA-BD and the heteroduplex resulting in the observed ablation of catalytic activity at the 5⬘-most cleavage sites on the RNA. (B) MOE substitutions at the 5⬘-pole of the ASO are positioned adjacent to the catalytic domain of enzyme.
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 69
THE RNase H MECHANISM
69
with 2⬘-methoxy residues hybridized to RNA [60]. Specifically, the central deoxyribonucleotides exhibited the eastern-biased sugar conformation preferred by RNase H1, whereas the flanking 2⬘-methoxy residues exhibited a northern sugar conformation. Importantly, the deoxyribonucleotides adjacent to the 2⬘-methoxy residues were also shown to exhibit a northern sugar conformation suggesting the conformational transmission of the northern-biased 2⬘-methoxy residues into adjacent deoxyribonucleotides [60]. Given that heteroduplexes containing northern-biased nucleotides within the DNA strand do not support human RNase H1 activity [35], the attenuation of the human RNase H1 activity observed for the chimeric heteroduplexes is likely due to the conformational transmission of the northern-biased MOE residues into the adjacent deoxyribonucleotides. To better understand the mechanisms of the observed reduction in catalytic efficiency of chimeric substrates containing MOE nucleotides and to begin to identify means to mitigate these effects, we introduced modified nucleotides at the MOE/DNA junction of the chimeric ASO to modulate the transmission of conformation of the MOE substitutions into the area of the duplex in which cleavage occurs (Figure 2.17) [61]. In addition, mismatched base pairs were introduced at various positions in the chimeric substrate and the initial cleavage rates (V0) for the modified heteroduplexes were compared with the wild-type DNA/RNA heteroduplex. (A)
B
O
O
O
B
F
O
O O
SCH 3
O
O
O P O
O P O
O P O
O
O
O
2′-ara-F
2′-S-Me
LNA CH 3
(B)
O
F O
N
O F
O O
F
N
N
O
CH 3
O F
O
O P O
O P O
O
O
N-Me-T
TFI (C)
B
O
O
5’-UCAAAUCCAGAGGCUAGCAG 3’-AGTTTAGGTCTCCGATCGTC 5’-UCAAAUCCAGAGGCUAGCAG 3’-AGTTTAGGTCTCCGATCGTC
Figure 2.17 Structure of the nucleotide modifications. (A) Modified nucleotides containing conformationally biased sugars include the southern-biased 2⬘-methylthiothymidine (2⬘-S-Me-T), the northernbiased locked nucleic acid (LNA) and the eastern-biased 2⬘-ara-fluorothymidine (2⬘-ara-F-T). (B) Structures of the modifications designed to introduce conformational flexibility into the heteroduplex. These modifications include 2⬘-methoxyethoxy-N-methylthymidine (N-Me-T) and tetrafluoroindole (TFI). (C) Sequences of the heteroduplex substrates test with oligoribonucleotide (above) orientated 5⬘→ 3⬘ and the chimeric ASO (below) orientated 3⬘-5⬘. Underlined sequences indicate the position of the MOE residues. The bold sequences indicate the positions of the nucleotide modifications listed in (A) and (B).
CRC_8796_ch002.qxd
70
6/20/2007
9:30 PM
Page 70
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Consistent with the effects of the MOE modifications on human RNase H1 activity, the strong northern-biased locked nucleic acid (LNA) modification positioned at either junction exacerbated the negative effects of the MOE modifications resulting in slower human RNase H1 cleavage rates compared with the MOE chimeric substrates. In contrast, enhanced cleavage rates were observed for the eastern-biased 2⬘-ara-fluorothymidine and bulge-inducing N-methylthymidine modifications positioned at the 5⬘-DNA/3⬘-MOE junction as well as the southern-biased 2⬘-methylthiothymidine positioned at the 5⬘-MOE/3⬘-DNA junction [61]. The greatest improvement in activity was observed for the conformationally flexible tetrafluoroindole (TFI) modifications positioned at either junction. The TFI modification is predicted to -stack with adjacent nucleotides, but not form hydrogen bonds with the opposing RNA. Consistent with the predicted interactions of the TFI, the heterocycle of the ribonucleotide opposing the TFI deoxyribonucleotide had no effect on the human RNase H1 activity whereas nucleotide substitutions adjacent to the TFI significantly affected the cleavage rate [61]. In addition, mismatch base pairs exhibited similar effects on human RNase H1 activity as the TFI modifications [61]. Finally, the cleavage patterns for the modified heteroduplexes suggest that the junction modifications are modulating the conformation transmission of the MOE residues. Specifically, the LNA substitutions ablated the cleavage activity nearest the modifications. In contrast, the rate-enhancing junction modifications enhanced cleavage activity for the cleavage sites nearest these junction modifications [61].
2.6 IMPLICATIONS FOR ANTISENSE THERAPEUTICS The demonstration that human RNase H1 plays a dominant role in the activities of DNA-like ASOs suggests that additional studies that explore the substrate preferences, enzymology, and regulatory processes for RNase H1 should support improved design of antisense agents. In addition, the demonstration that increases in RNase H1 activity correlated with increases in potency suggests that recruitment of RNase H1 to the ASO–RNA duplex and/or cleavage of the RNA by the enzyme is limiting for ASO activity. We have demonstrated that human RNase H1 is comprised of an RNA-BD, a spacer region, and a catalytic domain. Once bound to the heteroduplex substrate, the RNA-binding and the catalytic domains are separated by approximately one helical turn with the RNA-binding domain positioned 3⬘ on the RNA to the catalytic domain. The architecture of the enzyme is used to sense subtle changes in the helical geometry of potential substrates such that the enzyme may bind to many nucleic acid structures, but will only cleave those structures with the appropriate characteristics. To be cleaved by human RNase H1, a substrate must display a minor groove of appropriate dimensions unobstructed by any substituent such as those deriving from 2⬘ modification of the deoxyribose. Further, the intra- and interphosphate distances of the heteroduplex substrate are crucial as is the flexibility of the backbone. Any strategy that would improve these processes should improve ASO potency. Clearly, MOE as well as phosphorothioate modifications inhibit human RNase H1 activity [26]. Given the beneficial properties of these modifications, designing chimeric ASOs for enhanced human RNase H1 activity should improve the potency of these chimeric drugs. For example, optimizing the placement of the DNA-like domains relative to preferred sites of cleavage. In addition, reducing the number of 2⬘-modified nucleotides should improve the enzyme activity. Obviously, as 2⬘-modified nucleotides improve affinity to target RNA, reducing the number of 2⬘-modified nucleotides would reduce the ability of the ASO to invade structured RNA sites resulting in fewer active sites in the mRNA. Identifying modified nucleotides with even greater affinity for the target RNA or more accessible sites should enable the need for fewer modifications. In fact, several “gap-widened” chimeric ASOs containing longer deoxyribonucleotide regions and fewer MOE residues have demonstrated improved potency in cell culture and in vivo (Swikowski, unpublished data).
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
Page 71
THE RNase H MECHANISM
71
Medicinal chemical approaches that optimize the structures of chimeric ASOs should also improve the potency of these drugs. For example, inserting modified nucleotides to modulate the transmission of the 2⬘-modified/RNA geometry into the RNA/DNA portion of the chimeric heteroduplex should also improve human RNase H1 activity. Specifically, modifications that disrupt base-stacking interactions or exhibit an eastern sugar conformation (e.g., N-Me-T and 2⬘-ara-F-T) should be positioned at the DNA/MOE junction adjacent the phosphate-binding pocket in the enzyme (Figure 2.4, Figure 2.16, and Figure 2.17). In contrast, modifications exhibiting conformational flexibility or the opposing southern sugar conformation (e.g., TFI and 2⬘-S-Me-T) should be positioned at the DNA/MOE junction adjacent the ribonucleotides downstream of the scissile phosphate (Figure 2.4, Figure 2.16, and Figure 2.17). The TFI modification can be used to modulate the negative effects of the 2⬘-alkoxy residues both upstream and downstream of the scissile phosphate irrespective of the heterocycle of the opposing nucleotide. However, the TFI modification should be positioned adjacent to the stable base pairs and not at sites that interact directly with the enzyme (Figure 2.4). Mismatch base pairs can also be used to enhance the human RNase H1 activity of the chimeric ASOs, although predicting favorable noncanonical base-pair substitutions may prove more difficult than TFI substitutions. Finally, given that the elimination half-lives and proinflammatory effects of chimeric ASO drugs are determined by the MOE residues, substitution of one or two MOE modifications at the junction should have only modest effects on the properties of these drugs. REFERENCES 1. Crooke, S. T. (1999) Molecular mechanisms of antisense drugs: human RNase H. Antisense Nucl. Acid Drug Dev. 9: 377–379. 2. Crooke, S. T. (2000) Progress in antisense technology: the end of the beginning. Methods Enzymol. 313: 3–45. 3. Crooke, S. T. (2001) In: Antisense Technology: Principles, Strategies and Applications. (Crooke, S. T., ed.) Marcel Dekker, New York, pp. 1–28. 4. Grishok, A., Tabara, H., and Mello, C. C. (2000) Genetic requirements for inheritance of RNAi in C. elegans. Science 287: 2494–2497. 5. Zamore, P. D., Tuschl, T., Sharp, P. A., and Bartel, D. P. (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25–33. 6. Stein, H. and Hausen, P. (1969) Enzyme from calf thymus degrading the RNA moiety of DNA–RNA hybrids: effect on DNA-dependent RNA polymerase. Science 166: 393–395. 7. Busen, W. (1980) Purification, subunit structure, and serological analysis of calf thymus ribonuclease HI. J. Biol. Chem. 255: 9434–9443. 8. Crouch, R. J. and Dirksen, M. L. (1982) In: Nucleases (Linn, S. M. and Roberts, R. J., eds.) Cold Spring Harbor. Cold Spring Harbor Press, Plainview, New York. 9. Kane, C. M. (1988) Renaturase and ribonuclease H: a novel mechanism that influences transcript displacement by RNA polymerase II in vitro. Biochemistry 27: 3187–3196. 10. Masutani, C., Enomoto, T., Suzuki, M., Hanaoka, F., and Ui, M. (1990) DNA primase stimulatory factor from mouse FM3A cells has an RNase H activity. Purification of the factor and analysis of the stimulation. J. Biol. Chem. 265: 10210–10216. 11. Eder, P. S. and Walder, J. A. (1991) Ribonuclease H from K562 human erythroleukemia cells. J. Biol. Chem. 266: 6472–6479. 12. Frank, P., Albert, S., Cazenave, C., and Toulme, J. J. (1994) Purification and characterization of human ribonuclease HII. Nucl. Acids Res. 22: 5247–5254. 13. Ohtani, N., Haruki, M., Morikawa, M., Crouch, R. J., Itaya, M., and Kanaya, S. (1999) Identification of the genes encoding Mn2⫹-dependent RNase HII and Mg2⫹-dependent RNase HIII from Bacillus subtilis: classification of RNases H into three families. Biochemistry 38: 605–618.
CRC_8796_ch002.qxd
72
6/20/2007
9:30 PM
Page 72
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION 14. Kanaya, S., Kohara, A., Miura, Y., Sekiguchi, A., Iwai, S., Inoue, H., Ohtsuka, E., and Ikehara, M. (1990) Identification of the amino acid residues involved in an active site of Escherichia coli ribonuclease H by site-directed mutagenesis. J. Biol. Chem. 265: 4615–4621. 15. Katayanagi, K., Miyagawa, M., Matsushima, M., Ishikawa, M., Kanaya, S., Ikehara, M., Matsuzaki, T., and Morikawa, K. (1990) Three-dimensional structure of ribonuclease H from E. coli. Nature 347: 306–309. 16. Kanaya, S., Katsuda-Nakai, C., and Ikebara, M. (1991) Importance of the positive charge cluster in Escherichia coli ribonuclease HI for the effective binding of the substrate. J. Biol. Chem. 266: 11621–11627. 17. Nakamura, H., Oda, Y., Iwai, S., Inoue, H., Ohtsuka, E., Kanaya, S., Kimura, S., Katsuda, C., Katayanagi, K., Morikawa, K., Miyashiro, H., and Ikehara, M. (1991) How does RNase H recognize a DNA RNA hybrid? Proc. Natl. Acad. Sci. 88: 11535–11539. 18. Kanaya, S. (1998) Enzymic activity and protein stability of E. coli ribonuclease HI. Ribonucleases H. INSERM, Paris, pp. 1–38. 19. Kogoma, T. and Foster, P. L. (1998) Physiological functions of Escherichia coli RNase HI. Ribonucleases H. INSERM, Paris, pp. 39–66. 20. Yang, W. and Steitz, T. A. (1995) Recombining the structures of HIV integrase, RuvC and RNase H. Structure 3: 131–134. 21. Cerritelli, S. M. and Crouch, R. J. (1998) Cloning, expression, and mapping of ribonucleases H of human and mouse related to bacterial RNase HI. Genomics 53: 300–307. 22. Wu, H., Lima, W. F., and Crooke, S. T. (1998) Molecular cloning and expression of cDNA for human RNase H. Antisense Nucl. Acid Drug Dev. 8: 53–61. 23. Nowotany, N., Gaidamakov, S. A., Crouch, R. J. and Yang, W. (2005) Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 121: 1005–1016. 24. Hughes, S. H., Arnold, E., and Hostomsky, Z. (1998) RNase H of retroviral reverse transcriptases. Ribonucleases H. INSERM, Paris, pp. 195–224. 25. Frank, P., Braunshofer-Reiter, C., Wintersberger, U., Grimm, R., and Busen, W. (1998) Cloning of the cDNA encoding the large subunit of human RNase HI, a homologue of the prokaryotic RNase HII. Proc. Natl. Acad. Sci. 95: 12872–12877. 26. Wu, H., Lima, W. F., and Crooke, S. T. (1999) Properties of cloned and expressed human RNase H1. J. Biol. Chem. 274: 28270–28278. 27. Berkower, I., Leis, J., and Hurwitz, J. (1973) J. Biol. Chem. 248: 5914–5921. 28. Lima, W., Wu, H., Nichols, J. G., Manalili, S. M., Drader, J.J., Hofstadler, S.A., Crooke, S.T. (2003) Human RNase H1 activity is regulated by a unique redox switch formed between adjacent cysteins. J. Biol. Chem. 278: 14906–14912. 29. Wu, H., Lima, W. F., Crooke, S. T. (2001) Investigating the structure of human RNase H1 by sitedirected mutagenesis. J. Biol. Chem. 276: 23547–23553. 30. Cerritelli, S. M. and Crouch, R. J. (1995) The non-RNase H domain of Saccharomyces cerevisiae RNase H1 binds double-stranded RNA: magnesium modulates the switch between double-stranded RNA binding and RNase H activity. RNA 1: 246–259. 31. Evans, S. P. and Bycroft, M. (1999) NMR structure of the N-terminal domain of Saccharomyces cerevisiae RNase HI reveals a fold with a strong resemblance to the N-terminal domain of ribosomal protein L9. J. Mol. Biol. 291: 661–669. 32. Lima, W. F., Mohan, V., and Crooke, S. T. (1997) The influence of antisense oligonucleotide-induced RNA structure on Escherichia coli RNase H1 activity. J. Biol. Chem. 272: 18191–18199. 33. Lima, W. F. and Crooke, S. T. (1997) Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry 36: 390–398. 34. Lima, W. F., Wu, H., and Crooke, S. T. (2001) In: Methods in Enzymology. Human RNases H. (Nicholson, A. W., ed.) Academic Press, San Diego, CA, pp. 430–440. 35. Lima, W. F., Nichols, J. G., Wu, H.-J., Prakash, T. P., Migawa, M. T., Wyrzykiewicz, T. K., Bhat, B., Crooke, S. T. (2004) Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J. Biol. Chem. 279: 36317–36326. 36. Lima, W. F., Wu, H., Nichols, J., Prakash, T. P., Ravikumar, V., and Crooke, S. T. (2003) Human RNase H1 uses one tryptophan and two lysines to position the enzyme at the 3⬘-DNA/5⬘-RNA terminus of the heteroduplex substrate. J. Biol. Chem. 278: 49860–49867.
CRC_8796_ch002.qxd
6/20/2007
9:30 PM
THE RNase H MECHANISM
Page 73
73
37. Hoffman, D. W., Cameron, C. S., Davies, C., White, S. W., and Ramakrishnan, V. (1996) Ribosomal protein L9: a structure determination by the combined use of X-ray crystallography and NMR spectroscopy. J. Mol. Biol. 264: 1058–1071. 38. Yang, W., Hendrickson, W. A., Crouch, R. J., and Satow, Y. (1990) Structure of ribonuclease H phased at 2 A resolution by MAD analysis of the selenomethionyl protein. Science 249: 1398–1405. 39. Denisov, A. Y., Noronha, A. M., Wilds, C. J., Trempe, J.-F., Pon, R. T., Gehring, K., and Damha, M. (2001) Solution structure of an arabinonucleic acid (ANA)/RNA duplex in a chimeric hairpin: comparison with 2⬘-fluoro-ANA/RNA and DNA/RNA hybrids. Nucl. Acids Res. 29: 4284–4293. 40. Wu, H., Lima, W.F., Zhang, H., Fan, A., Sun, H., and Crooke, S.T. (2004) Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. 279: 17181–17189. 41. Cerritelli, S. M., Frolova, E. G., Feng, C., Grinberg, A., Love, P. E., and Crouch, R. J. (2003) Failure to produce mitochondrial DNA results in embryonic lethality in RNase H1 null mice. Mol. Cell 11: 807–815. 42. Bambara, R. A., Murante, R. S., and Hendriksen, L. A. (1997) Enzymes and reactions at the eukaryotic DNA replication fork. J. Biol. Chem. 272: 4647–4650. 43. Lima, W. F., Rose, J. B., Nichols, J. G., Wu, H., Migawa, M. T., Wyrzykiewicz, T. K., Siwkowski, A. M., and Crooke, S. T. (2006) Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol. Pharmacol., 71: 83–91. 44. Jeong, H.-S., Backlund, P. S., Chen, H.-C., Karavanov, A. A., and Crouch, R. J. (2004) RNase H2 of Saccharomyces cerevisiae is a complex of three proteins. Nucl. Acid Res. 32: 407–414. 45. Lai, L., Yokota, H., Hung, L.-W., Kim, R., and Kim, S.-H. (2000) Crystal structure of archaeal RNase HII: a homologue of human major RNase H. Structure 8: 897–904. 46. Chapados, B. R., Chai, Q., Hosfield, D. J., Qiu, J., Shen, B., and Tainer, J. A. (2001) Structural biochemistry of a Type 2 RNase H: RNA primer recognition and removal during DNA replication. J. Mol. Biol. 307: 541–556. 47. Main, S. I. (1997) Comparative sequence analysis of ribonucleases HII, III, II, PH and D. Nucl. Acids Res. 25: 3187–3195. 48. Ohtani, N., Haruki, M., Morikowa, M., and Kanaya, S. (1999) Molecular diversity of RNases H. J. Biol. Chem. 88: 12–19. 49. Crooke, S. T. (2003) in Burger’s Medicinal Chemistry, 6th Edition. (Abraham, D. J., ed.) Vol. 5, Chapter 2, Wiley, New York, NY, pp. 115–166. 50. Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., and Baker, B. F. (2003) Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem. 278: 7108–7118. 51. Crooke, S. T., Lemonidis, K. M., Neilson, L., Griffey, R., Lesnik, E. A., and Monia, B. P. (1995) Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotideRNA duplexes. Biochem. J. 312: 599–608. 52. Chiang, M.-Y., Chan, H., Zounes, M. A., Freier, S. M., Lima, W. F., and Bennett, C. F. (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266: 18162–18171. 53. Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., Mcgee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., and Freier, S. M. (1993) Evaluation of 2⬘-modified oligonucleotides containing 2⬘-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268: 14514–14522. 54. Giles, R. V., Spiller, D. G., and Tidd, D. M. (1995) Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res. Dev. 5: 23–31. 55. Monia, B. P. (1997) First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. Anti-Cancer Drug Des. 12: 327–339. 56. Geary, R. S., Leeds, J. M., Fitchett, J., Burckin, T., Truong, L., Spainhour, C., Creek, M., and Levin, A. A. (1997) Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of c-raf-1 kinase expression. Drug Metab. Dispos. 25: 1272–1281. 57. Bost, F., McKay, R., Dean, N., and Mercola, D. (1997) The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells. J. Biol. Chem. 272: 33422–33429.
CRC_8796_ch002.qxd
74
6/20/2007
9:30 PM
Page 74
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION 58. Butler, M., Mckay, R., Popoff, I. J., Gaarde, W. A., Witchell, D., Murray, S. F., Dean, N. M., Bhanot, and S., Monia, B. P. (2002) Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 51: 1028–1034. 59. Yacyshyn B. R., Bowen-Yacyshyn M. B., Jewell L., Tami J. A., Bennett C. F., Kisner D. L., and Shanahan W. R. (1998) A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease. Gastroenterology 6: 1133–1142. 60. Nishizaki, T., Iwai, S., Ohtsuka, E., Nakamura, H. (1997) Solution structure of an RNA 2⬘-O-methylated RNA hybrid duplex containing an RNA–DNA hybrid segment at the center. Biochemistry 36: 2577–2585. 61. Lima, W. F., Rose, J. B., Nichols, J. G., Wu, H., Migawa, M. T., Wyrzykiewicz, T. K., Vasquez, G., Swayze, E. E., and Crooke, S. T. (2006) The positional influence of the helical geometry of the heteroduplex substrate on human RNase H1 catalysis. Mol. Pharmacol. 71: 73–82.
CRC_8796_ch003.qxd
4/24/2007
10:10 AM
Page 75
CHAPTER
3
Small RNA Silencing Pathways Alla Sigova and Phillip D. Zamore
CONTENTS 3.1 3.2
Introduction.............................................................................................................................75 Small Interfering RNAs..........................................................................................................76 3.2.1 Genesis of siRNAs......................................................................................................76 3.2.2 siRNA Strand Selection..............................................................................................77 3.3 miRNAs ..................................................................................................................................77 3.3.1 Biogenesis of miRNA Precursors...............................................................................78 3.3.2 Processing of miRNA Precursors into Mature miRNAs............................................79 3.4 The RNAi Enzyme Complex..................................................................................................79 3.4.1 RISC ...........................................................................................................................79 3.4.2 Structure of Argonaute Proteins .................................................................................80 3.5 RISC Assembly.......................................................................................................................81 3.6 Small RNA-Directed mRNA Destabilization and Translational Repression.........................82 3.7 Conclusions.............................................................................................................................83 References ........................................................................................................................................84
3.1 INTRODUCTION RNA silencing pathways use small RNA guides to destroy a complementary mRNA, inhibit its translation, or reduce its rate of transcription. RNA silencing was first discovered by plant scientists in 1990 during an attempt to engineer transgenic petunias overexpressing enzymes that limit flower pigment production [1,2]. Remarkably, the introduction of transgenes expressing either of the flower pigmentation pathway enzymes chalcone synthase or dihydroflavonol-4-reductase failed to produce more intensely pigmented flowers. Instead, the transgenes repressed—that is, “silenced”— expression of both the endogenous and transgenic copies, causing partial or complete loss of flower pigmentation. The phenomenon was therefore dubbed “cosuppression” to reflect the coordinate silencing of the transgene and the endogenous gene. In Neurospora crassa, a similar silencing phenomenon, “quelling,” was also discovered when additional copies of sequences from genes were introduced into the N. crassa genome, again causing an unexpected and dramatic reduction in the expression of the corresponding endogenous genes. Quelling proved to be reversible: the loss of the exogenous DNA from the genome restored expression 75
CRC_8796_ch003.qxd
4/24/2007
10:10 AM
76
Page 76
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
of the endogenous gene [3,4], suggesting that silencing required the active production of a silencing signal from the transgene. These earlier studies paved the way for the central breakthrough in understanding RNA silencing—the demonstration by scientists working on the nematode Caenorhabditis elegans that double-stranded RNA (dsRNA) triggers specific repression of genes corresponding to its sequence. RNA silencing was discovered in C. elegans when antisense RNA was used to inhibit the function of par-1 gene in a study reporting the positional cloning of the par-1 locus. While injection of antisense par-1 RNA gave the expected par-1 mutant phenotype, par-1 mRNA itself also disrupted par-1 function [5]. Fire, Mello, and their colleagues revolutionized our understanding of RNA-directed silencing, which came to be know as an RNA interference (RNAi), when they demonstrated that the presence of contaminating dsRNA in both the antisense and sense RNA transcripts was the silencing trigger [6], an insight for which they received the 2006 Nobel Prize in Medicine. They showed that dsRNA, but not purified sense or antisense RNA, induced potent and specific silencing in C. elegans. RNAi has quickly become the reverse genetics tool of choice, even in animals with long established genetic traditions. In plants, RNAi is being used to engineer crops with improved disease resistance and other economically desirable traits. The discovery that long dsRNA is converted to small interfering RNAs (siRNAs) [7], allowed RNAi to be extended to mammalian cells [8]. In fact, siRNA-based therapies for human disease are now being sought in biotechnology companies and academic laboratories, and several siRNA-based drugs are currently in clinical trials. In this chapter, we summarize our current understanding of the biological purpose and biochemical mechanisms underlying RNA silencing pathways.
3.2 SMALL INTERFERING RNAs 3.2.1
Genesis of siRNAs
In 1999, Hamilton and Baulcombe reported finding small (⬃25 nt) RNAs that correlated with posttranscriptional gene silencing (PTGS), the plant cousin of RNAi. They analyzed transgeneinduced PTGS of an endogenous gene, PTGS induced by transgenes without homology to an endogenous gene, systemic PTGS of GFP transgenic plants initiated by infiltration of a single leaf with Agrobacterium tumefaciens expressing GFP sequence, and the antiviral response triggered by infection with potato virus X [7]. In all four cases, ⬃25 nt sense and antisense RNAs complementary to the silenced mRNAs (or to the virus) were detected; these small RNAs were not found in plants in which no silencing response had been triggered. The authors suggested that the novel small RNAs were both the specificity determinants for RNA silencing and the mobile signal by which silencing spreads from the initial site of silencing (such as the Agrobacterium-infiltrated leaf) to the rest of the plant. Biochemical experiments conducted in animal cell extracts that could recapitulate RNAi demonstrated that the small RNAs—now called siRNAs—derive directly from the dsRNA that triggered silencing and function as guides for protein complexes that degrade the targeted mRNA. Cell-free systems recapitulating in vitro the conversion of dsRNA into siRNAs, the assembly of siRNAs into functional protein complexes, and the destruction of target RNAs were developed first in Drosophila, either from syncitial blastoderm embryos or cultured Drosophila S2 cells [9,10] and later from cultured human HeLa cells [11,12]. During the RNAi reaction, both strands of the long dsRNA trigger are processed to RNA segments 21–23 nt long [13] by the ribonuclease (RNase) III–like enzyme Dicer [14]. Consequently, siRNAs bear the hallmarks of RNase III cleavage products: they are double-stranded, have 2-nt overhangs at their 3⬘ ends, a monophosphate at the 5⬘ end, and 2⬘ and 3⬘ hydroxyls at the 3⬘ end [15–17]. Because siRNAs are short, they can be readily synthesized chemically and can be delivered by transfection to mammalian cells without provoking
CRC_8796_ch003.qxd
4/24/2007
10:10 AM
Page 77
SMALL RNA SILENCING PATHWAYS
77
undesirable sequence-independent responses. Thus, the discovery of the structure of siRNAs led rapidly to their use as triggers of sequence-specific RNAi in mammalian cultured cells [8,18] and in vivo in both rodents and primates [19–22]. 3.2.2
siRNA Strand Selection
Fulfilling the prediction of Hamilton and Baulcombe, siRNAs are the specificity determinants for RNA silencing, guiding the recognition of mRNA targets and directing their destruction. After their production from long dsRNA by Dicer, siRNAs are incorporated into a functional protein–RNA complex, the RNA-induced silencing complex (RISC) [23], through which they direct the endonucleolytic cleavage of the target 10 nt upstream of the 5⬘-most nucleotide of the siRNA [10,13,15–17,24,25]. For example, introduction of 21-nt siRNA duplexes in Drosophila embryo lysates or cultured mammalian cells leads to sequence-specific mRNA degradation [8,15,17,24]. To bind target mRNAs, the two strands of an siRNA duplex must be separated, and then one or both strands assembled separately into RISC. In vitro in Drosophila embryo lysate, efficient RISC assembly requires ATP [16,26]. Single-stranded siRNA can bypass the requirement for siRNA strand separation in vitro in Drosophila embryo lysate or HeLa cell S100 extracts and in vivo in cultured human cells, but the inherent instability of single-stranded RNA and its inefficient entry into the RNAi pathway limits its practical utility [11,17]. Which of the two siRNA strands assembles into RISC is not random. For convenience, the strand that forms RISC is termed the guide and the strand disfavored for RISC assembly is called the passenger. In flies and mammals, the target RNA does not influence the choice of guide strand. Thus, when the guide strand is complementary to the mRNA target, it directs its destruction. If the siRNA strand complementary to the target is the passenger strand, no cleavage will be observed. This explains why some synthetic siRNA duplexes are not active: they load the wrong strand into RISC. Which of two strands of an siRNA duplex is incorporated into RISC reflects the relative thermodynamic stability of the 5⬘ ends of the two siRNA strands [12,27]. Prediction of the active siRNA strand can be made by a nearest-neighbor analysis of the free energy of the two to four 5⬘ terminal base pairs of each siRNA strand [28,29]. siRNAs in which one strand dominates RISC assembly are said to be “functionally asymmetric.” Such functional asymmetry can be engineered into an siRNA by incorporating a mismatched nucleotide at or near the 5⬘ end of the siRNA strand intended to function as guide [12,30].
3.3 miRNAs A high degree of complementarity is required for a small RNA to direct endonucleolytic cleavage of a target RNA. When the small RNA pairs imperfectly with the target, it cannot cleave the target, but may nonetheless repress the translation and/or destabilize the RNA target. In animals, a large class of endogenous small RNAs, microRNAs (miRNAs), act to repress translation or reduce the stability of their mRNA targets (Fig. 3.1); only a few animal miRNAs pair extensively with their mRNAs targets, allowing them to promote endonucleolytic cleavage [31–33]. In contrast, all plant miRNAs likely direct endonucleolytic cleavage of the mRNAs whose expression they repress [34–36]. miRNAs are close relatives of siRNAs. They are the same length as siRNAs, can function in the same pathways, and differ from siRNAs only in the details of their biogenesis. miRNAs regulate expression of endogenous mRNAs, and some computational studies suggest that from one-third to all the genes in a typical animal are targeted by miRNAs at some developmental time or in some cell lineage [37–42]. miRNAs may even function to restrict the host range and tissue-tropism of viruses infecting mammals [43,44]. The human genome may encode thousands of miRNAs [45].
CRC_8796_ch003.qxd
4/24/2007
10:10 AM
Page 78
78
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
miRNA gene
polyA pri-miRNA cap Pasha Drosha pre-miRNA Nucleus Exportin 5
Cytoplasm
pre-miRNA Dicer-1 Loqs miRNA/miRNA* duplex
? Ago1
cap
ORF Ribosome
polyA
Target mRNA
Figure 3.1 The miRNA pathway in Drosophila.
3.3.1
Biogenesis of miRNA Precursors
miRNAs were first discovered as mutations that disrupt the timing of development in C. elegans [46,47]. miRNAs originate as much longer primary miRNAs (pri-miRNAs) [48]. pri-miRNAs are transcribed by RNA polymerase II, and thus contain a 5⬘ cap and a poly(A) tail (Fig. 3.1) [48,49]. A pri-miRNA may contain a single miRNA—with thousands of bases transcribed, apparently to yield a single 21 nt RNA guide—or several miRNAs, a polycistronic pri-miRNA. The majority of worm and human miRNAs reside in their own pri-miRNA transcripts, where as more than half of Drosophila miRNAs are polycistronic [50,51]. Some animal viruses also produce miRNAs [52–55]. Within the pri-miRNA, the mature miRNA resides in one arm of a ⬃70-nt stem-loop structure. In the nucleus, a complex of proteins, including the RNase III enzyme Drosha and its dsRNA-binding protein partner Pasha in flies or DGCR8 in mammals, recognizes the stem-loop, cleaves it about one helical turn up from the base of the stem, liberating a ⬃60-nt pre-miRNA [56–59]. Pasha/DGCR8 binds pri-miRNA, restricting Drosha to pri-miRNA processing [56,60]. Pasha comprises an N-terminal WW domain and two C-terminal dsRNA-binding domains. Similar to all RNase III enzymes, Drosha cleavage produces 2-nt, 3⬘ overhanging ends [56,61]. Exportin 5, a member of karyopherin  family of nucleocytoplasmic transport proteins, recognizes the characteristic terminal structure of the pre-miRNA, exporting it from the nucleus to the
CRC_8796_ch003.qxd
4/24/2007
10:10 AM
Page 79
SMALL RNA SILENCING PATHWAYS
79
cytoplasm [62,63]. In the cytoplasm, Dicer binds pre-miRNAs and cleaves off the loop, to generate a ⬃21-nt RNA duplex bearing 2-nt, 3⬘overhangs at each end [64–66]. This duplex therefore resembles an siRNA. Unlike siRNAs, the ⬃19-nt double-stranded region of the miRNA/miRNA* duplex contains strategically placed mismatches, G:U wobbles, and internal loops. Current data suggest that these discontinuities help align Drosha on the pri-miRNA and Dicer on the pre-miRNA [67]. The helical discontinuities also establish which of the two strands of the small RNA duplex becomes the mature miRNA, because the strand with the less stably base-paired 5⬘ end is preferably selected to become the miRNA, whereas the strand with the more stably base-paired 5⬘ end, the miRNA* strand, is degraded [12,27]. 3.3.2
Processing of miRNA Precursors into Mature miRNAs
Just as Drosha requires a dsRNA-binding protein partner to process pri-miRNAs, Drosophila Dicer-1 (Dcr-1) [68] requires its dsRNA-binding partner protein Loquacious (Loqs) to process premiRNAs [69–71]. Loqs contains three dsRBDs (two canonical dsRBDs at the N-terminus, and one noncanonical dsRBD at the C-terminus). Loqs not only stimulates the pre-miRNA processing activity of Dcr-1 in vitro, it also makes it specific. Indeed, Dcr-1 alone can process both long dsRNA and pre-miRNA substrates into ⬃21-nt small RNAs; Loqs restricts Dcr-1 to processing pre-miRNA, inhibiting this nonspecific effect [70]. Mammals appear to use two Loqs homologs, the transactivating response (tar) RNA-binding protein (TRBP) and PKR (protein kinase R) activating protein (PACT) as Dicer partner proteins [72–75]. Similar to Loqs, both TRBP and PACT contain three dsRNA-binding domains and use the third domain to bind Dicer [73,75]. Both proteins are not required for pre-miRNA processing by Dicer. TRBP and PACT may have partially redundant functions. Some studies suggest that TRBP also participates in loading of small RNAs into RISC [76,77], suggesting that TRBP functions like R2D2, the Drosophila partner protein of Dicer-2 (Dcr-2), to transfer the small RNA to Argonaute2 (Ago2). If TRBP functions in mammalian RISC loading, it is unlikely that Dicer also participates (unlike Drosophila Dcr-2), because Dicer mouse knockout cells are competent for siRNA-directed RNAi [78]. In contrast, depletion of PACT in cultured human cells decreases the abundance of mature miRNAs, but has little or no effect on siRNA-directed silencing of a reporter [73].
3.4 THE RNAi ENZYME COMPLEX 3.4.1
RISC
Small RNAs such as miRNAs and siRNAs function bound to members of the Argonaute family of proteins. Argonautes are proteins specialized for small RNA-directed target recognition. Plants and animals typically contain several distinct Argonaute proteins with apparently different functions. In flies and mammals, Ago2 mediates siRNA-directed RNAi [79,80]. (miRNAs can also associate with Ago2.) For historical reasons, any protein complex containing a small RNA and capable of directing posttranscriptional gene silencing is termed an RNA-induced silencing complex (RISC). RISC can be as simple as Ago2 loaded with siRNA [11,81], but because Argonaute proteins associate with auxiliary proteins suspected to enhance or modify their intrinsic activity, RISC may also be a multiprotein complex rivaling the ribosome in size [82]. Both Drosophila and human RISCs are Mg2⫹-dependent endonucleases producing a 3⬘ cleavage product bearing a 5⬘ phosphate and a 5⬘ cleavage product with 2⬘, 3⬘ hydroxyl termini [25,83]. While RISC does not require ATP for target recognition or cleavage [81,84], product release is a greatly facilitated by ATP, suggesting that an ATP-dependent RNA helicase acts to dissociate the cleavage products from the siRNA guide [84]. Alternatively, ATP may promote a conformational change in RISC itself, releasing the cleaved target. RISC is an enzyme, catalyzing multiple rounds of endonucleolytic target cleavage without consuming its guide siRNA [84,85]. Following cleavage by Drosophila Ago2-RISC,
CRC_8796_ch003.qxd
80
4/24/2007
10:10 AM
Page 80
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
the target fragments are degraded by the 3⬘-to-5⬘ activity of the exosome and by the 5⬘-to-3⬘ exonuclease XRN1 [86]. Although siRNAs typically pair fully with their target RNAs, the 5⬘, central, and 3⬘ regions of an siRNA make distinct contributions to binding and catalysis. Enzyme kinetics measurements and the structures of archael Argonaute proteins suggest that the first nucleotide of a small RNA guide (G1) does not participate in the binding of RISC with target mRNA [84,87,88]. Nucleotides G2 through G8 provide most of the energy of target binding. The importance of this region of the small RNA, which is called the seed sequence, emerged first from efforts to identify mRNAs regulated by microRNAs [39,41,42,89–91]. While the central and 3⬘ regions of a small RNA guide must also be base-paired with the target for Argonaute to catalyze cleavage, these bases contribute little energy to target binding [84]. In general, target cleavage requires base pairing of nucleotides 2 to12, which corresponds to one turn of A-form helix. In vitro, RISC is remarkably tolerant to mismatches. In vitro, up to nine contiguous mismatches at the 3⬘ end and up to five at the 5⬘ end are tolerated [25,84], although regulation by siRNAs with so little pairing with their target RNAs is unlikely to proceed through an endonucleolytic mechanism in vivo. 3.4.2
Structure of Argonaute Proteins
Argonaute proteins contain two highly conserved domains: the PAZ domain (first identified in the Drosophila protein Piwi and the plant proteins Argonaute and Zwille) and the PIWI domain [92]. The ⬃110 amino acid PAZ domain, found in both Argonaute and Dicer proteins, binds the two single-stranded 3⬘ nucleotides of a small RNA duplex [93–96]. The central domain of PAZ is a 5 or 6 strand, left-handed -barrel with two ␣-helices at the N-terminus. The PAZ domain resembles the oligonucleotide-binding “OB” fold present in some nucleic acid–binding proteins [97]. The sequences of PAZ domains diverge considerably, and the PAZ domain of Pyrococcus furiosus Argonaute was detected only by structural homology [98]. The structure of the PAZ domain is essentially unchanged by RNA binding, even though the siRNA 3⬘ tail is positioned deep inside a cleft lined with aromatic and basic amino acid side chains, which cannot accommodate terminal phosphate or paired nucleotides [93,94,99]. The PIWI domain is a structural homolog of the catalytic domain of RNase H [98], a discovery unanticipated by comparisons of the sequences of the two protein classes. Both RNase H and Argonaute proteins recognize A-form nucleic acid helices and use the sequence of one of the strands (DNA for RNase H, RNA for Argonaute) to direct cleavage of the other strand (RNA for both). Unlike RNase H, the Argonaute proteins remain stably bound to their nucleic acid guide, in part because the PIWI domain contains a 5⬘ phosphate-binding pocket that secures and aligns the siRNA guide strand on the protein. The phosphate-binding pocket is formed by the C-terminal carboxyl group of Argonaute bound to a divalent cation and is the most evolutionarily conserved feature of the PIWI domain [87,88]. Insertion of the 5⬘ phosphate of the siRNA guide strand into the binding pocket precludes pairing of the first base of the guide (G1) with the complementary base in the passenger strand or the RNA target (T1) [88], consistent with the earlier findings that unpairing the first base of the guide within an siRNA duplex promotes its incorporation into RISC [12] and that a mismatch between guide nucleotide G1 and target nucleotide T1 enhances, rather than disrupts, target cleavage [84]. The phosphate groups of guide strand nucleotides 2 through 5 interact extensively with amino acids in the PIWI domain, whereas few contacts are made with the passenger strand, consistent with the need to release the passenger strand and, later, the cleaved target RNA, from Argonaute. Little structural information is available about the geometry of the RNA in the catalytic cleft of the PIWI domain, but model building suggests that the scissile phosphate, which always lies between the target nucleotides paired to guide strand bases G10 and G11, resides within RNase H fold [100]. Biochemical data suggest that the target cleavage site is determined by the placement of the guide strand on Argonaute, not the length of the helix formed between the siRNA and its target
CRC_8796_ch003.qxd
4/24/2007
10:10 AM
Page 81
SMALL RNA SILENCING PATHWAYS
81
[10,13,15–17,24,25]. Similar to RNase H, the Argonaute PIWI domain contains a trio of conserved amino acids required for catalysis [101]. In RNase H, Asp-Asp-Glu (DDE) residues coordinate two metal ions at the active site; in the catalytic center of Pyrococcus furiosis Argonaute, the two metal ions are coordinated by two aspartic acids and a histidine (DDH). The metal ions—likely Mg2⫹—are proposed to recruit a water or hydroxide ion as the nucleophile attacking the phosphodiester bond and to stabilize the transition state during catalysis. When these catalytic residues in human Ago2 are mutated, siRNA-directed mRNA cleavage is abolished, supporting the view that the other human Argonaute proteins, Ago1, Ago3, and Ago4, cannot direct endonucleolytic cleavage of their targets because they lack the appropriate catalytic amino acids [79,81].
3.5 RISC ASSEMBLY RISC assembly, the process by which a small RNA is loaded into an Argonaute protein, has been most extensively studied for Drosophila Ago2. Assembly of Drosophila Ago2-RISC in vitro is a highly ordered process (Fig. 3.2). The central step in Drosophila Ago2-RISC assembly is formation of the RISC loading complex (RLC), which requires Dcr-2, its dsRNA-binding partner protein R2D2, and is stimulated by ATP [26,68,102]. Production of the RLC requires binding of a heterodimeric complex of Dcr-2 and R2D2 to the siRNA duplex, but other proteins are likely required, as the RLC is considerably larger than a complex containing only siRNA, Dcr-2, and R2D2 [26,102]. Dcr-2 alone binds poorly to siRNA, requiring R2D2 for stable binding [103,104]. Conversely, recombinant R2D2 does not detectably bind siRNA without Dcr-2 [105]. The central function of the RLC appears to be selecting which strand of an siRNA duplex will be loaded into Ago2—the guide strand—and which will be degraded—the passenger strand. The Dcr-2/R2D2 heterodimer binds an siRNA duplex with a nonrandom orientation. R2D2 binds preferentially to the siRNA 5⬘ end with more double-stranded RNA character, i.e., the more thermodynamically stable end. Dcr-2 therefore lies near the 5⬘ end of the guide strand. The Dcr-2/R2D2 heterodimer is thus primary sensor in Drosophila of siRNA thermodynamic stability [104]. Binding of Dcr-2/R2D2 to the siRNA promotes its loading into RISC, perhaps because Ago2 can bind Dcr-2 directly [106]. Selection of the siRNA guide strand does not appear to be coupled to the polarity of dsRNA processing by Dcr-2, suggesting that newly generated siRNA are released from Dcr-2 and then reenter the Dcr-2-dependent Ago-2-RISC assembly pathway [107]. Surprisingly, separation of the two strands of an siRNA occurs after they are loaded into Ago2. Initially, siRNA unwinding was presumed to precede loading of the guide strand into Ago2 [16]. The first hints that this model was flawed were the findings that siRNA unwinding requires Ago2 [108] and that double-stranded siRNA accumulates in the RLC in lysates prepared from ago2 mutant embryos [104]. Current data suggest that first Dcr-2 and then R2D2 is exchanged for Ago2, placing the 5⬘ phosphate of the guide strand of the double-stranded siRNA in the phosphate-binding pocket of Ago2 [109,110]. The single-stranded RNA-binding PAZ domain of Ago2 is hypothesized to bind the 3⬘ end of the guide strand, displacing R2D2. For an siRNA duplex, the resulting configuration of siRNA on Ago2 is essentially the same as an Ago2:siRNA complex bound to a target RNA. In vitro and cell culture data suggest that endonucleolytic cleavage of the passenger strand initiates its displacement from Ago2, generating a functional RISC in which the guide strand is ready to bind an mRNA target [111–113]. In vitro data also suggest that Ago2-catalyzed cleavage of the passenger strand facilitates loading of siRNA into human Ago2-RISC [111]. Moreover, the same mechanism is likely used for miRNA/miRNA* duplexes that have both a paired central region—that is, one that permits passengerstrand cleavage—and a fully paired seed sequence [111]. Recall that the seed sequence is a specialized region of a small RNA guide—roughly nucleotides 2 through 8—that provides most of the binding energy for target recognition. The seed is thought to be created when a small RNA binds an Argonaute protein. Thus, the special properties of the seed do not exist before the siRNA or
CRC_8796_ch003.qxd
4/24/2007
10:10 AM
Page 82
82
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION dsRNA
Dicer-2 R2D2
siRNA duplex
ATP
RLC
ATP
Ago2
ATP? Ago2
polyA
cap
ATP polyA Figure 3.2
cap
Drosophila RISC assembly.
miRNA/miRNA* duplex binds Argonaute. After binding Argonaute, the passenger strand or miRNA* strand is hypothesized to be tethered to its complement mainly through the seed sequence. Small RNA duplexes with disrupted seed sequences (e.g., miRNA/miRNA* sequences with a mismatch or G:U wobble within the seed region) likely release the passenger strand without the need to cleave it, because little holds the two strands of the small RNA together once the duplex binds an Argonaute protein.
3.6 SMALL RNA-DIRECTED mRNA DESTABILIZATION AND TRANSLATIONAL REPRESSION The first examples of miRNA-directed regulation led to the idea that animal miRNAs bind imperfectly to multiple sites in the 3⬘ untranslated region (UTR) of the mRNAs they regulate. This view was reinforced by computational efforts to predict miRNA targets, which relied heavily on the evolutionary conservation of mRNA sequences complementary to the miRNA seed sequence,
CRC_8796_ch003.qxd
4/24/2007
10:10 AM
Page 83
SMALL RNA SILENCING PATHWAYS
83
because conservation is simpler to detect in UTRs than in coding sequences, which are constrained to encode a functional protein [41,42,91,114]. Recently, algorithms have been proposed to predict miRNA targets without resort to sequence conservation [40]. These methods suggest that miRNAs also regulate targets by binding in the 5⬘ UTR and coding sequence. The success of this newer computational approach to predict biologically important miRNA–mRNA regulatory relationships remains to be determined, and experimental approaches suggest that 3⬘ UTR sequences are generally more amenable to miRNA-like regulation than other mRNA regions [115–117]. Initial studies of the C. elegans miRNA lin-4, the first discovered miRNA, demonstrated that lin-4 directs repression of lin-14 mRNA posttranscriptionally and suggested that repression occurs through a block to translation of LIN-14 protein [118,119]. Surprisingly, repression of LIN-14 protein synthesis by lin-4 did not appear to alter the association of either lin-14 mRNA with polysomes or the length of the lin-14 poly(A) tail, consistent with repression of LIN-14 translation after the initiation of protein synthesis. Similar conclusions were reached for a second lin-4-regulated gene, lin-28 [120,121]. More recently, a reexamination of the mechanism by which the miRNA let-7 regulates expression of lin-41 and by which lin-4 regulates lin-14 and lin-28 suggests that these miRNAs act mainly by decreasing the stability of their mRNA targets, rather than by altering their rates of translation [122]. Apparently conflicting data have also been reported for human miRNA regulatory mechanisms. In cultured human cells, endogenous let-7 represses translation of a reporter construct by decreasing the rate of translational initiation [123,124]. In contrast, siRNAs engineered to bind imperfectly to multiple sites in the 3⬘ untranslated region of a reporter mRNA appear to repress protein synthesis without altering the rate of translational initiation [125–127]. miRNAs can sequester their mRNA targets in cytoplasmic Processing bodies (P-bodies), and both miRNA-directed mRNA destruction and translational repression may reflect sequestration of the mRNA in P-bodies [123,128–131]. The human Argonaute proteins Ago1 and Ago2 directly associate with the P-body component GW182; depletion of GW182 impairs small RNA-directed silencing of a reporter mRNA [132–134]. Mutations in Ago1 and Ago2 that prevent them from localizing to P-bodies disrupt small RNA-independent translational inhibition of target mRNA when the Argonaute proteins are tethered to the 3⬘ UTR of the target mRNA through a bacteriophage RNAbinding protein [132]. Yet, RCK/p54, a putative DEAD box helicase protein and a general repressor of translation found in P-bodies, interacts with hAgo1 and hAgo2, and this interaction as well as miRNA-directed translational repression of target mRNAs is independent of P-body integrity [135]. Thus it remains possible that miRNA-directed translational repression does not require P-bodies per se, but rather that the relocalization of miRNA-repressed mRNAs to P-bodies is a consequence of translation repression [135]. Adding to the plethora of proposed mechanisms for miRNA-directed regulation of mRNA expression, Drosophila, zebrafish, and mammalian miRNAs can also promote mRNA degradation by triggering poly(A) tail shortening and by promoting removal of the 5⬘ cap [124,134,136,137]. A more detailed molecular understanding of all these proposed mechanisms for miRNA function awaits the development of robust in vitro systems that recapitulate both the loading of miRNAs into RISC and the subsequent repression of target mRNA expression by miRNAprogrammed Argonaute protein complexes.
3.7 CONCLUSIONS The impact of RNAi technology on biology and biotechnology cannot be overestimated. The idea that small RNA-directed regulatory pathways eluded detection decades after the discovery of tRNAs, snRNAs, and ribozymes is stunning. Our molecular understanding of the diversity of small silencing RNAs and the pathways that produce, sort, and use them to regulate gene expression continues to grow at a breathtaking pace. Moreover, fundamental advances in the biochemistry of RNA silencing pathways are rapidly being converted into practical technologies for the silencing of gene
CRC_8796_ch003.qxd
84
4/24/2007
10:10 AM
Page 84
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
expression in basal eukaryotes, plants, and animals. Finally, the development of siRNAs as therapy for human disease continues to show great promise. We may soon see small RNA drugs in clinical use to improve human health.
REFERENCES 1. van der Krol, A.R. et al. Flavonoid genes in petunia: addition of a limited number of gene copies may lead to a suppression of gene expression, Plant Cell, 2, 291, 1990. 2. Napoli, C., Lemieux, C., and Jorgensen, R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans, Plant Cell, 2, 279, 1990. 3. Cogoni, C. et al. Transgene silencing of the al-1 gene in vegetative cells of Neurospora is mediated by a cytoplasmic effector and does not depend on DNA-DNA interactions or DNA methylation, EMBO J., 15, 3153, 1996. 4. Romano, N., and Macino, G. Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences, Mol. Microbiol., 6, 3343, 1992. 5. Guo, S., and Kemphues, K.J. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed, Cell, 81, 611, 1995. 6. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391, 806, 1998. 7. Hamilton, A.J., and Baulcombe, D.C. A species of small antisense RNA in posttranscriptional gene silencing in plants, Science, 286, 950, 1999. 8. Elbashir, S.M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, Nature, 411, 494, 2001. 9. Hammond, S.M. et al. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells, Nature, 404, 293, 2000. 10. Tuschl, T. et al. Targeted mRNA degradation by double-stranded RNA in vitro, Genes Dev., 13, 3191, 1999. 11. Martinez, J. et al. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi, Cell, 110, 563, 2002. 12. Schwarz, D.S. et al. Asymmetry in the assembly of the RNAi enzyme complex, Cell, 115, 199, 2003. 13. Zamore, P.D. et al. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals, Cell, 101, 25, 2000. 14. Bernstein, E. et al. Role for a bidentate ribonuclease in the initiation step of RNA interference, Nature, 409, 363, 2001. 15. Elbashir, S.M., Lendeckel, W., and Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs, Genes Dev., 15, 188, 2001. 16. Nykanen, A., Haley, B., and Zamore, P.D. ATP requirements and small interfering RNA structure in the RNA interference pathway, Cell, 107, 309, 2001. 17. Schwarz, D.S. et al. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways, Mol. Cell, 10, 537, 2002. 18. Caplen, N.J. et al. Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference, Hum. Mol. Genet., 11, 175, 2002. 19. Giladi, H. et al. Small interfering RNA inhibits hepatitis B virus replication in mice, Mol. Ther., 8, 769, 2003. 20. Zimmermann, T.S. et al. RNAi-mediated gene silencing in non-human primates, Nature, 441, 111, 2006. 21. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs, Nature, 432, 173, 2004. 22. Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis, Nat. Med., 9, 347, 2003. 23. Hammond, S.M. et al. Argonaute2, a link between genetic and biochemical analyses of RNAi, Science, 293, 1146, 2001. 24. Elbashir, S.M. et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate, EMBO J., 20, 6877, 2001.
CRC_8796_ch003.qxd
4/24/2007
10:10 AM
Page 85
SMALL RNA SILENCING PATHWAYS
85
25. Martinez, J., and Tuschl, T. RISC is a 5⬘ phosphomonoester-producing RNA endonuclease, Genes Dev., 18, 975, 2004. 26. Tomari, Y. et al. RISC assembly defects in the Drosophila RNAi mutant armitage, Cell, 116, 831, 2004. 27. Khvorova, A., Reynolds, A., and Jayasena, S.D. Functional siRNAs and miRNAs exhibit strand bias, Cell, 115, 209, 2003. 28. Xia, T. et al. Thermodynamic parameters for an expanded nearest-neighbor model for formation of RNA duplexes with Watson-Crick base pairs, Biochemistry, 37, 14719, 1998. 29. O’Toole, A.S. et al. Comprehensive thermodynamic analysis of 3⬘ double-nucleotide overhangs neighboring Watson-Crick terminal base pairs, Nucleic Acids Res., 34, 3338, 2006. 30. Schwarz, D.S. et al. Designing siRNA that distinguish between genes that differ by a single nucleotide, PLoS Genet., 2, 1307, 2006. 31. Naguibneva, I. et al. The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation, Nat. Cell Biol., 8, 278, 2006. 32. Yekta, S., Shih, I.H., and Bartel, D.P. MicroRNA-directed cleavage of HOXB8 mRNA, Science, 304, 594, 2004. 33. Davis, E. et al. RNAi-mediated allelic trans-interaction at the imprinted Rtl1/Peg11 locus, Curr. Biol., 15, 743, 2005. 34. Jones-Rhoades, M.W., and Bartel, D.P. Computational identification of plant microRNAs and their targets, including a stress-induced miRNA, Mol. Cell, 14, 787, 2004. 35. Lindow, M., and Krogh, A. Computational evidence for hundreds of non-conserved plant microRNAs, BMC Genomics, 6, 119, 2005. 36. Zhang, B., Pan, X., and Anderson, T.A. Identification of 188 conserved maize microRNAs and their targets, FEBS Lett., 580, 3753, 2006. 37. Lim, L.P. et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs, Nature, 433, 769, 2005. 38. Rajewsky, N. microRNA target predictions in animals, Nat. Genet., 38 (suppl.), S8, 2006. 39. Brennecke, J. et al. Principles of microRNA-target recognition, PLoS Biol., 3, e85, 2005. 40. Miranda, K.C. et al. A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes, Cell, 126, 1203, 2006. 41. Lewis, B.P., Burge, C.B., and Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets, Cell, 120(1), 15, 2005. 42. Lewis, B.P. et al. Prediction of mammalian microRNA targets, Cell, 115, 787, 2003. 43. Lecellier, C.H. et al. A cellular microRNA mediates antiviral defense in human cells, Science, 308, 557, 2005. 44. Jopling, C.L. et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA, Science, 309, 1577, 2005. 45. Berezikov, E. et al. Phylogenetic shadowing and computational identification of human microRNA genes, Cell, 120(1), 21, 2005. 46 Reinhart, B.J. et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans, Nature, 403, 901, 2000. 47. Lee, R.C., Feinbaum, R.L., and Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell, 75, 843, 1993. 48. Lee, Y. et al. MicroRNA maturation: stepwise processing and subcellular localization, EMBO J., 21, 4663, 2002. 49. Cai, X., Hagedorn, C.H., and Cullen, B.R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs, RNA, 10, 1957, 2004. 50. Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 2004. 51. Aravin, A.A. et al. The small RNA profile during Drosophila melanogaster development, Dev. Cell, 5, 337, 2003. 52. Cai, X. et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed, PLoS Pathog., 2, e23, 2006. 53. Pfeffer, S. et al. Identification of virus-encoded microRNAs, Science, 304, 734, 2004. 54. Pfeffer, S. et al. Identification of microRNAs of the herpesvirus family, Nat. Methods, 2, 269, 2005. 55. Sullivan, C.S. et al. SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells, Nature, 435, 682, 2005.
CRC_8796_ch003.qxd
86
4/24/2007
10:10 AM
Page 86
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION 56. Lee, Y. et al. The nuclear RNase III Drosha initiates microRNA processing, Nature, 425, 415, 2003. 57. Denli, A.M. et al. Processing of primary microRNAs by the Microprocessor complex, Nature, 432, 231, 2004. 58. Gregory, R.I. et al. The microprocessor complex mediates the genesis of microRNAs, Nature, 432, 235, 2004. 59. Han, J. et al. The Drosha-DGCR8 complex in primary microRNA processing, Genes Dev., 18, 3016, 2004. 60. Yeom, K.H. et al. Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing, Nucleic Acids Res., 2006. 61. Basyuk, E. et al. Human let-7 stem-loop precursors harbor features of RNase III cleavage products, Nucleic Acids Res., 31, 6593, 2003. 62. Yi, R. et al. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs, Genes Dev., 17, 3011, 2003. 63. Lund, E. et al. Nuclear export of microRNA precursors, Science, 303, 95, 2004. 64. Hutvagner, G. et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA, Science, 293, 834, 2001. 65. Grishok, A. et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing, Cell, 106, 23, 2001. 66. Ketting, R.F. et al. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans, Genes Dev., 15, 2654, 2001. 67. Han, J. et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex, Cell, 125, 887, 2006. 68. Lee, Y.S. et al. Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways, Cell, 117, 69, 2004. 69. Forstemann, K. et al. Normal microRNA maturation and germ-line stem cell maintenance requires Loquacious, a double-stranded RNA-binding domain protein, PLoS Biol., 3, e236, 2005. 70. Saito, K. et al. Processing of pre-microRNAs by the Dicer-1-Loquacious complex in Drosophila cells, PLoS Biol., 3, e235, 2005. 71. Jiang, F. et al. Dicer-1 and R3D1-L catalyze microRNA maturation in Drosophila, Genes Dev., 19, 1674, 2005. 72. Maniataki, E., and Mourelatos, Z. A human, ATP-independent, RISC assembly machine fueled by premiRNA, Genes Dev., 19, 2979, 2005. 73. Lee, Y. et al. The role of PACT in the RNA silencing pathway, EMBO J., 25, 522, 2006. 74. Gregory, R.I. et al. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing, Cell, 123, 631, 2005. 75. Haase, A.D. et al. TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing, EMBO Rep., 6, 961, 2005. 76. Doi, N. et al. Short-interfering-RNA-mediated gene silencing in mammalian cells requires Dicer and eIF2C translation initiation factors, Curr. Biol., 13, 41, 2003. 77. Chendrimada, T.P. et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing, Nature, 436, 740, 2005. 78. Kanellopoulou, C. et al. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing, Genes Dev., 19, 489, 2005. 79. Liu, J. et al. Argonaute2 is the catalytic engine of mammalian RNAi, Science, 305, 1437, 2004. 80. Meister, G. et al. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs, Mol. Cell, 15, 185, 2004. 81. Rivas, F.V. et al. Purified Argonaute2 and an siRNA form recombinant human RISC, Nat. Struct. Mol. Biol., 12, 340, 2005. 82. Pham, J.W. et al. A Dicer-2-dependent 80s complex cleaves targeted mRNAs during RNAi in Drosophila, Cell, 117, 83, 2004. 83. Schwarz, D.S., Tomari, Y., and Zamore, P.D. The RNA-induced silencing complex is a Mg2⫹-dependent endonuclease, Curr. Biol., 14, 787, 2004. 84. Haley, B., and Zamore, P.D. Kinetic analysis of the RNAi enzyme complex, Nat. Struct. Mol. Biol., 11, 599, 2004. 85. Hutvagner, G., and Zamore, P.D. A microRNA in a multiple-turnover RNAi enzyme complex, Science, 297, 2056, 2002.
CRC_8796_ch003.qxd
4/24/2007
10:10 AM
Page 87
SMALL RNA SILENCING PATHWAYS
87
86. Orban, T.I., and Izaurralde, E. Decay of mRNAs targeted by RISC requires XRN1, the Ski complex, and the exosome, RNA, 11, 459, 2005. 87. Ma, J.B. et al. Structural basis for 5⬘-end-specific recognition of guide RNA by the A. fulgidus Piwi protein, Nature, 434, 666, 2005. 88. Parker, J.S., Roe, S.M., and Barford, D. Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex, Nature, 434, 663, 2005. 89. Lai, E.C. Micro RNAs are complementary to 3⬘ UTR sequence motifs that mediate negative posttranscriptional regulation, Nat. Genet., 30, 363, 2002. 90. Rajewsky, N., and Socci, N.D. Computational identification of microRNA targets, Dev. Biol., 267, 529, 2004. 91. Krek, A. et al. Combinatorial microRNA target predictions, Nat. Genet., 37, 495, 2005. 92. Cerutti, L., Mian, N., and Bateman, A. Domains in gene silencing and cell differentiation proteins: the novel PAZ domain and redefinition of the Piwi domain, Trends Biochem. Sci., 25, 481, 2000. 93. Ma, J.B., Ye, K., and Patel, D.J. Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain, Nature, 429, 318, 2004. 94. Lingel, A. et al. Nucleic acid 3⬘-end recognition by the Argonaute2 PAZ domain, Nat. Struct. Mol. Biol., 11, 576, 2004. 95. Song, J.J. et al. The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes, Nat. Struct. Biol., 10, 1026, 2003. 96. Yan, K.S. et al. Structure and conserved RNA binding of the PAZ domain, Nature, 426, 468, 2003. 97. Arcus, V. OB-fold domains: a snapshot of the evolution of sequence, structure and function, Curr. Opin. Struct. Biol., 12, 794, 2002. 98. Song, J.J. et al. Crystal structure of Argonaute and its implications for RISC slicer activity, Science, 305, 1434, 2004. 99. Collins, R.E., and Cheng, X. Structural domains in RNAi, FEBS Lett., 579, 5841, 2005. 100. Yuan, Y.R. et al. Crystal structure of A. aeolicus argonaute, a site-specific DNA-guided endoribonuclease, provides insights into RISC-mediated mRNA cleavage, Mol. Cell, 19, 405, 2005. 101. Nowotny, M. et al. Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis, Cell, 121, 1005, 2005. 102. Pham, J.W., and Sontheimer, E.J. Molecular requirements for RNA-induced silencing complex assembly in the Drosophila RNA interference pathway, J. Biol. Chem., 280, 39278, 2005. 103. Liu, Q. et al. R2D2, a bridge between the initiation and effector steps of the Drosophila RNAi pathway, Science, 301, 1921, 2003. 104. Tomari, Y. et al. A protein sensor for siRNA asymmetry, Science, 306, 1377, 2004. 105. Liu, X. et al. Dicer-2 and R2D2 coordinately bind siRNA to promote assembly of the siRISC complexes, RNA, 12, 1514, 2006. 106. Tahbaz, N. et al. Characterization of the interactions between mammalian PAZ PIWI domain proteins and Dicer, EMBO Rep., 5, 189, 2004. 107. Preall, J.B. et al. Short interfering RNA strand selection is independent of dsRNA processing polarity during RNAi in Drosophila, Curr. Biol., 16, 530, 2006. 108. Okamura, K. et al. Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways, Genes Dev., 18, 1655, 2004. 109. Tomari, Y., and Zamore, P.D. Perspective: machines for RNAi, Genes Dev., 19, 517, 2005. 110. Filipowicz, W. RNAi: the nuts and bolts of the RISC machine, Cell, 122, 17, 2005. 111. Matranga, C. et al. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes, Cell, 123, 607, 2005. 112. Rand, T.A. et al. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation, Cell, 123, 621, 2005. 113. Leuschner, P.J. et al. Cleavage of the siRNA passenger strand during RISC assembly in human cells, EMBO Rep., 7, 314, 2006. 114. Stark, A. et al. Identification of Drosophila MicroRNA targets, PLoS Biol., 1, E60, 2003. 115. Fedorov, Y. et al. Off-target effects by siRNA can induce toxic phenotype, RNA, 12, 1188, 2006. 116. Jackson, A.L. et al. Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing, RNA, 12, 1197, 2006.
CRC_8796_ch003.qxd
88
4/24/2007
10:10 AM
Page 88
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
117. Reynolds, A. et al. Induction of the interferon response by siRNA is cell type- and duplex lengthdependent, RNA, 12, 988, 2006. 118. Wightman, B., Ha, I., and Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans, Cell, 75, 855, 1993. 119. Olsen, P.H., and Ambros, V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation, Dev. Biol., 216, 671, 1999. 120. Moss, E.G., Lee, R.C., and Ambros, V. The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA, Cell, 88, 637, 1997. 121. Seggerson, K., Tang, L., and Moss, E.G. Two genetic circuits repress the Caenorhabditis elegans heterochronic gene lin-28 after translation initiation, Dev. Biol., 243, 215, 2002. 122. Bagga, S. et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation, Cell, 122, 553, 2005. 123. Pillai, R.S. et al. Inhibition of translational initiation by let-7 microRNA in human cells, Science, 309, 1573, 2005. 124. Humphreys, D.T. et al. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function, Proceedings of the National Academy of Science USA, 102, 16961, 2005. 125. Petersen, C.P. et al. Short RNAs repress translation after initiation in mammalian cells, Mol. Cell, 21, 533, 2006. 126. Doench, J.G., Petersen, C.P., and Sharp, P.A. siRNAs can function as miRNAs, Genes Dev., 17, 438, 2003. 127. Doench, J.G., and Sharp, P.A. Specificity of microRNA target selection in translational repression, Genes Dev., 18, 504, 2004. 128. Liu, J. et al. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies, Nat. Cell Biol., 7, 719, 2005. 129. Andrei, M.A. et al. A role for eIF4E and eIF4E-transporter in targeting mRNPs to mammalian processing bodies, RNA, 11, 717, 2005. 130. Sheth, U., and Parker, R. Targeting of aberrant mRNAs to cytoplasmic processing bodies, Cell, 125, 1095, 2006. 131. Teixeira, D. et al. Processing bodies require RNA for assembly and contain nontranslating mRNAs, RNA, 11, 371, 2005. 132. Liu, J. et al. A role for the P-body component GW182 in microRNA function, Nat. Cell Biol., 7, 1261, 2005. 133. Jakymiw, A. et al. Disruption of GW bodies impairs mammalian RNA interference, Nat. Cell Biol., 7, 1267, 2005. 134. Behm-Ansmant, I. et al. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes, Genes Dev., 20, 1885, 2006. 135. Chu, C.Y., and Rana, T.M. Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54, PLoS Biol., 4, e210, 2006. 136. Wu, L., Fan, J., and Belasco, J.G. MicroRNAs direct rapid deadenylation of mRNA, Proceedings of the National Academy of Science USA, 103, 4034, 2006. 137. Giraldez, A.J. et al. Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs, Science, 312, 75, 2006.
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 89
CHAPTER
4
Splice Switching Oligonucleotides as Potential Therapeutics Peter Sazani, Maria A. Graziewicz, and Ryszard Kole
CONTENTS 4.1 4.2 4.3 4.4 4.5
4.6
Introduction.............................................................................................................................90 Pre-mRNA Splicing................................................................................................................90 Alternative Splicing ................................................................................................................92 Splice Switching Oligonucleotides.........................................................................................93 Therapeutic Targets of SSOs ..................................................................................................94 4.5.1 Restoration of Defective Gene Function by SSOs .....................................................94 4.5.1.1 -Globin ......................................................................................................94 4.5.1.2 Dystrophin ...................................................................................................95 4.5.1.3 Cystic Fibrosis Transmembrane Conductance Regulator ...........................95 4.5.1.4 Tau ...............................................................................................................96 4.5.1.5 Lamin A.......................................................................................................96 4.5.1.6 Survival Motor Neurons..............................................................................97 4.5.1.7 OA1 .............................................................................................................97 4.5.2 Modification of Natural Alternative Splicing as a Potential Therapeutic Tool..........98 4.5.2.1 Bcl-x ............................................................................................................98 4.5.2.2 PSMA ..........................................................................................................98 4.5.2.3 WT1.............................................................................................................99 4.5.2.4 CD40 ...........................................................................................................99 4.5.2.5 MyD88 ........................................................................................................99 4.5.2.6 AChE ...........................................................................................................99 4.5.2.7 Polyadenylation Regions...........................................................................100 Other Mechanisms to Alter RNA Splicing...........................................................................100 4.6.1 Hybridization Strategies ...........................................................................................100 4.6.1.1 ESSENCE..................................................................................................100 4.6.1.2 TOSS .........................................................................................................101 4.6.1.3 Trans-Splicing ...........................................................................................101 4.6.1.4 snRNA .......................................................................................................102 4.6.2 Global Strategies.......................................................................................................103 4.6.2.1 RNAi..........................................................................................................103 4.6.2.2 Small Molecules........................................................................................103 89
CRC_8796_ch004.qxd
90
5/25/2007
7:00 AM
Page 90
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
4.7 An Assay for Splice Switching Oligonucleotide Potency....................................................104 References ......................................................................................................................................105
4.1 INTRODUCTION Recent studies found that there are ⬃26,000 human genes, 70% of which undergo alternative splicing [1–3]. Thus, alternative splicing allows increased diversity of the proteins encoded by a limited number of primary transcripts. This tightly regulated process leads to splice variants with unique, sometimes opposing, functions, and is a part of normal organism physiology and development [4–6]. It has also been associated with several genetic diseases (-thalassemia, muscular dystrophy, cystic fibrosis [CF], and others) as well as with several types of cancer [7]; an estimated 15–50% of genetic disorders result from mutations that alter pre-mRNA splicing [8–11]. This chapter reviews antisense-based technologies to manipulate alternative and correct aberrant splicing. This approach may be critical for the treatment of a number of diseases, especially those where targeting by small molecules is not applicable. Antisense oligonucleotides (AONs) are typically applied as targeted downregulators of mRNA translation. This action is achieved by base pairing of specific 2-deoxyoligonucleotides with the targeted mRNA, a process that elicits destruction of the mRNA by RNase H, an enzyme that catalyzes RNA breakdown in an RNA/DNA duplex [12]. In recent years, the manipulation of splicing has been accomplished with chemically modified AONs that do not activate RNase H, thereby redirecting aberrant or alternative splicing rather than causing destruction of the targeted pre-mRNA, thus upregulating the synthesis of correct and/or therapeutic gene products. Benefits of such approach include possible use as a method to determine function of gene isoforms, positive readout assay for antisense activity, and most importantly, therapeutic potential for genetic diseases and a variety of other disorders that can be addressed by manipulation of alternative splicing of specific genes. In this chapter we will review pertinent literature since 2001, the time of publication of the previous edition of this volume, to present.
4.2 PRE-mRNA SPLICING Most eukaryotic pre-mRNAs contain coding fragments, or exons, and noncoding fragments, or introns, the latter of which must be removed by the splicing machinery before a mature mRNA is formed (Figure 4.1). For a comprehensive review of pre-mRNA splicing, including its alternative processing, refer to the following reviews [8,13,14]. Here, we present only a brief description of the process, highlighting the topics relevant to the use of AONs to manipulate aberrant and alternative splicing. The splicing machinery, or spliceosome, is a complex system based on multiple interactions among specific sequences in the pre-mRNA, small U-rich nuclear RNAs (snRNAs) forming nucleoprotein complexes (e.g., U1–U6 snRNP), heterogeneous nuclear ribonucleoproteins (e.g., polypyrimidine tract-binding protein [PTB/hnRNPI]), and numerous serine–arginine-rich (SR) family proteins [15–17]. The snRNPs are highly involved in the removal of the introns and splicing of the exons. Proteins from hnRNP family contain RNA-binding domains and auxiliary regions that participate in protein–protein interaction, and play a role as splicing repressors [18,19]. SR proteins have the opposing function, and are responsible for spliceosome stabilization and bridging the 3 and 5 splicing sites. At the C-terminus, SR proteins contain SR domains involved in protein–protein interactions and at the N-terminus region there are one or two RNA-binding domains, shown to interact with purine-rich exonic splicing enhancers (ESEs) in several exons [13,20–27]. Serine–arginine domains have also been found in core splicing regulating factors such as U2AF65 (U2 auxiliary factor 65 kDa) and U2AF35 or alternative splicing regulator TRA in Drosophila melanogaster [28–30].
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 91
SPLICE SWITCHING OLIGONUCLEOTIDES AS POTENTIAL THERAPEUTICS (A)
+
5′ss
E S KAG GURAGU E
(B)
− ISS
YNCURAY
+ ISE
91
3′ss
−
Y AGG
E S S
A
(C)
A Figure 4.1
Schematic representation of pre-mRNA processing. (A) Schematic exon–intron–exon structure. The conserved pre-mRNA sequences are recognized by the splicesome complex. (B) In the first transesterification reaction, the adenosine nucleotide within conserved branch point motif attacks the 5-most phosphodiester bond at the 5 splice site, resulting in the upstream exon displacement; the intron assumes lariat structure. (C) In the second trans-esterification reaction, the nucleoside at the 3 end of the released exon attacks the 3 end phosphodiester bond of the intron, completely releasing the intronic lariat and forming a new phosphodiester bond between the two neighboring exons. Boxes, exons; line, intron; ESE, exonic splicing enhancer; ISS, intronic splicing silencer; ISE, intronic splicing enhancer; ESS, exonic splicing silencer; , elements enhancing splicing; , sequences suppressing splicing; KAG GURAGU, Y AGG, conserved 5 and 3 splice site motifs, respectively;YNCURAY, branch point sequence.
Chemically, pre-mRNA splicing takes place at exon–intron junctions (5 and 3 splice sites) via two trans-esterification steps. The spliceosome catalyzing this reaction is comprised of up to 100 proteins and 5 snRNAs [16]. The spliceosome component that interacts with pre-mRNA the earliest is U1 snRNA [31,32], which hybridizes with the 5 splice site sequence via base pairing of its nine 5-most nucleotides. Next, U2 snRNP is bound, via base pairing of its internal region with the branch point sequence positioned 20–40 nucleotides upstream from the 3 splice site. This binding is stabilized by other splicing factors, including U2AF binding to the polypyrimidine tract and the 3 splice site, and splicing factor 1 binding to the branch point. SR proteins bind to ESEs and interact with U2AF, U1 snRNP, and the branch point [29]. Numerous rearrangements of spliceosome then take place, leading to dissociation of U1 and U4 snRNPs, and association of U5 snRNP simultaneously with the 5 and 3 sites. The first trans-esterification reaction, leads to formation of the intron lariat structure and displacement of the upstream exon. In the second reaction, the nucleoside at the 3 end of the released exon interacts with the phosphodiester bond at the 3 end of the intron. The intron lariat is then released and a phosphodiester bond is formed with the downstream exon resulting in spliced mRNA. Each splicing event requires de novo assembly and disassembly of the spliceosome [33]. In addition to the branch point and 5 and 3 splice sites involved in splicing, which are moderately conserved, other cis-acting RNA sequences are present within introns and exons, which have proven equally necessary for accurate and correct processing of pre-mRNA. Sequences termed exonic and intronic splicing enhancers (ESEs and ISEs, respectively) stimulate, while exonic and intronic splicing silencers (ESSs and ISSs, respectively) block inclusion of certain exons. ESEs and ISEs are recognized by SR proteins, whereas ESSs and ISSs are recognized by a complex often containing hnRNPs. One of the most studied ESEs regulates the inclusion of the female-specific exon 4 in the doublesex (dsx) gene of D. melanogaster; the ESE consists of six repeats of a 13 nucleotide
CRC_8796_ch004.qxd
92
5/25/2007
7:00 AM
Page 92
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
consensus sequences and a purine-rich element positioned between repeats 5 and 6 [34]. This element binds an SR protein and two splicing regulators, TRA and TRA2 [28]. In human genes, ESE sequences contain mostly purines, however no sequence consensus has yet been described. However, based on knowledge of sequences known to bind SR proteins, an algorithm to predict ESEs (ESEfinder) in transcripts has been developed [35]. Several ESSs have been described. For example, an ESS was found within exon IIIb of fibroblast growth factor receptor 2 (FGFR2); it consists of crucial UAGG sequence, and has been demonstrated to inhibit splicing of IIIb exon from the FGFR2 pre-mRNA [36]. A systematic screen for ESS sequences has been conducted [37,38], and this body of work has led to the hypothesis that ESSs are responsible for the repression of the vast number of pseudoexons, which have relatively strong 5 and 3 splice sites yet are not spliced into the mRNA and remain within intronic sequences. ESS has thus emerged as an important cis-acting element in the regulation of splicing. ISEs were found to be involved in efficient transcript splicing of genes such as -tropomyosin (ISE motif (A/T)GGG), human GH-1 gene (ISE motif GGX1–4GGG) or human -globin, which contains motif GGGX0–4 GGG [39–41]. One example of ISS comes from studies on FGFR2 gene splicing, where the specific sequence has been demonstrated to regulate the exclusion of exon IIIb from FGFR2 pre-mRNA. The identified ISS sequence consists of a polypyrimidine-rich region that binds PTB [42].
4.3 ALTERNATIVE SPLICING Sequence elements within pre-mRNA that participate in the selection of splice sites include the relative match of the 3 and 5 splice sites and branch points to their respective consensus sequences, some secondary structures, ESEs (for comprehensive review see Refs. [8,43]), and most likely other enhancer and silencer elements discussed above. Experimental introduction of mutations that increase the match between a branch point or a splice site and their corresponding consensus sequences resulted in inclusion of exons that were otherwise skipped [20,44]. Other studies showed that splice site mutations resulting in an exclusion of adjacent exons could also activate cryptic splicing sites [45]. Likewise, manipulation of polypyrimidine track, and introduction or removal of ESEs/ESSs affected splice site choice [46–49]. This data suggest that splice site selection is the result of competition between splice sites and sequence elements for splicing factors during the assembly of spliceosome [50–52]. Observations that the choice of splicing pathway depends on the availability of constitutive splicing factors and the presence/absence of gene-specific splicing factors further support this notion [51,53]. The levels and ratios between splicing factors in different cell types are key in splicing regulation. For example, hnRNP A1 functionally opposes the SR protein SF2/ASF during 5 splice site selection; SF2/ASF enhances proximal 5 splice site selection, while higher hnRNPA1 to SF2/ASF ratio promotes splicing at the distal 5 splice site. This ratio has been demonstrated to vary 100-fold in different tissues [54]. In general, different interaction patterns between the pre-mRNA sequence elements and splicing factors determine tissue-specific expression of majority of the pre-mRNAs [55,56]. Different outcomes of alternative splicing include (but are not limited to) exon skipping, exon inclusion, splicing out or retention of an intron. Retained introns become part of a coding sequence—an exon—whereas a skipped exon becomes part of the spliced-out intron (Figure 4.2). This suggests that a single mechanism is responsible for both outcomes. In addition, splice site selection can be influenced by alternative polyadenylation sites and vice versa. In some cases, transcripts can be initiated at different transcription start sites, which results in the synthesis of mRNA with different first exons. In some cases, for example, splicing of thalassemic -globin pre-mRNA, even temperature can affect splice site seletion [57]. More in-depth description of alternative splicing machinery and its regulation can be found in these comprehensive reviews [8,43,58].
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 93
SPLICE SWITCHING OLIGONUCLEOTIDES AS POTENTIAL THERAPEUTICS (A)
(B)
A
B
(i)
Figure 4.2
C
(ii) A
93
B
C
A
(iii) A
C
(i) A
B
C
A A′
B
A′
(ii) B
A
C
Schematic representation of alternative splicing. (A) Alternative exon or intron skipping/inclusion: (i) exon B inclusion; (ii) exon B skipping; (iii) intron retention. (B) Alternative 5 splice site may induce skipping of fragment of an exon: (i) use of 5 proximal splice allows inclusion of the whole exon A; (ii) use of 5 distal splice site results in inclusion of incomplete exon A. Similarly, alternative 3 splice sites can be utilized (not shown). Boxes, exons; solid line, intron.
The proteomic complexity due to alternative splicing prompted development of methods allowing prediction of alternative gene splicing patterns based on alignment of genomic sequences with transcript sequences [59–62]. The technologies utilize user-supplied sequences as well as gene predictions generated by Ensambl, Acembly, Genscan (ASmodeler) [62] or graph-based gene finder EuGENE [61,62]. Among others, mouse, rat, and human genomes can currently be analyzed for potential alternative splicing events using the aforementioned approaches. Another algorithm, ExonScan, uses splice site, branch point, ESE, and ESS scores to predict exon selection [38]. The incorporation of cis-acting sequences into splicing prediction programs has significantly increased their accuracy.
4.4 SPLICE SWITCHING OLIGONUCLEOTIDES The expanding field of modification of the splicing patterns of genes is based on early work by Dominski and Kole [63] in cell-free extracts. In this work, human -globin pre-mRNAs containing splicing mutations were targeted with antisense 2-O-methyl (2OMe) oligonucleotides to restore correct splicing. The mutations, -110 (in the first intron), and IVS2-705 and IVS2-654 (in the second intron) had been previously identified as leading to -thalassemia. AONs targeted against the branch point sequence in the first intron (-110), or aberrant 5 and cryptic 3 splice sites activated by IVS2-705 and IVS2-654 in the second intron, significantly reversed the aberrant and restored correct splicing. These studies demonstrated that the AONs could compete with splicing factors for splicing elements and therefore alter the manner in which pre-mRNA was spliced, restoring the correct function of the defective gene without downregulating its expression. In general, AONs can serve as splice switching oligonucleotides (SSOs) in three ways: (i) by restoring correct splicing of a specific gene, (ii) by modification of natural alternative splicing, shifting the balance towards one type of splicing product, and (iii) by generating an unnatural splice variant. This approach may be used to study the mechanisms of splice site selection. More importantly, because variations in splicing are clearly associated with disease states, SSO-induced modulation of splicing should produce clinically beneficial splice variants. All three SSO mechanisms require that the oligonucleotides do not activate RNA cleavage by RNase H, which would destroy the pre-mRNA before splicing can occur. Such oligonucleotides include 2OMe, 2-O-methoxyethyl (MOE), and 2-O-aminopropyl, phosphoramidate, and methylphosphonate derivatives, as well as locked nucleic acid (LNA) [64], peptide nucleic acid (PNA), and morpholinobased oligomers [65]. They productively compete with the splicing factors for target sequences in pre-mRNA during splicing and, in addition, these modifications improve oligonucleotide target binding.
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
94
Page 94
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
4.5 THERAPEUTIC TARGETS OF SSOs Below we present examples of genes where altered splicing is a cause of disease or where modulation of splicing may translate into a therapeutic effect. These clinically relevant outcomes can be achieved by either restoration of defective gene function or modification of natural alternative splicing. 4.5.1
Restoration of Defective Gene Function by SSOs
4.5.1.1 -Globin -Thalassemia is a genetic blood disorder resulting from defective -globin gene expression that leads to partial or complete ablation of -globin, a hemoglobin subunit [66]. The result is a decreased oxygen-transport capacity of red blood cells, expansion of the bone marrow, and fatal iron overload. There are ⬃200 different mutations in the human -globin gene but the most common ones disrupt splicing of intron 1 and 2 of -globin pre-mRNA. In the general population the frequency of the thalassemic gene is about 1 in 300, while in those who are of Mediterranean, South East Asian or African ancestry the risk of carrying it is about 1 in 30 [67]. A series of recent reports from this laboratory demonstrated correction of splicing in cells of thalassemia patients with point mutations at nucleotides 654, 705, and 745 of intron 2 using splice switching morpholino oligonucleotides [68–70]; see also selected reviews [71–74]. The mutations create an additional 5 splice site and activate a cryptic 3 splice site, and lead to inclusion of an aberrant exon-like sequence in the spliced -globin mRNA. Blocking these splice sites with morpholino oligonucleotides resulted in correction of -globin pre-mRNA splicing, and subsequently, led to hemoglobin upregulation in erythropoietic progenitor cells from IVS2-654 and IVS2-745 forms of thalassemia, as well as in erythroid cells from the mouse model of IVS2-654 thalassemia. Relatively high doses (45 M) of morpholino oligomer, used for effective splicing correction and -globin upregulation in human erythropoietic progenitor cells, did not affect sequence specificity and seemed to have little toxicity. Another -globin mutation, HbE, was also successfully targeted by this approach. Note that only morpholino oligonucleotides were taken up and effective in splicing modulation in erythroid progenitor cells; the other chemistries discussed in the previous section were not. Oligonucleotide delivery with cationic lipids was unsuccessful; these cells seem particularly sensitive to cationic lipid toxicity (data not shown). In vivo experiments in IVS2-654 thalassemia mouse model showed that morpholino oligonucleotides conjugated with Tat-like peptides were effective in systemic delivery by i.v. injection. Thirteen-day treatment restored ⬃10% of human hemoglobin expression. This resulted in visible improvement of red blood cell morphology (Figure 4.3) (Svasti and Kole, unpublished). This is a promising result since no more than 20% levels of hemoglobin are needed to eliminate or drastically reduce blood transfusions, the current treatment for thalassemia patients.
M-tat D-0
M-tat D-13
Normal
Figure 4.3 Red blood cell morphology is improved in thalassemic IVS2-654 mice treated with M-tat oligonucleotide inducing splicing repair of IVS2-654 -globin pre-mRNA. Wright–Giemsa staining of blood smears.
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 95
SPLICE SWITCHING OLIGONUCLEOTIDES AS POTENTIAL THERAPEUTICS
95
4.5.1.2 Dystrophin Mutations that result in the formation of stop codons in the coding exons of dystrophin gene are the main causes of Duchenne muscular dystrophy (DMD) [75]. A similar, but milder form of the disease, Becker muscular dystrophy (BMD), is associated with deletions that maintain the reading frame and as a result produce shorter, partially functional variants of dystrophin protein. It was hypothesized that skipping the mutated exon would remove the stop codon mutation and restore the reading frame, allowing for at least partial recovery of dystrophin function. This hypothesis was proven correct, in a series of papers showing that in cultured cells derived from the mdx dystrophic mouse, SSO targeted to the splice sites of the mutated exon 23 caused exon skipping and restoration of the reading frame [76–80]. Similar results were shown in cells derived from a canine model of muscular dystrophy [81]. Local administration of SSOs in vivo was also able to restore the mdx reading frame in mice. Mann et al. [78] demonstrated that 2OMe oligonucleotides complexed with cationic lipids targeted to the 5 splice site of the exon 23 of mdx caused exon skipping and the production of revertantmuscle fibers when locally injected into the muscle tissue mouse. Similar results were obtained with 2-O-methyl oligonucleotides delivered to muscle tissue by electroporation [82]. Recently, morpholino oligomers were delivered locally into muscle by hybridizing to a DNA oligonucleotide and complexing with a cationic lipid. This treatment led to significant increases in functionaldystrophin, as detected by Western blot and immunostaining [83]. Impressively, the delivery of 2-O-methyl oligonucleotides with the aid of the F127 block copolymer by local injection into the muscle induced a shift in splicing that produced functional amounts of dystrophin [84]. Treated mice exhibited the ability to exert more force with their contralateral muscles. The combination of the oligonucleotide and F127 was nonimmunogenic. More recently, systemic delivery of SSOs in the mdx mouse has been accomplished, using the same F127/2-O-methyl formulation injected intravenously, as either a single or three weekly very high doses of ⬃100 mg/kg of the oligonucleotide [85]. Following the treatment, mdx mice showed evidence of dystrophin-containing muscle fibers at multiple sites, including the quadriceps, biceps, diaphragm, abdomen but not heart. These fibers were still detectable 6 weeks after a single administration. No toxicity was detected as a result of treatment. Similar impressive restoration of function in the quadriceps and other muscles was obtained using systemically delivered morpholino dystrophin SSOs at 100 mg/kg [86]. Cultures from different human muscular dystrophy patients, containing several known diseasecausing mutations, were also successfully targeted with SSOs to restore gene function [87–93]. A “humanized” mouse model of muscular dystrophy has also been developed and has been used to confirm the activity of human-targeted SSOs in vivo [94]. Together, this body of preclinical work demonstrates the power and feasibility of SSOs to treat muscular dystrophy. Both the toxicity profile and the delivery method are compatible with human drug treatment. Clinical trials will determine the extent of the benefit of SSOs in human muscular dystrophy patients. Peculiarly, Takeshima et al. [95,96] reported that an oligodeoxynucleotide, capable of activating RNaseH, induced skipping of dystrophin exon 20 from tissues of a patient with a mutation in exon 19. They also showed efficacy after i.v. infusion of the oligonucleotide into the patient, the first clinical demonstration of SSOs. The efficacy of the oligodeoxynucleotide is puzzling, since RNaseH should destroy the premRNA before splicing. In fact, dystrophin does appear to be downregulated in treated samples.
4.5.1.3 Cystic Fibrosis Transmembrane Conductance Regulator CF is a disorder resulting from loss of function of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a cyclic adenosine monophosphate (cAMP)-regulated chloride channel. CF is characterized by severe pulmonary and pancreatic disease, male infertility associated with congenital bilateral absence of vas deferens (CBAVD), and high electrolyte concentration in sweat [97].
CRC_8796_ch004.qxd
5/25/2007
96
7:00 AM
Page 96
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
The most common and severe mutation, F508, prevents the protein from being localized in apical plasma membrane. Spliceosome-mediated RNA trans-splicing (SMaRT) with recombinant adenoviral vectors that expressed pretrans-splicing molecules (PTMs) was demonstrated to partially restore CFTR chloride channel activity in polarized human F508 CF airway epithelial cells, but the application of the adenovirus proved to be of limited efficiency [98]. More recently, recombinant adenoassociated vectors carrying PTM that would bind to intron 9 of CFTR pre-mRNA and trans-splice the correct sequence of human CFTR exons 10–24 into the endogenous pre-mRNA were tested, providing conductance restoration to ⬃14% of that of normal human airway epithelia [99]. The SMaRT technology will be discussed in more detail further in this chapter. Milder cases of CF are characterized by late onset and/or less severe pulmonary complications, and CBVAD. Less than 2% of all CF cases are associated with a mutation 3849 10 kb C to T in CFTR intron 19. The mutation has an increased prevalence in patients with mild form of CF as well as in Ashkenazi Jews [100]. It generates an aberrant 5 splice site and activates a cryptic 3 splice site. Friedman et al. [101] reported that three cell lines, 3T3 mouse fibroblasts, C127 mouse epithelial cells, and CFT human tracheal cells, all carrying CFTR with this mutation, when treated with antisense 2-O-methyl oligonucleotides that target either aberrant donor or acceptor splice site or to the included exon-like fragment, showed dosedependent increase in CFTR protein production. Delivery of both oligonucleotides had additive effect. More recent approach demonstrated that increase in expression of two splicing factors, Htra2-beta1 and SC35, increased the level of correct CFTR mRNA and resulted in the production of functionally correct CFTR channel in CF-derived epithelial cells carrying the 3849 10 kb C to T mutation [102].
4.5.1.4 Tau Tau is a neuron-specific microtubule-associated protein and a key element of neuron integrity and axonal transport, regulating microtubule stability and dynamics [103–105]. The human tau gene contains 16 exons and encodes six splice variants. Alternative splicing of exons 2, 3, and 10 results in tau protein containing 3 (Tau3R) or 4 (Tau4R) microtubule-binding repeats [105–107]. In fetal brain, Tau3R is a dominant form while later in the postnatal period Tau4R levels increase to balance Tau3R; in normal adult human brain Tau3R/Tau4R ratio is ⬃1 [107]. Several neurodegenerative diseases, termed tauopathies, which result from imbalance in the Tau3R/Tau4R ratio, are associated with the presence of profuse filamentous deposits containing hyperphosphorylated tau in neurons and glia of affected individuals. Tauopathies include Down’s syndrome (DS), Pick’s disease (PiD), some variants of prion diseases, Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), and frontotemporal dementias. Point mutations in exon 10 and the following intron of the tau gene are associated with tauopathy described as frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), with symptoms similar to those of AD [108]. In normal human neurons exon 10 of the tau gene is skipped, due to the fact that a hairpin structure within pre-mRNA masks its 5 splice site and prevents the efficient binding of U1 snRNP. The mutations disrupt the hairpin, leading to inclusion of exon 10 into mature tau mRNA. Kalbfuss et al. [109] used two rat cell lines, neuronal phoechromocytoma PC12 cells and AR42J pancreatic acinar cells, expressing tau protein that included exon 10, as models for oligonucleotide treatment of FTDP-17. 2-O-methyl-phosphorothioate oligonucleotides, targeted to either the 3 or 5 splice site of tau exon 10, restored exon 10 skipping in a dose-dependent manner. In addition, in AR42J cells, the decrease in the level of exon 10-containing variant, which includes a microtubule-binding element, led to rearrangement of the cytoskeletal structure, a phenomenon that can reflect a potentially clinically beneficial outcome.
4.5.1.5 Lamin A Lamins are proteins that polymerize to form a meshwork of filaments localized predominantly on the inner surface of the inner nuclear membrane. In humans, two genes encoding lamins B1 and B2 are expressed constitutively in somatic cells; in embryonic cells alternative splicing of B2 gene
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 97
SPLICE SWITCHING OLIGONUCLEOTIDES AS POTENTIAL THERAPEUTICS
97
leads to synthesis of B3 [110]. One gene (LMNA) [110,111] codes for A-type lamin splice variants, lamin C, A, and A10 that differ in the splicing of exon 10; their expression is regulated during the development process [112–117]. Lamin C contains the complete 111 nucleotide sequence of exon 10, whereas lamin A contains only the 5 90 bases of this exon through the use of alternative 5 splice site, and lamin A10 lacks exon 10 altogether [118]. Mutations in LMNA are associated with a number of genetic diseases, such as cardiomyopathies with involvement of variable skeletal muscles, peripheral neuropathy, premature ageing syndromes or partial lipodystrophy disorders. The majority of patients suffering from Hutchinson-Gilford progeria syndrome (HGPS), a form of the premature ageing, are carriers of heterozygous silent substitution at codon 608 localized in exon 11 of the LMNA gene [119,120]. The mutation activates an exonic cryptic donor splice site positioned four nucleotides upstream. The resulting pre-mRNA is spliced at this site, producing LMNA mRNA that lacks 150 nucleotides at the end of exon 11. Thus the mutant lamin A protein carries an internal deletion of 50 amino acids. Observed consequences involve morphological changes of nuclei in HGPS cell lines [119–122], up to sixfold reduction in cellular levels of lamin B, another major element of the lamina meshwork, as well as other lamina-associated polypeptides (LAP2s) [122]. Removal of the truncated lamin A from the cells is a key to successful rescuing of the ageing phenotype in HGPS fibroblasts. Scaffidi and Misteli [122] have reported that while introduction of a wild-type lamin A did not correct cellular symptoms, premature ageing phenotypes of HGPS fibroblasts were efficiently suppressed by splicing correction with a morpholino oligonucleotide targeted to the aberrant 5 splice site. This approach not only allows for synthesis of normal lamin A, but also eliminates or significantly diminishes synthesis of its mutated form.
4.5.1.6 Survival Motor Neurons Spinal muscular atrophy (SMA), an autosomal recessive neurodegenerative disorder associated with the selective destruction of spinal cord -motor neurons, is a leading cause of infant mortality from genetic disorders. SMA results from mutation or deletion of the survival-of-motor-neuron gene, SMN1. A nearly identical SMN1 paralog, SMN2, expresses only limited amounts of functional protein. It retains a correct reading frame but carries translationally silent, single oligonucleotide transition at position 6 of exon 7, which leads to exon 7 skipping [123–125] and production of truncated, unstable protein [124]. In their recent report, Cartegni et al. [126] suggest that skipping of exon 7 in SMN2 pre-mRNA splicing occurs via the loss of the SF2/ASF-dependent ESE. It has been reported that both, in patients suffering from SMA and in mouse models for the disease, increase in expression of SMN2, observed when multiple copies of SMN2 are present, can diminish SMA symptoms [127–130]. Some of the efforts to restore synthesis of the full-length active isoform of survival motor neuron (SMN) protein have been directed towards developing drugs that would encourage SMN2 exon 7 inclusion into its mature mRNA. It was suggested that blocking of exon 8 3 splice site should shift the balance towards exon 7 retention. This was achieved by designing 2-O-methyl oligonucleotides that targeted the 3 splice site in cell lines constitutively expressing SMN2 minigene constructs [131]. Another group was successful in achieving the same goal by utilizing 2-O-methyl oligonucleotides complementary to ISSs and ISEs positioned, respectively, upstream and downstream from the exon 7 [132–134].
4.5.1.7 OA1 Ocular albinism type 1 is the most common cause of ocular albinism. It is associated with mutations of the OA1 gene located on chromosome X. Recently, in a family with the X-linked type of ocular albinism, a novel point mutation has been identified within intron 7 of the gene that creates a new acceptor splice site [135]. In affected patients, levels of correct OA1 mRNA were low and the alternatively spliced variant of mRNA, containing a 165 bp fragment of intron 7 retained between exons 7 and 8, was also detected. The new transcript contained a premature stop codon and
CRC_8796_ch004.qxd
5/25/2007
98
7:00 AM
Page 98
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
was unstable [135]. The identified mutation was a G A substitution which created a consensusbinding motif for ASF/SF2. In addition, it activated a cryptic donor splice site leading to the inclusion of intron 7 fragment between exons 7 and 8. The authors demonstrated that treatment of the patient’s melanocytes with antisense morpholino oligonucleotide complementary to the mutationcontaining gene sequence induced skipping of the intronic inclusion, rescuing expression of OA1 gene and protein [135]. 4.5.2
Modification of Natural Alternative Splicing as a Potential Therapeutic Tool
4.5.2.1 Bcl-x Bcl-x is a member of the bcl-2 family of genes that regulates apoptosis. Utilizing two alternative 5 splice sites, the gene undergoes alternative splicing that generates transcripts encoding two protein isoforms characterized by antagonistic functions: the longer, antiapoptotic bcl-xL and shorter, proapoptotic bcl-xS [136]. Several cancers are associated with bcl-xL overexpression, including hematomas, neuroblastomas, myelomas, lymphomas, prostate, and breast cancers [137,138]. This phenomenon is linked to resistance to chemotherapeutics, apoptosis inhibition, and poor clinical prognosis. Overexpression of bcl-xS, in contrast, was demonstrated to induce apoptosis in cancer cell lines. Therefore, blocking the xL (proximal) 5 splice can lead to an increase in bcl-xS/bcl-xL ratio, thereby inhibiting antiapoptotic signals while at the same time enhancing proapoptotic message; the result is potential growth inhibition or death of tumor cells. Several reports show the anticancer value of bcl-xL mRNA downregulation, achieved via AONs that promote its RNase H-mediated cleavage [139–144]. However, simultaneous upregulation of the proapoptotic bcl-xS variant by bcl-x SSO was found more potent, particularly in PC3 cells, than standard AONs at inducing apoptosis [145]. In other cell lines, including A549 and MCF7, oligonucleotides targeted to the downstream alternative 5 splice site in bcl-x exon 2 led to decreased bcl-xL expression, increased bcl-xS expression, and sensitized cell to death by chemotherapeutic agents or UV radiation [139,145,146]. Therefore, upon successful delivery to tumor cells, bcl-x SSOs may be a powerful drug against cancers that are normally refractory to treatment. Overexpression of the bcl-xL mRNA and protein does not only apply to cancer. It has been reported in psoriasis, where it has been linked to lack of apoptosis in psoriasis plaques [147–149]. Shifting splicing of bcl-xL pre-mRNA in psoriasis-affected individuals can be beneficial, especially considering that it would not be necessary to eradicate all affected cells to achieve significant improvement in patients. It may also potentially increase patient response to standard apoptosisinducing treatments, such as methotrexate or UV radiation.
4.5.2.2 PSMA Prostate-specific membrane antigen (PSMA), encoded by the folate hydrolase (FOLH1) gene, is a largely extracellular membrane-anchored protein that is highly expressed in cancerous prostate tissue and nonprostatic tumor neovasculature. Recently, the treatment of LNCap cells with SSOs shifted splicing of FOLH1 pre-mRNA from the full-length PSMA to three different splice variants: the cytoplasmic PSM alternatively spliced at exon 1 and two other isoforms, PSMA6 and PSMA18, which lack exons 6 and 18, respectively [150]. Decrease in membrane PSMA levels was observed, accompanied by increased levels of PSM, PSM6, and PSM18 mRNAs. While the PSM isoform was demonstrated to retain enzymatic activity, two other splice variants were inactive. The function of PSMA in prostate cancer is currently unclear, but it may act as a transport or signaling protein, due to the presence of cytoplasmic MXXXL internalization motif [151,152], and demonstrated the ability to internalize in response to ligand binding; it is possible that its splice variants, PSMA6 and PSMA18, expected to retain that motif, could compete with and disrupt normal PSMA signaling/transporting pathway.
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 99
SPLICE SWITCHING OLIGONUCLEOTIDES AS POTENTIAL THERAPEUTICS
99
4.5.2.3 WT1 Wilms’ tumor suppressor (WT1) gene plays key role in mammalian urogenital development. Dysregulation of this gene has been associated with many human cancers, including kidney malignancy in children (Wilms’ tumor) [153], leukemias [154], and breast cancer [155]. WT1 is a transcription factor that activates transcription of specific genes and inhibits transcription of certain genes that are upregulated in patients with Wilms’ tumor. WT1 pre-mRNA can be alternatively spliced at two regions, so that mature mRNA can include/exclude either a region coding for three amino acids—KTS—at the end of exon 9 (WT1 KTS) [156,157] or exon 5 [158]. The splice variant containing exon 5 is elevated in Wilms’ tumor and leukemia [158]. Specific targeting of WT1 transcripts containing exon 5 with antisense oligonucleotide led to the death of HL60 leukemia cells, which suggests that disruption of exon 5 splicing may serve as a proapoptotic signal [159]. In addition, in HL60 cells gene expression profiles, analyzed after WT1 exon 5-targeted antisense oligonucleotide treatment, revealed upregulation of thrombospondin 1, a known WT1 target, which correlated well with cell death [159].
4.5.2.4 CD40 CD40 is a cell membrane protein that together with its ligand, CD154, plays a key role in the initiation and propagation of immune responses. The CD40–CD154 signaling pathway affects immune responses in cellular and animal model systems and inhibition of CD40 function may lead to some therapeutic benefits in inflammatory and autoimmune diseases [160]. Expression of cell surface-associated CD40 protein can be downregulated by a PNA oligomer that binds to the 5 splice site of exon 6 in CD40 pre-mRNA [161]. The PNA alters constitutive splicing which results in accumulation of CD40 transcript lacking exon 6 and, as a consequence CD40 protein without the transmembrane domain. Decrease in membrane-bound CD40 led to the inhibition of CD40-dependent induction of IL-12 in murine macrophages [161]. These data suggest that PNA oligomers may act as efficient inhibitors of membrane-bound CD40, therefore allowing for modulation of immune response.
4.5.2.5 MyD88 Another example of potential modulation of proinflammatory stimuli by splicing alteration comes from studies on systemic delivery in mice of MOE SSO targeted to MyD88 pre-mRNA. [162]. MyD88 is an adaptor protein involved in proinflammatory cytokines signaling pathway leading to phosphorylation of IL-1R-associated kinase (IRAK-1) and activation of the NF-B transcription factor [163,164]. SSO targeted to the 5 splice site of exon 2 increased the ratio of MyD88 to MyD88(S)—a variant that lacks the ability to couple IRAK-1 to NF-B in cell culture and in livers of treated mice. Reduction of proinflammatory signaling via IL-1R pathway was detected [162].
4.5.2.6 AChE Alternatively spliced variants of the acetylcholine-hydrolyzing enzyme acetylcholinesterase (AChE) have been implicated in the progression of such neurodegenerative diseases such as Parkinson’s, Alzheimer’s, and neuromuscular disorders such as myasthenia gravis (recently reviewed in Ref. [165]). Alternative splicing of the AChE gene results in three species of AChE mRNA: synaptic AChE-S, joining exon 4 and 6, the principal multimeric enzyme in normal brain and muscle; soluble, monomeric readthrough AChE-R that retains intron 4 and exon 5, present in embryonic and tumor cells and induced under psychological, chemical, and physical stress; and glypiated dimers of erythrocytic AChE-E, associated with red blood cell membranes, in which exons 4 and 5 are joined directly (reviewed in Ref. [166]). Antisense-mediated degradation of AChE
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 100
100
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
mRNA has been demonstrated to prevent AChE-R overexpression and to lessen the symptoms in rat model of myasthenia gravis [167], a closed-head injury model in mice [168], and in mice with enhanced stress-induced memory impairments and fear [169].
4.5.2.7 Polyadenylation Regions It has been demonstrated that AONs can be used to increase abundance of certain mRNAs, and therefore levels of certain proteins, via modifying polyadenylation patterns and thus limiting message degradation [170]. Alternative polyadenylation sequences, often more than two, have been discovered at the 3 end of pre-mRNAs of multiple genes [171]. These pre-mRNAs often contain destabilization sequences that are responsible for mRNA degradation [172]. Hybridization of specific 2-O-MOE phosphorothioate oligonucleotides to the 3-most polyadenylation region of E-selectin blocked polyadenylation at this site and redirected it to upstream cryptic sites. The effect was that shorter transcripts contained fewer destabilization regions, which led to increased mRNA stability and altered protein expression [170].
4.6 OTHER MECHANISMS TO ALTER RNA SPLICING As highlighted above, one can potentially manipulate alternative splicing through the use of a target-optimized, hybridizing, and RNase H-inactive oligonucleotide. This strategy is extremely useful for inducing the skipping of one or several coding exons, for controlling the preferential use of alternative 3 or 5 splice sites, and, as will be discussed below, for enhancing exon inclusion. These alternatives comprise the majority of observed splicing events. SSOs therefore represent the simplest and generally most effective splice modulation approach. However, other hybridizationbased alternative splicing techniques have also been developed. These technologies further expand the functionality of SSOs, adapt the technology as gene therapy, and suggest the possibility for global control of alternative splicing with small molecules. 4.6.1
Hybridization Strategies
4.6.1.1 ESSENCE Exon-specific splicing enhancement by small chimeric effectors (ESSENCE) is a PNA oligonucleotide-based approach designed to enhance the inclusion of the targeted, alternatively or aberrantly, spliced exon into the spliced mRNA. The technology is based on manipulating the function of ESEs [173]. An ESSENCE PNA oligonucleotide contains a covalently bound peptide SR domain at the 3 end, designed to mimic SR proteins known to bind ESEs. This oligonucleotide bound internally to the exon targeted for inclusion is expected to promote SR-protein-mediated exon definition and enhance exon inclusion into mature mRNA. Cartegni and Krainer [174] demonstrated the effectiveness of this approach on both BRCA1 and SMN2 pre-mRNA. Correct splicing of BRCA1 exon 18 requires recognition of an intact ESE by the SR protein ASF/SF2. In a mutation found to be prevalent among patients with ovarian cancer [175], the ESE is inactivated by a point mutation and exon 18 is skipped, resulting in improper translation and inactivation of the gene product. ESSENCE PNA oligonucleotides targeted near the mutated ESE restored exon 18 inclusion in mRNA in a sequence- and dose-dependent fashion. Likewise, targeting exon 7 in nonfunctional SMN2 pre-mRNA with ESSENCE oligonucleotides led to enhancement of its inclusion in mRNA. As mentioned above, activation of SMN2 is a potential therapy for SMA. Although in these examples the SR domain enhanced the ability of the oligonucleotide to force inclusion of the targeted exon, it did not appear absolutely essential for activity [174]. For example, a PNA oligomer of identical sequence targeted to BRCA1 but lacking a 3 SR tail was able to induce
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 101
SPLICE SWITCHING OLIGONUCLEOTIDES AS POTENTIAL THERAPEUTICS
101
50–55% exon 18 inclusion compared to 25% for the scrambled sequence control and 75% for the optimized ESSENCE oligonucleotide. It seems that an oligonucleotide alone targeted to a putative exon may increase its inclusion, though the mechanism of this action is unclear. It is possible that the oligonucleotide is competing with splicing factors such as hnRNP A1 [176] for binding of other elements, such as ESSs, that serve to decrease exon inclusion. If so, this may indicate that simple oligonucleotides, depending on whether targeted to enhancer or silencer sequences within the exon, may achieve opposite effects, exon skipping or exon inclusion. ESSENCE was also applied to alternative splicing of bcl-x. An antisense 12-mer PNA with an RS domain tail at its “3” end, was targeted to a region upstream of the distal (xS) 5 splice site of exon 2 [177]. The antisense portion was targeted such that it did not bind at any ESE or ESS sites. Therefore, in contrast to the previous ESSENCE examples, the PNA alone did not influence alternative splicing, but addition of the RS tail enabled induction of splice switching to the xS form, where the ratio of xLxS fell from 11.4 to 4.9 in HeLa cells. These data definitively demonstrate that RS conjugates can influence alternative splicing by recruiting splicing factors to underused splice sites. Interestingly, the cell culture results were obtained by delivery of the PNAs essentially by free uptake at high concentrations (up to 50 M). The use of a better cell culture delivery method for neutral or positively charged oligomers such as scrape loading [178] may result in more efficient splice shifting. In a similar approach, Skordis and colleagues [179] used a tail containing an ESE to increase the inclusion of SMN2 exon 7. Briefly, an oligonucleotide targeted internally to exon 7 was extended with a 5 tail containing an ASFSF2-binding site. The tail recruited the SR protein andenhanced exon 7 inclusion in a sequence- and dose-dependent manner. This approach differs from ESSENCE in that the SR protein functionality is built directly into the oligonucleotide in the latter.
4.6.1.2 TOSS Targeted oligonucleotide silencers of splicing (TOSS) are AONs with overhanging 3 or 5 tails designed to recruit factors that inhibit selection of a targeted splice site. These oligonucleotides repress splicing of a targeted exon either by recruiting hnRNP A1, which represses splice site recognition, or by competing for binding of other critical splicing factors at the target site. In the first iteration of TOSS [180], AONs were designed upstream of the preferentially used proximal, -xL 5 splice site of bcl-x such that, alone, it did not cause an increase in distal 5 splice site utilization. The antisense oligonucleotide induced splice switching when a 20-mer 5 tail consisting of the consensus-binding sequence for hnRNP A1, which recognizes and binds to ESSs [37,38], was added. Cationic lipid-mediated delivery of this TOSS resulted in a dose-dependent increase in the bcl-xS/bcl-xL isoform ratio, while the same oligonucleotide without the 5 tail did not. Furthermore, depletion of hnRNP A1 by siRNA reduced the efficacy of the TOSS, suggesting that it acts by recruiting hnRNP A1, repressing the proximal splice site, and forcing selection of the distal site. The action of TOSS targeted to bcl-x was increased through the use of other linear and branched 5 and 3 tails [181]. A 5 tail containing the -globin branch site had splice switching activity greater than tailless or poly U-tail-containing oligonucleotides, though only a fraction as potent as the hnRNP TOSS. Furthermore, placement of the same tail at the 3 end, or with the tail extended to include the 5 splice site did not increase activity relative to the hnRNP TOSS. Interestingly, the use of TOSS with 3 branched tails that mimic the intron lariat intermediate had splice switching activity similar to the hnRNP TOSS. Functional studies demonstrated that the branched tail TOSS acts by recruiting U1 snRNP.
4.6.1.3 Trans-Splicing The oligonucleotide- or vector-based use of trans-splicing mechanisms for gene modulation/ repair is also referred to as SMaRT. This technology exploits the ability of the spliceosome to splice
CRC_8796_ch004.qxd
5/25/2007
102
7:00 AM
Page 102
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
together two exons from different transcripts. The phenomenon of trans-splicing was originally described in lower organisms, such as trypanosomes, but was found to be present in higher organisms including mammals (see Ref. [182] for a thorough review). Trans-splicing is very similar to cissplicing (see above), in that a branched intermediate is formed as a result of the first transesterification reaction. However, trans-splicing produces a Y-shaped intermediate instead of a lariat, because each exon to be ligated is free and not connected by a single intron. The second transesterification proceeds in a manner very similar to cis-splicing, with the corresponding release of the Y-shaped intermediate. Thus exons from related or unrelated primary transcripts can be joined to form a hybrid mature mRNA. To induce trans-splicing for the purpose of gene modulation/repair [183], an RNA called PTM [184] is introduced into the site of pre-mRNA splicing (e.g., nuclear extracts, the nucleus of live cells, etc.). The PTM consists of the 3 portion of an intron—with an intact branch point, poly-Y tract, and 3 splice site—and a single “exon” immediately downstream. The “exon” may be a natural exon, or a fragment of cDNA comprising of several exons spliced together, as long as the 3 splice site consensus sequence is maintained. Additionally, the PTM contains at its 5 end a sequence complementary to the branch point of the intron targeted for trans-splicing. Thus, for a given target pre-mRNA, the PTM masks the natural branch point of a targeted intron, and increases the probability of a trans-esterification reaction between the 5ss of the targeted intron and the branch point on the PTM. In the next step, the second trans-esterification ligates the upstream exon of the target pre-mRNA to the exon of the PTM. The result is a hybrid mRNA, with native coding sequence at the 5 end and coding sequence from the PTM at the 3 end. There are several situations, where invoking trans-splicing may be the most practical means of gene modulation/repair. A striking example is the CFTR gene, whose gene spans ⬃200 kb, with a cDNA of ⬃4 kb. The size of CFTR gene or even cDNA makes its replacement via viral vectors difficult. Mansfield et al. [185] transfected 293T cells with a CFTR F508 minigene containing the mutant codon in exon 10 and the natural intron 9. These cells produced aberrant CFTR. When cotransfected with a PTM targeted to intron 9 and containing the remaining correct CFTR exons 10–24, a detectable level of trans-splicing occurred at an estimated rate of 12%, and normal CFTR protein was produced. In a follow-up study, endogenous F508 CFTR was corrected by transsplicing in CF bronchial xenografts in mice, at a rate of 16% [98]. More recently, vectors (rAAV) were used to deliver CFTR F508 PTMs to polarized airway epithelia [99], the goal of providing a permanent therapy for CF. Further studies are needed to determine the feasibility of this approach. Other genes targeted with PTMs include collagen XVII [186,187], tau [188], CD40 Ligand [189], and most notably, coagulation factor VIII [190]. In the latter, a mouse model of FVIII deficiency was used in which exon 16 contained an insertion of neomycin resistance, preventing proper translation of the protein. Repair of this defective FVIII required a PTM targeted to intron 15 and contained FVIII exons 16–26. Delivery of the PTM construct, either delivered and expressed directly from a plasmid or expressed via an adenoviral vector, induced FVIII production by the liver. Though the effects were transient, treatment resulted in increased FVIII activity and coagulation. These results are striking, considering that the investigators estimate that only 2–6% of mutant transcripts are being corrected by trans-splicing. Thus, FVIII represents a potentially excellent target for SMaRT technology.
4.6.1.4 snRNA U7 snRNA is a nonspliceosomal snRNA, which participates exclusively in histone mRNA processing (see Ref. [191] for review) via hybridization to the 3 region of histone pre-mRNA region. As an expressed nuclear RNA with a natural antisense binding sequence, U7 snRNA was altered for inducing splice modulation of targeted pre-mRNA by removing the antihistone pre-mRNA sequence and replacing it with the sequence of interest. This has been done successfully with several genes. Furthermore, since the modified U7 snRNAs can be expressed, driven by an RNA polymerase III promoter, they offer a potentially stable source of splice switching molecules.
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 103
SPLICE SWITCHING OLIGONUCLEOTIDES AS POTENTIAL THERAPEUTICS
103
This approach was investigated as a potential treatment for thalassemia. The same antisense sequence used in SSOs [192] was substituted into U7 at the antihistone pre-mRNA-binding site [193]. Stable transfection of the modified U7 snRNA into HeLa cells expressing the mutant -globin gene partially but permanently restored correct splicing and protein expression. Similar results were also obtained using combinations of modified U7 [194] or a modified U1 snRNA [195]. More recently, modified U7 snRNAs in a lentiviral vector were delivered to human thalassemic bone marrow ex vivo, and restoration of -globin expression was detected. These studies point the way to a possible cure for -thalassemia, if a vector targeting blood progenitor cells can be isolated [196]. Dystrophin was also targeted with modified U7 constructs. In C2C12 cells and immortalized muscle cells from an mdx muscular dystrophy mouse model, modified U7 snRNAs were shown to induce skipping of mutant exons that harbor premature stop codons, thus restoring the reading frame and generating a shorter but more functional dystrophin protein. Impressively, modified U7 snRNAs delivered to the mdx mouse via an AAV vector showed long-term upregulation of functional dystrophin after a single administration [197]. Modified U1 constructs are now being evaluated for the same purpose [198]. Other targets have been targeted with moderate success including SMN [199] and human immunodeficiency virus (HIV) [200]. 4.6.2
Global Strategies
4.6.2.1 RNAi Small interfering RNA (siRNA) can be used to target splicing factors and thereby affect alternative splicing. For example, Kashima and Manley [201] show that RNAi targeted to hnRNP can alter splicing of exon 7 of SMN2. According to their model, hnRNP binds to a novel ESS that prevents Tra2 from binding its cognate ESE, and prevents U2AF interaction with the 3 splice site adjacent to exon 7. By reducing hnRNP with the appropriate siRNA, Tra2 binding can take place and exon 7 inclusion is increased. This approach may have therapeutic implications in the treatment of SMA [202]. Massiello and colleagues [203,204] investigated a cis-acting ceramide response element (CRCE1) located in the alternatively spliced region of exon 2 of bcl-x and which binds the splicing factor SAP155. In its normal phosphorylated state, SAP155 promotes usage of the xL splice site, while the addition of ceramide to cell-free splicing extracts causes SAP155 to be altered by an unknown mechanism, and the xS splice site becomes more favored. Downregulation of SAP155 by RNAi in A549 cells had the same, albeit modest effect. siRNA targeted towards splicing factor SC35 was recently used to restore correct splicing in human fibroblasts derived from a patient with pyruvate dehydrogenase (PDH) complex deficiency, which causes mental retardation [205]. The patient had a mutation that increased SC35 binding to an intron of PDH pre-mRNA, causing activation of a cryptic 5 splice site. Titration of SC35 by siRNA almost completely abrogated the use of the cryptic site and significantly increased the quantity of properly spliced PDH mRNA and protein. As with other global strategies, extensive evaluation of possible off-target effects needs to be examined. It will be extremely important in the development of RNAi or small molecules as splice modulators to establish the consequences of altering a general splicing factor such as ASF/SF2, hnRNP A1, SAP155 or SC35 on the expression of other genes.
4.6.2.2 Small Molecules The spliceosome is a large conglomerate of proteins and RNAs that must assemble uniquely to each site of pre-mRNA splicing. It is reasonable to assume, therefore, that small molecules can alter the assembly such that alternative splice site selection is altered. This was found to be the case for dimethyl sulfoxide (DMSO), which is often used to induce differentiation in certain tumor cell
CRC_8796_ch004.qxd
104
5/25/2007
7:00 AM
Page 104
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
lines, or simply as a diluent for compounds not easily dissolved in water. In the study, DMSO was shown to modulate alternative splicing of the neurospecific, NCAM, via an effect on the activity of hnRNP A1 [206]. Small molecules can be used to modulate other proteins involved in alternative splicing. Muraki and colleagues recently screened for and found a small molecule inhibitor of Clk (cdc2-like kinase), a protein kinase that phosphorylates SR proteins, including ASFSF2. As mentioned above, the phosphorylation state of SR proteins regulates its influence on alternative splicing. In cell-free extracts, TG003 (a benzothiozole compound) inhibited kinase activity of Clk1 and prevented splicing of -globin pre-mRNA, with a Ki of 10 nM. In vivo, in Xenopus embryos, TG003 prevented developmental errors that arise from overexpression of Clk. This data suggest that small molecules targeting SR proteins may be used to treat disease. However, the data also show that alternative splicing of Clk1 and SC35 are also altered by TG003. Since Clk1 and SC35 themselves can influence splicing, it is unclear if this has a feedback effect, or if it is simply a side effect. More studies are required to determine the global impact of this inhibitor on splicing. Soret and colleagues [207] discovered a group of indole compounds that specifically bind to and inhibit ASFSF2 in cell-free splicing reactions. In addition to having good affinity for intact but not denatured or truncated ASFSF2 (Kd 200–400 nM), some compounds inhibited ASFSF2-dependent splicing in a dose-dependent manner, while affecting ASFSF2-independent splicing constructs only at very high concentrations. These compounds also abrogated aberrant and restored correct splicing of chimeric -globin pre-mRNA constructs. Interestingly, splicing steps required for HIV disease progression are also inhibited by the indoles, together indicating possible therapeutic drug targets. Tazi and colleagues [208] have also found diospyrin derivatives that inhibit topoisomerase I and alter pre-mRNA splicing in cell-free extracts, and have discovered indole compounds that selectively inhibit topoisomerase I over ASFSF2 [207]. Determining the therapeutic utility of the indole and diospyrin molecules requires studies in live cells and living organisms.
4.7 AN ASSAY FOR SPLICE SWITCHING OLIGONUCLEOTIDE POTENCY Simultaneous downregulation of aberrant splicing with upregulation of the correct splice variant is a unique feature of splicing manipulation by SSO. In addition to its therapeutic applications, it also has utility as an assay for antisense oligonucleotide potency. This laboratory has developed such an assay, based on the aberrant splicing of human -globin intron 2 containing the thalassemic IVS2-654 mutation. The intron was inserted into the coding sequence for enhanced green fluorescence protein (EGFP), and was stably expressed in both HeLa cells [209], and in a transgenic mouse line, which ubiquitously expresses the construct [210]. When RNase H-inactive oligonucleotides targeted to the 654 mutation (SSO-654) are successfully taken-up by the nucleus of cells, mRNA containing the correct EGFP reading frame is generated, and the cells become fluorescent. In the HeLa cell culture system, the ability of oligomers to be taken into the cell, reach the nucleus and shift splicing of the reporter gene was examined. It was found that, in the absence of a delivery agent, uncharged or positively charged compounds (e.g., morpholino, PNA) were more apt to reach the nucleus from the extracellular media than negatively charged oligonucleotides (e.g., 2OMe, 2-O-MOE) [209]. Furthermore, the addition of four positively charged lysines increased the free uptake activity of PNA. Follow-up studies by Thierry et al. [211] show that the addition of up to eight lysines also imparted increased activity of PNA SSOs. Moulton et al. [212,213] also showed that positively charged HIV Tat- and arginine-rich peptides and derivatives significantly increased uptake and activity of morpholino SSOs in cell culture. In another study, base modifications for MOE and PNA were also tested in the EGFP assay in the Kole lab [214]. We found that guanine derivative such as phenoxazine and G-clamp, which is tricyclic and is capable of Hoogstein basepairing, modestly improved the activity of oligomers delivered by cationic lipids.
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 105
SPLICE SWITCHING OLIGONUCLEOTIDES AS POTENTIAL THERAPEUTICS 0.75
1.5
3
6
12
25
105 0 mg/kg Ab Co
Figure 4.4
Splice switching of EGFP-654 pre-mRNA by LNA oligonucleotides in transgenic mice. Increasing concentrations of LNA SSO-654 were administered i.p. once daily for 4 days and whole liver was analyzed by RT-PCR the following day for the ratio of abberantly (Ab) or correctly (Co) spliced EGFP mRNA. The data indicate that as little as 0.75 mg/kg/day induced correction of aberrantly spliced EGFP-654, and that 25 mg/kg induced almost a complete shift from Ab to Co.
Using the EGFP-654 transgenic mouse, we compared the in vivo efficacy of SSO-654 of different oligonucleotide chemistry: 2OMe, MOE, morpholino, PNA, and LNA. In our original screen, we found that MOE and PNA had good activity in vivo in several tissues, and particularly high activity in the liver and small intestine. In particular, the addition of a 4-lysine tail to PNA significantly increased its efficacy, with a 50% shift in splicing detected in liver after daily i.p. injections of 50 mg/kg for 4 days [210]. The data regarding the PNA–peptide conjugates was applied to improve the antisense activity of oligomers directed towards CD40 [161,215,216]. More recently, we tested the efficacy of LNA and found them to be at least 10-fold more potent than other chemistries in the liver, small intestine, and colon [217]. For example, 50% shift in splicing was achieved with only 6 mg/kg, and achieved ⬃90% shift in splicing with only 25 mg/kg, injected i.p. as above (Figure 4.4). Interestingly, in contrast to MOE and PNA, LNA functional distribution was limited to these organs. Furthermore, LNA showed limited but detectable SSO activity when delivered orally by gavage in PBS, with no other delivery adjuvant. These data suggest that LNA are potent SSOs suitable for clinical development. The data discussed above suggest that cell culture activity studies may or may not be predictive of efficacy in vivo (see also Refs. [71,72,196]). MOE oligonucleotides are clearly potent SSOs in the liver and small intestine in mice, yet in cell culture they require mechanical or chemical delivery agents for nuclear activity. In contrast, peptide conjugates appear to be effective in both systems. The variations in the efficacy of different modified oligomers in in vivo versus in vitro is likely due to their interactions with serum proteins in the blood, which may aid in the delivery of negatively charged oligonucleotides by binding them and extending their half-life in the circulation.
REFERENCES 1. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD, Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays, Science, 302, 2141–2144, 2003. 2. Modrek B, Lee C, A genomic view of alternative splicing, Nat Genet, 30, 13–19, 2002. 3. Graveley BR, Alternative splicing: increasing diversity in the proteomic world, Trends Genet, 17, 100–107, 2001. 4. Pascual M, Vicente M, Monferrer L, Artero R, The Muscleblind family of proteins: an emerging class of regulators of developmentally programmed alternative splicing, Differentiation, 74, 65–80, 2006. 5. Schwerk C, Schulze-Osthoff K, Regulation of apoptosis by alternative pre-mRNA splicing, Mol Cell, 19, 1–13, 2005. 6. Pan YX, Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters, DNA Cell Biol, 24, 736–750, 2005. 7. Kalnina Z, Zayakin P, Silina K, Line A, Alterations of pre-mRNA splicing in cancer, Genes Chromosomes Cancer, 42, 342–357, 2005.
CRC_8796_ch004.qxd
106
5/25/2007
7:00 AM
Page 106
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
8. Matlin AJ, Clark F, Smith CW, Understanding alternative splicing: towards a cellular code, Nat Rev Mol Cell Biol, 6, 386–398, 2005. 9. Caceres JF, Kornblihtt AR, Alternative splicing: multiple control mechanisms and involvement in human disease, Trends Genet, 18, 186–193, 2002. 10. Faustino NA, Cooper TA, Pre-mRNA splicing and human disease, Genes Dev, 17, 419–437, 2003. 11. Pagani F, Baralle FE, Genomic variants in exons and introns: identifying the splicing spoilers, Nat Rev Genet, 5, 389–396, 2004. 12. Crooke S, Antisense Drug Technology, Marcel Dekker, New York, 2001. 13. Cartegni L, Chew SL, Krainer AR, Listening to silence and understanding nonsense: exonic mutations that affect splicing, Nat Rev Genet, 3, 285–298, 2002. 14. Spellman R, Rideau A, Matlin A, Gooding C, Robinson F, McGlincy N, Grellscheid SN, Southby J, Wollerton M, Smith CW, Regulation of alternative splicing by PTB and associated factors, Biochem Soc Trans, 33, 457–460, 2005. 15. Staley JP, Guthrie C, Mechanical devices of the spliceosome: motors, clocks, springs, and things, Cell, 92, 315–326, 1998. 16. Burge C, Tuschl T, Sharp P, Splicing of precursors to mRNAs by the spliceosomes, In: The RNA World, 2, Gesteland R, Cech T, Atkins J, eds., CSHL Press, Cold Spring Harbor, NY, 1999, pp. 525–560. 17. Penalva LO, Ruiz MF, Ortega A, Granadino B, Vicente L, Segarra C, Valcarcel J, Sanchez L, The Drosophila fl(2)d gene, required for female-specific splicing of Sxl and tra pre-mRNAs, encodes a novel nuclear protein with an HQ-rich domain, Genetics, 155, 129–139, 2000. 18. Krecic AM, Swanson MS, hnRNP complexes: composition, structure, and function, Curr Opin Cell Biol, 11, 363–371, 1999. 19. Dreyfuss G, Kim VN, Kataoka N, Messenger-RNA-binding proteins and the messages they carry, Nat Rev Mol Cell Biol, 3, 195–205, 2002. 20. Hoffman BE, Grabowski PJ, U1 snRNP targets an essential splicing factor, U2AF65, to the 3 splice site by a network of interactions spanning the exon, Genes Dev, 6, 2554–2568, 1992. 21. Zahler AM, Lane WS, Stolk JA, Roth MB, SR proteins: a conserved family of pre-mRNA splicing factors, Genes Dev, 6, 837–847, 1992. 22. Zahler AM, Neugebauer KM, Lane WS, Roth MB, Distinct functions of SR proteins in alternative premRNA splicing, Science, 260, 219–222, 1993. 23. Fu XD, The superfamily of arginine/serine-rich splicing factors, RNA, 1, 663–680, 1995. 24. Wang Z, Hoffmann HM, Grabowski PJ, Intrinsic U2AF binding is modulated by exon enhancer signals in parallel with changes in splicing activity, RNA, 1, 21–35, 1995. 25. Manley JL, Tacke R, SR proteins and splicing control, Genes Dev, 10, 1569–1579, 1996. 26. Blencowe BJ, Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases, Trends Biochem Sci, 25, 106–110, 2000. 27. Black DL, Mechanisms of alternative pre-messenger RNA splicing, Annu Rev Biochem, 72, 291–336, 2003. 28. Lynch KW, Maniatis T, Assembly of specific SR protein complexes on distinct regulatory elements of the Drosophila doublesex splicing enhancer, Genes Dev, 10, 2089–2101, 1996. 29. Shen H, Kan JL, Green MR, Arginine–serine-rich domains bound at splicing enhancers contact the branchpoint to promote prespliceosome assembly, Mol Cell, 13, 367–376, 2004. 30. Shen H, Green MR, A pathway of sequential arginine–serine-rich domain-splicing signal interactions during mammalian spliceosome assembly, Mol Cell, 16, 363–373, 2004. 31. Krainer A, Eukaryotic mRNA Processing, Oxford University Press, Oxford, 1997. 32. Yu YT, Scharl, EC, Smith, CM, Steitz, JA, The Growing World of Small Nuclear Ribonucleoproteins, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY, 1999. 33. Moore MJ, Query, CC, Sharp, PA, Splicing of Precursors to mRNA by the Splicesomes, Cold Spring Harbor Laboratory Press, Cold Spring Harbour, NY, 1993. 34. Lynch KW, Maniatis T, Synergistic interactions between two distinct elements of a regulated splicing enhancer, Genes Dev, 9, 284–293, 1995. 35. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR, ESEfinder: a web resource to identify exonic splicing enhancers, Nucl Acids Res, 31, 3568–3571, 2003. 36. Del Gatto F, Gesnel MC, Breathnach R, The exon sequence TAGG can inhibit splicing, Nucl Acids Res, 24, 2017–2021, 1996.
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 107
SPLICE SWITCHING OLIGONUCLEOTIDES AS POTENTIAL THERAPEUTICS
107
37. Wang Z, Xiao X, Van Nostrand E, Burge CB, General and specific functions of exonic splicing silencers in splicing control, Mol Cell, 23, 61–70, 2006. 38. Wang Z, Rolish ME, Yeo G, Tung V, Mawson M, Burge CB, Systematic identification and analysis of exonic splicing silencers, Cell, 119, 831–845, 2004. 39. McCarthy EM, Phillips JA, 3rd, Characterization of an intron splice enhancer that regulates alternative splicing of human GH pre-mRNA, Hum Mol Genet, 7, 1491–1496, 1998. 40. Sirand-Pugnet P, Durosay P, Brody E, Marie J, An intronic (A/U)GGG repeat enhances the splicing of an alternative intron of the chicken beta-tropomyosin pre-mRNA, Nucl Acids Res, 23, 3501–3507, 1995. 41. McCullough AJ, Berget SM, G triplets located throughout a class of small vertebrate introns enforce intron borders and regulate splice site selection, Mol Cell Biol, 17, 4562–4571, 1997. 42. Carstens RP, Wagner EJ, Garcia-Blanco MA, An intronic splicing silencer causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through involvement of polypyrimidine tract binding protein, Mol Cell Biol, 20, 7388–7400, 2000. 43. Garcia-Blanco MA, Baraniak AP, Lasda EL, Alternative splicing in disease and therapy, Nat Biotechnol, 22, 535–546, 2004. 44. Dominski Z, Kole R, Cooperation of pre-mRNA sequence elements in splice site selection, Mol Cell Biol, 12, 2108–2114, 1992. 45. Krawczak M, Reiss J, Cooper DN, The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences, Hum Genet, 90, 41–54, 1992. 46. Dominski Z, Kole R, Selection of splice sites in pre-mRNAs with short internal exons, Mol Cell Biol, 11, 6075–6083, 1991. 47. Dominski Z, Kole R, Identification and characterization by antisense oligonucleotides of exon and intron sequences required for splicing, Mol Cell Biol, 14, 7445–7454, 1994. 48. Dominski Z, Kole R, Identification of exon sequences involved in splice site selection, J Biol Chem, 269, 23590–23596, 1994. 49. Dominski Z, Kole R, Effects of exon sequences on splicing of model pre-mRNA substrates in vitro, Acta Biochim Pol, 43, 161–173, 1996. 50. Herbert A, Rich A, RNA processing and the evolution of eukaryotes, Nat Genet, 21, 265–269, 1999. 51. Lopez AJ, Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation, Annu Rev Genet, 32, 279–305, 1998. 52. Wang Y, Selvakumar M, Helfman D, Alternative pre-mRNA splicing, In: Eukaryotic mRNA Processing, Krainer A, ed., Oxford University Press, New York, 1997, pp. 242–278. 53. Caceres JF, Misteli T, Screaton GR, Spector DL, Krainer AR, Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity, J Cell Biol, 138, 225–238, 1997. 54. Caceres JF, Stamm S, Helfman DM, Krainer AR, Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors, Science, 265, 1706–1709, 1994. 55. Roberts GC, Smith CW, Alternative splicing: combinatorial output from the genome, Curr Opin Chem Biol, 6, 375–383, 2002. 56. Smith CW, Valcarcel J, Alternative pre-mRNA splicing: the logic of combinatorial control, Trends Biochem Sci, 25, 381–388, 2000. 57. Gemignani F, Sazani P, Morcos P, Kole R, Temperature-dependent splicing of beta-globin pre-mRNA, Nucl Acids Res, 30, 4592–4598, 2002. 58. Garcia-Blanco MA, Making antisense of splicing, Curr Opin Mol Ther, 7, 476–482, 2005. 59. Bonizzoni P, Rizzi R, Pesole G, Computational methods for alternative splicing prediction, Brief Funct Genomic Proteomic, 5, 46–51, 2006. 60. Castrignano T, Rizzi R, Talamo IG, De Meo PD, Anselmo A, Bonizzoni P, Pesole G, ASPIC: a web resource for alternative splicing prediction and transcript isoforms characterization, Nucl Acids Res, 34, W440–W443, 2006. 61. Foissac S, Schiex T, Integrating alternative splicing detection into gene prediction, BMC Bioinf, 6, 25, 2005. 62. Kim N, Shin S, Lee S, ASmodeler: gene modeling of alternative splicing from genomic alignment of mRNA, EST and protein sequences, Nucl Acids Res, 32, W181–W186, 2004. 63. Dominski Z, Kole R, Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides, Proc Natl Acad Sci USA, 90, 8673–8677, 1993.
CRC_8796_ch004.qxd
108
5/25/2007
7:00 AM
Page 108
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
64. Vester B, Wengel J, LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA, Biochemistry, 43, 13233–13241, 2004. 65. Mercatante D, Sazani P, Kole R, Modification of alternatice splicing pathways as a potential chemotherapy for cancer and other diseases, Curr. Cancer Drug Targets, 1, 211–230, 2001. 66. Schwartz E, Benz, EJ, The thalassemia syndrome, In: Hematology, Basic Principles and Practice, Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, and Silberstein LE, eds., Churchill Livingstone, London, Edinburgh, 1995, pp. 586–610. 67. Huisman TH, Frequencies of common beta-thalassemia alleles among different populations: variability in clinical severity, Br J Haematol, 75, 454–457, 1990. 68. Lacerra G, Sierakowska H, Carestia C, Fucharoen S, Summerton J, Weller D, Kole R, Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients, Proc Natl Acad Sci USA, 97, 9591–9596, 2000. 69. Suwanmanee T, Sierakowska H, Fucharoen S, Kole R, Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder, Mol Ther, 6, 718–726, 2002. 70. Suwanmanee T, Sierakowska H, Lacerra G, Svasti S, Kirby S, Walsh C, Fucharoen S, Kole R, Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides, Mol Pharmacol, 62, 545–553, 2002. 71. Kole R, Williams T, Cohen L, RNA modulation, repair and remodeling by splice switching oligonucleotides, Acta Biochim Pol, 51, 373–378, 2004. 72. Kole R, Vacek M, Williams T, Modification of alternative splicing by antisense therapeutics, Oligonucleotides, 14, 65–74, 2004. 73. Vacek M, Sazani P, Kole R, Antisense-mediated redirection of mRNA splicing, Cell Mol Life Sci, 60, 825–833, 2003. 74. Sazani P, Kole R, Modulation of alternative splicing by antisense oligonucleotides, Prog Mol Subcell Biol, 31, 217–239, 2003. 75. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, Muller CR, Lindlof M, Kaariainen H et al., The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion, Am J Hum Genet, 45, 498–506, 1989. 76. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G, Modification of splicing in the dystrophin gene in cultured mdx muscle cells by antisense oligoribonucleotides, Hum Mol Genet, 7, 1083–1090, 1998. 77. Wilton SD, Lloyd F, Carville K, Fletcher S, Honeyman K, Agrawal S, Kole R, Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides, Neuromuscular Disord, 9, 330–338, 1999. 78. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, Morgan JE, Partridge TA, Wilton SD, Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse, Proc Natl Acad Sci USA, 98, 42–47, 2001. 79. Dickson G, Hill V, Graham I, Screening for antisense modulation of dystrophin pre-mRNA splicing, Neuromuscular Disord, 12, S67, 2002. 80. Mann CJ, Honeyman K, McClorey G, Fletcher S, Wilton SD, Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy, J Gene Med, 4, 644–654, 2002. 81. McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD, Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD, Gene Ther, 13, 1373–1381, 2006. 82. Wells KE, Fletcher S, Mann CJ, Wilton SD, Wells DJ, Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle, FEBS Lett, 552, 145–149, 2003. 83. Gebski BL, Mann CJ, Fletcher S, Wilton SD, Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle, Hum Mol Genet, 12, 1801–1811, 2003. 84. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, Fletcher S, Partridge TA, Wilton SD, Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse, Nat Med, 9, 1009–1014, 2003. 85. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G, Partridge T, Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles, Proc Natl Acad Sci USA, 102, 198–203, 2005. 86. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, Partridge TA, Lu QL, Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology, Nat Med, 12, 175–177, 2006.
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 109
SPLICE SWITCHING OLIGONUCLEOTIDES AS POTENTIAL THERAPEUTICS
109
87. Takeshima Y, Wada H, Yagi M, Ishikawa Y, Minami R, Nakamura H, Matsuo M, Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient, Brain Dev, 23, 788–790, 2001. 88. van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT, van Ommen GJ, Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells, Hum Mol Genet, 10, 1547–1554, 2001. 89. Aartsma-Rus A, Bremmer-Bout M, Janson A, den Dunnen J, van Ommen G, van Deutekom J, Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy, Neuromuscular Disord, 12, S71, 2002. 90. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F, van Ommen GJ, van Deutekom JC, Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients, Hum Mol Genet, 12, 907–914, 2003. 91. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, van Deutekom JC, Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense, Am J Hum Genet, 74, 83–92, 2004. 92. Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC, Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells, Gene Ther, 11, 1391–1398, 2004. 93. Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC, Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons, Mol Ther, 14, 401–407, 2006. 94. Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, Kaman WE, Janson AA, Vossen RH, van Ommen GJ, den Dunnen JT, van Deutekom JC, Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides, Mol Ther, 10, 232–240, 2004. 95. Takeshima Y, Yagi M, Wada H, Ishibashi K, Nishiyama A, Kakumoto M, Sakaeda T, Saura R, Okumura K, Matsuo M, Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy, Pediatr Res, 59, 690–694, 2006. 96. Takeshima Y, Yagi M, Wada H, Matsuo M, Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle, Brain Dev, 27, 488–493, 2005. 97. Welsh MJ, Tsui, L-C, Boat, TF, Beaudet, LA, Cystic Fibrosis, McGraw-Hill, New York, 1995. 98. Liu X, Jiang Q, Mansfield SG, Puttaraju M, Zhang Y, Zhou W, Cohn JA, Garcia-Blanco MA, Mitchell LG, Engelhardt JF, Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing, Nat Biotechnol, 20, 47–52, 2002. 99. Liu X, Luo M, Zhang LN, Yan Z, Zak R, Ding W, Mansfield SG, Mitchell LG, Engelhardt JF, Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells, Hum Gene Ther, 16, 1116–1123, 2005. 100. Abeliovich D, Lavon IP, Lerer I, Cohen T, Springer C, Avital A, Cutting GR, Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population, Am J Hum Genet, 51, 951–956, 1992. 101. Friedman KJ, Kole J, Cohn JA, Knowles MR, Silverman LM, Kole R, Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides, J Biol Chem, 274, 36193–36199, 1999. 102. Nissim-Rafinia M, Aviram M, Randell SH, Shushi L, Ozeri E, Chiba-Falek O, Eidelman O, Pollard HB, Yankaskas JR, Kerem B, Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation, EMBO Rep, 5, 1071–1077, 2004. 103. Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E, Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer’s disease, J Cell Biol, 143, 777–794, 1998. 104. Utton MA, Connell J, Asuni AA, van Slegtenhorst M, Hutton M, de Silva R, Lees AJ, Miller CC, Anderton BH, The slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants in cultured neurons, J Neurosci, 22, 6394–6400, 2002. 105. Andreadis A, Brown WM, Kosik KS, Structure and novel exons of the human tau gene, Biochemistry, 31, 10626–10633, 1992.
CRC_8796_ch004.qxd
110
5/25/2007
7:00 AM
Page 110
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
106. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA, Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease, Neuron, 3, 519–526, 1989. 107. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA, Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain, EMBO J, 8, 393–399, 1989. 108. Kar A, Kuo D, He R, Zhou J, Wu JY, Tau alternative splicing and frontotemporal dementia, Alzheimer’s Dis Assoc Disord, 19, Suppl 1, S29–S36, 2005. 109. Kalbfuss B, Mabon SA, Misteli T, Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17, J Biol Chem, 276, 42986–42993, 2001. 110. Hoger TH, Zatloukal K, Waizenegger I, Krohne G, Characterization of a second highly conserved B-type lamin present in cells previously thought to contain only a single B-type lamin, Chromosoma, 99, 379–390, 1990. 111. Furukawa K, Hotta Y, cDNA cloning of a germ cell specific lamin B3 from mouse spermatocytes and analysis of its function by ectopic expression in somatic cells, EMBO J, 12, 97–106, 1993. 112. Broers JL, Raymond Y, Rot MK, Kuijpers H, Wagenaar SS, Ramaekers FC, Nuclear A-type lamins are differentially expressed in human lung cancer subtypes, Am J Pathol, 143, 211–220, 1993. 113. Fisher DZ, Chaudhary N, Blobel G, cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins, Proc Natl Acad Sci USA, 83, 6450–6454, 1986. 114. Gerace L, Burke B, Functional organization of the nuclear envelope, Annu Rev Cell Biol, 4, 335–374, 1988. 115. Krohne G, Benavente R, The nuclear lamins. A multigene family of proteins in evolution and differentiation, Exp Cell Res, 162, 1–10, 1986. 116. Lin F, Worman HJ, Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C, J Biol Chem, 268, 16321–16326, 1993. 117. McKeon FD, Kirschner MW, Caput D, Homologies in both primary and secondary structure between nuclear envelope and intermediate filament proteins, Nature, 319, 463–468, 1986. 118. Machiels BM, Zorenc AH, Endert JM, Kuijpers HJ, van Eys GJ, Ramaekers FC, Broers JL, An alternative splicing product of the lamin A/C gene lacks exon 10, J Biol Chem, 271, 9249–9253, 1996. 119. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS, Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome, Nature, 423, 293–298, 2003. 120. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, Levy N, Lamin: a truncation in Hutchinson–Gilford progeria, Science, 300, 2055, 2003. 121. Csoka AB, Cao H, Sammak PJ, Constantinescu D, Schatten GP, Hegele RA, Novel lamin A/C gene (LMNA) mutations in atypical progeroid syndromes, J Med Genet, 41, 304–308, 2004. 122. Scaffidi P, Misteli T, Reversal of the cellular phenotype in the premature aging disease Hutchinson–Gilford progeria syndrome, Nat Med, 11, 440–445, 2005. 123. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M et al., Identification and characterization of a spinal muscular atrophy-determining gene, Cell, 80, 155–165, 1995. 124. Lorson CL, Hahnen E, Androphy EJ, Wirth B, A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy, Proc Natl Acad Sci USA, 96, 6307–6311, 1999. 125. Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH, McPherson JD, A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2, Hum Mol Genet, 8, 1177–1183, 1999. 126. Cartegni L, Hastings ML, Calarco JA, de Stanchina E, Krainer AR, Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2, Am J Hum Genet, 78, 63–77, 2006. 127. Monani UR, Coovert DD, Burghes AH, Animal models of spinal muscular atrophy, Hum Mol Genet, 9, 2451–2457, 2000. 128. Wirth B, Brichta L, Schrank B, Lochmuller H, Blick S, Baasner A, Heller R, Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number, Hum Genet, 119, 422–428, 2006.
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 111
SPLICE SWITCHING OLIGONUCLEOTIDES AS POTENTIAL THERAPEUTICS
111
129. Brichta L, Holker I, Haug K, Klockgether T, Wirth B, In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate, Ann Neurol, 59, 970–975, 2006. 130. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H, Treatment of spinal muscular atrophy by sodium butyrate, Proc Natl Acad Sci USA, 98, 9808–9813, 2001. 131. Lim SR, Hertel KJ, Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3 splice site pairing, J Biol Chem, 276, 45476–45483, 2001. 132. Miyajima H, Miyaso H, Okumura M, Kurisu J, Imaizumi K, Identification of a cis-acting element for the regulation of SMN exon 7 splicing, J Biol Chem, 277, 23271–23277, 2002. 133. Miyaso H, Okumura M, Kondo S, Higashide S, Miyajima H, Imaizumi K, An intronic splicing enhancer element in survival motor neuron (SMN) pre-mRNA, J Biol Chem, 278, 15825–15831, 2003. 134. Singh NK, Singh NN, Androphy EJ, Singh RN, Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron, Mol Cell Biol, 26, 1333–1346, 2006. 135. Vetrini F, Tammaro R, Bondanza S, Surace EM, Auricchio A, De Luca M, Ballabio A, Marigo V, Aberrant splicing in the ocular albinism type 1 gene (OA1/GPR143) is corrected in vitro by morpholino antisense oligonucleotides, Hum Mutat, 27, 420–426, 2006. 136. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB, bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death, Cell, 74, 597–608, 1993. 137. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC, Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers, Am J Pathol, 148, 1567–1576, 1996. 138. Xerri L, Hassoun J, Devilard E, Birnbaum D, Birg F, BCL-X and the apoptotic machinery of lymphoma cells, Leukemia Lymphoma, 28, 451–458, 1998. 139. Taylor JK, Zhang QQ, Wyatt JR, Dean NM, Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides, Nat Biotechnol, 17, 1097–1100, 1999. 140. Taylor MF, Paulauskis JD, Weller DD, Kobzik L, In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-alpha mRNA, J Biol Chem, 271, 17445–17452, 1996. 141. Xu L, Ferry AE, Monteiro C, Pace BS, Beta globin gene inhibition by antisense RNA transcripts, Gene Ther, 7, 438–444, 2000. 142. Nita ME, Ono-Nita SK, Tsuno N, Tominaga O, Takenoue T, Sunami E, Kitayama J, Nakamura Y, Nagawa H, Bcl-X(L) antisense sensitizes human colon cancer cell line to 5-fluorouracil, Jpn J Cancer Res, 91, 825–832, 2000. 143. Heere-Ress E, Thallinger C, Lucas T, Schlagbauer-Wadl H, Wacheck V, Monia BP, Wolff K, Pehamberger H, Jansen B, Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy, Int J Cancer, 99, 29–34, 2002. 144. Wacheck V, Losert D, Gunsberg P, Vornlocher HP, Hadwiger P, Geick A, Pehamberger H, Muller M, Jansen B, Small interfering RNA targeting bcl-2 sensitizes malignant melanoma, Oligonucleotides, 13, 393–400, 2003. 145. Mercatante DR, Mohler JL, Kole R, Cellular response to an antisense-mediated shift of Bcl-x premRNA splicing and antineoplastic agents, J Biol Chem, 14, 14, 2002. 146. Mercatante DR, Kole R, Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression, Biochim Biophys Acta, 1587, 126–132, 2002. 147. Yamamoto T, Nishioka K, Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy, Skin Pharmacol Appl Skin Physiol, 16, 50–58, 2003. 148. Takahashi H, Manabe A, Ishida-Yamamoto A, Hashimoto Y, Iizuka H, Aberrant expression of apoptosis-related molecules in psoriatic epidermis, J Dermatol Sci, 28, 187–197, 2002. 149. Kocak M, Bozdogan O, Erkek E, Atasoy P, Birol A, Examination of Bcl-2, Bcl-X and bax protein expression in psoriasis, Int J Dermatol, 42, 789–793, 2003. 150. Williams T, Kole R, Analysis of prostate-specific membrane antigen splice variants in LNCap cells, Oligonucleotides, 16, 186–195, 2006. 151. Lupold SE, Hicke BJ, Lin Y, Coffey DS, Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen, Cancer Res, 62, 4029–4033, 2002.
CRC_8796_ch004.qxd
112
5/25/2007
7:00 AM
Page 112
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
152. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, Bander NH, Rajasekaran AK, A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen, Mol Biol Cell, 14, 4835–4845, 2003. 153. Slater RM, Mannens MM, Cytogenetics and molecular genetics of Wilms’ tumor of childhood, Cancer Genet Cytogenet, 61, 111–121, 1992. 154. Saglio G, Carturan S, Grillo S, Capella S, Arruga F, Defilippi I, Rosso V, Rauco M, Marina Liberati A, Cilloni D, WT1 overexpression: a clinically useful marker in acute and chronic myeloid leukemias, Hematology, 10, Suppl 1, 76–78, 2005. 155. Silberstein GB, Van Horn K, Strickland P, Roberts CT, Jr., Daniel CW, Altered expression of the WT1 Wilms’ tumor suppressor gene in human breast cancer, Proc Natl Acad Sci USA, 94, 8132–8137, 1997. 156. Lee SB, Haber DA, Wilms’ tumor and the WT1 gene, Exp Cell Res, 264, 74–99, 2001. 157. Bor YC, Swartz J, Morrison A, Rekosh D, Ladomery M, Hammarskjold ML, The Wilms’ tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron, Genes Dev, 20, 1597–1608, 2006. 158. Renshaw J, King-Underwood L, Pritchard-Jones K, Differential splicing of exon 5 of the Wilms’ tumour (WTI) gene, Genes Chromosomes Cancer, 19, 256–266, 1997. 159. Renshaw J, Orr RM, Walton MI, Te Poele R, Williams RD, Wancewicz EV, Monia BP, Workman P, Pritchard-Jones K, Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival, Mol Cancer Ther, 3, 1467–1484, 2004. 160. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, Anderson DM, Gimpel SD, Davis-Smith T, Maliszewski CR et al., Molecular and biological characterization of a murine ligand for CD40, Nature, 357, 80–82, 1992. 161. Siwkowski AM, Malik L, Esau CC, Maier MA, Wancewicz EV, Albertshofer K, Monia BP, Bennett CF, Eldrup AB, Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing, Nucl Acids Res, 32, 2695–2706, 2004. 162. Vickers TA, Zhang H, Graham MJ, Lemonidis KM, Zhao C, Dean NM, Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2-Omethoxyethyl-modified oligonucleotide, J Immunol, 176, 3652–3661, 2006. 163. Burns K, Martinon F, Esslinger C, Pahl H, Schneider P, Bodmer JL, Di Marco F, French L, Tschopp J, MyD88, an adapter protein involved in interleukin-1 signaling, J Biol Chem, 273, 12203–12209, 1998. 164. Janssens S, Burns K, Tschopp J, Beyaert R, Regulation of interleukin-1- and lipopolysaccharideinduced NF-kappaB activation by alternative splicing of MyD88, Curr Biol, 12, 467–471, 2002. 165. Meshorer E, Soreq H, Virtues and woes of AChE alternative splicing in stress-related neuropathologies, Trends Neurosci, 29, 216–224, 2006. 166. Grisaru D, Sternfeld M, Eldor A, Glick D, Soreq H, Structural roles of acetylcholinesterase variants in biology and pathology, Eur J Biochem, 264, 672–686, 1999. 167. Brenner T, Hamra-Amitay Y, Evron T, Boneva N, Seidman S, Soreq H, The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis, FASEB J, 17, 214–222, 2003. 168. Shohami E, Kaufer D, Chen Y, Seidman S, Cohen O, Ginzberg D, Melamed-Book N, Yirmiya R, Soreq H, Antisense prevention of neuronal damages following head injury in mice, J Mol Med, 78, 228–236, 2000. 169. Nijholt I, Farchi N, Kye M, Sklan EH, Shoham S, Verbeure B, Owen D, Hochner B, Spiess J, Soreq H, Blank T, Stress-induced alternative splicing of acetylcholinesterase results in enhanced fear memory and long-term potentiation, Mol Psychiatry, 9, 174–183, 2004. 170. Vickers TA, Wyatt JR, Burckin T, Bennett CF, Freier SM, Fully modified 2 MOE oligonucleotides redirect polyadenylation, Nucl Acids Res, 29, 1293–1299, 2001. 171. Gautheret D, Poirot O, Lopez F, Audic S, Claverie JM, Alternate polyadenylation in human mRNAs: a large-scale analysis by EST clustering, Genome Res, 8, 524–530, 1998. 172. Shaw G, Kamen R, A conserved AU sequence from the 3 untranslated region of GM-CSF mRNA mediates selective mRNA degradation, Cell, 46, 659–667, 1986. 173. Sanford JR, Ellis J, Caceres JF, Multiple roles of arginine/serine-rich splicing factors in RNA processing, Biochem Soc Trans, 33, 443–446, 2005. 174. Cartegni L, Krainer AR, Correction of disease-associated exon skipping by synthetic exon-specific activators, Nat Struct Biol, 10, 120–125, 2003.
CRC_8796_ch004.qxd
5/25/2007
7:00 AM
Page 113
SPLICE SWITCHING OLIGONUCLEOTIDES AS POTENTIAL THERAPEUTICS
113
175. Muller D, Bonaiti-Pellie C, Abecassis J, Stoppa-Lyonnet D, Fricker JP, BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect, Fam Cancer, 3, 15–20, 2004. 176. Chabot B, LeBel C, Hutchison S, Nasim FH, Simard MJ, Heterogeneous nuclear ribonucleoprotein particle A/B proteins and the control of alternative splicing of the mammalian heterogeneous nuclear ribonucleoprotein particle A1 pre-mRNA, Prog Mol Subcell Biol, 31, 59–88, 2003. 177. Wilusz JE, Devanney SC, Caputi M, Chimeric peptide nucleic acid compounds modulate splicing of the bcl-x gene in vitro and in vivo, Nucl Acids Res, 33, 6547–6554, 2005. 178. Partridge M, Vincent A, Matthews P, Puma J, Stein D, Summerton J, A simple method for delivering morpholino antisense oligos into the cytoplasm of cells, Antisense Nucl Acid Drug Dev, 6, 169–175, 1996. 179. Skordis LA, Dunckley MG, Yue B, Eperon IC, Muntoni F, Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts, Proc Natl Acad Sci USA, 100, 4114–4119, 2003. 180. Villemaire J, Dion I, Elela SA, Chabot B, Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides, J Biol Chem, 278, 50031–50039, 2003. 181. Gendron D, Carriero S, Garneau D, Villemaire J, Klinck R, Elela SA, Damha MJ, Chabot B, Modulation of 5 splice site selection using tailed oligonucleotides carrying splicing signals, BMC Biotechnol, 6, 5, 2006. 182. Mayer MG, Floeter-Winter LM, Pre-mRNA trans-splicing: from kinetoplastids to mammals, an easy language for life diversity, Mem Inst Oswaldo Cruz, 100, 501–513, 2005. 183. Puttaraju M, Jamison SF, Mansfield SG, Garcia-Blanco MA, Mitchell LG, Spliceosome-mediated RNA trans-splicing as a tool for gene therapy, Nat Biotechnol, 17, 246–252, 1999. 184. Schroder W, Rudlowski C, Biesterfeld S, Knobloch C, Hauptmann S, Rath W, Expression of CD44(v5-10) splicing variants in primary ovarian cancer and lymph node metastases, Anticancer Res, 19, 3901–3906, 1999. 185. Mansfield SG, Kole J, Puttaraju M, Yang CC, Garcia-Blanco MA, Cohn JA, Mitchell LG, Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing, Gene Ther, 7, 1885–1895, 2000. 186. Dallinger G, Puttaraju M, Mitchell LG, Yancey KB, Hintner H, Bauer JW, Collagen 17A1 gene correction using spliceosome mediated RNA trans-splicing (SMaRTtrade mark) technology, J Invest Dermatol, 115, 332, 2000. 187. Dallinger G, Puttaraju M, Mitchell LG, Yancey KB, Yee C, Klausegger A, Hintner H, Bauer JW, Development of spliceosome-mediated RNA trans-splicing (SMaRT) for the correction of inherited skin diseases, Exp Dermatol, 12, 37–46, 2003. 188. Rodriguez-Martin T, Garcia-Blanco MA, Mansfield SG, Grover AC, Hutton M, Yu Q, Zhou J, Anderton BH, Gallo JM, Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies, Proc Natl Acad Sci USA, 102, 15659–15664, 2005. 189. Tahara M, Pergolizzi RG, Kobayashi H, Krause A, Luettich K, Lesser ML, Crystal RG, Transsplicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency, Nat Med, 10, 835–841, 2004. 190. Chao H, Mansfield SG, Bartel RC, Hiriyanna S, Mitchell LG, Garcia-Blanco MA, Walsh CE, Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing, Nat Med, 9, 1015–1019, 2003. 191. Schumperli D, Pillai RS, The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein, Cell Mol Life Sci, 61, 2560–2570, 2004. 192. Sierakowska H, Sambade MJ, Agrawal S, Kole R, Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides, Proc Natl Acad Sci USA, 93, 12840–12844, 1996. 193. Gorman L, Suter D, Emerick V, Schumperli D, Kole R, Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs, Proc Natl Acad Sci USA, 95, 4929–4934, 1998. 194. Suter D, Tomasini R, Reber U, Gorman L, Kole R, Schumperli D, Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human beta-thalassemic mutations, Hum Mol Genet, 8, 2415–2423, 1999. 195. Gorman L, Mercatante DR, Kole R, Restoration of correct splicing of thalassemic beta-globin premRNA by modified U1 snRNAs, J Biol Chem, 275, 35914–35919, 2000.
CRC_8796_ch004.qxd
114
5/25/2007
7:00 AM
Page 114
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
196. Vacek MM, Ma H, Gemignani F, Lacerra G, Kafri T, Kole R, High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA, Blood, 101, 104 –111, 2003. 197. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, Danos O, Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping, Science, 306, 1796–1799, 2004. 198. Denti MA, Rosa A, D’Antona G, Sthandier O, De Angelis FG, Nicoletti C, Allocca M, Pansarasa O, Parente V, Musaro A, Auricchio A, Bottinelli R, Bozzoni I, Chimeric adeno-associated virus/antisense U1 small nuclear RNA effectively rescues dystrophin synthesis and muscle function by local treatment of mdx mice, Hum Gene Ther, 17, 565–574, 2006. 199. Madocsai C, Lim SR, Geib T, Lam BJ, Hertel KJ, Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs, Mol Ther, 12, 1013–1022, 2005. 200. Liu S, Asparuhova M, Brondani V, Ziekau I, Klimkait T, Schumperli D, Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A, Nucl Acids Res, 32, 3752–3759, 2004. 201. Kashima T, Manley JL, A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy, Nat Genet, 34, 460–463, 2003. 202. Hofmann Y, Wirth B, hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-beta1, Hum Mol Genet, 11, 2037–2049, 2002. 203. Massiello A, Salas A, Pinkerman RL, Roddy P, Roesser JR, Chalfant CE, Identification of two RNA cis-elements that function to regulate the 5 splice site selection of Bcl-x pre-mRNA in response to ceramide, J Biol Chem, 279, 15799–15804, 2004. 204. Massiello A, Roesser JR, Chalfant CE, SAP155 Binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5 splice site selection of Bcl-x pre-mRNA, FASEB J, 20, 1680–1682, 2006. 205. Gabut M, Mine M, Marsac C, Brivet M, Tazi J, Soret J, The SR protein SC35 is responsible for aberrant splicing of the E1alpha pyruvate dehydrogenase mRNA in a case of mental retardation with lactic acidosis, Mol Cell Biol, 25, 3286–3294, 2005. 206. Bolduc L, Labrecque B, Cordeau M, Blanchette M, Chabot B, Dimethyl sulfoxide affects the selection of splice sites, J Biol Chem, 276, 17597–17602, 2001. 207. Soret J, Bakkour N, Maire S, Durand S, Zekri L, Gabut M, Fic W, Divita G, Rivalle C, Dauzonne D, Nguyen CH, Jeanteur P, Tazi J, Selective modification of alternative splicing by indole derivatives that target serine–arginine-rich protein splicing factors, Proc Natl Acad Sci USA, 102, 8764–8769, 2005. 208. Tazi J, Bakkour N, Soret J, Zekri L, Hazra B, Laine W, Baldeyrou B, Lansiaux A, Bailly C, Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diospyrin derivatives, Mol Pharmacol, 67, 1186–1194, 2005. 209. Sazani P, Kang SH, Maier MA, Wei C, Dillman J, Summerton J, Manoharan M, Kole R, Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs, Nucl Acids Res, 29, 3965–3974, 2001. 210. Sazani P, Gemignani F, Kang SH, Maier MA, Manoharan M, Persmark M, Bortner D, Kole R, Systemically delivered antisense oligomers upregulate gene expression in mouse tissues, Nat Biotechnol, 20, 1228–1233, 2002. 211. Thierry AR, Abes S, Resina S, Travo A, Richard JP, Prevot P, Lebleu B, Comparison of basic peptidesand lipid-based strategies for the delivery of splice correcting oligonucleotides, Biochim Biophys Acta, 1758, 364–374, 2006. 212. Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL, Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides, Bioconjug Chem, 15, 290–299, 2004. 213. Moulton HM, Hase MC, Smith KM, Iversen PL, HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers, Antisense Nucl Acid Drug Dev, 13, 31–43, 2003. 214. Sazani P, Astriab-Fischer A, Kole R, Effects of base modifications on antisense properties of 2-Omethoxyethyl and PNA oligonucleotides, Antisense Nucl Acid Drug Dev, 13, 119–128, 2003. 215. Albertshofer K, Siwkowski AM, Wancewicz EV, Esau CC, Watanabe T, Nishihara KC, Kinberger GA, Malik L, Eldrup AB, Manoharan M, Geary RS, Monia BP, Swayze EE, Griffey RH, Bennett CF, Maier MA, Structure–activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid, J Med Chem, 48, 6741–6749, 2005. 216. Maier MA, Esau CC, Siwkowski AM, Wancewicz EV, Albertshofer K, Kinberger GA, Kadaba NS, Watanabe T, Manoharan M, Bennett CF, Griffey RH, Swayze EE, Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids, J Med Chem, 49, 2534–2542, 2006. 217. Roberts J, Palma E, Sazani P, Orum H, Cho M, Kole R, Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice, Mol Ther, 14, 471–475, 2006.
CRC_8796_s002.qxd
5/3/2007
03:14 PM
Page 115
PART
II
The Basics of Oligonucleotide-Based Therapeutics
CRC_8796_s002.qxd
5/3/2007
03:14 PM
Page 116
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 117
CHAPTER
5
Basic Principles of Antisense Drug Discovery Susan M. Freier and Andrew T. Watt
CONTENTS 5.1 5.2
Introduction .........................................................................................................................118 Design of Antisense Oligonucleotids ..................................................................................118 5.2.1 Gene Sequence Alignment ......................................................................................118 5.2.2 Identification of Cross Reactors ..............................................................................119 5.2.3 Selection of ASO Target Sites .................................................................................119 5.2.3.1 Correlation of Activity with Gene Feature ..............................................119 5.2.3.2 Correlation of Activity with Calculated Secondary Structure in Target or ASO ..........................................................................................120 5.2.3.3 Correlation of Activity with Sequence Motifs in the ASO ......................122 5.2.3.4 Correlation of Activity with Cell-Free Properties ....................................122 5.2.3.5 Correlation of Activity with Multiple Properties .....................................122 5.2.4 Exclusion of ASOs ..................................................................................................123 5.2.4.1 Sequence Motifs Associated with Non-Antisense Activities ...................123 5.2.4.2 Reduction of Nontarget Genes .................................................................123 5.2.5 Sequence Variants Due to Polymorphism ...............................................................123 5.2.6 Cross-Species ASOs ................................................................................................124 5.2.7 Summary of Considerations for ASO Design .........................................................127 5.2.8 How Many ASOs to Design and Test? ....................................................................127 5.3 Primary Screen for Active ASOs .........................................................................................128 5.3.1 Activity Assay ..........................................................................................................128 5.3.1.1 Kinetic RT-PCR ........................................................................................129 5.3.1.2 Activity Assays Other Than Kinetic RT-PCR ..........................................130 5.3.1.3 Other Considerations for Choice of Screening Assay .............................131 5.3.1.4 Positive and Negative Controls for Screening Assays .............................134 5.4 Follow-Up Assays ................................................................................................................134 5.4.1 In Vitro .....................................................................................................................134 5.4.2 In Vivo ......................................................................................................................135 5.5 Comparison of in Vitro Activity to in Vivo Activity ............................................................135 5.6 Summary ..............................................................................................................................138 References .....................................................................................................................................138
117
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 118
118
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
5.1 INTRODUCTION It has been nearly 30 years since the first reports of inhibition of gene expression using an antisense oligonucleotide (ASO) [1]. Although many technological hurdles remained to be solved, the potential of antisense inhibitors for therapeutic applications was clearly apparent at that time. Antisense oligonucleotides offered specificity rarely attainable with small molecule inhibitors. Specific isoforms of proteins could be targeted, allowing direct inhibition of one part of a pathway without affecting related pathways. The approach was universal. With only partial sequence of any RNA, that RNA and its products could be inhibited. Because the mechanism is universal and the chemical structures of ASOs are so similar, lessons learned for ASOs against one molecular target transferred to ASOs for other molecular targets. The result is several ASOs currently in development for a broad range of indications (Chapters 21–28). In addition to the therapeutic utility of ASOs, their value as a tool for functional genomics has been huge. With the availability of the complete genome sequence for human and many model organisms, it has become straightforward in many cases to identify a gene-specific inhibitor and evaluate its function in vitro and in vivo. ASOs have become a fast, effective mechanism for target validation. A gene-specific inhibitor can be quickly identified and tested in a disease model in vivo. The results of that study provide a rapid validation of the target before embarking on expensive screens for a small molecule inhibitor or development of a human antisense therapeutic. Since completion of the human genome sequence, Isis has identified and characterized antisense inhibitors for more than 3000 molecular targets. We will summarize below what has been learned about efficient and effective discovery of antisense oligonucleotides for purposes of functional genomics and direct drug discovery. We will address design of ASOs, screening of ASOs, and follow-up confirmation of active ASOs. We will end with a discussion of the correlation between in vitro target reduction and in vivo target reduction. Later stages of antisense drug discovery including pharmacokinetics, pharmacodynamics, and pharmacology of ASOs in vivo are thoroughly covered elsewhere in this volume.
5.2 DESIGN OF ANTISENSE OLIGONUCLEOTIDS As mentioned above, one attraction of antisense technology is the universality of the approach and the simplicity of drug design. If RNA sequence is known, antisense sequence is easy to work out. The process, however, is not that simple. Decisions must be made with respect to length, chemical modifications, and target site. As discussed in Chapters 1, 2, and 10–14, 2⬘–O–methoxyethyl chimeric ASOs possess desirable properties for antisense therapeutics. These ASOs support RNase H and directly cause decay of the RNA target. Many alternative chemistries and structures continue to be investigated (Chapters 6 and 17–20). The bulk of our experience, however, has been with 5-10-5 MOE gapmers, 20-mer fully phosphorothioate ASOs with five 2⬘–O–methoxyethyl sugars on each end and ten deoxyribose sugars in the gap. Thus, this chapter will focus on finding the optimal 5-10-5 MOE gapmer; Chapter 17 and others mentioned above will discuss effects of varying this basic structure. Although most of the data described are for 5-10-5 MOE gapmers, the processes described below can be applied to any ASO structure and modification including siRNAs and single-stranded ASOs that use double-stranded RNASes for target cleavage. ASOs that work by blocking translation or altering RNA processing may have additional restrictions, both for ASO design and for measurement of ASO activity. 5.2.1
Gene Sequence Alignment
The first step in ASO design is to identify the molecular target(s). The gene of interest may have been selected because it was known to be important in specific biological pathways or diseases. Alternatively, it may have been selected because little was known and the ASO will be used for
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 119
BASIC PRINCIPLES OF ANTISENSE DRUG DISCOVERY
119
functional genomics studies. In either case, one begins with a gene. The purpose of the sequence alignment is to identify the primary transcript(s) for this gene and all mRNA products. Although I refer to the final products after splicing and polyadenylation as mRNAs, they can equally well be processed noncoding RNAs. We have been successful in targeting spliced and unspliced noncoding RNA as well as coding RNAs using gapmer ASOs. Alternative starts of transcription and alternative polyadenylation will lead to alternative primary transcripts. The reason for identifying these alternative transcripts is to ensure that ASOs are complementary to the pre-mRNA for all variant mRNAs. If one wants to specifically target only one transcription variant, ASOs can be designed to unique regions of primary transcripts [2]. If, however, one wants to inhibit all variants, it is important to ensure that ASOs are complementary to the primary transcripts for all variants. Similarly, identification of mRNA variants is important when designing reverse transcriptase polymerase chain reaction (RT-PCR) primers or other detection methods to be used in the screening assay. If multiple mRNA variants are present, it is important that the assay detect and, if possible, distinguish the variants. ASOs that cross exon:exon junctions can be active [3]; so identification of splice variants is necessary to recognize which processed transcripts will be targeted by these exon:exon ASOs. For many genes, the literature can provide information on known primary and processed RNA variants. For others, the best sources of information are the public sequence databases such as Genbank. Complementary DNAs (cDNAs) and expressed sequence tags (ESTs) can be aligned on the genome using BLAST [4] and common variants can be identified. Possible variants can also be identified by comparison to other species. If, for example, there are three alternate starts of transcription in human resulting in three alternate exons 1 and if three similar exons can be found upstream of the same gene in the rat genome, one could speculate the three alternate exons 1 are also used in rat. 5.2.2
Identification of Cross Reactors
One advantage of antisense technology is that it can be used to specifically target one member of a family of similar gene products. To recognize this specificity, one must avoid ASO binding to other members of the family. Cross-reacting RNAs can be identified by a homology search versus databases of RNAs in the same species. Any gene with even weak homology to the target gene is classified as a potential cross reactor for both ASO design and RT-PCR primer selection. 5.2.3
Selection of ASO Target Sites
There are typically thousands of sites on an mRNA and tens of thousands of sites on a premRNA that can be targeted by ASOs. Thus, any method that can select active ASOs from these thousands of candidates is of value. Many computational and experimental methods have been used and are reviewed elsewhere [5]. Here, I will focus on those that have been tested in the drug discovery process at Isis.
5.2.3.1 Correlation of Activity with Gene Feature Figure 5.1 shows screening data for ASOs designed to different regions of a pre-mRNA target. Active ASOs occurred in all regions of the target. These data were combined with similar data for hundreds of other targets in an attempt to correlate gene feature with ASO activity. Overall, correlation was weak. Active ASOs were found in the untranslated regions (UTRs), coding sequence (CDS), introns, splice sites (intron:exon and exon:intron junctions), and exon:exon junctions. When the correlation was tested using only lead ASOs with confirmed in vivo activity, similar results were obtained; all regions were represented. Activity of oligos complementary to introns [6] provides strong evidence that these ASOs act on RNA in the nucleus before splicing occurs. Activity of ASOs that target an exon–exon junction
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 120
120
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
[3] suggests that these ASOs also act on the spliced product. This activity may be in the nucleus, after splicing and before export, or it may occur on the mRNA in the cytoplasm.
5.2.3.2 Correlation of Activity with Calculated Secondary Structure in Target or ASO Figure 5.2 depicts the hybridization steps required for an ASO to bind to its RNA target site. If only hybridization were important, activity would correlate with the free energy required to open up binding sites in the ASO and RNA target and the free energy of duplex formation between the ASO and the target RNA. Researchers at the Mathew’s Lab, University of Rochester Medical Center, have provided programs to calculate free energies for each of the steps in Figure 5.2 [7].
140
Neg cont
mRNA (% untreated control)
UTR extensions
120 100 80
5′ UTR
3′ UTR CDS
60
Intron
40 20 0
Oligo Stop
Start Exon:exon
Figure 5.1
Splice
Sites
Screening data for 71 ASOs to a single gene target in human T-24 cells.
Target
Target structure
Duplex formation
Total binding
Antisense oligonucleotide Figure 5.2
Intra- and intermolecular oligo self structure
Total binding of an ASO to an RNA target consists of three steps. Self-structure in the ASO must be removed and secondary structure in the RNA target must be opened up. Finally, the ASO binds to the denatured target site with favorable free energy.
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 121
BASIC PRINCIPLES OF ANTISENSE DRUG DISCOVERY
121
Mathews and colleagues (http://rna.urmc.rochester.edu/rnastructure.html) and many others have reported similar strategies [8–20]. Good correlation between calculated binding free energies and observed antisense activity has been reported for data in a single experiment [7,15]. When data were combined for screens against multiple targets performed under similar conditions, correlations became weaker. Figure 5.3a shows data for 349 20-mers comparing antisense activity to free energy of duplex formation. Although the correlation was weak, it was in the expected direction and, due to the large number of samples, was significant. For this set of ASOs, a filter of ⌬G° ⬍ ⫺35 kcal/mol increased the hit rate from 14% to 24% (Figure 5.3b). The number of active ASOs, however, was reduced from 49 to 5 and the number of candidates was reduced from 349 to 21. A receiver operator curve (ROC) for these data is shown in Figure 5.3c. Good specificity can be achieved but not without a big loss in sensitivity. Similar results were reported by Matveeva et al.; restrictive filtering of candidate ASOs based on free energy calculations improved the fraction (a)
Inactive
(b)
Active
120
100
Percent oligos
mRNA (% untreated control)
120 100 80 60
80 16
300
60
40
40 20
R = 0.22
20
P = 3 × 10−5
5
49 0
0 −40 −30 −20 −10 Free energy of duplex formation (kcal/mol)
No dG filter
Sensitivity
(c) 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0
−35 kcal/mol 0
0.2
0.4
0.6
0.8
1
1-Specificity Figure 5.3
(a) Correlation of antisense activity with the free energy of duplex formation for 349 ASOs from several screens against several targets. (b) Effect of a free-energy prefilter on activity profile of ASOs. (c) Receiver–operator curve for data in Figure 5.3a. Active ASOs were defined as those with RNA levels ⬍25% control. The free-energy cutoff was varied from ⫺40 kcal/mol to ⫺10 kcal/mol and the effect on sensitivity ([active ASOs predicted to be active]/[all active ASOs]) and specificity ([inactive ASOs predicted to be active]/[all inactive ASOs]) was plotted. Area under this curve was 0.72.
CRC_8796_ch005.qxd
122
5/24/2007
11:37
Page 122
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
active and greatly reduced the number of active ASOs identified [14]. Thus, if there are sufficient candidate ASOs and sufficient active ASOs, a strategy using thermodynamic cutoffs can improve hit rates but not to 100%. The weak correlation of ASO activity with calculated free energies for the processes in Figure 5.2 is likely due to two factors. First, the thermodynamic calculations are not perfect. Few thermodynamic parameters are available for modified ASOs [21] and predictions of free energy for unfolding a region of an RNA are still being improved [22,23]. The main source of the discrepancy, however, is that the process in Figure 5.2 is too simple. The ASO is not binding to a folded mRNA at equilibrium but to a transcript that is undergoing refolding as it is processed. Proteins bind both to the transcript and to the ASO. The process is kinetic, not equilibrium. Enzyme kinetics of RNAse H or other terminating mechanisms must be considered. Mismatched sites on other RNAs may compete for binding of the ASO. Given the complexity of the process, it is not surprising that thermodynamic predictions of ASO binding are not sufficient to fully explain ASO activity. Despite the relatively weak correlations reported above, target structure has been shown to play a role in antisense activity. Vickers et al. prepared several constructs containing a complementary site for a single ASO [24]. The RNA sequence surrounding the site was varied to produce transcripts in which the ASO binding site was in a region with more or less secondary structure. By using the same ASO for each experiment, they were able to show that potency of a single ASO was reduced when that ASO was complementary to a structured site in the target RNA.
5.2.3.3 Correlation of Activity with Sequence Motifs in the ASO Experimental correlation of antisense activity with sequence motif has led to identification of motifs positively or negatively correlated with antisense activity [13,25,26]. As for the thermodynamic considerations presented above, the correlation is not strong, so selection of ASOs based on motif rules can improve specificity but not without a big loss in sensitivity.
5.2.3.4 Correlation of Activity with Cell-Free Properties Several investigators have used in vitro–transcribed mRNA or cell extracts to experimentally evaluate ASO activity before performing the cellular assay [16,17,27–35]. Although correlations between activity in the cell-free assay and cellular antisense activity have been reported, there seems to be little advantage to these cell-free assays. They are often more difficult than the direct cellular screen and the lack of strong correlation does not preclude the need for cellular assays. The cell-free assays that could be advantageous are those that sample the full set of ASO binding sites. These include arrays [27,34,36] and combinatorial library approaches [28,29,37,38]. In principle, these strategies could sample more sequence space than a typical screening experiment in cell culture. In practice, however, technical limitations and the lack of strong correlation between the cell-free results and antisense activity in cell culture have limited the utility of these approaches.
5.2.3.5 Correlation of Activity with Multiple Properties The lack of strong correlation for any of the above properties with antisense activity led to an attempt to simultaneously correlate multiple properties with antisense activity. We began with antisense activity data for about 30,000 ASOs and filtered the set to create a training set of ⬃10,000 ASOs with reproducible activity, which were tested under similar conditions. Thermodynamic properties, sequence motifs, and gene feature properties discussed above were included. Both decision tree and neural net models were used to mine the data. The resulting hybrid model for prediction of antisense activity was used to design 39 ASOs to each of 25 target genes. A second set of 39 ASOs was designed using a more traditional approach without use of the
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 123
BASIC PRINCIPLES OF ANTISENSE DRUG DISCOVERY
123
computational models. When activity was measured for these ASOs, the percentage of active ASOs increased slightly when the models were used, but overall, activity profiles were very similar using the two methods. To date, results from computational methods for prediction of antisense activity have been disappointing. Hit rates have not improved enough to substantially reduce the number of ASOs to be screened. The methods have also not resulted in identification of leads with greater potency than those identified by more traditional screens. 5.2.4
Exclusion of ASOs
5.2.4.1 Sequence Motifs Associated with Non-Antisense Activities Although methods to predict active ASOs have met with limited success, methods to exclude ASOs have been successful. Some sequence motifs have been associated with non-antisense-based pharmacology and exclusion of ASOs with these motifs can reduce the likelihood of confusing pharmacological results later during the discovery process. Immunostimulation in rodents or primates can result from treatment with ASOs containing motifs with unmodified CpG [39,40]. More recently, it has been observed that certain pyrimidine-rich motifs were overrepresented in a small set of ASOs that were hepatotoxic in mice (S. Burel and S. Henry, Isis Pharmaceuticals, unpublished results). A thorough definition of the motif is still in progress. It has long been recognized that strings of guanosine can result in nonantisense activity [28,41]. Avoidance of ASOs containing these motifs may help avoid pharmacological results complicated by ASO activity beyond the pharmacological effect of target reduction.
5.2.4.2 Reduction of Nontarget Genes Studies such as those in Figure 5.4 have demonstrated that even a single mismatch can reduce ASO activity and three mismatches essentially obliterate activity in vitro and in vivo. Candidate ASOs are filtered to have more than three mismatches to potential cross-reactive targets. Potential cross-reacting transcripts are identified as described above. Each ASO is compared to each site on this list of cross reactors, and no ASO with three or fewer mismatches is considered for screening. The most common sequence alignment tool, BLAST [4], cannot be used for this process as the smallest window size is seven and it is possible for a 20-mer ASO to bind to a target site with three mismatches and no region of seven pairs in a row. The alignment tool FASTA [42] allows a window size as small as one and could be used for this comparison. The strategy described avoids ASOs that would hybridize to identified “cross reactors.” It would not, however, identify a single mismatched 20-mer site in an otherwise nonhomologous gene. To identify all potential mismatched sites, one would need to test each candidate ASO versus the entire transcripome. At Isis, we have developed a rapid string-searching algorithm optimized for this purpose. Even with our optimized algorithm, that process is too slow for testing tens of thousands of candidates. Thus we postpone the transcriptome search until after the initial in vitro screen, when there are only about 10 candidate ASOs (see Figure 5.9). Another strategy for avoiding cross-reactive oligonucleotides is to avoid repeat features. These are sequences that appear frequently in the genome and ASOs complementary to them are likely to hit several other genes. Simple repeat features can be identified by DUSTMAPPER [43] and complex repeats can be identified using Repeatmasker [44]. 5.2.5
Sequence Variants Due to Polymorphism
In general, it is desirable for a human ASO therapeutic to inhibit all genetic variants of a gene. Thus known sites of polymorphism should be avoided.
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 124
124
5.2.6
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Cross-Species ASOs
The lead antisense compound in one species is often not the lead compound in another species. This can increase the work necessary for development. For example, the human lead must be tested in rats for “chemical” toxicity and the rat lead must be tested in rats for toxic effects of target knockdown. If the human and rat leads were the same compound, the work and cost would be reduced. There is, therefore, incentive to design “cross-species” ASOs. Fortunately, in 2006, extensive genomic sequence is available for human and many organisms used in disease models (e.g., mouse, rat, dog, pig, chimp, rhesus monkey, rabbit). For most genes, sequence can be identified for several species of interest. If homology is sufficient, cross-species ASOs can be designed.
22023-1
(a)
8
6
4
2
Base mismatch
FAS mRNA
(b)
Saline saline
22023
2MM
4MM
6MM
8MM
FAS mRNA (c)
C-raf mRNA levels (% control)
120 4-6 Mismatch
100 80
3 Mismatch
60
2 Mismatch
40 1 Mismatch
20 ISIS 11061
0 0
100
200
300
400
500
600
700
Oligonucleotide concentration (nM) Figure 5.4 Comparison of target reduction in vitro and in vivo for a series of matched and mismatched ASOs. (a) Levels of Fas mRNA in mouse AML cells treated in vitro with a matched or mismatched ASOs. (b) Levels of Fas mRNA in mouse liver after in vivo treatment (40 mg/kg1, 4 times daily, i.p.) with the same ASOs. RNA levels measured using a ribonuclease protection assay. Data from Zhang et al. [56]. (c) Levels of C-raf-kinase mRNA in cells treated with increasing concentrations of Isis 11061 or mismatched ASOs. (d) Levels of C-raf kinase mRNA in livers of mice treated with Isis 11061 or mismatched ASOs (J. Johnston and B. Monia, Isis Pharmaceuticals, unpublished data). (e) Levels of C-raf-kinase mRNA in cells treated with increasing concentrations of Isis 11061(full deoxy) or 15770 (MOE-gapmer). (f) Levels of C-raf kinase mRNA in livers of mice treated with Isis 11061 or 15770.
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 125
BASIC PRINCIPLES OF ANTISENSE DRUG DISCOVERY
125
(d) 140 C-raf mRNA (% control)
120 100 80 60 40 20
at c m
m M
is
is 6
5
4
h
h at c
h M
is M
is M 3
m
at c m
m is M 2
at c
h
h at c
h at c m is M 1
IS IS
11 06 1
Sa lin e
0
Oligonucleotide (e)
Neg control
deoxy/P=S 11061
2′-MOE/P=S 15770
120
C-raf mRNA levels (% control)
100 80 60 40 20 0 100
0
200
300
400
500
600
Oligonucleotide concentration (nM) (f) Saline
ISIS 11061 25 mg/kg
ISIS 15770 25 mg/kg
C-raf
C-raf mRNA (% control)
100 80 50 mg/kg 60 25 mg/kg 10 mg/kg
40 20 0 ISIS 11061
ISIS 15770 Oligonucleotide
Figure 5.4
(Continued )
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 126
126
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Even if cross-species ASOs can be identified, they are frequently concentrated in the CDS or maybe only one region of the CDS. Data in Figures 5.1 and 5.5 combined with results from thousands of screens performed at Isis have demonstrated that lead ASOs can come from anywhere on the transcript. Thus, it may be prudent to screen ASOs from all regions of the transcript even if they are not all cross-species. It is also critical to note that just because an ASO is complementary to two species, it may not be sufficiently active in both species. For example, a lead in mouse may not be a lead in rat, even though it is complementary to rat. The final decision to use a cross-species ASO
(a) 140
120
mRNA (% UTC)
100
80
60
40
20
UTC cont 1 cont 2 1 6 10 15 17 22 24 27 29 32 37 41 45 50 55 71 80 84 86 88 89 90 91 98 99 104 105 112 115 116 121 124 130 135 141 145 148 158 275 287 291 293 296 334 336 355 357 362 367 369 371 intron intron intron intron intron intron
0
Position on mRNA (b) 15 nM
No treatment
44 nM
133 nM
400 nM
140 120
mRNA (% UTC)
100 80 60 40 20 0 22
27
55
287
291
362
Neg.cont. Neg.cont. Neg.cont.
Figure 5.5 (a) Screening data for 57 ASOs to a single gene target in mouse primary hepatocytes. Levels of mRNA are expressed as percent of the untreated control (transfection reagent, no oligo). (b) Confirmatory dose-response data for six of the most active ASOs from the screen.
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 127
BASIC PRINCIPLES OF ANTISENSE DRUG DISCOVERY
127
depends on the cost savings and convenience of having only one ASO for studies in multiple species weighed against any reduced potency of a cross-species lead compared with a species-specific lead. Experience at Isis suggests that if a gene is well enough conserved so that at least a hundred wellseparated cross-species ASOs can be designed throughout the mRNA, cross-species leads can be identified that are nearly as active and as potent as non-cross-species leads. In practice, success rates have been good for identification of lead mouse-rat or human-monkey ASOs; but success rates have been lower for identification of lead ASOs with good activity in both rodents and primates. It is possible to use the same strategy to design ASOs complementary to two genes from related families such as AKT1 and AKT2. The disadvantage of such an approach is that potency versus the two targets is usually not identical; so, at any dose, the degree of target knockdown is not equal. If an isoform-specific ASO is designed for each target, then they can be dosed simultaneously and the degree of target reduction can be controlled independently for each target. 5.2.7
Summary of Considerations for ASO Design
The selection of ASOs for screening is a balance of several factors and, depending on the planned use for an ASO, priority of each factor may change. Typically, however, the primary filter as been to avoid cross-reactive ASOs and those with potential aptameric motifs. The second priority has been cross-species design. The number of cross-species ASOs selected depends on the degree of sequence homology and the importance of cross-species homology to the planned studies for that oligo. The final criterion has been calculated prediction of activity using the hybrid decision tree/neural net model described above. 5.2.8
How Many ASOs to Design and Test?
Figure 5.5a shows screening results for 57 ASOs targeted to a single gene. Although “hit rates” vary by target, these results are quite typical. About one third of the ASOs tested reduced target mRNA below 40% control; 12% reduced it below 25% control; and only 7% reduced it below 20% control. Thus, an “active” ASO that reduced target by 60% or more could likely have been identified by testing three to six ASOs at random from this set. Screening 10 ASOs would have identified, on average, about one compound that reduced target better than 25% control. In this example, screening of 57 candidate ASOs identified four candidates with activity below 20% control. It is clear that screening 57 ASOs identified more candidates and more active candidates than would have been obtained testing only three or ten ASOs. The question becomes, “Was it worth it?” The answer is almost always yes. First, target validation is easier with the most potent and most active ASO. It is usually unknown what degree of target inhibition will be required to produce the desired pharmacology. With a potent, active, dose-responsive ASO, target levels can be “dialed down” as low as necessary to evaluate the pharmacological effect. Second, if one is screening for a human therapeutic, it is advantageous to find the most potent drug because therapeutic doses will be smaller, ultimately improving therapeutic index and reducing manufacturing costs. Screening more oligonucleotides may also offer broader intellectual property protection and will provide the drug development organization with potential backup compounds, should they be needed. In practice, for human development candidates, we have often screened several hundred ASOs to a single target. Rarely, however, has continued screening identified an ASO that was clearly more active than any among the first 200. There are also economies of scale when more compounds are tested. Eighteen control samples, including 13 untreated controls, are run on each screening plate, regardless of the number of test compounds. Development of a screening assay often costs about as much as synthesis and testing of 50–75 ASOs. With these relatively high fixed costs, the incremental cost of screening more compounds is small. We have found robotic sample handlers to be efficient and effective for ASO
CRC_8796_ch005.qxd
5/24/2007
11:37
128
Page 128
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
synthesis and sample handling, processing, and analysis, supporting the use of microtiter plates for these processes. The combination of economy of scale, the efficiency of using microtiter plates and robotic sample handling, and the desire for at least a few very active ASO inhibitors has led us to typically screen 78 candidate ASOs for one target or 37 ASOs for each of two targets on a single 96-well plate. This screening strategy has typically resulted in two to eight lead compounds for subsequent evaluation.
5.3 PRIMARY SCREEN FOR ACTIVE ASOs Although algorithms for ASO design can improve screening hit rates to some extent and help avoid oligonucleotides with undesirable properties that may show up later in the discovery process, it is still necessary and cost-effective to synthesize candidate ASOs and screen them for antisense activity before evaluating pharmacological effects of ASO treatment. The efficiency and efficacy of the entire antisense drug discovery process depends on the efficiency and efficacy of the initial process of lead identification. In this section, we will discuss options for initial ASO screening and include technical advice to improve reliability of screening results. 5.3.1
Activity Assay
As is the case for most screening exercises, the selection of an assay that is easy to perform and gives accurate results for ASO activity is critical. Assay development and validation can require more resources than the ASO screen itself but investment in a reliable screening assay is always worthwhile. Initial screens of ASOs have usually been performed in cell culture in vitro. If screening data are to be useful, they must be robust and reproducible. There should be good correlation between activity in the screening assay and activity in subsequent experiments. The ideal screen should avoid both false negative and false positive leads. One important criterion for the screening endpoint is that it should directly measure the molecular target of the ASO. If downstream events are followed, both false positive and false negative results can be obtained. If a pharmacological endpoint is used, slow kinetics can result in a false negative. Typically, ASO treatment results in reduction of mRNA levels, which in turn results in reduction of target protein levels followed by changes along a signaling pathway that ultimately results in a pharmacological phenotype. Depending on protein half-life and kinetics of downstream processes, it can be several days between ASO treatment and the pharmacological endpoint. For example, Dean et al. [45] reported that treatment of A549 cells with an anti-PKC ASO resulted in near-maximal reduction of mRNA as early as 4 h after treatment. After 48 h, mRNA levels began to recover, probably due to cell division and resulting dilution of ASO. A second ASO treatment at 48 h was required to maintain mRNA knockdown until 72 h, at which time protein reduction and pharmacalogical effects of pharbol 12-mystirate 13-acetate (PMA) stimulation on ICAM1 mRNA were observed. In another report, effects of ASO treatment on adipocyte differentiation were not observed until 10 days in cell culture [46]. If assays such as these were used for screening and the treatment regimen and time allowed were not sufficient for the pharmacological endpoint to be observed, an active ASO would appear as a false-negative. Pharmacological assays can also result in false-positives. Non-hybridization-based pharmacological effects of ASOs have been reported [28,41,47]. Often, these effects are observed in the absence of target RNA reduction. Thus, if reduction of the target RNA were used as the primary endpoint, these false-positives would not be reported. Oligonucleotides with robust activities that do not work via an antisense mechanism can become useful therapeutics [39,48,49]. In this chapter, however, we will treat oligonucleotides with non-antisense activities as undesirable false-positives.
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 129
BASIC PRINCIPLES OF ANTISENSE DRUG DISCOVERY
129
5.3.1.1 Kinetic RT-PCR For ASOs that support RNase H, the primary event is cleavage of the pre-mRNA or mRNA at the ASO binding site. Cleavage is usually followed by rapid degradation of the RNA. The earliest measurable effect is disappearance of the mRNA and measurement of mRNA loss is the assay of choice. Although there are many quantitative assays for mRNA, we have found real-time reverse transcriptase polymerase chain reaction (RT-PCR) to have several advantages. First, it is sensitive. Typically, cells are treated with ASO in a 96-well plate from which 50–200 ng of total RNA can be recovered. For most target mRNAs, as little as 10–20 ng of total RNA will give a strong real-time RT-PCR signal. Thus, multiple measurements can be made from a single treatment well. Second, RT-PCR assays for new targets are relatively easy to design; all that is needed is mRNA sequence. Much has been written about the design of primers and probes for real-time RT-PCR and we will not repeat that here. We will, however, mention a few guidelines that have increased our success rates. These guidelines are most important for genes that are very weakly expressed because they help avoid a false signal from nontarget genes. ●
●
●
As much as possible, use an amplicon that crosses an exon–exon junction. This will prevent the signal from contaminating DNA or pre-mRNA. Avoid all repeat motifs. This can be easily done by using Repeatmasker before design of the primer probes [44]. Identify related transcripts in the same gene “family” (e.g., JNK1, JNK2, and JNK3 or proteins with zinc-finger domains). Mask out any regions in the target mRNA that have even weak homology to these potential cross reactors.
Additional advantages of kinetic RT-PCR for mRNA quantitation are reviewed by Bustin [50]. This review addresses many of the issues to be considered when developing a real-time RT-PCR assay for ASO screening, including options for fluorescent probes and issues such as one-step versus twostep RT-PCR, standard curves, and normalization. One drawback of PCR for ASO screening is that it measures levels of intact amplicon RNA only. Thus, if RNA cleavage occurs at the ASO binding site but cleavage products are long lived, then the RT-PCR signal would not detect cleavage outside the amplicon and false-negatives could result. It is tempting, therefore, to design RT-PCR probes to span the ASO binding site. This, however, can result in false-positive results. ASOs complementary to the amplicon of the RT-PCR reaction have been found to inhibit the RT-PCR signal (S. Davis, Isis Pharmaceuticals, unpublished results). The presumed mechanism of inhibition is the binding of the ASO to the primers, probe, RNA, or amplification products, resulting in reduced amplification. Although RNA purification methods remove most of the ASO from a treated sample, we have encountered examples where enough ASO was carried over into the RNA such that RT-PCR was inhibited. Figure 5.6a shows the effect of five different ASOs on mRNA levels after treatment in cultured cells. Two different real-time RT-PCR primer-probe sets were used to measure mRNA levels. ASOs 1–3 did not overlap the amplicon of either primer set and measured mRNA levels were similar for both sets. In contrast, each of the other two ASOs overlapped the amplicon of one of the primer sets. For both these ASOs, the signal from the amplicon overlapping the ASO was reduced compared with that from the amplicon away from the ASO, consistent with the observation that ASO “carry-over” can inhibit RT-PCR when the ASO is within the PCR amplicon. Figure 5.6b shows results of a screen in which two of the ASOs overlapped the amplicon completely and two others partially overlapped the amplicon. The two ASOs contained within the amplicon appeared more active than any others in the screen. Screening data with active “amplicon oligos” needs to be confirmed using a PP-set away from the ASO binding site. Although uncommon, ASOs that cleave target RNA and result in stable products have been observed [51]. Depending on placement of the RT-PCR probes, such ASOs could result in falsenegatives. The best way to avoid these false-negatives is to use a Northern blot assay with a full length cDNA probe so that all products can be detected and their lengths measured.
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 130
130
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION (a)
PP set A
PP set B
140 1
mRNA (% control)
120
2
3
4
5
Amplicon set B
100
Amplicon set A mRNA
80 60 40 20 0 UTC
1
2
3
4
5
(b)
140
mRNA (% control)
120 100 80
Amplicon 232
312
60 40 20 UTC UTC neg cont 1 neg cont 2 78 90 99 100 110 135 146 185 214 265 270 310 334 339 380 465 511 516 525 605 620 713 814 840 848 1125 1133 1200 1219 1260 1284 1300 1320 1351 1369 1388
0
ASO position on mRNA
Figure 5.6
Demonstration of “amplicon effect”. (a) Human HepG2 cells were transfected with five ASOs complementary to different regions of a target mRNA. RNA was isolated and analyzed by TAQ-man RT-PCR using two different primer-probe sets. Positions of the ASOs and the primer-probes are shown in the inset. (b) Human A549 cells were transfected with ASOs complementary to different regions of a target mRNA. The two ASOs that completely overlap the PCR amplicon are highlighted.
5.3.1.2 Activity Assays Other Than Kinetic RT-PCR Screening of ASOs that do not result directly in cleavage of target RNA requires a screening assay other than quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). If the primary event is inhibition of translation, then a protein assay is required. An assay for protein activity can be used but can be susceptible to direct inhibition of protein activity by an oligonucleotide [41]. If the mechanism of action is redirection of splicing, variant-specific RT-PCR can be used [52]. Northern blots and ribonucleoase protection assays can be used to measure loss of mRNA but usually require more RNA and are lower throughput than RT-PCR. Other hybridizationbased assays for mRNA that do not rely on target amplification such as b-DNA probes have also been used successfully for evaluation of mRNA target reduction by ASOs [53].
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 131
BASIC PRINCIPLES OF ANTISENSE DRUG DISCOVERY
131
Finally, one can design a reporter assay with a simple readout such as luciferase activity. The disadvantage of such an assay is that it is indirect and thus subject to false-positive and false-negative results as discussed above for indirect assays. In addition, if the target RNA is expressed as part of the reporter system, it is not the natural target and accessibility of target sites to ASOs may not mimic the endogenous target.
5.3.1.3 Other Considerations for Choice of Screening Assay In addition to the choice of assay for RNA, there are other decisions to be made when designing a screening assay. Criteria for selection of cell lines are straightforward; the cell line must express the target at a quantitatively reproducible level and it should be possible for the cells to be transfected with oligonucleotide. There are no data indicating any advantage of selecting a cell line related to the ultimate target cell in vivo. Activity profiles appear to be independent of cell line as long as the same transcript is expressed in both lines. Precision of the screening data is more important than the tissue source of the cell line. When no cell line can be found that expresses the target of interest, a few options are still available. The first is primary cells. Primary cells such as hepatocytes, endothelial cells, neurons, and adipocytes have been used successfully to screen for active ASOs [54]. A second possibility is to clone the transcript and screen in transiently or stably transfected cells. Figure 5.7(a) shows a screen of ASOs targeting a message expressed off a cDNA clone transiently transfected into COS-7 cells. The most obvious features of this screen are the lack of strong inhibition by any ASO and the relatively high variability observed for the less active ASOs. The relatively poor activity is partly due to the relatively high level of plasmid DNA in these transfected cells compared to expressed mRNA levels. Despite pretreatment of the RNA with DNase, there was sufficient plasmid DNA in the screening samples to result in a high background signal. Inhibition of an endogenous target using a monkey positive control also suggested that ASO transfection efficiency was not optimal. Despite the noisy screen, retest of the most active nonamplicon ASOs (marked with arrows in Figure 5.7a) demonstrated clear, reproducible, dose-responsive activity of the leads (Figure 5.7b). Assays using stable transfectants have typically resulted in greater activity and more reproducible results (Figure 5.7c). The most plausible explanation for this observation is that integration of the cDNA into the host genome reduced the amount of DNA background in the RNA fraction. Although both transiently and stably transfected expression vectors have been successfully used to screen for active antisense inhibitors, one must consider the fact the primary transcript is mRNA, often with shortened UTR sequence, and is thus a different target than the endogenous pre-mRNA. Limited data available on the correlation of ASO activity between endogenous target and cDNA target suggest that leads identified using cloned cDNAs can provide ASOs that are active in vivo [55]. This correlation, however, would be expected to vary on a target-by-target basis. A third option for targets that cannot be screened in cell culture is to screen directly in vivo. If the target is expressed in a tissue where an ASO is known to distribute and be active, a screen of 10–20 ASOs in vivo can find compounds with good activity. Figure 5.8 shows data for 21 ASOs targeting a single mRNA in mouse kidney. Four active ASOs were easily identified. In vivo screening is costly and slow, so fewer compounds can be tested but it may be the best option for high-value targets that cannot be screened in cells. As mentioned above, cells lines for in vitro screens must be reproducibly transfectable with ASOs. For many cultured cells, commercially available cationic lipid preparations can be used to transfect oligonucleotides. Transfection conditions should, however, be optimized for each cell line and ASO chemistry. Transfection conditions reported to be effective for plasmids may not work for oligonucleotides. Transfection of fluorescently labeled oligonucleotides can result in fluorescent cells but those conditions have not always resulted in ASO activity. To assess ASO transfection, it is essential to observe target knockdown using a positive-control ASO targeting a gene expressed in the selected cell line. PTEN is a broadly expressed target and ISIS 116847 has been shown to effectively
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 132
132
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
(a)
CDS Amplicon
211
516
140
1299
605
120
mRNA (% control)l
100
80
60
40
0
12 31 92 189 236 326 350 361 367 382 389 395 415 435 442 449 463 471 521 545 551 569 575 580 604 619 626 635 640 677 683 698 708 717 722 750 757 775 784 794 828 853 883 935 941 946 951 985 993 1027 1032 1040 1060 1080 1085 1103 1119 1203 1211 1217 1247 1254 1259 1265 1270 1278 1288 1341 1367 1402 1430 1449
20
ISIS # (b) No treatment 13 nM
40 nM 120 nM
140
120
mRNA (% control)
100
80
60
40
20
0
ASO 442 Figure 5.7
Control ASO
Screening data for ASOs targeting an mRNA expression vector. (a) Antisense activity for ASOs complementary to a cDNA expression vector transiently transfected into COS-7 cells. Only ASOs within the CDS were complementary to the expressed mRNA. (b) Dose-response curve for the most active compound from panel a. (c) Screen of ASOs to a different cDNA target expressed in stably transfected CHO cells.
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 133
BASIC PRINCIPLES OF ANTISENSE DRUG DISCOVERY (c)
133
Amplicon 428
503
140
120
mRNA (% control)
100
80
60
40
0
UTC neg cont neg cont 28 40 50 71 84 116 141 191 217 227 280 303 352 379 403 421 433 441 461 468 493 520 534 551 564 570 586 591 598 614 630 637 642 648 662 667 674 755 857 878 890 923 928 936 942 954 964 978 984 989 1037 1043 1050 1078 1087 1193 1205 1219 1253 1259 1273 1279 1284 1292 1298 1335 1342 1353 1364 1373 1379 1404 1418 1456 1474 1527 1575
20
Pos on cDNA
mRNA (% saline control)
Figure 5.7
(Continued )
140
Amplicon
120
1487 1587
100 80 60 40 20
Figure 5.8
1676
1520
1205
1133
1107
1066
977
949
712
604
541
503
449
410
293
263
211
147
92
110
59
saline
0 Pos on mRNA
In vivo screening of 21 ASOs. Mice were dosed twice weekly for two weeks. Kidney RNA was harvested 24 h after the last dose.
inhibit PTEN in primate and rodent cells. Thus, it is a useful control for optimization of transfection conditions. For lipid transfection, conditions that should be optimized are the composition of the lipid cocktail, concentration of lipid, and ratio of lipid concentration to ASO concentration. Cell density and culture medium also affect transfection efficiency. When optimizing transfection conditions, one optimizes for the greatest potency and activity without nonspecific activity or toxicity. Nonspecific activity can be monitored using nontarget ASOs. Total RNA can be measured using Ribogreen RNA quantitation reagent. A significant and dose-responsive decrease in the ribogreen
CRC_8796_ch005.qxd
5/24/2007
134
11:37
Page 134
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
signal is typically correlated with cytotoxicity and suggests that the transfection conditions are too harsh and may result in nonantisense effects of the ASOs. Electroporation provides an alternative to lipid transfection agents. Optimization is even more important for electroporation because the window between effective transfection conditions and cell death can be small. The most important parameters to be varied have been voltage and ASO concentration. Less frequently, optimization of cell volume and path length has further improved transfection efficiency.
5.3.1.4 Positive and Negative Controls for Screening Assays Three kinds of controls are important for an ASO screen. The first is untreated control (UTC) samples. These are cells treated with culture medium, transfection reagent, and no oligonucleotide. Levels of mRNA for all ASO treated samples are normalized to UTC. Thus, more UTC samples will reduce the standard error for all data points. Pooled UTC RNA is also used to prepare the standard curve for RT-PCR. Pooling wells ensures that the sample is representative and the use of UTC samples rather than RNA prepared in a separate experiment ensures that the amplification per cycle will be as identical as possible between standards and test samples. The second type of control is a negative-control oligonucleotide of the same chemistry. Seventy-eight ASOs are typically screened in each experiment; so it is unreasonable to include mismatched or scrambled controls for each test oligonucleotide at this stage. We usually include two ASOs complementary to no target as negative controls in every experiment and usually observe no significant target reduction compared with untreated controls. Finally, a positive-control ASO should be included. This should be an ASO such as ISIS 116847 that has been reproducibly active against its PTEN target in all cell lines. The positive-control ASO provides confirmation of adequate transfection and provides an estimate of the amount of target reduction expected from an active ASO in this particular experiment.
5.4 FOLLOW-UP ASSAYS 5.4.1
In Vitro
Once leads have been identified in the screening assay, follow-up assays should be performed. The purpose of these assays is to compare the leads for activity and potency in multiple assays and to identify, as quickly as possible, any false-positive ASOs that passed through the screen. First, the screening assay should be repeated on the most active compounds over a range of concentrations to determine relative potency and efficacy of the lead candidates. Figure 5.5b shows a repeat doseresponse experiment for six of the most active compounds from Figure 5.5a. This experiment helps distinguish small differences in potency and efficacy between the most active compounds from the initial screen. Additional assays of mRNA target reduction can also be employed. These include northern blots, ribonucleoase protection assays, RT-PCR with alternate primer sets, and alternate detection probes. The purpose of these alternate mRNA assays is to confirm that the reduction in the RT-PCR signal observed with the primary assay is truly representing a reduction in cellular mRNA. This second RNA assay is particularly important if one of the leads lies within the amplicon of the initial primer set (see above). Although apparent activity of an “amplicon ASO” can be artifactual, frequently the activity has been reproduced using a northern blot or a primer set away from the ASO binding site, indicating that the result was not an artifact. Another possible follow-up assay is to repeat the in vitro dose response in an additional cell line. If the primary transcript differed between cell lines, it would be possible for an ASO to be active in one cell line but not another. For example, different sites of initiation of transcription would result in a region of pre-mRNA being transcribed in one cell line but not another and ASOs to that region being active on one cell line but not another. This scenario has been avoided by using expression
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 135
BASIC PRINCIPLES OF ANTISENSE DRUG DISCOVERY
135
databases such as dbEST to identify alternative sites for transcription initiation and termination and, if ASOs are targeted to these regions, to use transcript-specific probes to measure the effect on each transcript. In practice, the only time we have found ASO activity not to reproduce between cell lines was when transfection was ineffective in the second cell line. This was immediately recognized by lack of activity with the positive-control ASO. Inhibition of protein also provides confirmation that the ASO is reducing the target of choice. As mentioned above, the major concern when assaying for protein reduction is to make sure that enough time has elapsed between ASO treatment and protein assay for preexisting protein to decay. It is not necessary to perform all the secondary in vitro assays described. They provide confirmation of antisense activity and multiple comparisons of the most active oligonucleotides to ensure that the most active and potent are carried to the next step. Depending on cost and resources, it may be prudent to postpone or omit some of the in vitro follow-up assays and move rapidly to in vivo confirmation. 5.4.2
In Vivo
For nonhuman targets, the final step in lead identification usually is screening for target reduction in vivo. In general, we have compared the top four ASOs identified in the in vitro dose-response experiment in an in vivo study at a single dose with reduction of target RNA as the primary endpoint. Secondary endpoints such as serum levels of transaminases, creatinine, urea, body weight, and organ weight were used to identify ASOs with non-target-related toxicity. Often, the top two compounds have been repeated in dose response in vivo before initiation of pharmacological assays. Identification of two leads that reduce target in vivo allowed pharmacological results to be confirmed with a second compound that effectively reduced the target gene.
5.5 COMPARISON OF IN VITRO ACTIVITY TO IN VIVO ACTIVITY Figure 5.9 summarizes the process described above. One begins with a list of all possible ASOs to an RNA transcript and ends with about two ASOs to be used in pharmacology models in vivo. If the ASO will be used only for in vitro functional genomics, the last two steps are, of course, unnecessary. The top two to four ASOs from the in vitro confirmation and dose response can be used to test pharmacology in vitro. However, if one is screening for a human antisense therapeutic or doing functional genomics in a model organism, the critical point in this flow scheme is the transition from in vitro to in vivo. If this process is to be effective, the best ASOs from the cellular screens must be the best ASOs in vivo. Years of experience of in vitro screening followed by testing in vivo has provided substantial evidence that relative efficacy and potency measured in vitro correlates reasonably well with efficacy and potency in vivo. There are two lines of evidence to support this correlation. Affinity of an ASO for its RNA target can be reduced in a systematic and controlled fashion by introducing mismatches between the ASO and the target. Table 5.1 shows Isis 22023 and a series of mismatched ASOs for mouse Fas. Figure 5.4 reports the effect of these ASOs on FAS expression in tissue culture (Figure 5.4a) and in mouse liver (Figure 5.4b). Activities of the ASOs were similar in vitro and in vivo [56]. Table 5.1 also describes Isis 11061, which targets mouse C-raf kinase and a series of ASOs with 1–6 mismatches to the target. Figure 5.4c presents in vitro data for these ASOs, measuring inhibitions of mRNA levels as a function of oligonucleotide concentration. ASO potency clearly decreased with increasing number of mismatches. When these same ASOs were tested for target reduction in mouse liver, the same relative activity was observed (Figure 5.4d). ASO affinity can also be increased by incorporation of high-affinity sugar modifications into the sequence. Figure 5.4e demonstrates the increase in potency of 11061 in vitro when the five residues in each “wing” were modified with high-affinity 2⬘–O–methoxyethyl sugars. The same increase in activity was observed in vivo (Figure 5.4f).
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 136
136
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Generate all ASOs complementary to pre-mRNA and variant mRNAs
~10,000
Evaluate in silico
~100
Screen in vitro
~10
Confirm in vitro with alternate endpoints and dose response ~4 Screen in vivo at a single dose
~2
Dose response ~2 in vivo
Pharmacology in vivo
Figure 5.9 Flow scheme for selection of leads ASOs for any gene target. All possible ASOs to the unprocessed RNA are generated and filtered in silico to generate a set of about 100 oligonucleotides for synthesis. A primary screen of these 100 oligonucleotides in cells reduces the number of leads about 10-fold. Further cellular assays allow ranking of the screening leads and selection of a few ASOs for evaluation in a screen in vivo followed by a dose-response experiment in vivo. The end result is typically two ASOs with good activity and potency in vivo for use in pharmacology assays.
Table 5.1 ASOs to Fas and c-RAF Kinase and Mismatched ASOs. All ASOs to FAS Were 2⬘⬘ MOE Chimeras. ASOs to c-RAF Were Oligodeoxynucleotides, Except ISIS 15570 Which Was a 2⬘⬘ MOE Chimera. Isis #
Sequence
Mismatches
Target
TM(°C)
22023 29834 29835 29836 29837 11061 13490 13491 13492 13493 13494 13495 15770
TCCAG CACTTTCTTT TCCGG TCCAG CACCTTTTTT TCCGG TCCAG CTCCTTTTAT TCCGG TCCAT CTCCTTTTAT GCCGG TCGAT CTCCTTTTAT GCCCG ATGCATTCTGCCCCCAAGGA ATGCATTCTCCCCCCAAGGA ATGCATTCTCGCCCCAAGGA ATGCATTCCCGCCCCAAGGA ATGCATTCCCGTCCCAAGGA ATGCATTACCGTCCCAAGGA ATGCATTACCGTACCAAGGA ATGCA TTCTGCCCCC AAGGA
0 2 4 6 8 0 1 2 3 4 5 6 0
Fas Fas Fas Fas Fas C-raf C-raf C-raf C-raf C-raf C-raf C-raf C-raf
ND ND ND ND ND 60.5 45.8 42.2 33.8 25.0 – – –
A second line of evidence supporting the correlation between activity in vitro and activity in vivo comes from an unpublished study by N. Dean and colleagues at Isis. They compared rankorder potency in vitro and rank-order efficacy in vivo for a series of 44 ASOs to 13 targets expressed in mouse liver. For each of these targets, in vitro screening was performed as described above. In vitro activity was confirmed by repeating the screening assay at several doses for the most active
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 137
BASIC PRINCIPLES OF ANTISENSE DRUG DISCOVERY
137
ASOs. In each case, 3–4 ASOs from the in vitro study were tested in vivo for their ability to reduce target mRNA in mouse liver. Using a Pearson’s product-moment correlation test, the correlation coefficient between in vitro and in vivo was 0.61 with p ⬍ 0.0001 for a highly significant positive correlation between the activity of the ASO in vivo compared to potency in vitro. In every case (13 genes), if both the rank 1 and rank 2 ASO (in vitro) were evaluated in vivo, at least one of these gave target down-regulation in liver more than 50%. None of the rank 1 or rank 2 ASOs were inactive in vivo (⬍25% reduction). Four examples of this correlation are shown in Figure 5.10. ASOs with good potency in vitro demonstrated good efficacy in vivo. The four targets in Figure 5.10 and the other nine targets used for the correlation study described above were selected because the target was expressed primarily in liver hepatocytes and ASO
In vitro
In vivo Target mRNA (% control)
120 100 80 60 40
A Rank 3
5 10 25 50 100 200
5 10 25 50 100 200
0
5 10 25 50 100 200
20
No oligo
Target mRNA (% control)
Target 1
B Rank 1
120 100 80 60 40 20 0 Saline
C Rank 2
A Rank 3
B Rank 1
C Rank 2
Target mRNA (% control)
120 100 80 60 40
10 25 50 100 200
10 25 50 100 200
10 25 50 100 200
0
10 25 50 100 200
20 No oligo
Target mRNA (% control)
Target 2
D Rank 3
E Rank 1
F Rank 2
G Rank 4
120 100 80 60 40 20 0
Saline
D Rank 2
E Rank 1
F Rank 3
G Rank 4
Saline
H Rank 1
I Rank 4
J Rank 3
K Rank 2
5 10 25 50 100 200
5 10 25 50 100 200
5 10 25 50 100 200
5 10 25 50 100 200
Target mRNA (% control)
180 160 140 120 100 80 60 40 20 0 No oligo
Target mRNA (% control)
Target 3
H Rank 1
I Rank 4
J Rank 3
K Rank 2
150
100
50
0
120
Target mRNA (% control)
Target mRNA (% control)
Target 4 100 80 60 40 20 0
0
5
10 25 50 L Rank 2
5
10 25 50 M Rank 3
5
10 25 50 N Rank 1
120 100 80 60 40 20 0
Saline
L Rank 2
M Rank 1
N Rank 3
Figure 5.10 Comparison of in vitro potency to in vivo activity for ASOs to four targets. The most potent ASOs from the in vitro assay were tested in vivo for target reduction in mouse liver.
CRC_8796_ch005.qxd
138
5/24/2007
11:37
Page 138
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
distribution to hepatocytes is high. In this case where target expression was the highest in cell types to which ASO distributes, the correlation between in vitro and in vivo was excellent. The correlation between good activity in vitro and in vivo can be less good where other tissues and cell types are considered. There are some tissues and cell types where standard unformulated ASOs distribute poorly. For targets expressed in those cell types in those tissues, in vivo activity will be poor regardless of in vitro activity. When an ASO has shown good potency in vitro and does not demonstrate good efficacy in vivo, we have usually been able to explain the result by multiple cell types in the target tissue and differential expression and differential ASO distribution to the multiple cell types. For example, ASO activity is better in hepatocytes than in nonparenchymal cells. If a liver target is expressed at higher levels in nonparenchymal cells compared to parenchymal cells, an ASO that shows good activity in primary hepatocytes in vitro would appear less active in vivo because the bulk of the target is in a cell type where ASOs are less active. Another explanation for in vitro results not correlating with in vivo results is the proinflammatory effects of the oligonucleotide. As discussed elsewhere in this volume, some oligonucleotide sequences can produce profound proinflammatory effects including cell infiltrates and induction of a target gene. In some cases, the antisense effects in a tissue can be masked by an infux of inflammatory cells that express the target gene at higher levels than normal parenchymal cells. Alternatively, the proinflammatory effect of the oligonucleotide could lead to induction of the target gene in parenchymal cells, attenuating specific antisense effects. 5.6 SUMMARY The process described above for antisense lead identification is designed to move from a large number of candidates to the most active and potent compounds as quickly and efficiently as possible. It is designed to find the best compounds and avoid any with activity other than direct reduction of the intended target. Figure 5.9 illustrates the process by which tens of thousands of candidate ASOs are filtered down to two compounds for evaluation in pharmacology models. With robotic synthesis and sample handling, the time required for the in vitro portion of this process can be as short as a week, although 3–4 weeks has been more common. Scale-up synthesis and in vivo testing requires another 4–10 weeks. The bottom line is that one can select a target and have two specific inhibitors with confirmed in vivo activity within a few months. Not only is the process fast, but also the success rate has been high. Some targets have taken longer due to some of the technical issues discussed above but, in the end, active compounds have been identified to almost every target attempted. The success of this approach can be attributed to the universality of the principles of antisense, coupled with lessons learned over the past 15–20 years of antisense research. REFERENCES 1. M. L. Stephenson and P. C. Zamecnik; Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide; Proceedings of the National Academy of Science USA; 75; 285–258; 1978. 2. K. V. Prasanth, S. G. Prasanth, Z. Xuan, S. Hearn, S. M. Freier, C. F. Bennett, M. Q. Zhang, and D. L. Spector; Regulating gene expression through RNA nuclear retention; Cell; 123; 249–263; 2005. 3. B. A. Zinker, C. M. Rondinone, J. M. Trevillyan, R. J. Gum, J. E. Clampit, J. F. Waring, N. Xie, D. Wilcox, P. Jacobson, L. Frost, P. E. Kroeger, R. M. Reilly, S. Koterski, T. J. Opgenorth, R. G. Ulrich, S. Crosby, M. Butler, S. F. Murray, R. A. McKay, S. Bhanot, B. P. Monia, and M. R. Jirousek; PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice; Proceedings of the National Academy of Science USA; 99; 11,357–11,362; 2002. 4. S. F. Altschul, W. Gish, W. Miller, E. W. Myers, and D. J. Lipman; Basic local alignment search tool; J. Mol. Biol.; 215; 403–410; 1990.
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 139
BASIC PRINCIPLES OF ANTISENSE DRUG DISCOVERY
139
5. M. Lutzelberger and J. Kjems; Strategies to identify potential therapeutic target sites in RNA; in: Handbook of Experimental Pharmacology; V. A. Erdmann, J. Brosius, and J. Barciszewski, Eds; Vol. 173; Springer, Berlin, 2006; pp. 243–259. 6. T. A. Vickers, S. Koo, C. F. Bennett, S. T. Crooke, N. M. Dean, and B. F. Baker; Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis; J. Biol. Chem.; 278; 7108–7118; 2003. 7. D. H. Mathews, M. E. Burkard, S. M. Freier, J. R. Wyatt, and D. H. Turner; Predicting oligonucleotide affinity to nucleic acid targets; RNA; 5; 1458–1469; 1999. 8. P. Arrigo, G. Ivaldi, and P. P. Cardo; In silico determination of potential antisense targets for human beta-globin variants; In Silico Biol.; 2; 143–150; 2002. 9. X. Bo, S. Lou, D. Sun, W. Shu, J. Yang, and S. Wang; Selection of antisense oligonucleotides based on multiple predicted target mRNA structures; BMC Bioinformatics; 7; 122; 2006. 10. X. Bo and S. Wang; TargetFinder: a software for antisense oligonucleotide target site selection based on MAST and secondary structures of target mRNA; Bioinformatics; 21; 1401–1402; 2005. 11. A. M. Chalk and E. L. Sonnhammer; Computational antisense oligo prediction with a neural network model; Bioinformatics; 18; 1567–1575; 2002. 12. R. K. Far, J. Leppert, K. Frank, and G. Sczakiel; Technical improvements in the computational target search for antisense oligonucleotides; Oligonucleotides; 15; 223–233; 2005. 13. M. C. Giddings, A. A. Shah, S. Freier, J. F. Atkins, R. F. Gesteland, and O. V. Matveeva; Artificial neural network prediction of antisense oligodeoxynucleotide activity; Nucleic Acids Res.; 30; 4295–4304; 2002. 14. O. V. Matveeva, D. H. Mathews, A. D. Tsodikov, S. A. Shabalina, R. F. Gesteland, J. F. Atkins, and S. M. Freier; Thermodynamic criteria for high hit rate antisense oligonucleotide design; Nucleic Acids Res.; 31; 4989–4994; 2003. 15. V. Patzel, U. Steidl, R. Kronenwett, R. Haas, and G. Sczakiel; A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability; Nucleic Acids Res.; 27; 4328–4334; 1999. 16. M. Scherr, J. J. Rossi, G. Sczakiel, and V. Patzel; RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts; Nucleic Acids Res.; 28; 2455–2461; 2000. 17. G. Sczakiel; Theoretical and experimental approaches to design effective antisense oligonucleotides; Front. Biosci.; 5; D194–201; 2000. 18. S. A. Shabalina, A. N. Spiridonov, and A. Y. Ogurtsov; Computational models with thermodynamic and composition features improve siRNA design; BMC Bioinformatics; 7; 65; 2006. 19. R. A. Stull, L. A. Taylor, and F. C. Szoka, Jr.; Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices; Nucleic Acids Res.; 20; 3501–3508; 1992. 20. N. Toschi; Influence of mRNA self-structure on hybridization: computational tools for antisense sequence selection; Methods; 22; 261–269; 2000. 21. E. Kierzek, D. H. Mathews, A. Ciesielska, D. H. Turner, and R. Kierzek; Nearest neighbor parameters for Watson-Crick complementary heteroduplexes formed between 2⬘-O-methyl RNA and RNA oligonucleotides; Nucleic Acids Res.; 34; 3609–3614; 2006. 22. D. H. Mathews; Revolutions in RNA secondary structure prediction; J. Mol. Biol.; 359; 526–532; 2006. 23. D. H. Mathews and D. H. Turner; Prediction of RNA secondary structure by free energy minimization; Curr. Opin. Struct. Biol.; 16; 270–278; 2006. 24. T. A. Vickers, J. R. Wyatt, and S. M. Freier; Effects of RNA secondary structure on cellular antisense activity; Nucleic Acids Res.; 28; 1340–1347; 2000. 25. G. C. Tu, Q. N. Cao, F. Zhou, and Y. Israel; Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design; J. Biol. Chem.; 273; 25,125–25,131; 1998. 26. O. V. Matveeva, A. D. Tsodikov, M. Giddings, S. M. Freier, J. R. Wyatt, A. N. Spiridonov, S. A. Shabalina, R. F. Gesteland, and J. F. Atkins; Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity; Nucleic Acids Res.; 28; 2862–2865; 2000. 27. R. Bakalova, Z. Zhelev, H. Ohba, and Y. Baba; Quantum dot-conjugated hybridization probes for preliminary screening of siRNA sequences; J. Am. Chem. Soc.; 127; 11,328–11,335; 2005. 28. D. J. Ecker, T. A. Vickers, R. Hanecak, V. Driver, and K. Anderson; Rational screening of oligonucleotide combinatorial libraries for drug discovery; Nucleic Acids Res.; 21; 1853–1856; 1993.
CRC_8796_ch005.qxd
140
5/24/2007
11:37
Page 140
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
29. S. P. Ho, Y. Bao, T. Lesher, R. Malhotra, L. Y. Ma, S. J. Fluharty, and R. R. Sakai; Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries; Nat. Biotechnol.; 16; 59–63; 1998. 30. S. P. Ho, D. H. Britton, Y. Bao, and M. S. Scully; RNA mapping: selection of potent oligonucleotide sequences for antisense experiments; Methods Enzymol.; 314; 168–83; 2000. 31. O. Matveeva, B. Felden, A. Tsodikov, J. Johnston, B. P. Monia, J. F. Atkins, R. F. Gesteland, and S. M. Freier; Prediction of antisense oligonucleotide efficacy by in vitro methods; Nat. Biotechnol.; 16; 1374–1375; 1998. 32. M. Ooms, K. Verhoef, E. Southern, H. Huthoff, and B. Berkhout; Probing alternative foldings of the HIV-1 leader RNA by antisense oligonucleotide scanning arrays; Nucleic Acids Res.; 32; 819–827; 2004. 33. M. Sohail, G. Doran, S. Kang, S. Akhtar, and E. M. Southern; Structural rearrangements in RNA on the binding of an antisense oligonucleotide: implications for the study of intra-molecular RNA interactions and the design of cooperatively acting antisense reagents with enhanced efficacy; J. Drug Target; 13; 61–70; 2005. 34. M. Sohail, H. Hochegger, A. Klotzbucher, R. L. Guellec, T. Hunt, and E. M. Southern; Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo; Nucleic Acids Res.; 29; 2041–2051; 2001. 35. S. P. Walton, G. N. Stephanopoulos, M. L. Yarmush, and C. M. Roth; Thermodynamic and kinetic characterization of antisense oligodeoxynucleotide binding to a structured mRNA; Biophys. J.; 82; 366–377; 2002. 36. S. Duan, D. H. Mathews, and D. H. Turner; Interpreting oligonucleotide microarray data to determine RNA secondary structure: application to the 3⬘ end of Bombyx mori R2 RNA; Biochemistry; 45; 9819–9832; 2006. 37. W. F. Lima, V. Brown-Driver, M. Fox, R. Hanecak, and T. W. Bruice; Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity; J. Biol. Chem.; 272; 626–638; 1997. 38. O. Matveeva, B. Felden, S. Audlin, R. F. Gesteland, and J. F. Atkins; A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures; Nucleic Acids Res.; 25; 5010–5016; 1997. 39. A. M. Krieg; Therapeutic potential of Toll-like receptor 9 activation; Nat. Rev. Drug Discov.; 5; 471–484; 2006. 40. A. M. Krieg, A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman; CpG motifs in bacterial DNA trigger direct B-cell activation; Nature; 374; 546–549; 1995. 41. C. F. Bennett, M. Y. Chiang, L. Wilson-Lingardo, and J. R. Wyatt; Sequence specific inhibition of human type II phospholipase A2 enzyme activity by phosphorothioate oligonucleotides; Nucleic Acids Res.; 22; 3202–3209; 1994. 42. W. R. Pearson and D. J. Lipman; Improved tools for biological sequence comparison; Proceedings of the National Academy of Science USA; 85; 2444–2448; 1988. 43. J. C. Wootton and S. Federhen; Analysis of compositionally biased regions in sequence databases; Methods Enzymol.; 266; 554–571; 1996. 44. A. Smit, R. Hubley, and P. Green; RepeatMasker; http://repeatmasker.org; 2006. 45. N. M. Dean, R. McKay, T. P. Condon, and C. F. Bennett; Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters; J. Biol. Chem.; 269; 16,416–16,424; 1994. 46. C. Esau, X. Kang, E. Peralta, E. Hanson, E. G. Marcusson, L. V. Ravichandran, Y. Sun, S. Koo, R. J. Perera, R. Jain, N. M. Dean, S. M. Freier, C. F. Bennett, B. Lollo, and R. Griffey; MicroRNA143 regulates adipocyte differentiation; J. Biol. Chem.; 279; 52,361–52,365; 2004. 47. W. Wang, H. J. Chen, A. Schwartz, P. J. Cannon, C. A. Stein, and L. E. Rabbani; Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides; J. Clin. Invest.; 98; 443–450; 1996. 48. D. J. Ecker, J. R. Wyatt, T. A. Vickers, R. Buckheit, J. Roberson and J.-L. Imbach; Novel guanosine quartet structure binds to the HIV envelope and inhibits envelope mediated cell fusion; Nucleos. Nucleot.; 14; 1117–1127; 1995.
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 141
BASIC PRINCIPLES OF ANTISENSE DRUG DISCOVERY
141
49. E. W. Ng, D. T. Shima, P. Calias, E. T. Cunningham, Jr., D. R. Guyer, and A. P. Adamis; Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease; Nat. Rev. Drug. Discov.; 5; 123–132; 2006. 50. S. A. Bustin; Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays; J. Mol. Endocrinol.; 25; 169–193; 2000. 51. T. P. Condon and C. F. Bennett; Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells; J. Biol. Chem.; 271; 30,398–30,403; 1996. 52. T. A. Vickers, H. Zhang, M. J. Graham, K. M. Lemonidis, C. Zhao, and N. M. Dean; Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2⬘-O-methoxyethyl-modified oligonucleotide; J. Immunol.; 176; 3652–3661; 2006. 53. J. Soutschek, A. Akinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Elbashir, A. Geick, P. Hadwiger, J. Harborth, M. John, V. Kesavan, G. Lavine, R. K. Pandey, T. Racie, K. G. Rajeev, I. Rohl, I. Toudjarska, G. Wang, S. Wuschko, D. Bumcrot, V. Koteliansky, S. Limmer, M. Manoharan, and H. P. Vornlocher; Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs; Nature; 432; 173–178; 2004. 54. L. M. Watts, V. P. Manchem, T. A. Leedom, A. L. Rivard, R. A. McKay, D. Bao, T. Neroladakis, B. P. Monia, D. M. Bodenmiller, J. X. Cao, H. Y. Zhang, A. L. Cox, S. J. Jacobs, M. D. Michael, K. W. Sloop, and S. Bhanot; Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism; Diabetes; 54; 1846–1853; 2005. 55. S. P. Ho, L. K. Takahashi, V. Livanov, K. Spencer, T. Lesher, C. Maciag, M. A. Smith, K. W. Rohrbach, P. R. Hartig, and S. P. Arneric; Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor; Brain Res. Mol. Brain Res.; 89; 29–40; 2001. 55. H. Zhang, J. Cook, J. Nickel, R. Yu, K. Stecker, K. Myers, and N. M. Dean; Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis; Nat. Biotechnol.; 18; 862–867; 2000.
CRC_8796_ch005.qxd
5/24/2007
11:37
Page 142
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 143
CHAPTER
6
The Medicinal Chemistry of Oligonucleotides Eric E. Swayze and Balkrishen Bhat
CONTENTS 6.1
6.2
6.3
Introduction .........................................................................................................................144 6.1.1 Scope .......................................................................................................................144 6.1.2 Why Oligonucleotide Medicinal Chemistry Is Needed ...........................................144 6.1.2.1 Stability Is Insufficient ..............................................................................144 6.1.2.2 Pharmacokinetics Are Insufficient ............................................................144 6.1.2.3 Affinity Is Insufficient...............................................................................145 The Medicinal Chemistry Challenge....................................................................................145 6.2.1 Properties of Oligonucleotides .................................................................................145 6.2.2 Desired Properties of Oligonucleotide Drugs ..........................................................145 6.2.2.1 High Affinity and Specificity for the Receptor.........................................146 6.2.2.2 Ability to Effect the Desired Pharmacology.............................................146 6.2.2.3 Favorable Pharmacokinetics .....................................................................146 6.2.2.4 An Acceptable Therapeutic Index ............................................................147 6.2.2.5 Cost-Competitive Manufacture ................................................................147 Oligonucleotide Modifications ............................................................................................147 6.3.1 Potential Sites of Modification ................................................................................147 6.3.2 Backbone Modifications ..........................................................................................148 6.3.2.1 Furanose-Containing Phosphate Backbones ............................................148 6.3.2.2 Furanose-Containing Nonphosphate Backbones .....................................151 6.3.2.3 Sugar and Backbone Replacements .........................................................153 6.3.3 Sugar Modifications ................................................................................................154 6.3.3.1 2⬘-Modifications .......................................................................................154 6.3.3.2 Other Furnanose Substitution Positions ...................................................158 6.3.3.3 Bicyclic Sugars .........................................................................................158 6.3.3.4 Substitutions for the Ribofuranose Sugar ...............................................161 6.3.4 Heterocyclic Modifications .....................................................................................163 6.3.4.1 Pyrimidine 5⬘-Position Modifications ......................................................163 6.3.4.2 Tricyclic Cytosine Analogs ......................................................................165 6.3.4.3 Other Pyrimidine Modifications ..............................................................166 6.3.4.4 Purine Modifications ................................................................................166
143
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 144
144
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
6.3.5
Conjugates ...............................................................................................................167 6.3.5.1 Cholesterol Conjugates ............................................................................167 6.3.5.2 Fatty Acid Conjugates ..............................................................................168 6.4 Optimizing Oligonucleotide Drugs .....................................................................................169 6.4.1 General Strategies ....................................................................................................169 6.4.2 Oligonucleotide Design Strategies ..........................................................................169 6.4.2.1 Gapmer Designs ......................................................................................169 6.4.2.2 siRNA Designs .........................................................................................170 6.4.2.3 Occupancy Only Designs .........................................................................170 6.4.2.4 Aptamer Designs ......................................................................................171 6.5 Outlook ................................................................................................................................171 References .....................................................................................................................................172
6.1 INTRODUCTION 6.1.1
Scope
This review will focus on the properties that an oligonucleotide drug must have, the many modifications available to the medicinal chemist to engineer those properties into the oligonucleotide, and finally on motifs that have been utilized in oligonucleotide drugs and drug candidates. No attempt has been made to be exhaustively complete in the coverage. We have instead highlighted properties of modifications, and strategies that we feel are likely to be successful in drug development, of value to the field, as well as those that add to the understanding of oligonucleotide medicinal chemistry. Much of the discussion centers around RNase H–based antisense therapeutics, since most of the efforts to optimize oligonucleotide drugs has focused on that application. However, the chemical modifications and principles apply equally to other classes of oligonucleotide drugs, including immunostimulatory motifs, aptamers, microRNA inhibitors, and duplex small interfering RNAs (siRNAs). 6.1.2
Why Oligonucleotide Medicinal Chemistry Is Needed
6.1.2.1 Stability Is Insufficient Unmodified DNA and RNA are inherently unstable molecules in biological systems. This instability is primarily due to ubiquitous nucleases, which cleave the phosphodiester linkage, but can also be chemical in nature, particularly for RNA. This instability precludes the use of unstabilized nucleic acids as drugs, since they are destroyed before they have a chance to reach their target receptor after being administered to an animal. A chemical modification strategy is an obvious way to improve the stability of oligonucleotide drugs, and has been highly successful. In fact, this strategy is used by living cells to stabilize endogenous nucleic acids such as ribosomal and transfer RNAs, and cues for the medicinal chemist can be taken from the myriad of naturally occurring nucleoside modifications [1].
6.1.2.2 Pharmacokinetics Are Insufficient In addition to their susceptibility to attack by nucleases, the pharmacokinetics of RNA and DNA are still insufficient to make acceptable systemic therapeutics. Because they are small enough to be filtered by the glomerulus and are poorly protein-bound in plasma, unmodified oligonucleotides are rapidly filtered and excreted. Therefore, beyond the requirement for improved nuclease stability, the plasma half-life must be improved such that distribution to tissues can occur. Moreover, unmodified
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 145
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
145
oligonucleotides distribute poorly to tissues. This process is poorly understood, but appears to involve binding to acceptor sites on a tissue surface, which facilitates uptake.
6.1.2.3 Affinity Is Insufficient Because RNA is highly structured within a cell, any antisense drug must be able to compete with those structures. DNA, the initial antisense “lead” drug motif, has a lower affinity for RNA than RNA does for itself, which presents a thermodynamic problem that must be overcome. Increasing the intrinsic affinity for a complementary nucleic acid target is the most straightforward way to address this problem. Improving affinity should correlate with improvements in potency, until binding no longer becomes limiting.
6.2 THE MEDICINAL CHEMISTRY CHALLENGE 6.2.1
Properties of Oligonucleotides
Oligonucleotide drugs are intermediate in size between protein-based biological drugs and conventional small-molecule drugs. They range in length from about 13 nucleotides (the telomerase inhibitor GRN163L) to over 27 nucleotides (the aptamer Macugen, pegaptanib). Duplex drugs consisting of two strands (such as the antiviral siRNA ALN-RSV01) contain about 40 total nucleotides, in two distinct molecules held together by Watson–Crick base pairing. Most antisense oligonucleotides (ASOs) have a length of around 20 bases, which translates to a molecular weight of around 7000 atomic mass units. Due to the phosphate backbone, the same 20mer oligonucleotide has a formal negative charge of ⫺19, though not all of those residues are anionic at any given time. Electrospray ionization mass spectrometry experiments have indicated that at physiologic salt concentrations, 20–30% of the phosphates are charged, putting the likely actual negative charge of a 20mer oligonucleotide drug in the range ⫺4 to ⫺6 [2]. Because of their size and charge, the prevailing perception among medicinal chemists has been that oligonucleotides are not “drug-like” and would therefore not likely succeed as drugs. However, this line of thinking is somewhat shortsighted, as many successful small-molecule drugs are not very “drug-like,” nor are the highly successful protein-based therapeutics. Oligonucleotide drugs that utilize Watson–Crick base pairing as the mode of binding to the receptor (usually a target RNA) possess the unique property of having information encoded within their pharmacophore, which is essentially the nucleotide sequence. Molecules of this nature have been termed “informational drugs” [3]. This property allows a very high level of specificity to be easily achieved for the intended receptor, and furthermore allows for the rapid discovery of leads for diverse targets. Although the sequence is changed for each target, and results in changes to the drug properties at the microscopic level, the overall pharmacokinetic and toxicological profiles are similar within each class of oligonucleotides. Furthermore, the synthesis and manufacturing process is almost identical. These generic properties resulting from the nature of oligonucleotide receptor binding allow for large gains in the efficiency of lead discovery, optimization, and development. 6.2.2
Desired Properties of Oligonucleotide Drugs
Similar to all drugs, oligonucleotide drugs should have the following properties: (1) high affinity and specificity for the target receptor, (2) ability to effect the desired pharmacology (activate RNase H cleavage of mRNA, block VEGF action, etc.), (3) favorable pharmacokinetics (a component of which is stability), (4) an acceptable therapeutic index, and (5) manufacturing costs that make the product competitive in the marketplace.
CRC_8796_ch006.qxd
146
5/24/2007
12:03
Page 146
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
6.2.2.1 High Affinity and Specificity for the Receptor It is obvious that one must not make an exceedingly stable drug at the expense of large reductions in potency and specificity. Therefore, the ability to maintain binding to the receptor has been carefully balanced with the optimization of other properties. For traditional antisense approaches involving activation of RNase H, and especially steric blocking mechanisms, this means that modifications must retain, and preferably enhance, the ability to recognize their target RNA by Watson–Crick base pairing. This property is commonly measured by the melting temperature (Tm) of an oligonucleotide containing the modification of interest duplexed with a complementary strand of RNA. Specificity can be measured by studying the effects of mismatches. This approach has been well validated via correlations of activity in cell culture to affinity [4], and detailed structure–stability studies of many modifications have been undertaken [5]. For drugs that utilize an RNA-induced silencing complex (RISC)-based mechanism such as siRNAs, the interactions that govern binding to the mRNA receptor are not as clear, nor is it obvious whether high affinity for complementary RNA is a desired property. However, it is reasonably well established that Watson–Crick base-pairing rules determine the specificity of the drug, and they must therefore be maintained. For aptamer-derived drugs, affinity and specificity are likely key determinants of potency and efficacy. Unlike antisense approaches, the rules for specificity and affinity are no longer decipherable via the informational code of base-pairing rules, and as such optimization of a selected aptamer becomes much more akin to traditional drug optimization projects.
6.2.2.2 Ability to Effect the Desired Pharmacology For many drugs, binding to the receptor is sufficient to effect the desired pharmacology. For aptamers, this is likely to be the case as sterically blocking a receptor or binding a ligand will generally inhibit its function. However, for antisense approaches this is not always the case. The most widely used antisense drugs to date utilize RNase H cleavage of the target RNA to achieve their desired effects. Many studies have shown that modifications that are not substrates for RNase H activity are poor antisense drugs, despite being tight binders to their RNA complement, and presumably their receptor. siRNA drugs face a similar requirement in the ability to be loaded into the RISC complex and activate cleavage of the target. It is therefore crucial to examine modifications for their effects on these terminating events, and to understand these effects when designing oligonucleotide structure–activity relationship (SAR) series in optimization efforts.
6.2.2.3 Favorable Pharmacokinetics As discussed above, resistance to nucleases must be engineered into oligonucleotides for them to be useful as drugs. Nuclease stability is required but not sufficient for achieving a favorable pharmacokinetic profile. The drug must also distribute to the site of action, and persist at the site of action for a reasonable period of time. Unmodified nucleic acids are poorly bound to plasma proteins in vivo, and are therefore rapidly excreted to urine. For drugs such as aptamers that have their site of action in the blood compartment, modifications such as pegylation, which minimize or avoid renal filtration, are sufficient. However, for drugs that must distribute to tissues and penetrate cells to reach their target receptors, binding to other acceptor sites within the animal presumably mediates drug distribution. Thus, modifications that generally improve protein binding are often beneficial. However, strong protein-binding interactions can decrease the concentration of drug at the receptor site, and the effects are complex and difficult to predict. This underscores the necessity of early in vivo pharmacokinetic studies with new classes of oligonucleotide drugs, just as is commonplace with small-molecule drugs.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 147
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
147
6.2.2.4 An Acceptable Therapeutic Index As with all drugs, it should be obvious that known toxic modifications should be avoided. This is an especially important consideration for oligonucleotide drugs, as many nucleoside monomers have wide-ranging biological activities of their own. Known toxic sequence motifs should also be avoided. This can be achieved by building a database of toxic motifs, then filtering them out in a sequence selection process (see Chapter 5 of this volume). However, just as with small-molecule drug discovery, toxicological surprises occur, and detailed toxicological evaluation of new modifications, new usage contexts of these modifications, and new sequences must be conducted.
6.2.2.5 Cost-Competitive Manufacture Because oligonucleotide drugs are fairly large (molecular weight around 7000) molecules composed of monomeric building blocks, the cost of the monomers is a key driver in the ultimate cost of the active pharmaceutical ingredient. Therefore, monomers with intractably complex syntheses, or those for which there is no cheap source of starting materials, are likely doomed to fail for use in oligonucleotide drugs. This should not be overemphasized, as process chemists can work magic on even the most challenging syntheses, but it should not be ignored when choosing modifications to invest in for potential therapeutic use.
6.3 OLIGONUCLEOTIDE MODIFICATIONS 6.3.1
Potential Sites of Modification
A dinucleotide depicting subunits that may be modified to enhance oligonucleotide drug properties is shown in Figure 6.1. Modifications may be made to the backbone (including complete replacement of the sugar phosphate backbone), sugar, and heterocycle portion of the nucleic acid monomer. Additionally, many diverse moieties have been conjugated to various positions in the subunits, mainly in an attempt to alter the pharmacokinetic properties of the oligomer. There are approximately 25 positions for each dinucleotide that do not directly interfere with Watson–Crick base-pair hydrogen bonding. Most of these positions have been modified in at least one way, and studied for their effects on the properties of the resulting oligonucleotides. We highlight certain modifications and review their important characteristics in the following sections, divided according to structural class.
5′ end
4′
X
1′
Base (A, C, G, T)
5′
Linkage
3′
2′
O S P O O
R
Sugar
O O
3′ end
Conjugates
Base
Phosphorothioate
Figure 6.1
Base
R 2′-Substitution
Positions for modification on an oligonucleotide dimer subunit.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 148
148
6.3.2
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Backbone Modifications
Because the phosphodiester backbone of DNA and RNA is extremely sensitive to ubiquitous nucleases, it is poorly suited for therapeutic utility. The backbone was therefore a necessary and obvious first target for improvement with chemical modification. As a result, extensive medicinal chemistry research focused on the oligonucleotide backbone in order to find modifications that increased nuclease resistance and maintained or improved affinity and specificity to target RNA. Secondary goals included retaining the ability to efficiently recruit RNase H and improve pharmacokinetic properties in animals. The following sections highlight some of the more important backbone modifications that have found use in antisense technology.
6.3.2.1 Furanose-Containing Phosphate Backbones Phosphorothioate (PS) Phosphorothioate-containing oligonucleotides (Figure 6.2) represent by far the most widely used backbone modification for antisense drugs. The properties of the first-generation PS oligodeoxynucleotide antisense drugs have been extensively reviewed in a previous volume [6]. These differ from natural nucleic acids in that one of the nonbridging phosphate oxygen atoms is replaced with a sulfur atom. This substitution of a sulfur for oxygen in the phosphate ester confers several properties onto oligonucleotides, which are crucial for their use as systemic antisense drugs [7]. Foremost, the PS linkage greatly increases stability to nucleolytic degradation [8], such that PS oligonucleotides possess sufficient stability in plasma, tissues, and cells to avoid metabolism prior to reaching the target RNA after systemic administration to an animal. Secondly, but of importance for antisense applications,
O S P O O Phosphorothioate (PS) O H3C P O O
O S P O S O O
Methylphosphonate
O O P O O O P O O
O
B
O H3B P O O
O
3′-Methylene phosphonate
O
DNA phosphodiester (PO)
O P O O
O Phosphonoacetate
Figure 6.2
Phosphorodithioate
B
Furanose-containing phosphate backbones.
Boranophosphate
HN O P O O N3′→ P5′ phosphoramidate
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 149
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
149
PS oligodeoxynucleotides are able to efficiently elicit RNase H cleavage of the target RNA, which is critical for the success of most antisense drugs (see Chapter 2 of this volume). Additionally, the PS modification confers a substantial pharmacokinetic benefit by increasing the binding to plasma proteins, which prevents rapid renal excretion and facilitates binding to other acceptor sites that facilitate uptake to tissues [9]. While greatly increasing the stability of ASOs, PS-modified drugs are still subject to metabolism, and have tissue half-lives of 1–3 days [9], which is suboptimal for a parenterally administered drug. Furthermore, the PS modification reduces affinity for the target RNA (the ultimate biological receptor for ASO drugs) [8], which adversely effects potency. These limits can be effectively addressed with chimeric “gapmer” oligonucleotide designs, which will be discussed in this section. Introduction of each sulfur atom in the phosphate backbone generates a chiral center containing a mixture of diastereomers [10]. It has been reported that the stereoisomers have different and potentially complementary physiochemical properties (one is more stable, the other a better RNase H substrate), thereby prompting research efforts toward the stereo-controlled synthesis of chiral PS oligonucleotides [11]. Progress toward this goal has been reviewed recently [12]. However, thus far it has proven difficult to achieve a stereo-controlled synthesis via cost-competitive methods compatible with the current manufacturing process, which is able to provide antisense drugs at a reasonable cost (see Chapter 14 of this volume). Though often maligned, PS still remains the most successful modification to date in oligonucleotide therapeutics. It is difficult to envision a modification that will be able to completely displace PS from current antisense drugs, and other classes of oligonucleotides often employ PS to achieve the improved properties required for use as drugs.
Phosphorodithioate The phosphorodithioate backbone (Figure 6.2) modification was introduced by Caruthers and coworkers [13–15]. In this case, both nonbridging oxygen atoms of the phosphate linkage are replaced with sulfur. The phosphorus atom is therefore achiral. Though this modification rendered oligonucleotides nuclease-resistant and was found to support the RNase H mechanism of action, it suffered from loss of affinity and difficulty in scalable synthesis. Phosphorodithioate analogs were found to lead to stronger nonspecific protein binding than the PSs [16], which raised toxicity concerns. Recently, an improved synthesis was reported [17]; however, the disadvantages in affinity and protein binding properties have made this modification less desirable.
Boranophosphate In boranophosphate oligodeoxynucleotides, the nonbridging phosphodiester oxygen is replaced with a borane (BH3–) group (Figure 6.2). This DNA modification was introduced by Shaw and coworkers [18–20], and has been recently reviewed [21,22]. The boranophosphate is isoelectronic with phosphodiester, and isosteric with methylphosphonate group. It is considered to be more lipophilic than DNA, but due to the presence of negative charge is still highly water-soluble. There are reports suggesting that the boranophosphate-modified ASOs are considerably more stable to nucleases than natural DNA and slightly more stable than PS oligodeoxynucleotides [20]. Boranophosphate oligodeoxynucleotides have also been found to activate Escherichia coli RNase H and induce cleavage of target mRNA [23,24]. More recently, boranophosphate-modified siRNAs were tested in vitro and were found to be slightly more active than unmodified siRNAs. The level of activity and efficacy depended on the number and the position of boranophosphate residues in the molecule [25]. The lack of improved affinity for RNA targets coupled with the difficulty in chemical synthesis to produce sufficient quantities of boranophosphate-modified ASOs for studies in animals is likely to hinder further development of this modification for oligonucleotide drugs.
CRC_8796_ch006.qxd
5/24/2007
12:03
150
Page 150
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
N3 ⬘→P5 ⬘ Phosphoramidates and Thiophosphoroamidates In the phosphoramidate oligodeoxynucleotides, the 3⬘-amino group is substituted for 3⬘-oxygen in the deoxyribose ring and the nucleosides are linked via phosphoramidate monoester linkages (Figure 6.2). Synthesis of these compounds was first reported by Gryaznov and coworkers [26]. Phosphoramidates exhibit both high affinity toward complementary RNA (⌬Tm⬃2.5°C per modification) and high nuclease resistance [27,28]. Although these molecules do not activate RNase H, they have shown encouraging in vivo results. For example, a phosphoramidate-modified ASO was specifically used to down-regulate the expression of c-myc gene [29]. Moreover, in a leukemia model, the phosphoroamidates were found to outperform PS oligodeoxynucleotides via steric blocking of translation initiation [30]. Although possessing some promising properties, this modification was found to have low affinity to intra- and extracellular proteins and decreased acid stability relative to phosphodiester counterparts. To address these issues, thiophosphoramidate linkages were prepared. They were found to be more acid-stable when incorporated into oligonucleotides, and introduction of sulfur in place of one of the nonbridging oxygen atoms did not alter the RNA-binding properties of these compounds [31]. Recently, Wang et al. [32] used the N3⬘→P5⬘ thiophosphoramidate (GRN163) to study telomerase inhibition in vitro and in vivo in multiple myeloma and lymphoma with an oligonucleotide telomerase template antagonist. Oligonucleotide phosphoramidates, especially thiophosphoroamidates modified with various lipid groups, showed significant promise as antitelomerase agents [33]. The relatively well-established synthesis and attractive chemical and biophysical properties, including increased affinity and stability, makes them a promising backbone modification.
Phosphonoacetate, Thiophosphonoacetate, and Phosphonoformate These relatively new analogs discovered by Caruthers and his coworkers [34] possess an acetic acid functional group instead of a nonbridging oxygen atom at the internucleotide linkage. They are chiral at phosphorus and isoelectronic with the DNA at neutral pH [35]. Under physiological pH conditions, these analogs possess a negative charge and form stable, complementary A-like DNA/RNA duplexes. Phosphonoacetate (Figure 6.2), thiophosphonoacetate, and phosphonoformate oligodeoxynucleotides were found to support robust RNase H activity only when incorporated in the wings of gapmer (see Section 6.4, Figure 6.11) designs [36]. Appropriate placement of phosphonoformate within an oligonucleotide leads to improved affinity when paired with complementary RNA. They were highly resistant to snake venom phosphodiesterase, DNase 1, and the nucleases present in HeLa cell extracts. These analogs have been reported to enhance uptake in cell culture as well [36]. The progress in solid-phase synthesis as well as favorable biophysical and biochemical properties warrant further investigation of this modification in animal studies.
3⬘-Methylene Phosphonate 3⬘-Methylene-modified oligonucleotides have the 3⬘-hydroxyl of deoxy ribose replaced with a carbon atom. They are achiral, negatively charged, and isoelectronic with phosphodiesters. The incorporation of this modification in a DNA has been shown to lead to C3⬘-endo sugar pucker [37], which is expected to improve target RNA binding affinity. The synthesis of 3⬘-methylene H-phosphonate (Figure 6.2) nucleotides using modified Arbuzov reaction conditions allowed the synthesis of a number of oligonucleotides [38]. The 2⬘-modified-3⬘-methylene phosphonate–modified oligonucleotides showed excellent binding affinity to the complementary RNA with a ⌬Tm of up to 3.6°C per modification, relative to a PS DNA/RNA duplex. Substitution of this modification at the 3⬘-end rendered the oligonucleotide highly resistant to snake venom phosphodiesterase. Although some promising results have been observed with 3⬘-methylene-modified oligonucleotides, the lack of a robust synthetic method for nucleotide monomers and oligonucleotides has prevented the further advancement of this modification.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 151
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
151
Methylphosphonate Methylphosphonates (Figure 6.2) represent one of the earliest examples of neutral oligonucleotide analogs, and have one of the nonbridging oxygen atoms replaced by a methyl group. Early progress in the standard solid-phase synthesis of these molecules made possible a rigorous evaluation of the biophysical and biochemical properties of methylphosphonate-modified oligonucleotides. While providing high nuclease resistance, this modification does not support RNase H. Additionally, high methylphosphonate content in an oligomer leads to loss in affinity toward its complementary RNA and poor solubility. These shortcomings have made this modification less desirable. However, employing a design of methylphosphonates in the wings and PS DNA in the gap, oligonucleotides were utilized ex vivo for purging autografts in chronic myeloid leukemia [39]. Recently, Miller and his coworker [40] used 2⬘-O-methyl oligonucleotide hairpins containing methylphosphonate linkages against TAR RNA. Placement of the linkage showed a strong positional preference, and the configurations of the methylphosphonate linkages also affected binding affinity, with the Rp,Rp isomer showing significantly higher binding than the Sp,Sp isomer. These studies highlight a potential utility as site-specific modifications to improve nuclease resistance. However, many other modifications will accomplish this task, and the value of methylphosphonates to oligonucleotide drug applications remains unclear.
6.3.2.2 Furanose-Containing Nonphosphate Backbones Amides Amide-based backbones were prepared by De Mesmaeker and colleagues in an attempt to control the charge and chirality of the backbone. The design of these backbones consisted of dimeric nucleosides connected by various amide linkages, such that the resulting oligonucleotide consisted of alternating stretches of phosphodiester and amide linkages. A modest improvement in duplex stability with complementary RNA (⌬Tm of 0.5°C per modification) was observed with two positional isomers of the amide linkage [41,42]. The affinity for complementary DNA was somewhat lower for these amide dimers. It is argued that restricted rotation about the amide bond, with a preference for the trans isomer, preorganizes these backbones into a conformation that gives the oligomer a more favorable A-form-like geometry, which favors base pairing with RNA. Substituting the 2⬘-position in both units of the dimer with 2⬘-O-methyl further biased the conformation of the ribofuranoses to C3⬘-endo, which improved the binding affinity to ⌬Tm of up to 2–3°C per dimer [43]. Because two nucleosides are part of this “modification,” it should be noted that the affinity increase observed is just slightly improved relative to that seen with 2⬘-O-methyl RNA. Additional chemical SAR around the amide backbone was done and a 5⬘-(S )-C-methyl group further rigidified the backbone, which when combined with 2⬘-O-methyl-modified sugars (Figure 6.3) resulted in a
O
O O
O O
B OMe
O
NH
O
5′-(S)-methyl amide-3 Figure 6.3
O
O O
B OMe
B
S
OMe N
O
O
B
O MMI
Furanose-containing nonphosphate backbones.
O
B OMe
O Thioformacetal
B
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 152
152
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
⌬Tm of up to 4.4°C per dimer incorporation versus RNA complements [44]. The amide linkages are highly resistant to nucleases, but the stability of the amide linkage is unknown in vivo. Recently, a number of structural studies have been reported for a number of amide backbone analogs using NMR, crystallography, and molecular simulations to understand the SAR between nature, length, and steric properties of these molecules and possible reasons for their contribution to DNA/RNA duplex stability [45,46]. Despite these promising results, no significant biological data have been reported for these modified oligonucleotides. This perhaps is due to the fact that large-scale synthesis has not been achieved. Because of the ability to control charge and completely eliminate degradation due to nucleases while increasing affinity, modifications of this type merit further investigation, particularly in animal studies.
Methylene(methylimino) (MMI) Several nitrogen-containing backbone modifications similar to the amides that are achiral and have five-atom spatial separation between the two sugar residues were evaluated as dimeric nucleosides [47]. The best compounds were identified from biophysical studies as methylene(methylimino) (MMI, Figure 6.3) linkages with a 5⬘–O–NCH3–CH2– linkage and 2⬘–O–methyl or 2⬘–fluoro substitutions on each sugar [48]. It has been suggested that the presence of a 3⬘–C–C bond in the MMI linkage reduces the O–4⬘ and C–3⬘ gauche interaction compared to the natural phosphodiester backbone linkage. The data unambiguously reveal that combination of an appropriate 2⬘-modification with a neutral and achiral linkage provides oligomers with high affinity for an RNA target. For example, 2⬘–O–methyl or 2⬘–fluoro substituted MMI linkages increased the affinity for complementary RNA as much as 3.2 to 3.7°C ⌬Tm per modification. Because these modifications contain no phosphodiester, it is obvious that they will not be degraded at the modified backbone by nucleases. However, it was found that the dimer structures also stabilized the internal phosphodiester such that it was not degraded as well. This allows a molecule free of chirality and PS to be prepared, which carries only 50% of the charge of the parent. Unfortunately, none of the backbones studied to date support RNase H, relating their use for antisense applications to gapmer designs or stericblocking-type mechanisms. MMI-modified gapmers were found to be very potent in an RNase H enzymatic assay as well as reducing target mRNA of PKC-α and H-Ras in vitro. However, their in vivo activity was similar to 2⬘-methoxyethylribose (MOE) gapmers (unpublished results). Moreover, more rapid clearance and lower tissue levels of drug were observed for MMI ASOs with more than 50% MMI content. This can be attributed to a reduced number of PS linkages, which leads to decreased plasma protein binding and increased renal excretion.
Formacetal and Thioformacetal A very simple yet interesting backbone substitution is the formacetal, which replaces the phosphate diester with a methylene unit, and the related thioformacetal (Figure 6.3), which also replaces the 3⬘-side oxygen with a sulfur atom [49]. The formacetal-linked oligonucleotides bind in a sequence-specific manner, but with less affinity compared to unmodified oligonucleotides, but the thioformacetal linkage increases affinity slightly with dimeric incorporations and is neutral when incorporated as a thioformacetal pentamer [50]. The NMR structure of these duplexes has been studied and the stabilities rationalized based on the structure, which indicated that the thioformacetal adopted a northern sugar pucker [51]. An in vivo therapeutic application of a formacetal-modified oligonucleotide aptamer has been reported [52]. A systematic positional SAR was conducted that led to the selection of a modified aptamer with four formacetal groups that increased anticoagulant effect combined with extended half-life in monkeys, when compared to the parent aptamer. This result suggests that other rationally designed neutral backbones that are known to increase binding affinity and in vivo nuclease
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 153
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
153
stability might be useful for other aptamers selected for binding to therapeutically relevant protein targets.
Other Nonphosphate Backbones There are numerous other backbone modifications that contain guanidine, silyl, sulfone, sulfoxide, urea, carbamate, sulfide, etc. that are not discussed in this chapter, either because of lack of recent progress or perceived value for use in oligonucleotide drugs. Most have been covered to some extent in one or more of several reviews, and the interested reader is referred to these reviews [22,53–55].
6.3.2.3 Sugar and Backbone Replacements Morpholino Phosphorodiamidate Phosphorodiamidate morpholino oligonucleotides (Figure 6.4) are a class of backbone modification that has a morpholine ring as a replacement for the furanose, with a phosphorodiamidate linkage connecting the morpholine nitrogen atom with the hydroxyl group of the 3⬘-side residue. Because of the phosphorodiamidate linkage, morpholino oligonucleotides are neutral. These modifications are similar in affinity to DNA/DNA duplexes, and are nuclease-stable. However, they do not activate RNase H, and are primarily used in translation arrest or other steric blocking mechanisms such as alteration of splicing, where they have shown activity in animal models [56,57]. Morpholinos have advanced to human clinical trials and pharmacokinetic data were reported [58]. Morpholino oligonucleotides have been reviewed [59–61], and are covered in depth in Chapter 20 of this volume.
Hydroxyproline Backbones Use of a hydroxyproline sugar replacement in two different contexts has resulted in the trans-4-hydroxy-pyrrolidine-2-phosphonic acid (pHypNA) and HypNA-pPNA (Figure 6.4), which consists of a hydroxyproline-based monomer alternating with a phosphono-peptide nucleic acid monomer [62,63]. These analogs are stable to nucleases and maintain affinity for target nucleic acids; however, they are not strongly stabilizing and do not activate RNase H. They have been used in steric blocking mechanisms, where interesting results have been reported in cell culture [64,65].
(5′)
(5′)
O O N N P O O
(5′)
O B
N
N
O O
O
NH B
O
B
N
Morpholino
Sugar and backbone replacements.
O
NH B
N O O
Figure 6.4
NH B
B
N
O
O
P O
PNA (peptide nucleic acid)
CRC_8796_ch006.qxd
5/24/2007
12:03
154
Page 154
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Peptide Nucleic Acid (PNA) Peptide nucleic acids (Figure 6.4) are a radically different class of oligonucleotide analogs that contain a peptide replacement for the sugar phosphate backbone, yet maintain the ability to Watson–Crick base pair with complementary RNA and DNA [66]. First introduced by Nielsen and coworkers [67], PNAs are highly resistant to degradation by nucleases and proteases and are very stabilizing when paired with RNA and DNA. PNAs do not activate RNase H, and as such have been used in translation inhibition [68,69] and splicing modulation antisense mechanisms [57,70]. Recently, PNAs have been utilized to both activate [71] and inhibit transcription [72]. PNA and its properties are covered in depth in Chapter 18 of this volume. Despite their uncharged nature, PNAs do not cross cell membranes readily, and the cell culture data generated with PNAs have required methods to deliver them to cells. PNA oligonucleotides also have generally poor drug properties for in vivo applications. They have very low solubility and are very poorly protein-bound. These limitations have been addressed by conjugation of short peptides [73,74] and use of charged amino acids [75] in the PNA backbone, which serves to increase solubility. Importantly, the short peptides employed were able to dramatically improve tissue distribution. In a follow-up study from these advances [76], PNAs targeting a splice junction of PTEN, which alter PTEN splicing and reduce protein, were conjugated to 8mer lysine peptides. Compound administered at 40 mg/kg twice weekly for 3 weeks showed little activity in liver and kidney, which was surprising given the high drug concentrations achieved (108 and 408 M in liver and kidney, respectively). In contrast, robust activity was observed in adipose tissue, with an alteration of splice products observed concomitant with a dose-dependent down-regulation of PTEN protein. As in liver and kidney, a relatively high drug concentration of 79 M was achieved. A comparison of estimated EC50 values in adipose tissue between PNA and MOE ASOs shows that the MOE ASO is far superior, with an EC50 of around 1 M, as opposed to the 70–80 M value for the PNA. This ⬎50-fold difference in potency suggests that many hurdles remain for PNA oligonucleotide drugs. 6.3.3
Sugar Modifications
6.3.3.1 2 ⬘-Modifications To date, modifications to the 2⬘-position of the sugar moiety have provided the most value in the quest to enhance oligonucleotide drug properties. Preorganization of the sugar into an RNA-like 3′-endo pucker, or northern conformation in the furanose pseudorotation cycle [77], is responsible for the increased binding affinity. Furthermore, the proximity of the 2⬘-substituent to the 3⬘-phosphate in an oligonucleotide causes 2⬘-modified oligonucleotides to generally increase nuclease resistance. As such, 2⬘-modification generally adds two desirable properties to oligonucleotides with a single modification. Unfortunately, essentially all 2⬘-modifications greatly reduce or completely inhibit the ability of RNase H to cleave the RNA strand opposite the modification, which restricts the use of 2⬘-modifications for antisense purposes. This limitation has been minimized by use of a gapmer strategy, where regions of 2⬘-modified residues flank a central DNA region of the oligonucleotide. The 2⬘-modified “wings” thus serve to increase affinity and nuclease resistance, while the central gap region allows RNase H–mediated cleavage of the target RNA. Similar limitations are currently in the process of being elucidated for the use of 2⬘-modified nucleosides in siRNA duplexes, which must utilize the RNAi machinery. Considerably more flexibility is afforded for use in oligonucleotide drugs that do not require a terminating mechanism.
2⬘-Fluoro Modifications The increase in affinity observed with 2⬘-modifications is energetically driven by the electronegative substituent at the 2⬘-position [78]. As such, the 2⬘-fluoro (Figure 6.5) modification
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 155
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES O
B
O O
O
B
O O
F
155 O
B
O O
O
O O
O
2′-Fluoro O
B
O O
MOE (2′-O-methoxyethyl)
O
FANA
B
B
O
O O
HN O N
DMAOE
O O
O
OCH3
2′-O-methyl
B
O
O
O
Figure 6.5
NMAc
F O
O
HN
N DMAEAc
Sugar 2⬘-modifications.
imparts the highest binding affinity (⌬Tm ⬃ 2°C per modification, relative to DNA) for target RNA of the 2⬘-class of modifications [5]. The 2⬘-fluoro substitution also improves stability relative to RNA. These favorable properties have led to substitution of 2⬘-fluoro for RNA nucleosides in the design of the aptamer Macugen, currently marketed for wet age-related macular degeneration [79]. The 2⬘-fluoro modification has also been employed in the design of duplex siRNA oligonucleotides [80–82]. This substitution has allowed for the complete elimination of RNA from siRNAs, providing duplexes with increased stability and potency that act via activation of the RNAi pathway [83,84]. For antisense applications, since 2⬘-fluoro does not activate RNase H or improve nuclease stability beyond DNA, its use has been limited predominantly to cell culture [85,86]. The 2⬘-fluoro substituent has also been evaluated in the arabino configuration, which places the fluorine atom on the same face of the sugar as the base moiety to provide 2⬘-deoxy2⬘-fluoro-D-arabinonucleic acid (FANA, Figure 6.5) [87]. The arabino 2⬘-fluoro configuration also displays an enhancement of affinity toward complementary RNA, but is about half that observed with the ribo-2⬘-fluoro configuration. Structural studies have shown that FANA residues assume an O4⬘-endo pucker (eastern conformation) in B-DNA and a predominantly northern conformation in the context of an A-form duplex, and have rationalized the affinity enhancement based upon stereoelectronic conformational preorganization [88,89]. Uniformly modified FANA oligonucleotides have been shown to support RNase H–mediated cleavage of an RNA complement; however, the cleavage rates are reduced and antisense activity in mammalian cells was not observed for the uniformly modified FANA oligonucleotides [90]. However, a gapmer strategy using FANA wings surrounding a DNA gap increased both the affinity for an RNA target and the RNase H cleavage rates relative to a uniform DNA oligonucleotide, and the antisense potency in a luciferase reporter system was substantially improved [90]. These results have been extended to an endogenous target for both FANA gapmers and designs that employ alternating blocks of 3 FANA and DNA residues [91]. The utility of the FANA modification in siRNA duplexes has also been investigated. The optimal design consisting of a uniformly modified FANA sense strand and FANA overhangs on the antisense strand maintained potency and improved serum stability [92]. No in vivo studies employing FANA designs of this nature have been reported to date; so although promising, the ultimate value of FANA is still unknown.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 156
156
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
2⬘-O-Methyl and Methoxyethyl (MOE) 2⬘-O-Alkyl groups improve binding affinity to a lesser degree than the 2⬘-fluoro nucleosides, but impart a substantial degree of nuclease resistance to the resulting oligonucleotide. The use of 2⬘-O-methyl nucleosides (Figure 6.5) in siRNA holds promise in both the sense [93] and antisense strands. The steric requirements of the RNAi machinery for recognition of the antisense strand appear to restrict the use of bulkier modifications, while 2⬘-O-methyl is often well tolerated [94]. Minimal use of 2⬘-O-methyl nucleosides has been employed to stabilize siRNAs for successful in vivo proof of concept experiments [95,96], and to minimize off-target effects [97,98]. Gapmer designs employing 2⬘-O-methyl ASOs have been well investigated [85], and these designs have advanced to human clinical trials [99]. However, the overall profile of 2⬘-O-methyl gapmer ASOs is less appealing than that of other modifications currently in development. The 2⬘-O-methoxyethyl (MOE, Figure 6.5) modification is currently the most advanced of the 2⬘-modified series, and has entered clinical trials for multiple indications. MOE increases Tm by about ⫹2°C per modification versus RNA, relative to DNA, and greatly increases resistance to nucleases. It also appears to reduce certain nonspecific protein binding, which can reduce toxicities. MOE oligonucleotides have unique structural features evident from structural studies, which help explain the properties of MOE oligonucleotides [100]. MOE substitution at the 2⬘-position induces a C3⬘-endo (northern) conformation of the sugar, and the methoxyethyl substituent assumes a gauche orientation that traps water in a shell of hydration that includes the adjacent phosphate residue. This further increases rigidity of the C3⬘-endo sugar conformation, and the preorganization of the oligonucleotide into an A-form geometry is thought to largely account for the increased affinity for RNA. The increased nuclease resistance is most likely due to steric hindrance imparted by the methoxyethyl substituent combined with the shell of hydration created by the bound water. These fundamental properties of MOE have profound beneficial effects on the potency, pharmacokinetics, and toxicology of MOE containing antisense oligonucleotides, which are extensively reviewed in Chapters 10–14 of this volume. Systematic optimization of the design of MOE ASOs can further improve potency, which is reviewed in Chapter 17 of this volume, and optimization of other oligonucleotide drug classes such as aptamers and siRNA duplexes using MOE chemistry is expected to have similarly beneficial effects.
Lipophilic 2⬘-O-Alkyl Modifications A range of lipophilic 2⬘-O-alkyl groups have been investigated to varying extents in attempts to improve the pharmacokinetic properties of oligonucleotides. While the nuclease resistance of a given 2⬘-modification generally increases with increasing steric bulk, the affinity for target RNA decreases. The 2⬘-O-propyl modification carved out somewhat of a middle ground, in that it modestly increased both affinity and nuclease resistance, and the increased lipophilicity is presumably responsible for a demonstrated improvement in the plasma protein binding of fully phosphodiester 2⬘-O-propyl oligonucleotide [101]. However, the ultimate potency and nuclease resistance achieved were not sufficient to outperform 2⬘-O-methyl or MOE as ASO drugs. In an attempt to improve the protein binding, while maintaining the increased affinity and nuclease resistance of MOE, a methylthio ether version of MOE was tested. This compound improved protein binding as expected, maintained affinity, but showed greatly reduced nuclease resistance when compared to MOE. This was attributed to loss of organization of the side chain as demonstrated by structural analysis [102]. In a study comparing the effects of various lipophilic 2⬘-substituents, the affinity and nuclease resistance of propyl, butyl, 2-(fluoro)ethyl, 2-(trifluoro)ethyl, allyl, propargyl, and 2-(benzyloxy)ethyl 2⬘-O-substituents were compared and rationalized by crystallographic studies [103]. All groups improved affinity, with the largest gain due to the 2-(fluoro)ethyl side chain, which adopts
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 157
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
157
a conformational preorganization due to the gauche effect of the electronegative fluorine atom. The lowest level of nuclease resistance was found in the propargyl analog, followed by the bulky 2-(benzyloxy)ethyl derivative. The structural data are consistent with a stacking interaction of the aromatic benzyl group with the furanose ring of the adjacent 3⬘-side residue. This moves the side chain away from the phosphate linkage, and presumably reduces nuclease resistance due to decreased steric interactions. A 2⬘-O-2,4-dinitrophenyl substitution has been reported to provide enhanced affinity for target, increased nuclease resistance, and result in remarkable activities both in cell culture and in animals [104–107]. The nature of the way the modification has been prepared makes confirmation of these findings difficult, as the composition is prepared via reaction of an enzymatically prepared RNA with 1-fluoro-2,4-dinitrobenzene to generate a mixture of compounds with approximately 70% derivatization of the RNA 2⬘-position. Furthermore, the reported effects have been primarily against oncology targets and endpoints, no data against endogenous gene targets in normal animals has been reported, and no pharmacokinetic properties of the 2,4-dinitrophenyl RNA have been described. Thus, while the early data is encouraging and substitutions of this type are interesting, rigorous characterization of the drug substance and thorough pharmacokinetic/pharmacodynamic (PK/PD) relationships must be obtained for this modification to advance toward use in oligonucleotide therapeutics.
Cationic 2⬘-O-Alkyl Modifications The cationic 2′-O-aminopropyl [108] and corresponding dimethylaminopropyl version [109] have shown favorable binding affinity, with dramatically improved nuclease resistance. In an attempt to extend the increased nuclease resistance of these cationic modifications to the higher affinity seen with MOE, the terminal methoxy group of MOE was replaced with a guanidinium [110], and imidazole [103], or a (dimethylamino)ethoxy group to give a 2⬘-O-[2-[N,N-(dimethyl)aminoethoxy]ethyl] (DMAEOE) functionality [111]. These modifications display hybridization properties equal or superior to those of MOE, and nuclease resistance equal to that of the 2⬘-O-aminopropyl modification. However, in unpublished work from our laboratory, we have found that incorporation of DMAEOE nucleosides into the 5⬘ and 3⬘ wings of an active MOE gapmer did not translate to improved activity in animals. Despite increasing the concentration delivered to kidney, we found little to no inhibition of gene expression in kidney, whereas the corresponding MOE ASOs reduced target as expected. Whether this translates to other cationic modifications in other tissues remains to be determined. The less basic (dimethylaminooxy)ethyl (DMAOE, Figure 6.5) [112] substituent, which contains a hydroxylamine functionality, increased both nuclease resistance and affinity for RNA, yet maintained activity both in vitro and in vivo [113]. This suggests that cationic modifications inhibit antisense activity in animals, in spite of their improved affinity and nuclease resistance profiles. A conformation similar to that assumed by MOE can also be achieved by utilizing a carbamoylmethoxy or acetamide functionality [114]. These modifications have been prepared in both unsubstituted, methylated (NMAc, Figure 6.5), dimethylated, and the cationic dimethylaminoethylated (DMAEAc, Figure 6.5) versions [115]. As expected, the cationic version increased nuclease resistance the most. All substitution patterns increased affinity for RNA, with the NMAc having the best overall profile. In unpublished work from our laboratory, a gapmer substituting NMAc for MOE was found to be equipotent in vitro and in vivo to MOE in reducing PTEN mRNA in mouse liver. Additionally, NMAc has been found to substitute for MOE on the sense strand of siRNA designs (unpublished results). These results suggest that the acetamido 2⬘-modification has intriguing possibilities in both antisense and other oligonucleotide drug discovery efforts. As any amine can be used to form the amide on a nucleoside precursor, a diverse array of functionality can be introduced onto 2⬘-O-acetamido nucleosides, further illustrating the potential versatility of this substitution.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 158
158
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
6.3.3.2 Other Furnanose Substitution Positions In comparison to the 2⬘-modifications, comparatively little success has been had with other furanose modifications for antisense applications. Substitutions at the various carbon positions on the sugar ring have been investigated. 4⬘-C-methyl [116], hydroxymethyl [117,118], methoxymethyl, and aminomethyl [119,120] substitutions in general decrease affinity for target RNA, increase nuclease resistance substantially, favor a southern sugar conformation, and inhibit RNase H activity. Combination of 4⬘-C-aminomethyl with a 2⬘-fluoro substituent (Figure 6.6) provided an analog with increased affinity for both RNA and DNA targets, while maintaining the high level of nuclease resistance [121]. Substitutions at the 3⬘-C-position increase nuclease resistance somewhat, decrease binding affinity, and are inhibitory to RNase H activity [116,122,123]. Modification of the 5⬘-C-position with a methyl group has been shown to increase nuclease resistance and be modestly destabilizing; however, the compounds tested were diastereoisomeric mixtures [124], so the effects of the individual methyl isomers cannot be judged. Groups larger than methyl such as 5⬘-allyl have been prepared in pure form, and it was found that both isomers greatly improved nuclease stability relative to deoxy, and were about equally destabilizing [119]. 5⬘-C-aminomethyl, hydroxymethyl, and methoxymethyl analogs were also prepared in the (S) configuration, and found to be only slightly destabilizing in a mixed sequence having eight modifications spaced relatively evenly in a 19mer DNA parent sequence. The resulting sequences were highly stable to nucleases, and the 5⬘(S)-C-hydroxymethyl analog (Figure 6.6) supported cleavage of a duplex by RNase H [119]. The greatly increased nuclease stability of the 5⬘-C-substituted analogs, combined with the minimal disruption to binding affinity and overall structure of the nucleic acid underscores the potential of this class of modification for improving oligonucleotide drug properties.
6.3.3.3 Bicyclic Sugars Much effort has been invested in restricting the conformation of nucleosides via the conformational restraint introduced in making bicyclic nucleosides. As with traditional small-molecule drug optimization efforts, the rewards for correctly constraining a ligand are large entropic gains in binding affinity. This is most evident with the 2⬘,4⬘-bicyclic nucleic acids (2⬘,4⬘-BNAs) such as locked nucleic acid (LNA) and its analogs.
Locked Nucleic Acid (LNA, 2⬘,4⬘-BNA) The sugar modification showing the largest known improvement in binding affinity is a bicyclic system having the 4⬘-carbon tethered to the 2⬘-hydroxyl group, known as 2⬘,4⬘-BNA by Imanishi [125,126], and LNA by Wengel [127–129], who published shortly thereafter (Figure 6.7). This modification can also be thought of as a constrained analog of 2⬘-O-methyl RNA, where the 2⬘substituent is tethered to the 4⬘-C atom. This enforces a northern sugar pucker, which is essentially O
O O
B
O
HO
B
H2N O
F
4′-C-aminomethyl (with 2′-Fluoro)
Figure 6.6
Sugar modifications.
O 5′-(S)-hydroxymethyl
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 159
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES O O
O
O B
O
B
O
LNA (2′,4′-BNA) O
O
-L- LNA
O O
2′,4′-BNANC
B
O
ENA
O B
O NO
Figure 6.7
O O
O
O
O
159
O H O
B
O Oxetane 2′,3′-BNA
H
B
O
Tricyclo-DNA
Bicyclic sugars (BNAs).
identical to that adopted by A-form RNA and has been confirmed by structural analysis [130–132]. LNA shows dramatically improved hybridization properties relative to a DNA/RNA duplex, and improves nuclease resistance. The use of LNA in siRNAs has resulted in improved stability [133,134], and decreased immune stimulation [135], and LNA ASOs have successfully inhibited microRNA function in cell culture [136]. LNA has also been investigated for use in aptamer applications, as LNA/DNA hybrids were able to replace RNA in a TAR aptamer [137]. Replacement of specific nucleotides in the Tenascin-C binding aptamer TTA1 with LNA provided a molecule with improved target binding, stability in plasma, in vivo pharmacokinetics, and uptake to tumor [138], clearly demonstrating the potential of LNA to improve the in vivo properties of oligonucleotide aptamers. LNA has been reviewed in 2004, and many applications are highlighted [139]. Since uniform LNA oligonucleotides do not support RNase H [140], the most promising antisense applications of LNA employ a gapmer strategy. In a recent study, LNA gapmers targeted to H-Ras were able to reduce tumor growth with dosage levels of 1 mg/kg per day for 11 days of treatment, in the absence of toxicity as measured by plasma transaminase levels [141]. However, in an earlier study employing uniform LNA ASOs, transaminase levels were increased at a 5 mg/kg daily dose after 14 days [142]. In order to examine the effects on endogenous target genes, we examined the effects of LNA gapmers targeting mouse TRADD, PTEN, and ApoB in liver [143], and compared their potency and therapeutic index with the corresponding MOE gapmers. In some, but not all cases, the LNA gapmers increased potency, up to five- to tenfold over the MOE ASOs. However, they also showed profound hepatotoxicity as measured by serum transaminases, organ weights, and body weights. This toxicity was evident for multiple LNA sequences targeting each of the different biological targets, as well as in mismatch control sequences having no known mRNA targets. For example, the best LNA ASO targeting TRADD showed an ED50 of about 2 mg/kg when dosed twice weekly for 3 weeks. However, this ASO caused about fivefold and ⬎50-fold increases in liver transaminases at doses of about 5 and10 mg/kg, respectively. In contrast, a MOE ASO showed an ED50 of 13 mg/kg, and no toxicity at doses of over 40 mg/kg, which gave a ⬎86% reduction in target. These studies suggest that while LNA ASOs have the potential to improve antisense potency, they impose a significant risk of hepatotoxicity, which must be considered when designing LNAcontaining antisense therapeutics. The mechanism of the hepatotoxicity, as well as the sequence dependence of this toxicity, is unknown. LNA oligonucleotides are nearing human clinical trials, and will be reviewed in greater detail in Chapter 19 of this volume.
CRC_8796_ch006.qxd
5/24/2007
12:03
160
Page 160
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
␣-L-LNA After the discovery of LNA, the Wengel group investigated the duplex stability of the eight possible stereoisomers of LNA by preparing four diastereomeric isomers, and inferring the properties of the other four enantiomers by comparing their hybridization properties to both D-RNA and L-RNA [144]. This work resulted in the surprising observation that ␣-L-LNA (Figure 6.7), which contains the 2⬘,4⬘-bridge on the same side of the sugar as the nucleobases, along with an inversion of the 3⬘-hydroxy, has nearly the same affinity for target RNA as does LNA. All other isomers either did not hybridize, or were significantly reduced in affinity, relative to LNA. Subsequent structural studies showed ␣-L-LNA to assume a DNA-like southern conformation, and form H-form duplexes with target RNA [145,146]. These observations suggest that the dogma that a northern sugar pucker is the major determinant of high binding affinity is not necessarily correct, and that conformational preorganization is a major factor. Despite being locked into a southern conformation, ␣-L-LNA does not support RNase H, and has been utilized successfully in gapmer ASO designs [147]. ␣-L-LNA shows increased nuclease resistance over LNA, and evaluation of an ␣-L-LNA version of the H-Ras sequence for reduction of tumor growth in a xenograft model found it to be slightly more effective than LNA [141]. To date, the toxicological properties of ␣-L-LNA are unknown, and the potential of this interesting modification will only be understood with continued rigorous in vivo studies.
Other 2⬘,4⬘-Bicyclic Sugars Related to LNA are other classes of 2⬘,4⬘ linked BNAs such as 2⬘-amino and 2⬘-thio LNA [148]. These analogs were also studied in the H-Ras sequence, and found to be slightly less effective than LNA [141]. The tissue distribution was different, highlighting the ability to alter distribution by modulating charge and lipophilicity. Ethylene nucleic acid (ENA, Figure 6.7) contains a two-carbon-atom bridge as opposed to a single atom bridge, has similar affinity, and improved nuclease resistance relative to LNA [149]. ENA has shown antisense activity in cell culture in gapmer designs [150,151] and as uniformly modified ASOs working via a steric blocking mechanism [152]. Several other 2⬘,4⬘ BNA analogs have been reported, which include additional atoms [153] or rearrangement of the oxygen and carbon atoms [154], both of which reduce hybridization relative to LNA and ENA, but are still stabilizing. Substitution of a hydroxylamino moiety to give a 2⬘,4⬘-BNA having a 2⬘-O–N–C bridged system (2⬘,4⬘-BNANC, Figure 6.7) increased affinity slightly over LNA, and increased nuclease resistance [155]. As such, this modification appears superior to LNA in its biophysical properties.
1⬘,4⬘-Bicyclic Sugars A bicyclo[3.2.1]octane system employing a 1⬘-C,4⬘ bridge adopted an O4⬘-endo furanose conformation. The 1⬘-CH2–O–CH2-4⬘ bridging group adopted a chair-like conformation of the resulting 1,4-dioxane ring. It was modestly destabilizing to RNA, having a ⌬Tm of –1.5°C per modification [156]. This was ascribed in part to steric clashes involving the dioxane bridging ring, and highlights the unique properties of the 2⬘,4⬘-bicyclic structures in improving hybridization properties to DNA and RNA targets.
1⬘,2⬘-Bicyclic Sugars Oxetanes formed by 1⬘-C,2⬘-O bridges are highly destabilizing when paired to RNA, having a ⌬Tm of around ⫺5°C per modification for the pyrimidines, and do not support RNase H cleavage near the modification site. Interestingly, the purines were essentially neutral when paired to RNA complements, relative to the DNA. This is despite all nucleosides having a north-eastern conformational bias [157]. Not surprisingly, these modifications did not improve potency over PS oligodeoxynucleotides [158].
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 161
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
161
2⬘,3⬘-Bicyclic Sugars Both oxetane and tetrahydrofuran 2⬘-O,3⬘-C bridged arabinose derivatives, which have the bridging group on the alpha-face of the nucleoside, have been reported [159]. The oxetane analog (Figure 6.7) adopts an eastern-like O4⬘-endo sugar conformation in B-DNA [160], and showed an increase in affinity for target RNA, with a ⌬Tm of ⬃1°C per modification. It was destabilizing by about ⫺1°C versus DNA targets. The tetrahydrofuran, predicted to assume a C1⬘-exo conformation was highly destabilizing.
3⬘,5⬘-Bicyclic Sugars Analogs of DNA utilizing 5⬘-amino nucleosides and a P3⬘→N5⬘ phosphoramidite linkage are known to be destabilizing. This was corrected by constraint via a 3⬘-C,5⬘-N methylene bridge to provide a 5⬘-amino 3⬘,5⬘-BNA, which was neutral when paired to DNA and moderately stabilizing when paired to RNA [161]. A bicyclic DNA analog having a 3⬘-C,5⬘-C bridged bicyclo[3.3.0] octane system (bicycloDNA) [162] has been elaborated to a tricyclic analog having a spirocyclopropyl ring at the 5⬘-C position (tricyclo-DNA, Figure 6.7) [163]. This system has been shown to adopt a DNAlike southern conformation, increase affinity for complementary DNA and RNA, and increase nuclease resistance. Use in a mixed sequence gave an increase in Tm of over 2°C per modification versus an RNA target, and this same sequence improved potency over a 2⬘-O-methyl ASO in a splicing application in cell culture [164]. Uniformly modified tricyclo-DNA oligonucleotides from 11 to 15 bases in length were four- to fivefold more potent than the corresponding LNA oligonucleotides, despite having lower affinity for the complementary RNA by about 25°C [165]. This result was rationalized by the observation of differential distribution within cells by fluorescence microscopy after transfection. Because of these observations, tricycloDNA is an interesting modification that merits further investigation in animal studies for its antisense effects.
Other Bicyclic Sugar Modifications Early efforts at constraint of oligonucleotide monomers focused on the use of small rings to enforce a predominant sugar conformation. Carbocyclic nucleosides having cyclopropyl bridges on either side of the methylene substituted for the furanose oxygen atom were found to be slightly stabilizing with a 1⬘,6⬘ bridge, and slightly stabilizing with a 4⬘,6⬘ bridge [166–168]. Oxetane constrained bicyclic nucleosides having a 3⬘-O,4⬘-C bridging group involving the C3⬘ hydroxyl adopt a southern-type conformation [169]. When incorporated into oligonucleotides using a 2⬘,5⬘-linkage, they are modestly destabilizing to RNA with multiple incorporations, but can be stabilizing with single incorporations. The modification was highly destabilizing when paired with DNA, and increased nuclease resistance. However, somewhat surprisingly, the increase was not dramatic [170]. An isomeric alpha-L version was also highly destabilizing [171]. A trans-3⬘-C,4⬘-C bridged structure, which is restricted to a southern conformation, was strongly destabilizing when paired with RNA or DNA [172].
6.3.3.4 Substitutions for the Ribofuranose Sugar 4⬘-Thioribose A simple substitution of sulfur for the furanose oxygen in RNA or DNA provides 4⬘-thio nucleic acids. 2⬘-Deoxy-4⬘-thioribose was modestly stabilizing, and improved resistance to endo, but not 3⬘-exo nucleases [173]. Regardless of the properties conferred upon an oligonucleotide, the use of
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 162
162
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
2⬘-deoxy-4⬘-thioribose for oligonucleotide therapeutics would be unwise given the cellular toxicity of the nucleoside monomers. In contrast, the 4⬘-thioribose modification (4⬘-thio-RNA, Figure 6.8) is not known to suffer these limits. It has been prepared originally by Imbach. They showed that phosphodiester 4⬘-thio-RNA oligomers improved hybridization to RNA targets, and were significantly more resistant to cleavage by serum nucleases than unmodified phosphodiester RNA [174,175]. Crystallography studies have shown that 4⬘-thio-RNA hybridizes with complementary RNA sequences to form stable duplexes with standard A-form helical geometry [176]. As other nucleoside modifications incorporating sulfur have shown improved binding to plasma proteins, it is also possible that 4⬘-thio-RNA incorporated into oligonucleotides could alter pharmacokinetic properties, but to date, no in vivo studies have been reported. These properties make 4⬘-thio-RNA a structurally similar yet nuclease-resistant analog of wildtype RNA and hence attractive for applications in oligonucleotide drug optimization efforts. Accordingly, 4⬘-thio-RNA has been examined for applicability to siRNA applications, and shown to maintain [177] or slightly improve activity and stability [178] when utilized in certain contexts. 4⬘-Thio-RNA forms exceptionally stable duplexes when paired with a complementary 4⬘-thio-RNA strand [179]. This property, combined with the nuclease resistance profile, was exploited to optimize the stability of an aptamer [180].
Other Sugar Analogs Having Five-Membered Rings Substitution of the furanose oxygen atom with nitrogen and carbon has been explored to a lesser extent than 4⬘-thio-RNA. In general, carbocyclic neucleosides either reduce or do not substantially change affinity, depending upon the nature and location of other substituents [181,182]. Substitution of the methylene replacing the furanose oxygen with acylated aminosugars was strongly destabilizing [183]. Nuclease resistance was generally increased for both azasugars and carbocycles, but the profile of these modifications, especially given the difficulty of synthesis, did not merit continued investment. A threofuranosyl-(3→2⬘)-linked nucleic acid analog (TNA) has been prepared [184], which is stabilizing when paired with RNA. The structure of this duplex has been studied and provides a rationale for the affinity [185]. Additional phosphoramidite analogs of the TNA system are essentially neutral when paired with RNA, relative to an RNA/DNA duplex [185]. None of the TNA analogs have been investigated for antisense applications to date.
Sugar Analogs Having Six-Membered Rings Due to their increased conformational rigidity relative to furanoses, hexoses have the potential to have superior hybridization properties, and would be expected to be highly nuclease-resistant. Pyranosyl sugar–derived nucleic acids have been studied and reviewed extensively by Eschenmoser [186]. They often display excellent Watson–Crick base-pairing properties that have been rationalized by structural studies [187], but do not hybridize well to DNA or RNA. As such, they have not been explored for antisense applications of oligonucleotide drugs. However, they could have potential utility in aptamer-derived oligonucleotide drugs.
O
O S
O
B OH
4′-Thioribose
Figure 6.8
Sugar substitutions.
O O
O
B HNA
O O
O
B OCH3
2′-O-methyl ANA
O
B CeNA
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 163
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
163
In contrast, a family of hexitol-derived nucleic acids, pioneered and reviewed by Van Aerschot [188] and Herdewijn [189], hybridizes well to RNA. The lead modification in this family, termed hexitol nucleic acid (HNA, Figure 6.8) forms very stable duplexes with RNA (⌬Tm ⬃ ⫹3°C per modification), and is selective for RNA over DNA. HNA also has clear mismatch discrimination, and shows a high level of resistance to nucleases. HNA/RNA duplexes are poor substrates for RNase H, but antisense activity has been shown both in translation arrest or steric blocking mechanisms [190], and in gapmer motifs [191]. HNA has also been used to improve the properties of an anti-TAR aptamer [192]. An NMR structure of an HNA duplex has been solved, and its surprising similarity to A-form RNA structures provides insights into the mode of binding enhancement [193,194]. Analogs of HNA that have an additional hydroxyl in an axial (altritol derived sugar, ANA) conformation display improved hybridization to RNA, but those with the hydroxyl in an equatorial position (mannitol-derived sugar) show very poor affinity. Methylation of the hydroxyl group to provide 2⬘-O-methyl-ANA (Figure 6.8) further improved affinity (⌬Tm ⬃ ⫹4°C per modification), and simplified synthesis, providing the most promising hexitol nucleoside to date based on hybridization properties versus RNA targets [195]. Cyclohexenyl analogs of HNA (termed CeNA, Figure 6.8) contain an ethylene unit substituted for the furanose oxygen atom in DNA. They have been found to be modestly destabilizing toward DNA, and stabilizing when paired with RNA [196]. This has been attributed to flexibility introduced by the cyclohexenyl system as opposed to a more rigid cyclohexane system, and the flexibility demonstrated in an NMR study [197]. CeNA has been shown to support RNase H cleavage of an RNA complement, though at a high enzyme concentration and low efficiency. It is therefore likely that CeNA would have to be utilized in a gapmer motif for antisense applications. Therefore, because of lower affinity and complex synthesis relative to other sugar modifications, its potential utility is limited. 6.3.4
Heterocyclic Modifications
Historically, very few heterocycle modifications that increase nuclease resistance have been found. As such, modification of the heterocycle has focused mainly on increasing binding affinity for complementary nucleic acids. This may be accomplished through increasing stacking interactions, or by increasing the strength of the Watson–Crick base pairs. Preserving Watson–Crick hydrogen-bonding interactions is of critical importance for the recognition of the receptor by antisense drugs, and for maintaining the proper structure of aptamer-based drugs. This prohibits alteration of the hydrogen bond donor–acceptor footprint of the bases. Furthermore, substitution near the glycoside bond often disrupts the glycosidic torsion angle, which usually results in poor hybridization. These considerations place severe design constraints on modification to the heterocycles, such that there are very few positions on the heterocyclic bases that can be productively modified. It is therefore not surprising that in spite of more than two decades of significant research effort, there has been only modest progress in identifying a base-modified chemistry that demonstrated meaningful and safe in vivo pharmacology in animal models. In the following sections, we highlight some key heterocyclic modifications to highlight their unique properties, potential utilities, and known liabilities. A number of comprehensive review articles regarding heterocyclic modified oligonucleotides have been published, and we refer the interested reader to these for more in-depth coverage [198–200].
6.3.4.1 Pyrimidine 5⬘⬘-Position Modifications C5 Alkyl and Halogen Substitution The C5 position has been one of the most common places for chemical manipulations on pyrimidine heterocycles, as modification of this site has little effect on Watson–Crick base pairing. Furthermore, substitution at the 5-position places the modification directly above the 5⬘-side
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 164
164
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
heterocyclic base. This suggests substitutions that would be expected to enhance the base stacking properties should provide increases in affinity. For example, a simple modification such as substituting C5 hydrogen of deoxycytidine with a methyl group (Figure 6.9) improves the Tm of the DNA/RNA duplex by about 0.5°C per substitution [5] while a slightly larger group such as 5-ethyl was destabilizing [201]. Because of the affinity increase of the 5-methyl group, combined with reduction in immunostimulatory toxicities [202], 5-methylcytosine is broadly used in place of cytosine for most modified “C” nucleosides. The effect on affinity of a halogen substitution at C-5 position in pyrimidines is similar to methyl. For use in oligonucleotide therapeutics, however, 5-halopyrimidines should not be considered due to the chemical reactivity and biological activities of the bases and nucleosides.
Propynes Since the stacking interactions between the planar heterocycles of nucleic acids are in large part responsible for the stability of DNA and RNA duplexes [203], enhancing them with additional aromatic or -rich surfaces is a logical way to increase duplex stability, and presumably affinity for a target RNA. This prompted substituting the C5 position with a propynyl group (Figure 6.9) to enhance the stacking interactions in duplex helices [204]. Enhanced duplex stability (⌬Tm ⬃ ⫹2°C per modification) and potent gene-specific inhibition was achieved in vitro using T- and C-rich PS
O
O
NH
NH N
N
O
5-Propynyluracil NH2
N
N
N
O
N
5-Methylcytosine
N
N
N
N
N
N
NH2
N N
NH2
N N
NH2
NH
O
NH N
O
5-Thiazolylcytosine
O
NH
Guanine NH2 N2-Aminopropylguanine Figure 6.9
N
NH O
O NH
N
O
Phenoxazine
O
NH2
O
N N
O
5-Thiazolyluracil S
5-Propynylcytosine
Diaminopurine
Adenine
N
N
NH2
NH2 N
N
O
NH
O
NH2
Cytosine
N
N
NH2
N
N
S
O
N
NH
2-Thiothymine
Thymine
S
O
The DNA bases and selected heterocyclic modifications.
N N
O
G-Clamp
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 165
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
165
oligodeoxynucleotides poly-substituted with 5-propynyl nucleosides [205,206]. Mechanistic studies implicated RNase H cleavage and intracellular dissociation rates as the limiting factors in activity [207]. A length SAR study led to the discovery that poly propynylated ASOs as short as seven nucleotides in length could exert potent antisense effects [208]. Though this extremely short length has potential negative implications in terms of specificity for the target gene, there are many benefits including cost of manufacture. The presence of C-5 propynyl pyrimidine bases did not interfere with the RNase H cleavage kinetics but were found to be more toxic than unmodified counterparts when tested in vitro [209]. Monia and coworkers evaluated the effect of the propyne modification both in vitro and in vivo [210]. They found that 5-propynyl pyrimidine modification, whether incorporated as a deoxy nucleoside or as a MOE nucleoside, showed substantial increase in affinity toward complementary RNA target. However, the in vitro data show only a moderate increase in potency for a propyne PS oligodeoxynucleotide ASO targeting murine PTEN. No such improvement was observed with MOE gapmer ASOs containing 5-propynyl substitution, and all propynyl-modified ASOs were found to have similar or reduced potency as compared to the parent MOE gapmer. in vivo studies paralleled this result, where the MOE gapmer ASO was the most potent compound, and was not outperformed by any configuration of propyne ASO. Furthermore, the propynyl pyrimidine containing PS oligodeoxynucleotide induced severe liver toxicity after a single administration at 20 mg/kg and was lethal at 50 mg/kg. The hepatotoxicity was reduced by using a gap design ASO in which the C-propynyl group was placed only in MOE-modified nucleotides; however, potency was not increased, and toxicity was still evident. Given the lack of improvement in in vivo activity coupled with the severe in vivo toxicity, it is likely that C5 propynyl-modified oligonucleotides will not be useful in oligonucleotide drugs.
Thiazoles Several 5-heteroaryl-substituents that are coplanar with the pyrimidine ring have been shown to possess duplex-stabilizing properties due to increased stacking interactions [211]. Similar to the propynes, 5-thiazolo-substituted oligonucleotides (Figure 6.9) showed high affinity (⌬Tm about ⫹1.7°C) for complementary RNA, compared to DNA. The nature of the heterocycle is important, as protons adjacent to the biaryl linkage cause twisting of the C5 aromatic group out of plane, which decreases the stacking interaction and reduces the gain in affinity. Whether these modifications share the same toxicity profile with propynes is unknown, but it is possible they would have a different profile due to the differences in electronic effects between the alkyne and the thiazole heterocycle. However, unlike propynes and phenoxazines described below, they do not support RNase H or show activity in cell culture when incorporated throughout the oligonucleotide [207]. This discrepancy is as yet unexplained, but limits the use of thiazoles to gapmer designs where other modifications such as 2⬘- and bicyclic modifications adequately increase affinity. The utility of the thiazoles is therefore likely to be limited, regardless of their toxicity profile, unless they are additive in Tm with 2⬘-modifications.
6.3.4.2 Tricyclic Cytosine Analogs Phenoxazine Cytosine analogs containing a lipophilic phenothiazine or phenoxazine (Figure 6.9) substitution were synthesized and incorporated into ASOs by Matteucci and coworkers [212]. These tricyclic compounds were shown to specifically pair with guanosine, and increased affinity dramatically (⌬Tm ⫹6°C). Incorporation of 4-phenoxazine bases in a 7mer PS oligonucleotide targeting Tag expression showed a five-fold increase in relative binding affinity for its RNA target [213]. RNase H was found to cleave the tag RNA opposite to phenoxazine dimers. Most importantly, the
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 166
166
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
phenoxazine containing ASO had activity in cell culture without the aid of delivery methods, giving an IC50 of 5 M. Fluorescence labeling experiments found the uptake to be length-dependent, and showed nuclear staining only with phenoxazine-containing ASOs. These experiments suggest that lipophilicity and size of the oligonucleotide are important for uptake into cells, concepts well established among small-molecule medicinal chemists. Whether these observations translate to improved activity in vivo is unknown, and no animal results have been described in the intervening years since publication of the initial reports.
G-Clamp The success with phenoxazine led to the addition of an aminopropyl-substituted phenoxazine termed G-Clamp (Figure 6.9), which as a single incorporation in a 10mer sequence increased Tm by an astounding 18°C [214]. This affinity did not come at the expense of selectivity, as shown with mismatch studies. A model where the aminopropyl group forms an additional hydrogen bond to the major groove side of guanine in a C:G base pair was proposed to rationalize the results. A single substitution of a G-clamp into a 15mer PS oligonucleotide was found to enhance antisense activity compared to propynyl-modified ASO when tested in CV1 cells [215]. Furthermore, the G-clamp increased potency 25-fold when substituted into a 20mer PS oligodeoxynucleotide. The G-clamp modification, like the propynes and phenoxazines, is reported to support RNase H. The synthesis and subsequent structural studies on guanidinium-modified G-clamp has been reported [216]. The guanidinium G-clamp analog increased affinity in a similar manner as the original version, and structural data supported the major groove side hydrogen-bonding model originally proposed by Matteucci. The synthesis of 2⬘-O-methyl and MOE modified G-clamps along with their in vitro activity has been reported [217,218]. The analogs both improved potency in cellculture applications. As with the phenoxazine, whether this improved activity in cell culture will translate to improved in vivo activity remains unknown.
6.3.4.3 Other Pyrimidine Modifications The replacement of oxygen at the C2 and C4 positions of thymine have been investigated [219,220]. Sulfur is bulkier, more polarizable, and is a weaker hydrogen-bond acceptor compared to oxygen. As a result, it increases stacking interactions. Substitution of sulfur for oxygen at C4 of thymine gave a modest improvement in duplex stability, which is surprising, given the expected loss of a hydrogen-bond acceptor. Incorporation of 2-thiothymidine (Figure 6.9) leads to sequencedependent stabilization of the duplex. This is probably a combination of enhancement of stacking interactions, and an effect on sugar conformation, as the 2⬘-thio substitution imposes a C-3⬘-endo (northern) pucker. Combination of the 2-thio and a sugar-2⬘-modification such as 2⬘-fluoro or MOE improved thermodynamic stability and nuclease resistance, and the effects rationalized by crystallography studies [221]. No in vitro or in vivo activity has been reported to date.
6.3.4.4 Purine Modifications Diaminopurine The 2-amino-2⬘-deoxyadenosine modification employs a diaminopurine base (Figure 6.9), which donates a third hydrogen bond and is therefore analogous to a GC base pair [222,223]. The resulting increase DNA/RNA duplex stability is reflected in increases in Tm of between 1.4°C and 1.8°C per incorporation over the unmodified wild-type duplex [224]. Diaminopurine unfortunately increases the rate of depurination under acidic conditions, which limits the practical utility of this otherwise interesting modification.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 167
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
167
N2-Substituted Guanine Both an N2-imidazolylpropyl [225] and N2-aminopropyl [226] guanine analogs (Figure 6.9) showed a duplex stabilization (⌬Tm⫹1°C to⫹3.3°C) with a single substitution. The cationic group is believed to lie in the minor groove, making key new contacts with the phosphate backbone.
Deazapurines Several heterocyclic modifications have been reported in deaza series where a nitrogen atom was replaced with a carbon atom. These modifications did not improve affinity to any significant degree. However, the propynyl substitution on 2-amino-7-deaza-adenosine stabilizes duplexes considerably [227]. Increased RNA-binding affinity has also been reported for oligonucleotides incorporating 7-propynyl-7-deazadeoxy adenosine or 7-propynyl-7-deazadeoxyguanosine [228]. Despite these improvements, the use of 7-deazapurines carries a large toxicity risk, due to the known toxicities of this class of nucleosides. Furthermore, the synthesis of these compounds is laborious, making the preparation of quantities suitable for evaluation in animals difficult. 6.3.5
Conjugates
In attempts to alter and improve the pharmacokinetics of oligonucleotide drugs, many conjugation strategies have been investigated. In the simplest form, pegylation of an oligonucleotide to increase the size sufficiently to prevent renal filtration can dramatically improve plasma half-life. This is likely to be broadly useful for applications (such as aptamers) where the active compartment is in the plasma, but does not improve distribution to tissues. Conjugation of oligonucleotides to ligands that can bind to various acceptor sites would be expected to alter the pharmacokinetic properties of the oligonucleotide, and many attempts have been made to increase tissue and cellular uptake of oligonucleotide drugs via conjugation of various ligands. We will briefly address some recent applications of conjugated oligonucleotides, and refer the interested reader to comprehensive review articles for more in-depth coverage [229,230].
6.3.5.1 Cholesterol Conjugates Cholesterol conjugates of oligonucleotide are one of the most studied classes of conjugates. Cholesterol conjugation has been clearly shown to increase the exposure of an ICAM-1 targeted PS oligonucleotides to liver, with a concomitant reduction in exposure to kidney [101]. The cholesterol conjugate maintained activity in cell culture, and showed activity in vivo at doses where the unconjugated oligonucleotide had no effect [229]. This is consistent with improved distribution to liver. In subsequent pharmacokinetic studies, the uptake to liver endothelial cells was shown to be greatly increased, presumably due to increased binding to LDL for the cholesterol-conjugated oligonucleotide [231,232]. A bis-cholesterol conjugated oligonucleotide was found to lead to almost complete hepatic uptake of the oligonucleotide [233]. More recently, intravenously administered cholesterol-conjugated anti-microRNA oligonucleotides (Figure 6.10) resulted in inhibition of mirRNA function for the liver expressed miR-122. In this case, the cholesterol conjugation allowed use of a mostly phosphodiester oligonucleotide (2 or 3 PSs were used at each end for stability), which would be expected to have poor tissue uptake in the absence of the cholesterol conjugate [234]. Also described were broad systemic effects of the oligonucleotide in tissues other than liver, which is somewhat inconsistent with previous studies using fully PS cholesterol–conjugated oligonucleotides. The observed distribution of cholesterol-conjugated oligonucleotide to tissues other than liver is likely due to a combination of the phosphodiester backbone with the high (80 mg/kg) intravenous dose. Since the presence of high tissue concentrations of
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 168
168
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION B OCH3
O O O
5′
H (CH2)5 N
O
O
O P
S
N
O
O OH
3′-Cholesterol-conjugated microRNA inhibitor O
O N H
O OH
S P
O O HN S P O O
B
O
HN
B 12
H
GRN163L Figure 6.10 Design of lipophilic conjugates.
antisense oligonucleotide makes northern blot detection of the target microRNA technically problematic, the broad reduction of microRNA observed in many tissues should be interpreted with caution until verification of microRNA reduction can be achieved by another method. In a similar study, cholesterol conjugation was used to demonstrate activity of a duplex siRNA drug in mice. Conjugation of cholesterol at the 3⬘ end of sense strand of a duplex siRNA and intravenous administration gave reduction of apolipoprotein B (ApoB) mRNA in liver and jejunum, as well as the expected decrease in plasma levels of ApoB protein and cholesterol [96]. The nonconjugated ApoB siRNA was inactive. While clearly important for establishing proof of concept for the utility of chemical modifications to enable siRNA activity in vivo, the generality of this approach is unknown. Furthermore, cholesterol conjugation raises concerns regarding toxicity, and increased toxicity of cholesterol-conjugated oligonucleotides has been observed, although it is possible that this is due to increased tissue exposure [235]. While cholesterol conjugation may have utility as research tools, it is our opinion that cholesterol conjugation is unlikely to be broadly useful for oligonucleotide drugs.
6.3.5.2 Fatty Acid Conjugates In addition to cholesterol, other lipid groups can alter distribution of oligonucleotides in animals. Similar to cholesterol, but to a lesser degree, modification with fatty acid chains (C18 in this study) increased exposure to liver [101]. Lipid modification with a palmitoyl (C16) functionality has been shown to enhance the potency of a 13mer telomerase inhibitor (Figure 6.10) in cell culture and in vivo [236]. Increased levels of telomerase inhibition in xenograft tumor were demonstrated for the lipid conjugate, which correlated with increased drug levels relative to the unconjugated analog. This suggests that the appropriate lipophilic groups can influence uptake, distribution, and potency of oligonucleotides in vivo. Although detailed structure–activity relationships of various lipid conjugates have not been reported, nor have toxicology studies, we expect simple fatty acid conjugation to be useful for oligonucleotide drugs, especially for improving the pharmacokinetics of shorter oligonucleotides, or those with reduced PS content.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 169
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
169
6.4 OPTIMIZING OLIGONUCLEOTIDE DRUGS 6.4.1
General Strategies
It is extremely likely that no one modification will be found that confers optimal properties upon an oligonucleotide. By analogy, it would be unreasonable to expect one chemical substitution (a chlorine atom, for example) to confer increased potency, and improved pharmacokinetic properties upon a range of small molecules. Just as with traditional medicinal chemistry applied to small molecules, a successful oligonucleotide medicinal chemistry optimization must utilize various chemical modifications together, at the appropriate position in the oligonucleotide to achieve the desired outcome. For antisense oligonucleotide modifications, a heavy emphasis has often been given to biophysical properties such as affinity and stability to 3⬘-exonucleases such as snake venom phosphodiesterase. A modification that “passes” these tests was then substituted into a gapmer and a uniform design, and tested in cell culture. Seldom was the oligonucleotide optimized to suit the modification, which may help explain the often disappointing results and lack of a clear SAR. Furthermore, the endpoints must be sufficiently robust and relevant to provide a meaningful SAR set to guide the optimization process. The traditional path has been biophysical studies, followed by cell culture experiments, followed by in vivo studies with a few limited motifs. In general, we feel that time and effort spent studying model systems (such as complex reporter systems, cell free assays, cell uptake systems, etc.) does not get one closer to understanding the structural features responsible for activity in a system more relevant to improving drug properties (potency, pharmacokinetics, toxicity). Once a modification has demonstrated acceptable basic physiochemical properties (reasonable hybridization properties, for example), in vivo studies should be carried out with as many motifs as possible as soon as possible. Preferred endpoints for this optimization are drug levels and target reduction in liver, and measures of toxicity such as organ weights, body weights, and plasma transaminases. This type of approach is increasingly more tractable due to the availability of medium-scale synthesizers (like the Pharmacia AKTA) that consume low levels of amidite excess, such that less than about a gram of amidite can supply enough oligonucleotide for a first-pass mouse experiment. Murine TRADD, PTEN, and ApoB have been excellent systems for studying ASO designs using this paradigm. 6.4.2
Oligonucleotide Design Strategies
6.4.2.1 Gapmer Designs Current second-generation antisense drugs are combinations of three different monomer types: a PS backbone, a deoxyribose gap, and MOE wings (Figure 6.11). Each modification serves a purpose, and the placement is appropriate for that purpose. The 2⬘-deoxy gap region allows for the recruitment of RNase H by the oligonucleotide/target RNA duplex. The PS stabilizes the molecule to degradation by nucleases, and confers a fairly broad protein-binding character onto the molecule. This, among other things, prevents filtration by greatly increasing binding to plasma proteins. The MOE further increases nuclease resistance and stability in tissues, decreases toxicities, and increases binding affinity for the target RNA. These combined properties greatly improve potency and make the second-generation ASO platform very promising. This is exemplified by the performance of ISIS-301012 in early clinical trials, where it showed a dose dependent reduction of ApoB protein concurrent with lowering of LDL cholesterol. Doses as low as 100 mg/week produced statistically significant reductions in ApoB protein, and a dose of 200 mg/week reduced serum ApoB protein by 50% [237]. Second-generation MOE oligonucleotides are discussed in detail in Chapters 10–14 of this volume. This fairly simple combination of modifications can be further optimized for a specific utility by varying the size of the gap region, and/or the length of the molecule to improve activity, as discussed in Chapter 17 of this volume.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 170
170
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION 5′ Wing
3′ Wing
Gap
GCCTC AGTCTGCTTC GCACC HO
O S P O O
O
O
O
O
B O OCH3 O
O
B O
O S P O O
O
B
O O
B
O S P O O
O OCH3 O
B HO
OCH3 MOE
B O OCH3
DNA
MOE
Figure 6.11 Gap design of ISIS-301012, a second-generation antisense oligonucleotide.
6.4.2.2 siRNA Designs To date, two general strategies of chemical modification have been employed when optimizing siRNA for systemic in vivo activity. The first approach aspires to remove as much RNA from the molecule as possible to maximize stability. This has been employed in a viral hepatitis model to show activity in reducing viral titer [81,82]. The design consisted of all 2⬘-fluoro and 2⬘-deoxy residues in the sense strand, which was further stabilized with inverted deoxy abasic residues at each end. This was combined with a heavily 2⬘-fluoro- and 2⬘-O-methyl-modified antisense strand that contained only a few RNA residues at the 5⬘ end. To improve exonuclease stability, PS linkages were employed at the 3⬘-end of the antisense strand. In a slightly different approach, the RNA has also been completely eliminated from the duplex siRNA by using alternating 2⬘-fluoro/ 2⬘-O-methyl motifs [83]. These designs improved potency in cell culture and stability, but no in vivo results have yet been reported. The second general approach is a more minimal modification strategy, where an siRNA lead is modified with 2⬘-O-methyl phosphorothioates at the 3⬘-ends to protect against exonucleases, and with 2⬘-O-methyl groups at precise sites within the duplex to protect against endonucleases. This strategy, when combined with a conjugation approach, gave activity in vivo [96]. Minimal 2⬘-Omethyl modification to specific locations in the sense and antisense strand have also been used to decrease the off-target effects of siRNAs [97]. Determining whether chemically modified siRNA designs will provide an acceptable therapeutic index with systemic administration at pharmacologically relevant doses requires designs that provide robust activity in animals. None of the current siRNA designs achieve this goal without the use of lipid formulations, and poor pharmacokinetic properties appear to be responsible for the observed discrepancy between potencies in cell culture and in animals. Detailed pharmacokinetic studies with modified siRNAs will be required to understand how to best optimize siRNA designs for in vivo activity. The properties of duplex RNA drugs such as siRNAs will be reviewed in detail in Chapters 16 and 17 of this volume.
6.4.2.3 Occupancy Only Designs Mechanisms that rely primarily on binding to target RNA include translation arrest, alteration of splicing, and inhibition of microRNA function. These mechanisms do not require activation of a termination event, and as such, the many high-affinity modifications that do not support terminating mechanisms can be applied in the optimization effort. This opens up design possibilities employing multiple modifications to improve potency and pharmacokinetics. In practice, however, most reports have focused on oligonucleotides uniformly substituted with a single modification.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 171
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
171
As PNA and morpholino oligonucleotides do not induce a terminating event, they have been extensively used to both modulate splicing and inhibit translation. PNA and morpholino ASOs are reviewed in Chapters 18 and 20 of this volume, respectively. Uniform MOE ASOs have been shown to modulate splicing [238], and inhibit translation [239]. Additionally, a uniform MOE ASO was shown to redirect polyadenylation to form a more stable mRNA that altered protein expression [240]. It is also possible to use antisense strategies to inhibit microRNAs, which are negative regulators of gene. In a recent application, a uniformly modified MOE PS inhibited the function of a microRNA in liver, causing reductions in cholesterol as well as expected changes in gene expression [241]. In a related cell culture study, multiple uniform, and some motifs containing multiple modifications were examined for their ability to inhibit a microRNA, and a clear SAR emerged suggesting that affinity as well as steric bulk were important factors [242]. It seems unlikely that any uniform modification strategy is optimal for all occupancyonly mechanisms, but detailed SAR studies employing multiple modifications have not been reported.
6.4.2.4 Aptamer Designs Aptamers have different design criteria than other oligonucleotides, as they must maintain binding to a target driven by three-dimensional structure, not Watson–Crick base pairing. Therefore, maintaining the three-dimensional structure is crucial during the optimization process. A common strategy is substitution of nucleosides in the stem structure with higher affinity and stabilizing modifications such as 2⬘-fluoro, 2⬘-O-methyl, LNA, or 4⬘-thioribose. To address pharmacokinetics, pegylation has been employed to prevent clearance of the aptamer from the desired compartment. Macugen (pegaptanib) is a result of this strategy, as it is pegylated, heavily modified with 2⬘-fluoro and 2⬘-O-methyl nucleosides, and contains only 2 unmodified RNA residues [79]. The use of the many modifications known to modulate the protein binding and stability of oligonucleotides holds promise for the development of aptamers having improved properties, including the ability to penetrate tissues and access intracellular targets. Aptamers are discussed in detail in Chapter 28 of this volume.
6.5 OUTLOOK Which modifications and designs hold the most promise for use in oligonucleotide drugs? Despite the common misperception that PS is something that should be engineered out of an oligonucleotide drug, it remains the backbone modification that has done the most to advance antisense technology. PS linkages improve stability while maintaining the ability to elicit RNase H activity, and contribute protein-binding properties that prevent rapid excretion and facilitate uptake to tissues. The most advanced sugar modification is MOE, which improves nuclease stability, affinity for target RNA, and can decrease toxicities. When combined with PS DNA using a gapmer design strategy, these properties produce molecules that display robust pharmacodynamic and pharmacological effects in animals, a goal that remains elusive for most other oligonucleotide drug classes. The success of this second-generation antisense design suggests that both MOE and PS will add substantial value to other oligonucleotide drug classes. Although less valuable for traditional antisense applications than MOE, 2⬘-fluoro and 2⬘-Omethyl have already been employed in the aptamer Macugen (pegaptanib), and are also likely to be useful for siRNA designs. Another sugar modification class that holds much promise is the BNAs, and LNA in particular. The large increases in affinity of the 2⬘,4⬘-BNAs such as LNA, combined with their increased stability to nucleases, makes them potentially important in many oligonucleotide drug applications. Although LNA oligonucleotides have entered clinical trials, some early experiments on the safety of LNA oligonucleotides in rodents raise concerns. It remains to be seen
CRC_8796_ch006.qxd
172
5/24/2007
12:03
Page 172
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
whether the toxicity profile of LNA is ultimately determined to be acceptable for broad use in oligonucleotide drugs. It should also be noted that there are many analogs of LNA in the 2⬘,4⬘-BNA class that have not been extensively investigated, and may not share this toxicity risk if it is found to be a liability. Less likely to be valuable are the heterocyclic modifications such as propynes, which have very significant toxicity liabilities, and G-clamp and other modifications that have unknown properties in vivo. Sugar replacements such as 4⬘-thioribose and HNA have interesting physiochemical properties, but appear to add little advantage over modifications such as MOE and the 2⬘,4⬘-BNAs for traditional antisense designs. Whether they will have utility in siRNAs, aptamers, or other drug classes remains to be seen. Neutral backbone modifications such as MMI have not progressed in recent years as in vivo studies on a few analogs have shown that they do not increase potency over simpler 2⬘-modifications such as MOE. Sugar-phosphate backbone replacements such as PNA and morpholino, continue to attract high levels of interest, but appear to be less potent than second-generation designs in vivo. This could be a result of less favorable pharmacokinetics, or not having an efficient terminating mechanism, or a combination of both. Lastly, modulating the protein-binding properties of oligonucleotides with simple lipophilic conjugates is likely to find utility; however, conjugate-directed cell and tissue targeting of oligonucleotides is not likely to succeed in therapeutic applications due to the complexity of designs and limitations of receptor-mediated uptake. Regardless of which modifications and designs ultimately prove useful, there is a promising future for oligonucleotide drugs, and therefore a need for oligonucleotide medicinal chemistry. It is clear that many good nucleic acid drug targets exist. In addition to traditional oligonucleotide drug targets such as coding RNAs, which continue to be exploited, new RNA targets are emerging. This is exemplified by the discovery of microRNAs, an entirely new class of RNAs, which are endogenous regulators of gene expression. Currently, the only practical way to “drug” these targets in a specific manner is using oligonucleotides. Thus, the application of sound medicinal chemistry principles to improve the potency and profile of oligonucleotide drugs holds much promise.
REFERENCES 1. Limbach, P. A., Crain, P. F., and McCloskey, J. A., Summary: the modified nucleosides of RNA, Nucleic Acids Res., 22, 2183–2196, 1994. 2. Griffey, R. H., Sasmor, H., and Greig, M. J., Oligonucleotide charge states in negative ionization electrospray-mass spectrometry are a function of solution ammonium ion concentration, J. Am. Soc. Mass Spectrom., 8, 155–160, 1997. 3. Cohen, J. S., Informational drugs: a new concept in pharmacology, Antisense Res. Dev., 1, 191–193, 1991. 4. McKay, R. A. et al., Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression, J. Biol. Chem., 274, 1715–1722, 1999. 5. Freier, S. M. and Altmann, K. H., The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes, Nucleic Acids Res., 25, 4429–4443, 1997. 6. Crooke, S. T., Antisense Drug Technology, Marcel Dekker, New York, 2001, p. 929. 7. Eckstein, F., Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev., 10, 117–121, 2000. 8. Stein, C. A. et al., Physicochemical properties of phosphorothioate oligodeoxynucleotides, Nucleic Acids Res., 16, 3209–3221, 1988. 9. Geary, R. S., Yu, R. Z., and Levin, A. A., Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides, Curr. Opin. Investig. Drugs, 2, 562–573, 2001. 10. Stec, W. J., Stereocontrolled synthesis of P-chiral analogs of oligonucleotides, in Antisense Research and Applications, Crooke, S. T. and Lebleu, B. L., eds., CRC Press, Boca Raton, FL, 1993, pp. 251–271. 11. Guga, P. et al., Oligo(nucleosides phosphorothioate)s, in Applied Antisense Oligonucleotide Technology, Stein, C. A. and Krieg, A. M., eds., Wiley, New York, 1998, pp. 23–50.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 173
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
173
12. Lu, Y., Recent advances in the stereocontrolled synthesis of antisense phosphorothioates, Mini Rev. Med. Chem., 6, 319–330, 2006. 13. Seeberger, P. H., Yau, E., and Caruthers, M. H., 2⬘-Deoxynucleoside dithiophosphates: synthesis and biological studies, J. Am. Chem. Soc., 117, 1472–1478, 1995. 14. Cummins, L. et al., Biochemical and physicochemical properties of phosphorodithioate DNA, Biochemistry, 35, 8734–8741, 1996. 15. Weisler, W. T. and Caruthers, M. H., Synthesis of phosphorodithioate DNA via sulfur-linked, baselabile protecting groups, J. Org. Chem., 61, 4272–4281, 1996. 16. Ghosh, M. K., Ghosh, K., and Cohen, J. S., Translation inhibition by phosphorothioate oligodeoxynucleotides in cell-free systems, Antisense Res. Dev., 2, 111–118, 1992. 17. Capaldi, D. C., Cole, D. L., and Ravikumar, V. T., Highly efficient solid phase synthesis of oligonucleotide analogs containing phosphorodithioate linkages, Nucleic Acids Res., 28, E40, 2000. 18. Spielvogel, B. F. et al., From boron analogues of amino acids to boronated DNA: potential new pharmaceuticals and neutron capture agents, Pure Appl. Chem., 63, 415, 1991. 19. Sood, A., Shaw, B. R., and Spiclvogel, B. F., Boron-containing nucleic acids. 2. Synthesis of oligodeoxynucleoside boranophosphates, J. Am. Chem. Soc., 112, 9000–9001, 1990. 20. Sergueev, D. S. and Shaw, B. R., H-Phosphonate approach for solid-phase synthesis of oligodeoxyribonucleoside boranophosphates and their characterization, J. Am. Chem. Soc., 120, 9417–9427, 1998. 21. Summers, J. S. and Shaw, B. R., Boranophosphates as mimics of natural phosphodiesters in DNA, Curr. Med. Chem., 8, 1147–1155, 2001. 22. Micklefield, J., Backbone modification of nucleic acids: synthesis, structure and therapeutic applications, Curr. Med. Chem., 8, 1157–1179, 2001. 23. Rait, V. et al., Boranophosphate nucleic acids—a versatile DNA backbone, Nucleos. Nucleot., 18, 1379–1380, 1999. 24. Rait, V. K. and Shaw, B. R., Boranophosphates support the RNase H cleavage of polyribonucleotides, Antisense Nucleic Acid Drug Dev., 9, 53–60, 1999. 25. Hall, A. H. et al., RNA interference using boranophosphate siRNAs: structure-activity relationships, Nucleic Acids Res., 32, 5991–6000, 2004. 26. Gryaznov, S. M. et al., Oligonucleotide N3⬘→P5⬘ phosphoramidates, Proc. Natl. Acad. Sci. USA, 92, 5798–5802, 1995. 27. Gryaznov, S. and Chen, J.-K., Oligodeoxyribonucleotide N3⬘→P5⬘ phosphoramidates: synthesis and hybridization properties, J. Am. Chem. Soc., 1994, 3143–3144, 1994. 28. Gryaznov, S. et al., Oligonucleotide N3⬘→P5⬘ phosphoramidates as antisense agents, Nucleic Acids Res., 24, 1508–1514, 1996. 29. Skorski, T. et al., Antileukemia effect of c-myc N3⬘→P5⬘ phosphoramidate antisense oligonucleotides in vivo, Proc. Natl. Acad. Sci. USA, 94, 3966–3971, 1997. 30. Faria, M. et al., Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo, Nat. Biotechnol., 19, 40–44, 2001. 31. Pongracz, K. and Gryaznov, S., Oligonucleotide N3⬘→P5⬘ thiophosphoramidates: synthesis and properties, Tetrahedron Lett., 40, 7661–7664, 1999. 32. Wang, E. S. et al., Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma, Blood, 103, 258–266, 2004. 33. Herbert, B. S. et al., Lipid modification of GRN163, an N3⬘→P5⬘ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition, Oncogene, 24, 5262–5268, 2005. 34. Dellinger, D. J. et al., Solid-phase chemical synthesis of phosphonoacetate and thiophosphonoacetate oligodeoxynucleotides, J. Am. Chem. Soc., 125, 940–950, 2003. 35. Yamada, C. M., Dellinger, D. M., and Caruthers, M. H., Synthesis and biochemical evaluation of phosphonoformate oligodeoxyribonucleotides, J. Amer. Chem. Soc., 128, 5251–5261, 2006. 36. Sheehan, D. et al., Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides, Nucleic Acids Res., 31, 4109–4118, 2003. 37. Heinemann, U. et al., Effect of a single 3⬘-methylene phosphonate linkage on the conformation of an A-DNA octamer double helix, Nucleic Acids Res., 19, 427–433, 1991. 38. An, H. et al., Synthesis of novel 3⬘-C-methylene thymidine and 5-methyluridine/cytidine H-phosphonates and phosphonamidites for new backbone modification of oligonucleotides, J. Org. Chem., 66, 2789–2801, 2001.
CRC_8796_ch006.qxd
174
5/24/2007
12:03
Page 174
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
39. Clark, R. E. et al., Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia, Bone Marrow Transplant., 23, 1303–1308, 1999. 40. Hamma, T. and Miller, P. S., Interactions of hairpin oligo-2⬘-O-methylribonucleotides containing methylphosphonate linkages with HIV TAR RNA, Antisense Nucleic Acid Drug Dev., 13, 19–30, 2003. 41. Leberton, J. et al., Comparison of two amides as backbone replacement of the phosphodiester linkage in oligodeoxynucleotides, Tetrahedron Lett., 35, 5225–5228, 1994. 42. De Mesmaeker, A. et al., Amides as a new type of backbone modification in oligonucleotides, Angew. Chem. Int. Ed. Engl., 33, 226, 1994. 43. De Mesmaeker, A. et al., Amide backbones with conformationally restricted furanose rings: highly improved affinity of the modified oligonucleotides for their RNA complements, Angew. Chem. Int. Ed. Engl., 35, 2790–2794, 1996. 44. De Mesmaeker, A. et al., Amide-modified oligonucleotides with preorganized backbone and furanose rings: highly increased thermodynamic stability of the duplexes formed with their RNA and DNA complements, Synlett, 1287–1290, 1997. 45. Mafalda, N. et al., Recognition of RNA by amide modified backbone nucleic acids: molecular dynamics simulations of DNA-RNA hybrids in aqueous solution, J. Am. Chem. Soc., 127, 6027–6038, 2005. 46. Pallan, P. S. et al., RNA-binding affinities and crystal structure of oligonucleotides containing fiveatom amide-based backbone structures, Biochemistry, 45, 8048–8057, 2006. 47. Sanghvi, Y. S. et al., Concept, discovery and development of MMI linkage: story of a novel linkage for antisense constructs, Nucleos. Nucleot., 16, 907–916, 1997. 48. Peoc’h, D. et al., Synthesis of 2⬘-substituted MMI linked nucleosidic dimers: an optimization study in search of high affinity oligonucleotides for use in antisense constructs, Nucleos. Nucleot. Nucleic Acids, 23, 411–438, 2004. 49. Jones, R. J. et al., Synthesis and binding properties of pyrimidine oligodeoxynucleoside analogs containing neutral phosphodiester replacements: the formacetal and 3⬘-thioforplacetal internucleoside linkages, J. Org. Chem., 58, 2983–2991, 1993. 50. Zhang, J., Shaw, J. T., and Matteucci, M. D., Synthesis and hybridization property of an oligonucleotide containing a 3-thioformacetal linked pentathymidylate, Bioorg. Med. Chem. Lett., 9, 319–322, 1999. 51. Cross, C. W., Rice, J. S., and Gao, X., Solution structure of an RNA:DNA hybrid duplex containing a 3⬘-thioformacetal linker and an RNA A-tract, Biochemistry, 36, 4096–4107, 1997. 52. He, G. X. et al., In vitro and in vivo activities of oligodeoxynucleotide-based thrombin inhibitors containing neutral formacetal linkages, J. Med. Chem., 41, 4224–4231, 1998. 53. Sanghvi, Y. S. and Cook, P. D., Carbohydrate modifications in antisense research, Oxford University Press, Washington, D.C., 1994, p. 260. 54. Sanghvi,Y. S., DNA with altered backbones in antisense applications, in Comprehensive Natural Products Chemistry, Barton, D. H. R., Nakanishi, K., and Kool, E. T., eds., Pergamon Press, Oxford, 1999, pp. 258–311. 55. Kurreck, J., Antisense technologies. Improvement through novel chemical modifications, Eur. J. Biochem., 270, 1628–1644, 2003. 56. Alter, J. et al., Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology, Nat. Med., 12, 175–177, 2006. 57. Sazani, P. et al., Systemically delivered antisense oligomers upregulate gene expression in mouse tissues, Nat. Biotechnol., 20, 1228–1233, 2002. 58. Devi, G. R. et al., In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors, Clin. Cancer Res., 11, 3930–3938, 2005. 59. Summerton, J., Morpholino antisense oligomers: the case for an RNase H-independent structural type, Biochim. Biophys. Acta, 1489, 141–158, 1999. 60. Summerton, J. et al., Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems, Antisense Nucleic Acid Drug Dev., 7, 63–70, 1997. 61. Summerton, J. and Weller, D., Morpholino antisense oligomers: design, preparation, and properties, Antisense Nucleic Acid Drug Dev., 7, 187–195, 1997. 62. Efimov, V. A. and Chakhmakhcheva, O. G., Synthesis of DNA mimics representing HypNA-pPNA hetero-oligomers, Methods Mol. Biol., 288, 147–164, 2005. 63. Efimov, V. A., Klykov, V. N., and Chakhmakhcheva, O. G., Phosphono peptide nucleic acids with a constrained hydroxyproline-based backbone, Nucleos. Nucleot. Nucleic Acids, 22, 593–599, 2003.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 175
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
175
64. Efimov, V. A. et al., Hydroxyproline-based DNA mimics provide an efficient gene silencing in vitro and in vivo, Nucleic Acids Res., 34, 2247–2257, 2006. 65. Morris, M. C. et al., Combination of a new generation of PNAs with a peptide-based carrier enables efficient targeting of cell cycle progression, Gene Ther., 11, 757–764, 2004. 66. Egholm, M. et al., PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules, Nature, 365, 566–568, 1993. 67. Nielsen, P. E. et al., Sequence-selective recognition of DNA by strand displacement with a thyminesubstituted polyamide, Science, 254, 1497–1500, 1991. 68. Nulf, C. J. and Corey, D., Intracellular inhibition of hepatitis C virus (HCV) internal ribosomal entry site (IRES)-dependent translation by peptide nucleic acids (PNAs) and locked nucleic acids (LNAs), Nucleic Acids Res., 32, 3792–3798, 2004. 69. Doyle, D. F. et al., Inhibition of gene expression inside cells by peptide nucleic acids: effect of mRNA target sequence, mismatched bases, and PNA length, Biochemistry, 40, 53–64, 2001. 70. Siwkowski, A. M. et al., Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing, Nucleic Acids Res., 32, 2695–2706, 2004. 71. Liu, B. et al., Transcription activation by a PNA-peptide chimera in a mammalian cell extract, Chem. Biol., 10, 909–916, 2003. 72. Janowski, B. A. et al., Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids, Nat. Chem. Biol., 1, 210–215, 2005. 73. Albertshofer, K. et al., Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid, J. Med. Chem., 48, 6741–6749, 2005. 74. Maier, M. A. et al., Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids, J. Med. Chem., 49, 2534–2542, 2006. 75. Haaima, G. et al., Peptide nucleic acids (PNAs) containing thymine monomers derived from chiral amino acids: hybridization and solubility properties of D-lysine PNA, Angew. Chem. Int. Ed., 35, 1939–1941, 1996. 76. Wancewicz, E. V. et al., Short basic peptides improve the pharmacokinetics and antisense activity of systemically delivered peptide nucleic acids, manuscript in preparation, 2007. 77. Altona, C. and Sundaralingam, M., Conformational analysis of the sugar ring in nucleosides and nucleotides. A new description using the concept of pseudorotation, J. Am. Chem. Soc., 94, 8205–8212, 1972. 78. Griffey, R. H. et al., New twists on nucleic acids: structural properties of modified nucleosides incorporated into oligonucleotides, in Carbohydrate Modifications in Antisense Research, Sanghvi, Y. S. and Cook, P. D., eds., Oxford University Press, Washington, D.C., 1994, pp. 212–224. 79. Ng, E. W. et al., Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease, Nat. Rev. Drug Discov., 5, 123–132, 2006. 80. Chiu, Y. L. and Rana, T. M., siRNA function in RNAi: A chemical modification analysis, RNA, 9, 1034–1048, 2003. 81. Morrissey, D. V. et al., Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication, Hepatology, 41, 1349–1356, 2005. 82. Morrissey, D. V. et al., Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs, Nat. Biotechnol., 23, 1002–1007, 2005. 83. Allerson, C. R. et al., Fully 2⬘-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA, J. Med. Chem., 48, 901–904, 2005. 84. Koller, E. et al., Competition for RISC binding predicts in vitro potency of siRNA, Nucl. Acids Res., gkl589, 2006. 85. Monia, B. P. et al., Evaluation of 2⬘-modified oligonucleotides containing 2⬘-deoxy gaps as antisense inhibitors of gene expression, J. Biol. Chem., 268, 14,514–14,522, 1993. 86. Kawasaki, A. M. et al., Uniformly modified 2⬘-deoxy-2⬘-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets, J. Med. Chem., 36, 831–841, 1993. 87. Damha, M. J. et al., Hybrids of RNA and arabinonucleic acids (ANA and 2⬘F-ANA) are substrates of ribonuclease H, J. Am. Chem. Soc., 120, 12,976–12,977, 1998. 88. Berger, I. et al., Crystal structures of B-DNA with incorporated 2⬘-deoxy-2⬘-fluoro-arabino-furanosyl thymines: implications of conformational preorganization for duplex stability, Nucleic Acids Res., 26, 2473–2480, 1998.
CRC_8796_ch006.qxd
176
5/24/2007
12:03
Page 176
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
89. Li, F. et al., 2⬘-Fluoroarabino- and arabinonucleic acid show different conformations, resulting in deviating RNA affinities and processing of their heteroduplexes with RNA by RNase H, Biochemistry, 45, 4141–4152, 2006. 90. Lok, C.-N. et al., Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2⬘-deoxy-2⬘-fluoro-D-arabinose and 2⬘-deoxyribose nucleotides, Biochemistry, 41, 3457–3467, 2002. 91. Kalota, A. et al., 2⬘-deoxy-2⬘-fluoro-beta-D-arabinonucleic acid (2⬘F-ANA) modified oligonucleotides (ON) effect highly efficient, and persistent, gene silencing, Nucleic Acids Res., 34, 451–461, 2006. 92. Dowler, T. et al., Improvements in siRNA properties mediated by 2⬘-deoxy-2⬘-fluoro-beta-Darabinonucleic acid (FANA), Nucleic Acids Res., 34, 1669–1675, 2006. 93. Kraynack, B. A. and Baker, B. F., Small interfering RNAs containing full 2⬘-O-methylribonucleotidemodified sense strands display Argonaute2/eIF2C2-dependent activity, RNA, 12, 163–176, 2006. 94. Prakash, T. P. et al., Positional effect of chemical modifications on short interference RNA activity in Mammalian cells, J. Med. Chem., 48, 4247–4253, 2005. 95. Zimmermann, T. S. et al., RNAi-mediated gene silencing in non-human primates, Nature, 441, 111–114, 2006. 96. Soutschek, J. et al., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs, Nature, 432, 173–178, 2004. 97. Jackson, A. L. et al., Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing, RNA, 12, 1197–1205, 2006. 98. Fedorov, Y. et al., Off-target effects by siRNA can induce toxic phenotype, RNA, 12, 1188–1196, 2006. 99. Goel, S. et al., A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1a in patients with advanced solid cancers, Invest. New Drugs, 24, 125–134, 2006. 100. Teplova, M. et al., Crystal structure and improved antisense properties of 2⬘-O-(2-methoxyethyl)-RNA, Nat. Struct. Biol., 6, 535–539, 1999. 101. Crooke, S. T. et al., Pharmacokinetic properties of several novel oligonucleotide analogs in mice, J. Pharmacol. Exp. Ther., 277, 923–937, 1996. 102. Prakash, T. P. et al., 2⬘-O-[2-(methylthio)ethyl]-modified oligonucleotide: an analogue of 2⬘-O[2-(methoxy)-ethyl]-modified oligonucleotide with improved protein binding properties and high binding affinity to target RNA, Biochemistry, 41, 11,642–11,648, 2002. 103. Egli, M. et al., Probing the influence of stereoelectronic effects on the biophysical properties of oligonucleotides: comprehensive analysis of the RNA affinity, nuclease resistance, and crystal structure of ten 2⬘-O-ribonucleic acid modifications, Biochemistry, 44, 9045–9057, 2005. 104. Shen, L., Chen, X., and Wang, J. H., A high-efficacy antisense RIalpha poly-DNP 21-nt RNA, Antisense Nucleic Acid Drug Dev., 13, 67–74, 2003. 105. Chen, X., Shen, L., and Wang, J. H., Poly-2⬘-DNP-RNAs with enhanced efficacy for inhibiting cancer cell growth, Oligonucleotides, 14, 90–99, 2004. 106. Liao, H. and Wang, J. H., Biomembrane-permeable and Ribonuclease-resistant siRNA with enhanced activity, Oligonucleotides, 15, 196–205, 2005. 107. Shen, L. et al., Silencing of human c-myc oncogene expression by poly-DNP-RNA, Oligonucleotides, 15, 23–35, 2005. 108. Griffey, R. H. et al., 2⬘-O-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides, J. Med. Chem., 39, 5100–5109, 1996. 109. Prakash, T. P. et al., Zwitterionic oligonucleotides with 2⬘-o-[3-(n,n-dimethylamino)propyl]-RNA modification: Synthesis and properties, Tetrahedron Lett., 41, 4855–4859, 2000. 110. Prakash, T. P. et al., 2⬘-O-[2-(guanidinium)ethyl]-modified oligonucleotides: stabilizing effect on duplex and triplex structures, Org. Lett., 6, 1971–1974, 2004. 111. Prhavc, M. et al., 2⬘-O-[2-[2-(N,N-dimethylamino)ethoxy]ethyl] modified oligonucleotides: symbiosis of charge interaction factors and stereoelectronic effects, Org. Lett., 5, 2017–2020, 2003. 112. Prakash, T. P. et al., Synthesis of 2⬘-O-[2-[(N,N-dimethylamino)oxy]ethyl] modified nucleosides and oligonucleotides, J. Org. Chem., 67, 357–369, 2002. 113. Prakash, T. P. et al., 2⬘-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo, Nucleic Acids Res., 32, 828–833, 2004.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 177
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
177
114. Pattanayek, R. et al., Structural rationalization of a large difference in RNA affinity despite a small difference in chemistry between two 2⬘-O-modified nucleic acid analogues, J. Am. Chem. Soc., 126, 15,006–15,007, 2004. 115. Prakash, T. P. et al., 2⬘-O-[2-(Amino)-2-oxoethyl] oligonucleotides, Org. Lett., 5, 403–406, 2003. 116. Lima, W. F. et al., Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis, J. Biol. Chem., 279, 36,317–36,326, 2004. 117. Nielsen, K. D. et al., Oligonucleotide analogues containing 4⬘-C-(hydroxymethyl)uridine: synthesis, evaluation and mass spectrometric analysis, Bioorg. Med. Chem., 3, 1493–1502, 1995. 118. Fensholdt, J., Thrane, H., and Wengel, J., Synthesis of oligodeoxynucleotides containing 4⬘-C(hydroxymethyl)thymidine: novel promising antisense molecules, Tetrahedron Lett., 36, 2535–2538, 1995. 119. Wang, G. et al., Biophysical and biochemical properties of oligodeoxy-nucleotides containing 4⬘-Cand 5⬘-C-substituted thymidines, Bioorg. Med. Chem. Lett., 9, 885–890, 1999. 120. Wang, G. and Seifert, W. E., Synthesis and evaluation of oligodeoxynucleotides containing 4⬘-Csubstituted thymidines, Tetrahedron Lett., 37, 6515–6518, 1996. 121. Pfundheller, H. M. and Wengel, J., Oligonucleotides containing 4⬘-C-aminomethyl-2⬘-modified thymidines show increased binding affinity towards DNA and RNA, Bioorg. Med. Chem. Lett., 9, 2667–2672, 1999. 122. Joergensen, P. N., Stein, P. C., and Wengel, J., Synthesis of 3⬘-C-(hydroxymethyl)thymidine: introduction of a novel class of deoxynucleosides and oligodeoxynucleotides, J. Am. Chem. Soc., 116, 2231–2232, 1994. 123. Svendsen, M. L. et al., Oligodeoxynucleotide analogs containing 3⬘-deoxy-3⬘-C-threohydroxymethylthymidine: synthesis, hybridization properties and enzymic stability, Tetrahedron, 49, 11,341–11,352, 1993. 124. Saha, A. K. et al., 5⬘-Me-DNA – a new oligonucleotide analog: synthesis and biochemical properties, J. Org. Chem., 60, 788–789, 1995. 125. Obika, S. et al., Synthesis of 2⬘-O,4⬘-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3⬘-endo sugar puckering, Tetrahedron Lett., 38, 8735–8738, 1997. 126. Obika, S. et al., Stability and structural features of the duplexes containing nucleoside analogs with a fixed N-type conformation, 2⬘-O,4⬘-C-methyleneribonucleosides, Tetrahedron Lett., 39, 5401–5404, 1998. 127. Koshkin, A. A. et al., LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerization, and unprecedented nucleic acid recognition, Tetrahedron, 54, 3607–3630, 1998. 128. Singh, S. K. et al., LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition, Chem. Commun., 455–456, 1998. 129. Wengel, J., Synthesis of 3⬘-C- and 4⬘-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA), Acc. Chem. Res., 32, 301–310, 1999. 130. Nielsen, K. E. et al., NMR studies of fully modified locked nucleic acid (LNA) hybrids: solution structure of an LNA:RNA hybrid and characterization of an LNA:DNA hybrid, Bioconjug. Chem., 15, 449–457, 2004. 131. Nielsen, K. E. and Spielmann, H. P., The structure of a mixed LNA/DNA:RNA duplex is driven by conformational coupling between LNA and deoxyribose residues as determined from 13C relaxation measurements, J. Am. Chem. Soc., 127, 15,273–15,282, 2005. 132. Petersen, M. et al., Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA:RNA hybrids, J. Am. Chem. Soc., 124, 5974–5982, 2002. 133. Elmen, J. et al., Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality, Nucleic Acids Res., 33, 439–447, 2005. 134. Braasch, D. A. et al., RNA interference in mammalian cells by chemically-modified RNA, Biochemistry, 42, 7967–7975, 2003. 135. Hornung, V. et al., Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7, Nat. Med., 11, 263–270, 2005. 136. Orom, U. A., Kauppinen, S., and Lund, A. H., LNA-modified oligonucleotides mediate specific inhibition of microRNA function, Gene, 372, 137–141, 2006. 137. Darfeuille, F. et al., LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1, Nucleic Acids Res., 32, 3101–3107, 2004. 138. Schmidt, K. S. et al., Application of locked nucleic acids to improve aptamer in vivo stability and targeting function, Nucleic Acids Res., 32, 5757–5765, 2004.
CRC_8796_ch006.qxd
178
5/24/2007
12:03
Page 178
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
139. Jepsen, J. S., Sorensen, M. D., and Wengel, J., Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology, Oligonucleotides, 14, 130–146, 2004. 140. Kurreck, J. et al., Design of antisense oligonucleotides stabilized by locked nucleic acids, Nucleic Acids Res., 30, 1911–1918, 2002. 141. Fluiter, K. et al., On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide, Chem. Biochem., 6, 1104–1109, 2005. 142. Fluiter, K. et al., In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides, Nucleic Acids Res., 31, 953–962, 2003. 143. Swayze, E. E. et al., Antisense oligonucleotides containing locked nucleic acid (LNA) improve potency and cause significant hepatotoxicity in animals., Nucl. Acids Res., 35, 687–700, 2007. 144. Rajwanshi, V. K. et al., The eight stereoisomers of LNA (locked nucleic acid): a remarkable family of strong RNA binding molecules, Angew. Chem. Int. Ed. Engl., 39, 1656–1659, 2000. 145. Nielsen, K. M. et al., alpha-L-LNA (alpha-L-ribo configured locked nucleic acid) recognition of DNA: an NMR spectroscopic study, Chemistry, 8, 3001–3009, 2002. 146. Nielsen, J. T., Stein, P. C., and Petersen, M., NMR structure of an alpha-L-LNA:RNA hybrid: structural implications for RNase H recognition, Nucleic Acids Res., 31, 5858–5867, 2003. 147. Frieden, M. et al., Expanding the design horizon of antisense oligonucleotides with alpha-l-LNA, Nucleic Acids Res., 31, 6365–6372, 2003. 148. Singh, S. K., Kumar, R., and Wengel, J., Synthesis of novel bicyclo[2.2.1] ribonucleosides: 2⬘-aminoand 2⬘-thio-LNA monomeric nucleosides, J. Org. Chem., 63, 6078–6079, 1998. 149. Morita, K. et al., 2⬘-O,4⬘-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug, Bioorg. Med. Chem. Lett., 12, 73–76, 2002. 150. Morita, K. et al., Synthesis and properties of 2⬘-O,4⬘-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides, Bioorg. Med. Chem., 11, 2211–2226, 2003. 151. Morita, K. et al., Inhibition of VEGF mRNA by 2⬘-O,4⬘-C-ethylene-bridged nucleic acids (ENA) antisense oligonucleotides and their influence on off-target gene expressions, Nucleos. Nucleot. Nucleic Acids, 25, 503–521, 2006. 152. Horie, M. et al., Comparison between properties of 2⬘-O,4⬘-C-ethylene-bridged nucleic acid (ENA) phosphorothioate oligonucleotides and N3⬘-P5⬘ thiophosphoramidate oligonucleotides, Nucleos. Nucleot. Nucleic Acids, 25, 231–242, 2006. 153. Hari, Y. et al., Synthesis and properties of 2⬘-O,4⬘-C-methyleneoxymethylene bridged nucleic acid, Bioorg. Med. Chem., 14, 1029–1038, 2006. 154. Wang, G. et al., Conformationally locked nucleosides. Synthesis and hybridization properties of oligodeoxynucleotides containing 2⬘,4⬘-C-bridged 2⬘-deoxynucleosides, Bioorg. Med. Chem. Lett., 9, 1147–1150, 1999. 155. Imanishi, T., Obika, S., and Miyashita, K., Nuclease resistant oligonucleotide analogue : 2⬘-O,4⬘-C-N-O bridged nucleic acid (2⬘,4⬘-BNANC) with efficient duplex and triplex formation, WO 2005021570, 2005. 156. Kvarno, L. and Wengel, J., Novel bicyclic nucleoside analogue (1S,5S,6S)-6- hydroxy-5-hydroxymethyl1-(uracil-1-yl)-3,8-dioxabicyclo[3.2.1]octane: synthesis and incorporation into oligodeoxynucleotides, J. Org. Chem., 66, 5498–5503, 2001. 157. Pradeepkumar, P. I. et al., Synthesis, physicochemical and biochemical studies of 1⬘,2⬘-oxetane constrained adenosine and guanosine modified oligonucleotides, and their comparison with those of the corresponding cytidine and thymidine analogues, J. Am. Chem. Soc., 126, 11,484–11,499, 2004. 158. Opalinska, J. B. et al., Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules, Nucleic Acids Res., 32, 5791–5799, 2004. 159. Christensen, N. K. et al., A novel class of oligonucleotide analogs containing 2⬘-O,3⬘-C-linked [3.2.0]bicycloarabinonucleoside monomers: synthesis, thermal affinity studies, and molecular modeling, J. Am. Chem. Soc., 120, 5458–5463, 1998. 160. Tommerholt, H. V. et al., NMR solution structure of dsDNA containing a bicyclic D-arabino-configured nucleotide fixed in an O4⬘-endo sugar conformation, Org. Biomol. Chem., 1, 1790–1797, 2003. 161. Sekiguchi, M. et al., Synthesis and properties of a novel bridged nucleic acid analogue, 5⬘-amino3⬘,5⬘-BNA, Nucleos. Nucleot. Nucleic Acids, 24, 1097–1100, 2005. 162. Bolli, M., Trafelet, H. U., and Leumann, C., Watson-Crick base-pairing properties of bicyclo-DNA, Nucleic Acids Res., 24, 4660–4667, 1996. 163. Renneberg, D. and Leumann, C. J., Watson-Crick base-pairing properties of tricyclo-DNA, J. Am. Chem. Soc., 124, 5993–6002, 2002.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 179
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
179
164. Renneberg, D. et al., Antisense properties of tricyclo-DNA, Nucleic Acids Res., 30, 2751–2757, 2002. 165. Ittig, D. et al., Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA, Nucleic Acids Res., 32, 346–353, 2004. 166. Altmann, K.-H. et al., 1⬘,6⬘-Methano carbocyclic thymidine: synthesis, x-ray crystal structure, and effect on nucleic acid duplex stability, Tetrahedron Lett., 35, 7625–7628, 1994. 167. Altmann, K.-H. et al., 4⬘,6⬘-Methano carbocyclic thymidine: a conformationally constrained building block for oligonucleotides, Tetrahedron Lett., 35, 2331–2334, 1994. 168. Marquez, V. E. et al., Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides?, J. Med. Chem., 39, 3739–3747, 1996. 169. Obika, S. et al., Synthesis and conformation of 3⬘,4⬘-BNA monomers, 3⬘-O,4⬘-C-methyleneribonucleosides, Tetrahedron, 58, 3039–3049, 2002. 170. Obika, S. et al., Preparation and properties of 2⬘,5⬘-linked oligodeoxyribonucleotide analogs containing 3⬘-O,4⬘-C-methylene-ribonucleosides, Bioorg. Med. Chem. Lett., 9, 515–518, 1999. 171. Madsen, A. S. et al., Synthesis, nucleic acid hybridization properties and molecular modelling studies of conformationally restricted 3⬘-O,4⬘-C-methylene-linked alpha-L-ribonucleotides, Carbohydr. Res., 341, 1398–1407, 2006. 172. Sekiguchi, M. et al., Synthesis and properties of trans-3⬘,4⬘-bridged nucleic acids having typical S-type sugar conformation, J. Org. Chem., 71, 1306–1316, 2006. 173. Jones, G. D. et al., Investigation of some properties of oligodeoxynucleotides containing 4⬘-thio-2⬘deoxynucleotides: duplex hybridization and nuclease sensitivity, Nucleic Acids Res., 24, 4117–4122, 1996. 174. Leydier, C. et al., 4⬘-Thio-RNA: synthesis of mixed base 4⬘-thio-oligoribonucleotides, nuclease resistance, and base pairing properties with complementary single and double strand, Antisense Res. Dev., 5, 167–174, 1995. 175. Bellon, L. et al., 4⬘-Thio-oligo-beta-D-ribonucleotides: synthesis of beta-4⬘-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase, Nucleic Acids Res., 21, 1587–1593, 1993. 176. Haeberli, P. et al., Syntheses of 4⬘-thioribonucleosides and thermodynamic stability and crystal structure of RNA oligomers with incorporated 4⬘ -thiocytosine, Nucleic Acids Res., 33, 3965–3975, 2005. 177. Hoshika, S. et al., RNA interference induced by siRNAs modified with 4⬘-thioribonucleosides in cultured mammalian cells, FEBS Lett., 579, 3115–3118, 2005. 178. Dande, P. et al., Improving RNA interference in mammalian cells by 4⬘-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2⬘O-alkyl modifications, J. Med. Chem., 49, 1624–1634, 2006. 179. Hoshika, S. et al., Investigation of physical and physiological properties of 4⬘-thioribonucleotide (4⬘-thioRNA), Nucleic Acids Res. Suppl., 3, 209–210, 2003. 180. Hoshika, S., Minakawa, N., and Matsuda, A., Synthesis and physical and physiological properties of 4⬘-thioRNA: application to post-modification of RNA aptamer toward NF-kappaB, Nucleic Acids Res., 32, 3815–3825, 2004. 181. Altmann, K.-H., Kesseiring, R., and Pieles, U., 6⬘-Carbon-substituted carbocyclic analogs of 2⬘-deoxyribonucleosides - synthesis and effect on DNA/RNA duplex stability, Tetrahedron, 52, 12,699–12,722, 1996. 182. Altmann, K.-H. et al., The evaluation of 2⬘- and 6⬘-substituted carbocyclic nucleosides as building blocks for antisense oligodeoxyribonucleotides, Bioorg. Med. Chem. Lett., 5, 431–436, 1995. 183. Altmann, K.-H. et al., Synthesis of an azathymidine and its incorporation in oligonucleotides, Angew. Chem., 106, 1735–1738, 1994. 184. Schoning, K. et al., Chemical etiology of nucleic acid structure: the alpha-threofuranosyl-(3⬘→2⬘) oligonucleotide system, Science, 290, 1347–1351, 2000. 185. Pallan, P. S. et al., Why does TNA cross-pair more strongly with RNA than with DNA? An answer from X-ray analysis, Angew. Chem. Int. Ed. Engl., 42, 5893–5895, 2003. 186. Eschenmoser, A., Chemical etiology of nucleic acid structure, Science, 284, 2118–2124, 1999. 187. Egli, M. et al., Crystal structure of homo-DNA and nature’s choice of pentose over hexose in the genetic system, J. Am. Chem. Soc., 128, 10,847–10,856, 2006. 188. Van Aerschot, A., Conformational restriction as a means for obtaining steric blocking antisense oligonucleotides, in Modified Nucleosides: Synthesis and Applications, Loakes, D. ed., Research Signpost, Kerala, India, 2002, pp. 17–32.
CRC_8796_ch006.qxd
180
5/24/2007
12:03
Page 180
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
189. Herdewijn, P., Conformationally restricted carbohydrate-modified nucleic acids and antisense technology, Biochim. Biophys. Acta, 1489, 167–179, 1999. 190. Vandermeeren, M. et al., Biological activity of hexitol nucleic acids targeted at Ha-ras and intracellular adhesion molecule-1 mRNA, Biochem. Pharmacol., 59, 655–663, 2000. 191. Kang, H. et al., Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides, Nucleic Acids Res., 32, 4411–4419, 2004. 192. Kolb, G. et al., Hexitol nucleic acid–containing aptamers are efficient ligands of HIV-1 TAR RNA, Biochemistry, 44, 2926–2933, 2005. 193. Lescrinier, E. et al., Solution structure of a HNA-RNA hybrid, Chem. Biol., 7, 719–731, 2000. 194. Maier, T. et al., Reinforced HNA backbone hydration in the crystal structure of a decameric HNA/RNA hybrid, J. Am. Chem. Soc., 127, 2937–2943, 2005. 195. Van Aerschot, A. et al., Improved hybridisation potential of oligonucleotides comprising O-methylated anhydrohexitol nucleoside congeners, Nucleic Acids Res., 29, 4187–4194, 2001. 196. Wang, J. et al., Cyclohexene nucleic acids (CeNA): serum stable oligonucleotides that activate RNase H and increase duplex stability with complementary RNA, J. Am. Chem. Soc., 122, 8595–8602, 2000. 197. Nauwelaerts, K. et al., Cyclohexenyl nucleic acids: conformationally flexible oligonucleotides, Nucl. Acids Res., 33, 2452–2463, 2005. 198. Herdewijn, P., Heterocyclic modifications of oligonucleotides and antisense technology, Antisense Nucleic Acid Drug Dev., 10, 297–310, 2000. 199. Revenkar, G. R. and Rao, T. S., DNA with Altered Bases, in Comprehensive Natural Products Chemistry, Barton, D. H. R., Nakanishi, K., and Kool, E. T., eds., Pergamon Press, Oxford, 1999, pp. 313–339. 200. Sanghvi, Y. S. et al., Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines, Nucleic Acids Res., 21, 3197–3203, 1993. 201. Sagi, J. et al., Destabilization of the duplex and the high-salt Z-form of poly(dG-methyl5dC) by substitution of ethyl for the 5-methyl group, Int. J. Biol. Macromol., 13, 329–336, 1991. 202. Henry, S. et al., Chemically modified oligonucleotides exhibit decreased immune stimulation in mice, J. Pharmacol. Exp. Ther., 292, 468–479, 2000. 203. Devoe, H. and Tinoco, I., Jr., The stability of helical polynucleotides: base contributions, J. Mol. Biol., 4, 500–517, 1962. 204. Froehler, Brian C. et al., Oligodeoxynucleotides containing C-5 propyne analogs of 2⬘-deoxyuridine and 2⬘-deoxycytidine, Tetrahedron Lett., 33, 5307–5310, 1992. 205. Wagner, R. W. et al., Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines, Science, 260, 1510–1513, 1993. 206. Moulds, C. et al., Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides, Biochemistry, 34, 5044–5053, 1995. 207. Gutierrez, A. J. et al., Antisense gene inhibition by C-5-substituted deoxyuridine-containing oligodeoxynucleotides, Biochemistry, 36, 743–748, 1997. 208. Wagner, R. W. et al., Potent and selective inhibition of gene expression by an antisense heptanucleotide, Nat. Biotechnol., 14, 840–844, 1996. 209. Wagner, R. W., Structure-activity relationships in cell culture, Ciba Found. Symp., 209, 142–154; discussion 154–157, 1997. 210. Shen, L. et al., Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo, Antisense Nucleic Acid Drug Dev., 13, 129–142, 2003. 211. Gutierrez, A. J. et al., 5-Heteroaryl-2⬘-deoxyuridine analogs. Synthesis and incorporation into highaffinity oligonucleotides, J. Am. Chem. Soc., 116, 5540–5544, 1994. 212. Lin, K.-Y., Jones, R. J., and Matteucci, M., Tricyclic 2⬘-deoxycytidine analogs: syntheses and incorporation into oligodeoxynucleotides which have enhanced binding to complementary RNA, J. Am. Chem. Soc., 117, 3873–3874, 1995. 213. Flanagan, W. M. et al., Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide, Nat. Biotechnol., 17, 48–52, 1999. 214. Lin, K.-Y. and Matteucci, M. D., A cytosine analog capable of clamp-like binding to a guanine in helical nucleic acids, J. Am. Chem. Soc., 120, 8531–8532, 1998. 215. Flanagan, W. M. et al., A cytosine analog that confers enhanced potency to antisense oligonucleotides, Proc. Natl. Acad. Sci. USA., 96, 3513–3518, 1999.
CRC_8796_ch006.qxd
5/24/2007
12:03
Page 181
THE MEDICINAL CHEMISTRY OF OLIGONUCLEOTIDES
181
216. Wilds, C. J. et al., Structural basis for recognition of guanosine by a synthetic tricyclic cytosine analogue: Guanidinium G-clamp, Helv. Chim. Acta, 86, 966–978, 2003. 217. Sazani, P., Astriab-Fischer, A., and Kole, R., Effects of base modifications on antisense properties of 2⬘-O-methoxyethyl and PNA oligonucleotides, Antisense Nucleic Acid Drug Dev., 13, 119–128, 2003. 218. Holmes, S. C. and Gait, M. J., The synthesis of 2⬘-O-methyl G-clamp containing oligonucleotides and their inhibition of the HIV-1 Tat-TAR interaction, Nucleos. Nucleot. Nucleic Acids, 22, 1259–1262, 2003. 219. Connolly, B. A. and Newman, P. C., Synthesis and properties of oligonucleotides containing 4-thiothymidine, 5-methyl-2-pyrimidinone-1-beta-D(2⬘-deoxyriboside) and 2-thiothymidine, Nucleic Acids Res., 17, 4957–4974, 1989. 220. Newman, P. C. et al., Incorporation of a complete set of deoxyadenosine and thymidine analogues suitable for the study of protein nucleic acid interactions into oligodeoxynucleotides. Application to the EcoRV restriction endonuclease and modification methylase, Biochemistry, 29, 9891–9901, 1990. 221. Diop-Frimpong, B. et al., Stabilizing contributions of sulfur-modified nucleotides: crystal structure of a DNA duplex with 2⬘-O-[2-(methoxy)ethyl]-2-thiothymidines, Nucleic Acids Res., 33, 5297–5307, 2005. 222. Howard, F. B. and Miles, H. T., 2NH2A X T helices in the ribo- and deoxypolynucleotide series. Structural and energetic consequences of 2NH2A substitution, Biochemistry, 23, 6723–6732, 1984. 223. Lamm, G. M. et al., Antisense probes containing 2-aminoadenosine allow efficient depletion of U5 snRNP from HeLa splicing extracts, Nucleic Acids Res., 19, 3193–3198, 1991. 224. Gryaznov, S. M. and Schultz, R. G., Stabilization of DNA:DNA and DNA:RNA duplex by substitutionof 2⬘-deoxyadenosine with 2⬘-deoxy-2-aminoadenosine, Terahedron Lett., 36, 2489–2492, 1994. 225. Ramasamy, K. S. et al., Remarkable enhancement of binding affinity of heterocycle-modified DNA to DNA and RNA. Synthesis, characterization and biophysical evaluation of N2-imidazolylpropylguanine and N2-imidazolylpropyl-2-aminoadenine modified oligonucleotides, Tetrahedron Lett., 35, 215–218, 1994. 226. Manoharan, M. et al., Oligonucleotides bearing cationic groups: N2-(3-aminopropyl)deoxyguanosine. Synthesis, enhanced binding properties and conjugation chemistry, Tetrahedron Lett., 37, 7675–7678, 1996. 227. Balow, G. et al., Biophysical and antisense properties of oligodeoxynucleotides containing 7-propynyl-, 7-iodo- and 7-cyano-7-deaza-2-amino-2⬘-deoxyadenosines, Nucleic Acids Res., 26, 3350–3357, 1998. 228. Buhr, C. A. et al., Oligodeoxynucleotides containing C-7 propyne analogs of 7-deaza2⬘-deoxyguanosine and 7-deaza-2⬘-deoxyadenosine, Nucleic Acids Res., 24, 2974–2980, 1996. 229. Manoharan, M., Oligonucleotide conjugates in antisense technology, in Antisense drug technology: Principles, strategies, and applications, Crooke, S. T., ed., Marcel Dekker, New York, 2001, pp. 391–470. 230. Manoharan, M., Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action, Antisense Nucleic Acid Drug Dev., 12, 103–28, 2002. 231. Bijsterbosch, M. K. et al., Delivery of cholesteryl-conjugated phosphorothioate oligodeoxynucleotides to Kupffer cells by lactosylated low-density lipoprotein, Biochem. Pharmacol., 62, 627–633, 2001. 232. Bijsterbosch, M. K. et al., Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation, Nucleic Acids Res., 28, 2717–2725, 2000. 233. Bijsterbosch, M. K. et al., bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver, J. Pharmacol. Exp. Ther., 302, 619–626, 2002. 234. Krutzfeldt, J. et al., Silencing of microRNAs in vivo with “antagomirs,” Nature, 43, 685–689, 2005. 235. Henry, S. P. et al., Toxicological properties of several novel oligonucleotide analogs in mice, Anticancer. Drug Des., 12, 1–14, 1997. 236. Herbert, B.-S. et al., Lipid modification of GRN163, an N3⬘-P5⬘ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition, Oncogene, 24, 5262–5268, 2005. 237. Kastelein, J. J. P. et al., Potent reduction of apolipoprotein B and LDL cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B, Circulation, in press, 2006. 238. Karras, J. G. et al., Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-a chain, Biochemistry, 40, 7853–7859, 2001.
CRC_8796_ch006.qxd
182
5/24/2007
12:03
Page 182
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
239. Baker, B. F. et al., 2⬘-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells, J. Biol. Chem., 272, 11,994–12,000, 1997. 240. Vickers, T. A. et al., Fully modified 2⬘ MOE oligonucleotides redirect polyadenylation, Nucleic Acids Res., 29, 1293–1299, 2001. 241. Esau, C. et al., miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting, Cell Metabol., 3, 87–98, 2006. 242. Davis, S. et al., Improved targeting of miRNA with antisense oligonucleotides, Nucl. Acids Res., 34, 2294–2304, 2006.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 183
CHAPTER
7
Basic Principles of the Pharmacokinetics of Antisense Oligonucleotide Drugs Arthur A. Levin, Rosie Z. Yu, and Richard S. Geary
CONTENTS 7.1 7.2
7.3
7.4
Introduction...........................................................................................................................184 Basic Chemistry....................................................................................................................185 7.2.1 Phosphorothioate Backbone .....................................................................................185 7.2.1.1 Phosphorothioate Chirality........................................................................185 7.2.1.2 Protein Binding .........................................................................................187 7.2.2 Methoxyethyl Modifications at the 2⬘ Position of Ribose .......................................188 7.2.2.1 Nuclease Resistance ..................................................................................188 7.2.2.2 Protein Binding .........................................................................................189 Absorption, Distribution, Metabolism, and Excretion .........................................................191 7.3.1 Absorption ................................................................................................................191 7.3.1.1 Parenteral ..................................................................................................191 7.3.1.2 Local Delivery...........................................................................................191 7.3.1.3 Enteral .......................................................................................................192 7.3.2 Distribution ...............................................................................................................192 7.3.2.1 Roles of Perfusion and Tissue Affinity .....................................................192 7.3.2.2 Plasma Protein Binding in Distribution ....................................................195 7.3.2.3 Distribution to Other Organs.....................................................................196 7.3.3 Metabolism ...............................................................................................................198 7.3.3.1 Enzymes Responsible for Metabolism......................................................199 7.3.3.2 Metabolites ................................................................................................200 7.3.3.3 Metabolism and Clearance........................................................................201 7.3.4 Excretion...................................................................................................................202 7.3.4.1 Overview of Excretion ..............................................................................202 7.3.4.2 Early Excretion and Protein Binding ........................................................203 7.3.4.3 Excretion of Metabolites ...........................................................................204 7.3.5 Summary of Absorption, Distribution, Metabolism, and Excretion ........................206 Application of Pharmacokinetics to the Design of Treatment Regimens ............................206 7.4.1 Steady-State Kinetics................................................................................................208 7.4.2 Dose and Schedule ...................................................................................................209
183
CRC_8796_ch007.qxd
184
5/25/2007
7:39 AM
Page 184
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
7.4.3 Relating Exposure and Effect...................................................................................211 7.4.4 Drug–Drug Interactions............................................................................................211 7.4.5 Remaining Questions................................................................................................211 References ......................................................................................................................................211
7.1 INTRODUCTION The pharmacokinetic properties of antisense oligonucleotides (ASOs) are best understood in the context of their physical and chemical properties. Charge, molecular weight, and amphipathic nature of the ASOs all influence the pharmacokinetics of phosphorothioate ASOs. This review will concentrate on how chemical modifications, particularly, the phosphorothioate modification and the 2⬘-methoxyethyl (MOE) modification, of second-generation ASOs improve the pharmacokinetic properties. The absorption, distribution, metabolism, and excretion of first-generation phosphorothioate oligodeoxynucleotides (ODNs) have been thoroughly characterized in laboratory animals and in human clinical trials [1–10]. Our understanding of the pharmacokinetics of phosphorothioate ASO drugs can be summarized as follows: phosphorothioate ODNs administered parenterally appear rapidly in plasma where they are bound to hydrophilic sites on plasma proteins and are thus protected from glomerular filtration. These hydrophilic sites are distinct from the hydrophilic sites where lipophilic drugs bind, and thus there is little competition for plasma protein binding by ASOs. Plasma kinetics are multiphasic with a short distribution phase that is on the order of hours, and then a terminal elimination phase that has half-lives on the order of days or weeks. The initial distribution phase is primarily related to binding and distribution to tissues with liver, kidney, lymph nodes, and spleen being the sites of highest binding and uptake. Phase clearance due to this initial clearance is dependent on protein binding. It is saturable, and therefore, the distribution kinetics are dose-dependent with clearance rates slowing and area under the plasma curve (AUC) increasing with increasing doses. Once bound to the cells, ASOs transit into cells by moving down concentration gradients from extracellular compartments to intracellular compartments, probably by shuttling from one protein-binding site to another across cell membranes. ASOs in cells bind to available targets, but the majority of the ASO in cells is likely bound to intracellular proteins. Within the cell, ubiquitous nucleases metabolize ASO drugs, not the cytochrome P450 enzymes that typically metabolize low-molecular-weight drugs. ASOs, therefore, do not compete with traditional small molecular weight drugs for metabolic processes, reducing the potential for drug–drug interactions. Whole body elimination is the result of metabolism in tissues, and a reequilibration of metabolites and parent drug out of tissues and into circulation, where they are ultimately excreted in the urine. These processes are very similar in laboratory animals and man. In fact the processes are similar enough that doses scale from species to species on the basis of body weight not surface area, allowing for good extrapolations from laboratory animals to man. The focus of the review is the “second generation” of ASOs that feature MOE groups on the 2⬘ position of nucleotides in the 3⬘ and 5⬘ termini (see Chapter 1, this volume). This configuration is the most widely used in clinical studies at present time and represents an advance over the unmodified phosphorothioate ODNs that constituted the first generation of antisense drugs, because of increased potency, reduced toxicity, and increased half-life. Many of the advantages associated with moving from the first-generation to the second-generation ASOs are directly related to improved pharmacokinetics and this review will describe our understanding of the fundamental biology and chemistry that modulate the pharmacokinetics of this new class of ASOs. (A list of sequences discussed in this chapter can be found in Table 7.1.)
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 185
BASIC PRINCIPLES OF THE PHARMACOKINETICS
185
Table 7.1 List of Sequences Discussed in This Chapter Isis Number or Other 2302
Sequence
Generation
GCCCAAGCTGGCATCCGTCA
5132
TCCCGCCTGTGACATGCATT
13650
TC C C GC CTGTGACATGC ATT
m
m
m
m
m
m
m
m
m
104838
GC TGATTAGAGAGAGGTC C C
107248 ATL1102
C TGAGTC TGTTTTC C ATTC T
m
m
m
m
m
m
m
m
112989 OGX-011
C AGC AGCAGAGTCTTCATC AT
113715
GC TC C TTC C AC TGATC C TGC
301012
m m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
m
GC C C AGTC TGC TTC GC AC C
Human Data
1
Y
1
Y
2
N
2
Y
2
Y
2
Y
2
Y
2
Y
Note: Underlined letters represent 2⬘-MOE-modified nucleotides; C ⫽5 Methyl C. m
7.2 BASIC CHEMISTRY 7.2.1
Phosphorothioate Backbone
The earliest attempts to produce antisense activity used unmodified DNA, which unfortunately was highly susceptible to the nuclease degradation. Ubiquitous nucleases cleave the phosphodiester bonds of native DNA, and as a result, circulating half-lives for unmodified ASOs are on the order of minutes. This rapid degradation was the predominate factor driving the pharmacokinetic profile of unmodified antisense DNA. Modifying the phosphodiester backbone of DNA to a phosphorothioate backbone dramatically alters the pharmacokinetic profile. The phosphorothioate modification substitutes one sulfur for one of the nonbridging oxygen atoms in the phosphodiester linkages. This modification yields ASOs with much greater utility as a result of the improved resistance to nucleases. The improvements in the utility go much further than the increase in nuclease resistance [11].
7.2.1.1 Phosphorothioate Chirality Thiation of the diester backbone of the ASO not only increases the resistance of the backbone to nucleases but, the substitution of sulfur changes the nature of the backbone and imparts chirality on each of the phosphorothioate linkages such that in any 20-mer ASO there are 219 Sp or Rp stereoisomers [11]. Combined, nuclease resistance and increased protein binding have profound influences on the pharmacokinetics of ASOs. Increased nuclease stability of phosphorothioate ASOs results in plasma half-lives that are 30–60 min compared to 1–2 min of phosphodiester ASOs. The nuclease resistance and the chirality produced by the substitution of the phosphorothioate for the phosphodiester linkages merit discussion, because the physical properties associated with this modification are important to both first- and second-generation ASOs. Nuclease resistance in phosphorothioate ASOs derives in part from the proximity of the sulfur on the nonbridging oxygen to metal ions in the active site of exonucleases. This proximity may cause the displacement of the metal ion from the active site. This effect was demonstrated in a model 3⬘–5⬘ exonuclease, DNA polymerase. X-ray crystallographic data support this hypothesis and apparent differences in sensitivity of the stereoisomers to exonuclease activity by this enzyme are consistent with the proposed conformation of the phosphorothioate ODN stereoisomers within the active site. The Sp stereoisomer apparently rests in the enzyme with the sulfur displacing the metal ions in the active site, while the Rp, the more rapidly degraded isomer, does not interfere with the active site metal ions
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 186
186
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
(reviewed in Ref. [11]). It is likely that the chirality of the phosphorothioate linkages may interfere with other nucleases in a similar manner, though different exonucleases may show differing preferences for Rp and Sp linkages depending on the nature of the active site of the enzyme. Alternatively, the sulfur may simply take the place of the oxygen in the diester linkage that would normally complex the Mg2⫹ ion at the active site. The differences in the ability of the sulfur to take on a negative charge versus that of oxygen could be expected to change the properties at the active site. This change would most likely occur because the hydrolysis of the phosphodiester linkage may proceed through the formation of a transient pentacoordinate phosphorous with two negatively charged oxygens (Figure 7.1). Substitution of one of the equatorial oxygens with sulfur would have negative consequences on the enzyme activity: (1) reduced binding of water which stabilizes the local negative charge on the atoms, making it more difficult to generate a second negative charge on the sulfur; and (2) reduction in Mg2⫹ binding to the location with a sulfur substitution. There is evidence for the latter effect in studies of ribozyme cleavage rates following diastereomeric phosphorothioate incorporation, where addition of Mn2⫹ rescues the inhibited cleavage activity of a phosphorothioate ribozyme [12]. It has also been shown that there is some reduction in nuclease activity at a distance from the phosphorothioate linkages, suggesting some transmission of the chirality effect [13]. This phenomenon would be best explained by changes in the packing of water molecules around the phosphorothioate backbone compared to the phosphodiester backbone [14]. The stereospecific effects on nuclease activity markedly affect the pharmacokinetics of phosphorothioate ASOs and this was most apparent in the rates of metabolism of first-generation phosphorothioate ASOs in plasma. The rates of disappearance of the full-length ASOs from plasma decrease overtime, suggesting that there was a slowing of metabolism (reviewed in Ref. [8]). These changes in rates could not be explained on the basis of first-order kinetics alone, but could be explained by the differences in susceptibility of the Rp and Sp linkages. Metabolism (or 3⬘ exonuclease activity) would proceed until a resistant (Sp) linkage was encountered, then metabolism would slow. Stereospecific differences in exonuclease activities are less important for second-generation ASOs. Because second-generation ASOs have 2⬘ modifications at the 3⬘ and 5⬘ termini that prevent exonuclease cleavage, the rate-limiting step in the metabolism of second-generation ASOs is not exonuclease-mediated, but rather endonuclease-mediated. The effects of chirality of phosphorothioate linkages have been explored using a model endonuclease from Serratia marcescens [15]. R −
O
R
R O P
O
O O
OH2
−
OH O
P
Mg 2+ O
−
O
O− Mg2+
OH
O R
O
P
R
HO R
R −
O
R
R O P
O
O S
OH2
−
OH O
P
Mg 2+ O
−
S− Mg 2+
O
OH
O R
R
HO Disfavored
Figure 7.1
S
P
R
Scheme comparing the interaction between a diester linkage and the metal ion of a nuclease and a phosphorothioate linkage and the same metal ion at the active site of a nuclease. The phosphorous of the diester linkage can form a pentavalent oxygen complex while the analogous complex with the phosphorothioate linkage is disfavored because of the less electronegativity of the sulfur (as indicated).
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 187
BASIC PRINCIPLES OF THE PHARMACOKINETICS
187
The endonuclease much like the exonuclease requires one of the nonbridging oxygens for the hydrolysis of the phosphodiester linkage. In a similar fashion, Sp diastereomer puts the sulfur in proximity to the Mg2⫹ and diminishes the activity of the enzyme while the Rp diastereomer does not. The Serratia endonuclease has significant homology to some mammalian endonucleases, suggesting that this mechanism might be broadly applicable. How the stereochemistry of the phosphorothioate linkage affects nuclease activity for other endonucleases has not been characterized. However, assuming that the reaction follows a similar scheme as the Serratia endonuclease, the active site will have a metal ion (probably Mg2⫹) and that sulfur substitution will interfere with the activity when the sulfur is oriented towards the metal ion. If endonucleases are sensitive to chirality, it might have important consequences for the disposition of second-generation drugs. Like the chirality effect for first-generation drugs, a chiral effect on the metabolism of second-generation drugs might result in a slowing of metabolism as the rapidly metabolized stereoisomers are degraded selectively, leaving only the slowly metabolized isomers. This type of effect would tend to result in longer half-lives with prolonged dosing.
7.2.1.2 Protein Binding The phosphorothioate modifications also alter the pharmacokinetic profile of ASOs as a result of their enhanced protein binding compared to ASOs with a phosphodiester backbone. The chemical basis for the increase in protein binding stems from the increased lipophilicity of the phosphorothioate linkage over the phosphodiester linkage as well as the increased “stickiness” of the thioate compared to the diester. Molecular interactions with water determine the form and function of macromolecules in solution [14]. In this regard, even slight changes in the lipophilicity of the backbone over the entire length of the ASOs can have marked consequences for the interactions of the oligomer with water and by extension with macromolecules, like proteins. At the gross level, phosphorothioate ODNs bind more promiscuously to cellular proteins than do phosphodiester ODNs [16]. Specific interactions with proteins are also enhanced by the addition of phosphorothioate linkages as was demonstrated with circular dichroism [17]. Why phosphorothioate ASOs bind to proteins with greater affinity has not been completely elucidated. Two possible explanations include increased lipophilicity and metal ion complexation. Interactions of the sulfurs in the phosphorothioate with metal ions (e.g., Mg2⫹) associated with specific proteins have been proposed for the affinity of phosphorothioate ASOs for proteins [11]. That the phosphorothioate linkages are a driving force in the binding of phosphorothioate ASOs was demonstrated using abasic phosphorothioate oligodeoxyriboses of various lengths. Binding was length-dependent, and like the binding of phosphorothioate ASOs, the binding of the phosphorothioate oligodeoxyribose was highly dependent on the species (H. Gaus, Isis unpublished observations). Unlike the inhibitory effects on nucleases, chirality does not appear to be a factor modulating the binding of phosphorothioate ASOs to human serum albumin, fibrinogen, or -globulin [18]. The importance of the plasma protein binding to the pharmacology, pharmacokinetics, and toxicity of phosphorothioate ASOs (both first and second generation) cannot be overstated. At concentrations in the micromolar range more than 90% of phosphorothioate ODNs are bound in plasma. There are sequence-dependent differences in protein binding at micromolar concentrations and binding can vary from 90 to 98% yielding varying amounts of free ASO (see below). And there are species differences in protein-binding affinities and capacity (Figure 7.2), as well as qualitative differences in ASO binding to specific protein in some species. Binding of phosphorothioate ASOs to circulating proteins spares these compounds from glomerular filtration and urinary excretion. As protein binding becomes saturated, for example, when a large bolus dose is administered, urinary excretion of full-length ASOs is increased. Urinary excretion increases as the degree of protein binding decreases and the amount of free or unbound ASO increases [9]. Because of species
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 188
188
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION Mouse
Monkey
Rat
Human
100
% Bound
95
90
85
80 ISIS 104838 Figure 7.2
ISIS 113715
ISIS 301012
Protein binding was determined by ultrafiltration [68] in whole plasma from mice, rats, monkey, and man at the concentration of 1 M (⬃7 g/mL). Data shown are means ⫾ SD of triplicate determinations.
differences, saturation will occur in different species at differing concentrations. For example, plasma proteins in the mouse have less ASO-binding capacity than rat or human (see Figure 7.2), and therefore, plasma protein binding in mice is saturated at lower concentrations than other species. Species differences in plasma protein binding are a significant contributing factor to species differences in pharmacokinetics. The enhanced nuclease resistance and protein binding that are imparted to ASOs by phosphorothioate linkages modulate the pharmacokinetics of ASO therapeutics. The additional chemical modifications that are made in the second-generation antisense compounds have even more profound effects. 7.2.2
Methoxyethyl Modifications at the 2⬘⬘ Position of Ribose
Second-generation ASOs were developed to improve on some of the characteristics of the ODNs of the first generation. Like the phosphorothioate modification, the addition of MOE groups to the 2⬘ position increases nuclease resistance and modifies protein binding.
7.2.2.1 Nuclease Resistance The MOE modification results in a remarkable increase in nuclease stability. While the phosphorothioate modification reduced the activity of exonucleases, the modification of the 2⬘ position nearly eliminates exonuclease activity. Nuclease resistance may result from (1) the replacement of a critical 2⬘ hydrogen with MOE, (2) steric effects of the MOE group or (3) tighter organization of water shell [19]. Whatever the exact structural basis for the nuclease resistance, the presence of the MOE groups makes the 2⬘-modified ASOs virtually impervious to degradation by circulating nucleases and most cellular nucleases as well. For therapeutic applications that depend on RNase H activity, MOE modifications are generally limited to the terminal nucleotides so as to protect the ends of the molecules from exonuclease degradation. The central region of the molecule is unmodified phosphorothioate ODN to support RNase H activity (see Lima et al., Chapter 2 in this volume). This arrangement in the so-called gapmer (or chimeric RNA–DNA–RNA-like configuration) takes advantage of the higher affinity and nuclease resistance of the MOE modifications and still supports the enzymatic activity of RNase H cleavage of the targeted mRNA. Without metabolic degradation due to exonuclease-mediated trimming of the termini, the slower (and presumably) more sequence-selective endonuclease-mediated
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 189
BASIC PRINCIPLES OF THE PHARMACOKINETICS
189
Absorbance (AU, x1E-03)
MOE gapmer 16 days
PS unmodified 10.0
A
6 days
B T27
ISIS 13650
3.0
ISIS 3521
5.0 Metabolites
13866
1.0 0
0 2.00
4.00 6.00 Time (min)
8.00
2.00
4.00 6.00 Time (min)
8.00
Figure 7.3 Capillary gel electrophoresis of renal extracts from monkeys treated with on the left: a secondgeneration oligodeoxynucleotide (ISIS 13650); right panel: a first-generation oligodeoxynucleotide (ISIS 3521). Monkeys were treated on alternate days for the duration shown.
cleavage of the central deoxy region becomes the dominant force in metabolism. The central region consisting of deoxy phosphorothioates is not nearly as resistant to nuclease-mediated cleavage and it is the cleavage of this central portion that appears to be the rate-limiting step of metabolism. The differences in the sites of metabolism of first- and second-generation ASOs yield different metabolic patterns (see this chapter, Section 7.3.3.2). When the metabolite patterns of gapmers are assessed by capillary gel electrophoresis (CGE) (Figure 7.3) or by liquid chromatography/mass spectroscopy (LC/MS), rather than seeing processive metabolite shortening a single nucleotide at a time, the major pattern consists of metabolites that have apparently been cleaved centrally in the deoxy region (presumably by endonucleases) followed by processive shortening of the cleavage products. The resistance to exonucleases and the slow metabolism by endonucleases yield compounds with long biological half-lives.
7.2.2.2 Protein Binding Phosphorothioate ASOs with 2⬘-MOE modifications have slightly lower affinity for plasma proteins compared with unmodified phosphorothioate ASOs. For example, with the addition of five MOE modifications to the 3⬘ end of a first-generation phosphorothioate ODN, the dissociation constants for albumen increased from ⬃18 to ⬃40 M. Interestingly, full MOE modification of the ASO only slightly diminished the affinity further [20]. Why MOE modifications of all riboses in an oligonucleotide did not further reduce the affinity is not understood, but might be related to secondary structure. The contribution of the phosphorothioate linkages in protein binding of second-generation ASOs is demonstrated in a compound with MOE modifications and only diester linkages. This compound had the weakest affinities for albumen with values in the range of 600–700 M [20]. The reduction in protein-binding affinity associated with the MOE modification can be attributed to some of the physical properties that have already been alluded to in this chapter. Probably, the most significant physical factor that distinguishes the MOE-modified ASOs from unmodified ASOs is the organization of a molecular shell of water that appears to be induced by the presence of the MOE side chain [19]. The MOE substituent in the context of the sugar backbone “chelates” water molecules (and possibly metal ions) between it and the backbone producing a structure that is encased in shells of water molecules, diminishing the potential contact between the “sticky” sulfur molecules and plasma or cellular proteins. (Note that this is the same phenomenon that reduces the accessibility of nucleases to the phosphate or phosphorothioate internucleotide bridges and enhances the nuclease stability.) Arrangement of the modifications within an ASO can also affect protein binding. ASOs with varying numbers of nucleotides modified with MOE groups have varying degrees of (plasma clearance and)
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 190
190
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
protein binding compared with a PS ODN with five MOE-modified nucleotides at the 5⬘ end (hemi) and PS full MOE (Figure 7.4a and Figure 7.4b). The degree of protein binding is inversely correlated with urinary excretion (Table 7.2, abstracted from Ref. [21]). The addition of phosphorothioate linkages and 2⬘-MOE substitutions modify protein binding and as a result alter ASO disposition.
Plasma clearance (mL/h)
(a) PO full MOE
160
Altern. PS/PO full MOE 120
80 PS hemi-MOE PS ODN
40 PS full MOE 0
(b)
50
% Dose excreted in urine
PO full MOE 40 30 Altern. PS/PO full MOE
20
PS hemi-MOE 10 0
PS ODN
PS full MOE 75
80
85
90
95
100
Percent bound Figure 7.4
Plasma protein binding predicts clearance (a) and urinary excretion (b). The 20-mer oligonucleotides were modified as follows: PO full MOE, 20-mer oligonucleotide with all sugars modified with 2⬘ MOE and a full diester backbone. Altern. PS/PO full MOE, internucleotide linkages alternated between phosphorothioate and phosphodiester, with every nucleotide modified with MOE. PS full MOE—fully phosphorothioate oligonucleotide with 5 terminal MOE groups on each of the 5⬘ and 3⬘ termini (aka second generation). PS hemi-MOE, a phosphorothioate backbone with 5 terminal nucleotides on the 3⬘ end modified at the 2⬘ position of the ribose with MOE. PS ODN, a full phosphorothioate backbone with 20 deoxynucleotides (first generation).
Table 7.2 Relationships between Extent of Protein Binding and Urinary Excretion
a b
ASO
Modification
Percent Bindinga
Urinary Excretionb
13650 15839 16592
5 MOE-10 deoxy-5 MOE 10 deoxy-7 MOE 20 MOE full diester
93.5–94.0 96.0–98.0 77.0–80.0
7.7 ⫾ 2.3 4.6 ⫾ 2.4 32.3 ⫾ 15.6
Plasma protein binding over the concentration ranges of 0.7–140 g/mL measure by ultrafiltrations. Urinary excretion after treatment of cynomolgus monkeys (n ⫽ 6–8) with 2 h infusions of 10 mg/kg of each ASO.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 191
BASIC PRINCIPLES OF THE PHARMACOKINETICS
191
7.3 ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION 7.3.1
Absorption
7.3.1.1 Parenteral Because of the molecular weight (⬃7000 Da) and negative charges of ASOs, gastrointestinal uptake is limited and parenteral routes of administration are typically used. Subcutaneous, intravenous infusions or intravitreal injections have been used to administer first-generation drugs. The reduced proinflammatory effects of second-generation ASOs (for review see Chapter 12, this volume) make them more suitable for subcutaneous injections. The plasma pharmacokinetics of subcutaneous injections and intravenous infusions are comparable, and studies in laboratory animals demonstrate that ultimately the distribution of ASO to various organs is also comparable with the exception of the local injection site and the draining lymph nodes. Following subcutaneous administration, both first- and second-generation ASOs are absorbed rapidly from the injection sites into the circulation. In clinical trials, after subcutaneous injection of a second-generation ASO, the time to maximum plasma levels, Tmax, ranged from 1.5 to 4.7 h as dose was increased from 25 to 200 mg (in a constant volume of 1 mL) [22]. The bioavailability of subcutaneous doses ranged from 36 to 82% over this dose range. Preclinical studies [23] and a clinical trial [22] suggest that bioavailability increases with concentration, but additional unpublished clinical studies have yielded less consistent concentration effects, such that it is not appropriate to generalize at this point. The kinetics at the local injection sites can affect local responses, as well as broader systemic pharmacokinetics and distribution. Reducing the concentration of ASO at the injection site is hypothesized to reduce local responses to injection. One approach to reducing concentrations of ASO at the active site is to dilute the formulation, and therefore, increase the surface area available for absorption from a subcutaneous depot. In theory, dilute solutions and greater surface area for absorption should reduce local concentrations and diminish local responses. The same phenomena would be expected to increase the rate of systemic absorption, and alterations of dose and volume can be considered as potential variables that can be manipulated. However, even with the present subcutaneous injection regimens of low volumes and relatively high concentrations, it is possible to demonstrate pharmacology, good tolerability, and high bioavailability.
7.3.1.2 Local Delivery Aerosol formulations, enema, and intravitreal injections have been used as local treatments. To treat lung disease, it is possible to achieve relatively high concentrations of ASO in the lung using aerosolized ASO [24]. The kinetics for a first-generation ODN have been characterized after inhalation exposure in mice. The kinetics of a first-generation ODN are dose-dependent with the lung clearing with a terminal elimination half-life of ⬃2 h. In contrast, studies with MOE-modified second-generation ASOs show that the terminal elimination half-life is greater than 4 days (unpublished observations). Like other local treatment therapies, the advantage to inhalation is that it is possible to achieve high local concentrations in a tissue that is not normally a site of significant accumulation. The lung does not normally accumulate ASOs after parenteral administration. Local treatments also have the added advantage of minimizing systemic exposure. For example, treatment of a monkey with 0.1 mg/kg via inhalation (estimated delivered dose) for three doses over 1 week resulted in lung concentrations of ⬃1 g/g. Yet in these same monkeys, concentrations in the liver and kidney were ⬍5% of the concentrations in lung. As drug is cleared from the lung, it will ultimately deposit in the kidney, but the amounts of drug administered via inhalation is far less than for systemic treatment, so it follows that total exposure will be less.
CRC_8796_ch007.qxd
5/25/2007
192
7:39 AM
Page 192
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Similarly, enema formulations have been successfully used to treat ulcerative colitis. In contrast to inhalation, where small amounts of drug could be used to treat local disease, in ulcerative colitis an enema formulation containing 240 mg of the first-generation drug alicaforsen was administered in clinical trials. In this case, the epithelium of the colon is exposed, but because of the limited permeability of the gut to highly charged ODNs, absorption is minimal and the total systemic exposure is minimal. Colonic epithelial biopsy samples taken within 12 h of administration of enemas in a phase 2 trial had concentrations up to 20 g/g. Plasma bioavailability in human subjects with ulcerative colitis ranged from 0.03 to 2.14% and the maximum concentration observed in plasma was only 0.126 g/mL [25]. The lack of significant absorption systemic absorption and the locally high concentrations work in favor of the efficacy of this local therapy. Intravitreal injections have been used to deliver both first- and second-generation drugs. With this form of local therapy the total dose administered into the eye is quite small (micrograms). Local sequestration seems to limit systemic exposure even further. Within the eye, the vitreous and the retina clear ASOs at different rates: vitreous faster than retina. For fomivirsen, the first marketed antisense drug, vitreous appeared to clear drug (over the course of days) as a result of distribution to tissue; in this case retina. For a second-generation version of fomivirsen, the tissue half-life was estimated as ⬎30 days. Both local metabolism and diffusion out of the eye contribute to the elimination of half-life from the eye (see Chapter 21 in this volume for a complete review of ocular use of ASOs). Again because of the small quantities of drug delivered to the eye, systemic exposure is minimized. However, that pattern of systemic distribution is similar, with liver and kidney accumulating most drugs.
7.3.1.3 Enteral The marked nuclease stability that is afforded by 2⬘-MOE modifications of second-generation ASOs provides the longevity in the gut that can be exploited for parenteral absorption. However, molecular size and charges on the ASOs limits transcellular absorption and researchers have relied on paracellular approaches to enhance uptake from the gut. Oral bioavailability of second-generation drugs (ISIS 104838 or ISIS 301012) is as high as 6–12% and pharmacology by the oral route has been demonstrated after administration of enterically coated solid dosage forms of ASOs combined with permeation enhancers (see Chapter 8 in this volume for a discussion of oral formulations and bioavailability). Once absorbed from the gut, the fate of the ASOis generally similar to intravenous and subcutaneous injections. Although liver is one of the sites of the greatest accumulation of ASO, first-pass effects are not important factors in determining the fate of ASO absorbed from the gut [26,27]. 7.3.2
Distribution
7.3.2.1 Roles of Perfusion and Tissue Affinity Distribution of ASOs like all other drugs is dependent upon permeability, blood flow, plasma protein binding, tissue, and cellular binding. Phosphorothioate ASOs (first and second generation) with their multiple negative charges and their protein-binding characteristics display disposition characteristics that are less dependent on blood flow and more dependent on factors that control the uptake of ASOs into cells. The initial distribution from plasma to tissues is relatively rapid with dose-dependent half-lives that range from 30 to 90 min after intravenous administration. Distribution half-lives are longer after the subcutaneous administration than after intravenous injection. The difference is related to prolonged absorption from the site of injection rather than a true difference in movement from plasma into tissues [7,23,28].
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 193
BASIC PRINCIPLES OF THE PHARMACOKINETICS
193
There are small differences in the distribution kinetics between first- and second-generation drugs. The greater nuclease stability of second-generation ASOs is offset by slightly less protein binding. The plasma profiles of the same sequence in a first- and second-generation configuration are similar. They are nearly superimposable if the sum of parent and ASO metabolites (total ASO) of the first-generation drug is compared with the intact second-generation drug (ISIS 13650) (Figure 7.5). Otherwise, the more rapid degradation by exonucleases shortens the half-life of the first-generation drug compared to the second. Both distribute to tissues in a dose-related manner. At higher doses, the distribution changes and more ASO goes to lower-avidity tissues, like spleen and lymph nodes due to saturation of uptake in liver and kidney [23]. Once absorbed from the site of injection or the gut, ASOs circulate bound to plasma proteins. Two plasma proteins that are known to bind phosphorothioate ASOs are albumen and alpha 2 macroglobulin. Another abundant protein, acid glycoprotein neither binds ASOs very well [29] nor was significant binding observed with purified LDL or HDL [30]. Protein binding is critical to the distribution of the ASO to target tissues. Chemical modifications that reduce binding result in a marked reduction in tissue concentrations and concomitant increases in ASO filtered by the glomeruli and excreted in urine (Table 7.2). This phenomenon can be observed when diester linkages are included in the ASO backbone or when MOE modifications are present or both or in shorter ASOs. The reduced protein-binding affinity of diester and MOE-modified compounds (or both modifications) allows more free ASO to circulate, resulting in increased renal uptake and greater urinary excretion (see Figure 7.4) [28]. In all our studies with parenterally administered first- and second-generation ASOs, we have observed that the initial clearance from plasma is nonlinear. Clearance decreases with increasing doses, and consequently, plasma AUC increases more than that would be predicted on the basis of dose alone [6,22,23,31–33]. Because the initial clearance is driven by distribution and tissue uptake the observation of dose-dependent kinetics implies that tissue uptake has some saturable component. ASOs bound to plasma proteins distribute rapidly to tissues from plasma as a result of binding to cell surface proteins. While the exact mechanisms for cell binding and uptake are not known, one can envision that ASOs would continually bind to available protein-binding sites in extracellular matrix or on cell surfaces. From there, bound ASOs continue traveling down the concentration gradients even crossing the cell membranes by exchange from cell surface protein to membrane or intracellular protein. In that way, the driving force for the movement into cells is the gradient from high concentrations to low. Shuttling has been described for ASO movement between cytoplasm and nucleus [34]. Protein binding
Plasma concentration (µg/mL)
1000 ISIS 13650 ISIS 5132 (Parent) ISIS 5132 (Total)
100
10
1 0
2
4
6
8
Time (h) Figure 7.5
Plasma concentrations of ISIS 5132 shown in dark triangles and total oligodeoxynucleotide shown in light triangles, compared with the plasma concentration of ISIS 13650 a second-generation oligonucleotide.
CRC_8796_ch007.qxd
194
5/25/2007
7:39 AM
Page 194
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
facilitates the movement of ASOs across barriers that would normally inhibit the movement of highly charged hydrophilic molecules. This mechanism of shuttling across membranes remains a hypothesis for this class of compounds, but has been previously described for organometallic compounds [35]. The transit of ASO from extracellular matrix to intracellular compartment has been visualized in livers of treated mice using immunohistochemistry [36] and in the kidneys of rats by vital microscopy with fluorescently tagged second-generation ASOs (S. Henry and B. Molitoris, unpublished observations). The identity of the proteins that are responsible for the transit of ASO from the extracellular to the intracellular compartments is not known, but the scavenger receptor has been implicated [37]. However, cellular distribution and pharmacology of ASOs in transgenic mice lacking the scavenger SR-A I/II did not differ appreciably from syngeneic controls [38]. Thus, this specific receptor is not responsible for the majority of uptake into liver and kidney. Other protein acceptors that are capable of binding and translocating ASOs across cell membranes must be responsible for cellular uptake. Membrane proteins that function as transporters are present in all organisms [39]. In considering the transport of drugs, two major superfamilies are generally considered: ABC (ATP binding cassette—requiring energy) and SLC (solute carrier—not requiring energy) transporters. It is known that the rate of transport across a biological membrane via transporter-mediated processes is characterized by saturability. There are multiple members of the SLC superfamily known to function primarily as nucleoside, nucleoside-sugar, and phosphate-sugar transporters. We believe that future work is likely to implicate membrane protein transporters in the facilitated uptake of ASOs as well. Whether they are known receptors or transporters, or whether proteins are acting as nonspecific transport vectors remains to be elucidated. What is clear is that there are differences in the level of avidity and uptake in different organs and tissues and that uptake is saturable at higher doses leading to dose-related plasma clearance and distribution. This distribution of ASO to tissues is determined by a combination of delivery of ASO, blood flow, possible residence time, and finally by the inherent avidity of the tissue for the ASO. The initial binding of ASO to the cell surface appears to be one of the events determining the organ distribution of ASOs. This hypothesis is based upon the observation that liver and kidney are the initial sites of distribution for ASOs with some additional accumulation occurring in the first 24 h after dosing [40]. There is a fractional increase in liver and kidney concentrations over the first 24 h that occurs during a period of marked redistribution at the cellular and subcellular level [41], but the initial organ distribution seems to predict for the sites of more permanent accumulation over time [23,33], suggesting that these organs have greater avidity for ASOs. The proteins responsible for this avidity may include heparin-like binding sites on laminin and fibronectin, and FGF [42–45]. Binding of first-generation ASOs to extracellular matrix was followed by internalization into cells particularly phagocytically active cells [36]. The early binding of ASOs to cells may be related to binding to these proteins, but the nature of the proteins that are ultimately associated with the internalization of the ASOs is not known. Phagocytically active cells like Kupffer cells, tissue macrophages, and proximal tubular cells have high avidity for ASO uptake suggesting that there are receptors on their cell surfaces. Preadministration of an ASO drug to mice can be used to saturate uptake by phagocytically active cells in the liver. When the binding sites on Kupffer cells approach saturation, lower affinity sites become accessible. Subsequent administration of a pharmacologically active ASO to mice that have been pretreated in this way improves the distribution of ASO to nonphagocytic cells in the liver and as a result improves pharmacologic activity in hepatocytes compared to nonpretreated mice (Geary and Sinkowski, unpublished data). Conversely, at plasma concentrations below 1 g/mL ASO tends to favor the binding sites with greater avidity in the liver like Kupffer cells, and it accumulates less in hepatocytes. The combination of the specific cellular binding sites and blood flow results in a distinctive pattern of organ and cell distribution for phosphorothioate ASOs. Experience with dozens of sequences, both first- and second-generation chemistries, demonstrates that the pattern of distribution is generally reproducible from sequence to sequence, and appears to be qualitatively similar from species to species. Kidney, liver, lymph node, spleen, and bone marrow are the organs that accumulate the highest concentrations of ASO and ASO metabolites (Figure 7.6). That lung and
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 195
BASIC PRINCIPLES OF THE PHARMACOKINETICS
195
Oligonucleotide concentration in tissue (µg/g)
300
Parent Total oligo 250
200
150
100
50
Ax
illa
ry
LN Br ai n Fa Ki t dn He Ki ey art dn co ey rte x m ed ul la Li ve O va r Sk Pa rie el n c s et al rea m s us c Sp le le e Te n st e U s te ru s
0
Figure 7.6
Bar graph distribution. Biodistribution of 2⬘ MOE ASO in monkeys; concentrations presented as average microgram oligo per gram tissue for a 20-mer partially modified 2⬘ MOE PS ASO, ISIS 113715 (n ⫽ 2); error bar represents range. Tissues assayed 24 h after single 1 h i.v. infusion of 3 mg/kg ISIS 113715. Assayed by capillary gel electrophoresis (CGE-UV).
heart are not sites of accumulation suggest that blood flow alone is not sufficient to explain the high levels of uptake by kidney and liver. In fact, the site with the highest blood flow in kidney is presumably the glomerulus and that is not a site that accumulates significant quantities of ASOs. In contrast, the renal proximal tubules may represent an extreme situation where there is ample delivery from both the ultrafiltrate and interstitial blood supply. Proximal tubular cells are phagocytically active cells that may be capable of taking up both free ASO as well as ASO bound by proteins that are normally reabsorbed in the proximal tubules [46]. As a result, the renal cortex and in particular the proximal tubular epithelium contains the highest concentrations of phosphorothioate ASOs, both first- and second-generation ASOs (reviewed in Ref. [47]). Blood flow (mL/g of tissue) to the liver is only 苲20% of that to the kidney. The four- to fivefold difference in perfusion between liver and kidney does not translate into four- to fivefold difference in tissue concentrations. Fenestrated capillaries expand the surface area available to the ASO and therefore an abundance of binding sites in the liver may compensate for the lower perfusion rates between liver and kidney.
7.3.2.2 Plasma Protein Binding in Distribution Although cellular avidity may ultimately dictate uptake into target organs, plasma protein binding can alter the relative distribution to kidney and liver of different sequences. There are sequence differences in protein binding. Sequences that bind less to plasma proteins have reduced uptake into liver and increased accumulation in kidney. There is an inverse relationship between extent of protein binding and the accumulation in rat and monkey kidneys after repeated intravenous or subcutaneous injections. In fact, for second-generation MOE-modified ASO sequences with the typical 5 MOE-10 ODNs-5 MOE nucleotides, differences in renal accumulation can be as high as twofold from one sequence to another (Figure 7.7).
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 196
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION Total oligo concentration (µg/g) in renal cortex
196 7000 r ² = 0.869
6000 5000 ISIS 113715
4000 ISIS 104838
3000 ISIS 107248
2000
ISIS 301012
1000
ISIS 112989
0 2
Figure 7.7
3
4 5 6 7 % Unbound to plasma protein
8
Renal cortex concentrations as a function of the percent oligonucleotide unbound at 1 M in monkey plasma using the method described in Ref. [28]. The renal cortex concentrations were determined from six subjects treated with each drug for 4–13 weeks at ⬃10 mg/kg/week.
Sequences with higher binding affinities with less circulation as free drug will have less accumulation in kidney and more accumulation in other organs. Protein binding can be used as a selection criterion for choosing ASOs for clinical development. Determination of protein binding is an empirical process at this time with no way to accurately predict which sequences will bind plasma proteins with greater or lesser affinity.
7.3.2.3 Distribution to Other Organs Independent of sequence, there is characteristic pattern of distribution of first- and secondgeneration phosphorothioate ASOs with significant distribution to the kidney and liver, as well as spleen, and lymph nodes, bone, and the cytoplasm of adipocytes [48–50]. Lymphoid tissue uptake can be explained partly by the presence of phagocytically active histiocytes and other mononuclear cells. It is possible to visualize ASO in phagolysosomes of histiocytes and tissue macrophages with hematoxylin staining. ASO is taken up by endocytosis, compartmentalized in endosomes, and the ASO is retained within these membrane-bound structures. The local concentrations of ASO in phagolysosomes are often sufficient such that they stain with hematoxylin (much like nuclear DNA). ASO in phagolysosomes probably accounts for much of the ASO accumulated in spleen and lymphoid organs. Similarly, the phagocytically active cells in bone and bone marrow may also account for the tissue concentrations observed in these tissues and that appears to be true based on the presence of basophilic granules in these cells and tissues. Muscles (either skeletal or cardiac) do not take up significant quantities of ASO, although low concentrations have been measured in this tissue. Close examination of muscle using immunohistochemistry or autoradiography demonstrates that resident macrophages in the stroma of a muscle contain ASOs in phagolysosomes and this accumulation may account in part for the ASO measured in muscles and heart. The accumulation of ASO in the cytoplasm of adipocytes is interesting and of therapeutic utility. It is interesting because unlike most compounds that accumulate in adipocytes, ASOs are hydrophilic not hydrophobic. Immunohistochemistry demonstrates clearly that there is ASO in the cytoplasmic fraction of the adipocyte, with little or no ASO in the lipid storage vacuole. The intensity of staining indicates that there is significant accumulation within the cytoplasm. Correcting for the fact that greater than 90%
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 197
BASIC PRINCIPLES OF THE PHARMACOKINETICS
197
of the cell mass is composed of the lipid droplet from which ASO is excluded, suggests that concentrations in the cytoplasm of adipocytes may rival the concentrations in hepatocytes. For example, in cynomolgus monkeys after 13 weeks of treatment with ISIS 113715 at 10 mg/kg/week concentrations in liver are 301 ⫾ 88.1 g/g, but only 37.3 ⫾ 14.4 g/g in adipose tissue from the same animals. Assuming that the lipid-free weight of the tissue is 10% of the total weight, then the corrected concentrations would be 10 times the observed concentration, and therefore, in the range of concentrations in liver. Significant concentrations in adipocytes predict that it should be possible to modulate the expression of disease-related genes in this cell type: a source of hormones and cytokines. Pharmacologically active concentrations of ASOs reach adipocytes and treatment of ob/ob mice with ISIS 113715 at 25 mg/kg twice weekly lowers the expression of its target gene PTP-1B in liver as well as in adipocytes [51]. Similar observations were made in monkeys treated with ISIS 113715. Because subcutaneous fat biopsies can be obtained in clinical studies, and ASOs are active and accumulate in fat, it may be possible to use fat biopsies for measuring pharmacologic effects (reductions in mRNA) and tissue concentrations of drug to directly measure exposure to human tissues (Figure 7.8). Phosphorothioate ASOs distribute to other organs and cell types, and for some tissues and targets cells, concentrations of ASO are not high enough to produce pharmacologic activity. For example, mature lymphocytes do not accumulate ASOs and antisense activity appears to be limited in T-cells. Immunohistochemistry studies demonstrate that endothelial cells accumulate ASO [36,37] at concentrations sufficient to reduce target mRNA levels, making them a potential site for pharmacologic intervention. Bone cells, particularly the phagocytically active osteoblasts, can take up ASO and this propensity for uptake may be exploitable for therapeutic use. Likewise, pancreatic islet cells accumulate ASOs to a degree that might be exploitable (ISIS, unpublished observations). Both first- and second-generation ASOs are highly charged hydrophilic molecules that do not appear to penetrate the blood–brain barrier, or the blood–testes barrier. However, like muscle, in the interstitial regions of the testes, resident macrophages contain ASO and this phagocytized ASO may account for low levels of antisense drugs observed in the testes as well (Figure 7.6). Ovaries are not afforded the same barrier. ASO can be measured in ovaries and can be visualized by immunohistochemistry in the stroma (depicted in Ref. [47]).
500 Intercept = 54.6
Liver concentration (µg/g)
Slope = 8.11 r ² = 0.923
400
300
200
100
0 0
10 20 30 40 Subcutaneous fat concentration (µg/g)
50
Figure 7.8 The relationship between concentrations of ISIS 113715 in liver of monkeys treated for 13 weeks with doses from 1 to 30 mg/kg/week versus concentrations in subcutaneous adipose tissue. Each animal on study is represented by single liver and fat values. The slope and the correlation coefficients are shown.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 198
198
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
The limited distribution from plasma to brain cells and cardiac myocytes makes these tissues unlikely targets for antisense intervention, despite the fact that selective inhibition or expression of some ion channel proteins in brain and muscle might be therapeutically useful. However, the limited distribution to these tissues can be considered as an advantage because the absence of significant concentrations of ASOs in brain and heart diminishes the risk for central nervous system (CNS) and cardiac effects: two common sites for adverse effects. That being said, direct administration to the CNS via intrathecal or intraventricular infusion or injections distributes within the CNS and may be useful therapeutically [52,53]. Another site that appears to be shielded from antisense distribution is the fetus. Though there has been a single report of transplacental antisense activity in early rodent embryos [54], studies of the transplacental kinetics of ASOs indicated that there is little or no fetal accumulation of ASO and relatively low levels of ASO taken up by the rodent placenta [55,56]. Even with constant infusions of ASO throughout gestation, little and in many cases no, ASO could be detected in fetal tissues [55]. These results have been consistently reproduced in teratogenicity studies in mice, rats, and rabbits with various second-generation ASOs (Henry, unpublished observations). In these studies only minimal exposure to the fetal liver and kidney can occasionally be measured. The placenta, despite high perfusion, is not a site of high accumulation of ASOs [55,56]. Distribution is one of the key factors that influences the activity of ASOs. The distinctive pattern of ASO distribution appears to be related to the avidity of tissues for ASO and to a lesser extent perfusion. The conclusion from this section of the review is that distribution is much more a function of the affinity of cells and tissues and less a function of delivery. 7.3.3
Metabolism
Metabolism is the major mechanism of whole body clearance of ASO drugs. ASOs like first- and second-generation antisense drugs are metabolized by nucleases, not the typical mixed function oxidases like the cytochromes P450 that metabolize traditional lipophilic low-molecular-weight drugs. ASOs are neither thought to be substrates for the P450 enzyme family, nor do they induce or inhibit the activity of cytochrome P450 at clinically relevant concentrations (Isis, unpublished observations). ISIS 301012 5′ - G C C T C a g t c t g c t t c G C A C C -3′ 5′-
-3′
2′-MOE
2′-MOE
deoxy
endonuclease
exonuclease
urine
+ + Figure 7.9
A scheme depicting the metabolism of a 20-mer second-generation oligonucleotide. The MOEmodified termini are depicted as capital letters or the ellipse-shaped ends of the molecule.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 199
BASIC PRINCIPLES OF THE PHARMACOKINETICS
199
Rather than cytochromes P450—mediated metabolism, ASOs are metabolized by nucleases. Exonuclease-mediated shortening of the ASO, which was a prominent mechanism of metabolism and clearance of first-generation phosphorothioate ODNs, has only a secondary role in the clearance of second-generation ASOs. The rate-limiting step is endonuclease cleavage yielding two fragments of the original compound. One fragment has a 3⬘ MOE terminus and the other a 5⬘ MOE terminus (depicted in Figure 7.9).
7.3.3.1 Enzymes Responsible for Metabolism The specific enzymes that metabolize second-generation ASOs are not known. Nucleases are ubiquitously distributed and it is possible to identify cleaved ASO metabolites in most tissues. Hepatic and renal homogenates are both capable of metabolizing second-generation ASOs in vitro (without the addition of exogenous energy sources such as nicotinamide–adenine dinucleotide phosphate [NADPH] regenerating systems or adenosine 5⬘-triphosphate [ATP]). The initial cleavage event results in two products each with a protected MOE terminus 5⬘ and 3⬘. These metabolites no longer bind to proteins with significant affinity, and are therefore, cleared from tissue. Because metabolites are cleared more quickly than they are formed, there is little accumulation of metabolites in tissues (in Figure 7.6, compare parent versus total ASO). Thus, it is not possible to use the amount of metabolites in a tissue as an index of metabolic capability of tissues. Clearance from tissues is dependent on metabolism so that differences in rates in metabolism or different tissues can be estimated based on elimination of half-lives for these tissues. On the basis of data for four second-generation ASOs, the behaviors of members of this class are similar, but there are slight differences in the half-lives in liver and kidney of monkeys treated for 4–13 weeks (Table 7.3, compare down the columns). For ISIS 104838 and 112989 the tissue half-lives are very similar in liver and kidney. These data are suggestive that for some sequences there may not be significant differences in the rates of metabolism in different organs. For ISIS 107248, 113715, and 301012 there are differences in tissue half-lives. The differences in metabolic rates between liver and kidney indicate that there could be differences in metabolic rates in different tissues or that there are more complex kinetics for some sequences (or they could simply reflect the small numbers of samples taken over a limited sampling time). We have already determined that for second-generation ASOs there are different rates of clearance in different cell types in the liver [57], and that some cell types within organs like the proximal tubular cells in kidney cortex tend to sequester ASO in phagolysosomes. Because of this sequestration, it is very likely that there are differences in metabolic rates in different tissues. In addition, it is likely that specific sequences may have different sensitivity to the endonucleolytic cleavage. Bacterial exonucleases exhibit a high degree of sequence specificity presumably for defense against viruses. Much of the nuclease activity in mammalian cells has been associated with the transcription machinery and DNA repair, and thus, the sequence specificity may differ from bacterial endonucleases. It is not known if the replication and repair-associated enzymes are the same ones responsible for catabolism of these synthetic ASOs. At high concentrations ssDNA [58], and by extension ASOs, may be able to compete effectively with the favored natural substrate. Multiple enzyme families have nuclease activity capable of catabolizing ASOs. The identification of the Table 7.3 Tissue Half-Lives in Days (SE) in Monkey’s Organsa Organ Liver Kidney cortex a
104838
107248
113715
301012
112989
13 (5) 15 (6)
22 (4) 14 (3)
8 (4) 16 (1)
37 (7) 17 (11)b
10 (2) 10 (2)
Organ samples collected at various times after the administration of loading regimens of four alternate day doses ⬃3mg/kg. b Appears to be a biphasic elimination for this sequence in renal cortex, elimination half-life was poorly estimated.
CRC_8796_ch007.qxd
5/25/2007
200
7:39 AM
Page 200
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
specific enzymes involved in ASOs is not critical for the development of antisense drugs, but having a more thorough understanding of the metabolic pathways will be useful for the technology as we refine it.
7.3.3.2 Metabolites Differences in metabolism from first- to second-generation ASOs are very apparent when comparing metabolic profile with CGE (Figure 7.3). When tissue samples or urine are analyzed by LC/MS, the nature of the metabolic process becomes more clear [28]. Typically a first-generation phosphorothioate ODN is metabolized into a ladder of ASO metabolites each differing by a single nucleotide as a result of single-nucleotide excision by exonucleases. Thus after administering a 20mer first-generation ODN, plasma and tissue contain a family of processively shortened ASOs starting at 19-mers and working down to shorter ASOs (Figure 3[b]). In contrast, administration of a second-generation ASO yields a very different pattern. The initial cleavage event in the metabolism of second-generation ASOs is mediated by an endonuclease, yielding two ASOs one with the 3⬘ MOE terminus and the other with the 5⬘ MOE terminus (see the metabolic scheme in Figure 7.9). The cleavage products have unprotected termini that can be substrates for either 5⬘ exonucleases or 3⬘ exonucleases. In tissues, ASO metabolites consistent with both 3⬘ and 5⬘ exonuclease metabolism have been identified [33,59]. The results of the combined endo- and exonuclease activities are ladders of chain-shortened cleavage products, many if not all of which can be identified in urine collected from treated animals or humans. Urine of treated animals or human subjects treated with a 5-10-5 type of second-generation ASO can have metabolites that range from the two possible 15-mers to the two possible MOE 5-mers and multiple combinations of each of the intermediate length metabolites [28]. Metabolites shorter than the length of the MOE termini would only be present if the MOE termini themselves were substrates for nucleases. That metabolites shorter than the MOE termini are generally undetectable in mass spectral analyses is suggestive that MOE mononucleotides are not generally liberated in the metabolic process. However, some exceptions to this generalization have been observed. For a limited number of sequences, we have observed single-nucleotide trimming of second-generation ASOs in tissues and plasma by either CGE or LC/MS: metabolites apparently the result of exonuclease cleavage. These metabolites can be observed in the initial distribution phase, suggesting that they are generated rapidly in plasma. The MOE mononucleotides that are released are not substrates for phosphorylation, and are therefore, unlikely to be incorporated into nucleotide triphosphates and ultimately into endogenous nucleotides. MOE mononucleotides are not inhibitors of DNA synthetic enzymes. Thus, MOE mononucleotides, if they are released should not interfere with endogenous nucleotide pools. The central deoxynucleotide portion of second-generation ASOs is subject to exonuclease cleavage, which results in the release of single nucleotides. The monodeoxynucleotides that are produced by exonuclease cleavage are identical to endogenous nucleotides with the exception of the thiophosphate group that theoretically might be present. However, the thiophosphate group is labile to oxidation and loss of the sulfur, making the terminal phosphate group identical to an endogenous nucleotide. Therefore, in contrast to MOE mononucleotides, any liberated deoxynucleotide would naturally be incorporated into the intracellular pool of endogenous nucleotides. Nucleotides that retain the thiophosphate group would be substrates for addition of one or two phosphate groups yielding a mixed phosphate thiophosphate di- or triphosphate nucleotide. The phosphorylation is possible, but the presence of the alpha thiophosphate would make it a thermodynamically disfavored reaction (discussed in Ref. [47]). Even if the alpha thiophosphate were phosphorylated and incorporated, base pairing and replication fidelity would be retained. In the metabolic scheme presented (Figure 7.9), other than the deoxymononucleotides, the metabolites that are characteristic of second-generation drugs are the shortened fragments with MOE termini and these appear to be excreted in urine.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 201
BASIC PRINCIPLES OF THE PHARMACOKINETICS
201
7.3.3.3 Metabolism and Clearance The rapid clearance of metabolites from the organs in which they are formed is demonstrated in two ways. First, there is no significant buildup of metabolic products. The concentration of parent ASO represents a very high fraction of the total ASO present in an organ or tissue (Table 7.4). With increasing time after injection, the fraction of ASO that is comprised of metabolites only increases slightly with the exception of spleen in which the ASO concentration diminished 90% over the 3-month period and may not be representative. With the exception of spleen, there was no meaningful buildup of metabolites. Thus, it appears that formation of metabolites is generally slower than clearance. Second, that metabolites are cleared as rapidly as they are formed is supported by the similarities in the half-life of the parent ASO and the half-life of total ASO (Table 7.5). There is a close correlation between the tissue half-lives observed in monkeys and the plasma terminal elimination half-lives observed in human subjects (Table 7.6). Comparing mean terminal elimination rates in human subjects treated with different second-generation ASOs, the terminal elimination half-lives in human subjects differed by as much as twofold depending on the sequence (Table 7.6). That these are sequence-related differences is confirmed by the similarities between the tissue half-lives determined in monkeys and the terminal elimination half-lives in man. Table 7.4 ISIS 301012 in Tissues from Monkeys Either 2 or 90 Days after the Last Dose 2 Days Sample
Concentration of ISIS 301012
Liver Kidney cortex Spleen Lymph node
1129 ⫾ 242 1593 ⫾ 518 291 ⫾ 125 767 ⫾ 255
90 Days Percent Intact Drug 99 ⫾ 25 94.7 ⫾ 6.2 96.7 ⫾ 5.3 96.1 ⫾ 3.4
Concentration of ISIS 301012
Percent Intact Drug
154 245 31.1 107
74 91.7 50.4 100
Note: Tissues from monkeys treated for 13 weeks with 20 mg/kg/week of ISIS 301012. N ⫽ 6 for 2 days after the last dose group and N ⫽ 2 for 90 days after the last dose group. Table 7.5 Half-Lives of ISIS 113715 and Total ASO in Tissues from Monkeysa Tissue
Parent t1/2 (day)
Axillary lymph Inguinal lymph Kidney cortex Kidney medulla Liver Spleen a
Total Oligo t1/2 (day)
9.8 11.3 15.6 23.2 7.9 11.8
9.5 11.9 16.1 26.1 7.7 10.8
ISIS 113715 tissue exposure parameters in the major tissues of distribution of the pharmacokinetic animals (3 mg/kg i.v. administered on days 1, 4, and 7 only). Tissue samples collected on study days 2, 8, 14, 21, 35, and 63 from two monkeys at each time point.
Table 7.6 Table of Terminal Elimination Half-Lives for 104838, 113715, and 301012
a
ASO
Sequence
t1/2 Livera
104838
GCTGATTAGAGAGAGGTCCC
13
t1/2 Kidneya 15
113715
GCTCCTTCCACTGATCCTGC
8
16
107248
CTGAGTCTGTTTTCCATTCT
22
14
301012
GCCTCAGTCTGCTTCGCACC
37
17
Tissue half-life (days) calculated from data obtained in studies in monkeys (see Table 7.3) b Terminal elimination half-life data from phase 1 clinical trials.
Terminal Elimination (day)b 12 (3)
⬃15 ⬃24 31 (11)
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 202
202
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
If endonuclease cleavage is truly the rate-limiting step in the degradation and clearance of the ASO, then it appears from the wide range of terminal elimination half-lives that there may be differences in the susceptibility of these compounds to degradation. The longer terminal elimination of ISIS 301012 suggests that it may be less prone to metabolism and clearance than the other sequences listed. The factors that control the susceptibility of the deoxy portion of the ASO need to be further characterized, as do the enzymes responsible for the catabolism. The nucleases that metabolize ASOs are thought to be ubiquitous and there is no induction of metabolism with repeated administration. The pattern and extent of metabolism are similar after single or multiple injections. However, there may be changes in terminal elimination half-lives that are dependent on dose or tissue exposure. For ISIS 104838 in a phase 1 study [22], half-life increased as dose was increased, but the number of subjects was only three per group. For ISIS 301012, the terminal elimination half-life ranged from 23 ⫾ 1 to 31 ⫾ 11 days in a phase 1 study in which subjects (n ⫽ six/group) treated with 50 or 200 mg/week [67]. The potential inhibitory effects of phosphorothioate ASOs on nucleases might explain the dose-related phenomenon. As studies are performed with larger cohorts with additional sequences, it will become more clear as to whether terminal elimination kinetics are dose-related for more sequences. Similarly, because ASO therapeutics have not yet been tested in large populations, we have not yet determined if there are polymorphisms in the human population that may affect the rates of nuclease-mediated metabolism and clearance of these compounds like those that have been seen with traditional drugs. 7.3.4
Excretion
The excretion of ASOs and ASO metabolites changes depending on the proximity to the last dose. Initial excretion rates are a function of protein binding while excretion rates at later times are a function of metabolism and the disposition of those metabolites.
7.3.4.1 Overview of Excretion The distinctly multiphasic behavior of ASOs in plasma influences their excretion. During the initial plasma clearance phase while ASOs are being distributed to tissues, excretion plays a minor role in plasma clearance. During this period the small amount of urinary excretion is the result of spilling 100 Total excreted
Percent radiolabel excreted
80 Urine
60 40
Carcass
20
Feces
0 −20
0
20
40 60 Time (days)
80
100
Figure 7.10 Excretion of radiolabel from rats treated with 5 mg/kg ISIS 113715 labeled with tritiums at nonexchangeable position of thymidines in MOE-modified wings. Each of the radiolabeled thymidines was 3 positions inward from the termini. The data are from three to six rats per time point.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 203
BASIC PRINCIPLES OF THE PHARMACOKINETICS
203
of the parent ASO (for second-generation drugs) in urine. The extent of excretion in this phase is dependent on the extent and capacity of plasma protein binding. Later during the equilibrium phase, the nature of the excreted products changes primarily from the excretion of the parent to the excretion of metabolites. The ultimate fate of second-generation ASOs is metabolism and urinary excretion, and to a much lesser extent fecal excretion. In a mass balance experiment, typical of secondgeneration ASOs, the urinary metabolites account for nearly 80% of the total dose, 90 days after administration of a single dose. A few percent of the administered dose was excreted with feces and the remainder had not yet been cleared from the carcass (Figure 7.10). This illustrates the importance of urinary excretion in the whole body clearance of the long-lived second-generation ASOs.
7.3.4.2 Early Excretion and Protein Binding After initial parenteral administration of ASOs, any fraction of drug that is not protein bound in plasma can be filtered by the glomerulus and potentially excreted in urine. There are some sequence-related differences in plasma protein binding and the differences translate into differences in degree of urinary excretion. The amount of free ASO correlates directly with the fraction of the dose excreted in urine in rats (Figure 7.11). Saturation of plasma protein binding often occurs at high doses in toxicology studies, resulting in a sharp increase in the fraction of drug excreted in urine of mice as dose is increased [10,31]. In primates the same holds true: though the capacity for plasma protein binding is greater. The fraction of the dose excreted as the parent compound in the urine is also dose dependent, increasing from 0.2 to 2.9% in monkeys treated with ISIS 301012 after single doses of 2 to 12 mg/kg. Similarly in clinical trials the fraction excreted in urine tends to increase with increasing dose. For ISIS 113715 a compound that binds to plasma proteins to a lesser degree than ISIS 301012 (see Figure 7.11), the fraction excreted in urine as parent compound increased from 0.2 to 7.4% over the dose range of 0.1 to 7.5 mg/kg. The percent of the drug excreted as intact drug (versus total ASO) also increased as dose increased. At 0.5 mg/kg, only 15% of the compound was excreted in urine intact compared to 81% intact after an intravenous infusion of 7.5 mg/kg, consistent with the concept that at high doses when protein binding is saturated there is a spilling of free parent drug into glomerular filtrate and ultimately urine (Table 7.7). However, the spillage of parent drug into the urine at 16 r ² = 0.808
% Dose excreted in urine
14 12
ISIS113715
10 8
ISIS 301012
6 ISIS 104838 4 2 ISIS112989
0 −2
2
3
4
5
6
7
8
% Unbound to plasma protein Figure 7.11 Amount of free oligonucleotide in whole plasma incubated with 1 M of the indicated secondgeneration oligonucleotides versus the percent of the dose excreted in urine 24 h after administration of the indicated oligonucleotides. The dose administered was ⬃10 mg/kg/week.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 204
204
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION Table 7.7 Urinary Excretion of ISIS 113715 in a Phase 1 Clinical Study in Normal Human Subjects % Dose Excreted in Urinea Dose (mg/kg) 0.5 1 2.5 5 7.5
Intact 0.2 0.2 0.6 3.2 7.4
(n ⫽ 2) ⫾ 0.1 ⫾ 0.6 ⫾ 2.7 ⫾ 4.4
Totalb 1.3 1.7 1.6 5.2 9.1
(n ⫽ 2) ⫾ 0.5 ⫾ 1.8 ⫾ 3.2 ⫾ 3.7
% Intact 15 13 38 62 81
Note : Urinary excretion of ISIS 113715 and total ASO over 24 h in humans (n ⫽ 3, except where noted; data presented as mean ⫾ standard deviation). a Urine samples (n ⫽ 3/study day) were collected over 24 h after a single dose. b Total ASO ⫽ sum of parent drug and all measurable ASO metabolites.
early times after injection is only a small contribution to total elimination compared to the total amount of drug administered. Excretion of ASO metabolites in urine contributes much more to the ultimate elimination of the drug.
7.3.4.3 Excretion of Metabolites Once the initial distribution phase is complete, there is equilibrium between plasma and tissues. At equilibrium, the levels of drug in plasma will be proportional to the concentration of drug in tissue. This concept is described in more detail in Chapter 11 (Geary et al., this volume). In addition to the equilibrium between tissue and plasma for the parent drug, there is also an exchange between tissue and plasma of the chain-shortened ASO metabolites. The metabolites formed in tissues (as a result of endo- and subsequent exonuclease) metabolism equilibrate down the concentration gradient from the intracellular compartment into extracellular fluid and then into plasma. Ultimately they are filtered in the kidney and excreted. The concentrations of parent drug at equilibrium are very low compared to the distribution phase. In the distribution phase, concentrations are in the microgram per milliliter range while in the equilibrium phase they are in the range of nanograms per milliliter and the metabolite concentrations at equilibrium are a fraction of that. Despite the low circulating concentrations of parent drug and metabolites at equilibrium, this redistribution of parent drug and ASO metabolites represents the major route of excretion for second-generation ASO drugs and these can be both found in the urine of laboratory animals and man (Figure 7.12, [28,68]). Because metabolites bind to proteins more weakly than the parent drugs, one question that we wanted to address is whether these metabolites are simply filtered in the kidney, or whether these shortened metabolites are filtered and then reabsorbed by the kidney. In light of what is known about the role of protein binding in cell uptake, the reduced protein binding of these shortmers could limit the efficiency of renal uptake. To test that hypothesis, studies on the disposition of the two 10-mer metabolites of ISIS 104838 was characterized in rats. One of the cleavage products had 5⬘ MOE groups and the other the MOE group on the 3⬘ end. Because of reduced plasma protein binding of the metabolites (Figure 7.13), the urinary excretion of the metabolites was considerably faster than that of the parent (Table 7.8), but in the first 24 h, the urinary excretion of the metabolites still only represented a small fraction of the administered metabolites, with the remainder appearing in the kidney (data not shown). Because these metabolites are reabsorbed readily by the kidney, one might expect that metabolites would accumulate in kidney, but they do not. The metabolic products apparently clear three to fivefold faster than the parent ASO itself. The metabolites themselves are also subjected to further metabolism, in particular the cleavage product with an unprotected 3⬘ end was subjected to further
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 205
BASIC PRINCIPLES OF THE PHARMACOKINETICS ISIS 104838
205
Metabolites
I.S. (0.25 µM)
5 mg/kg
Mouse, 0−24 h
Metabolites
ISIS 104838
I.S. (0.25 µM)
3 mg/kg
ISIS 104838
Metabolites
Monkey, 0−24 h
2 mg/kg
I.S. (0.25 µM)
Human, 2−4 h
Relative retention time
Figure 7.12 Capillary gel electrophoresis of urine collected from mice, monkeys, and humans treated with ISIS 104838 at the indicated doses.
100
% Bound
90
80
70 ISIS 104838 n-9 n-10
60
n-11 n-12
50 0.1
1
10
15
20
50
[ISIS 104838] in Plasma (µM)
Figure 7.13 Binding of ISIS 104838 and representative metabolites in whole human plasma. The oligonucleotides were incubated at the concentrations indicated and the percent bound determined by ultrafiltration.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 206
206
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION Table 7.8 Percent of Drug Excreted by Rats in Urine 7 Days after the Administration of ISIS 104838 or Two Metabolites Compound ISIS 104838 5⬘ Endo metabolite 10-mer 3⬘ Endo metabolite 10-mer
Parent (%) 0.2 2.5 4.1
Total Oligo (%) 1.1 3.6 5.2
metabolism before being excreted in urine. Taken together these data suggest that the fate of metabolites is more complex than simple filtration in the glomerulus and excretion in urine. 7.3.5
Summary of Absorption, Distribution, Metabolism, and Excretion
In summary, parenterally administered phosphorothioate ASOs circulate bound to plasma proteins. Unbound or free ASO is subjected to glomerular filtration and is excreted in urine reabsorbed into renal tubular cells. In the distribution phase (immediately after administration), ASO moves down a concentration gradient from plasma protein bound, to cell surface bound, and then to intracellular protein bound (Figure 7.14, top insert). Movement down the concentration gradients continues until equilibrium between plasma and tissue is obtained. At high enough concentrations, the steps in this process can be saturated, explaining in part some of the nonlinear kinetics observed. Tissue clearance is dependent on the loss of ASO from the system as a result of the urinary excretion of endonuclease-cleaved metabolites and intact ASO (Figure 7.14, top panel). Metabolism may be influenced by concentration of the substrate and by the chirality of the phosphorothioate linkages. Because of diminished protein binding compared to parent ASO, shortened ASO metabolites that are formed intracellularly move down a concentration gradient from the cellular compartment where they are formed to the circulation, and then to the kidney where the cleavage products are filtered and ultimately excreted (Figure 7.14, bottom panel). The nuclease resistance of secondgeneration drugs effectively slows catabolism, increasing the terminal elimination half-life and prolonging the pharmacologic activity.
7.4 APPLICATION OF PHARMACOKINETICS TO THE DESIGN OF TREATMENT REGIMENS One of the advantages in having a platform technology in which different drugs share so many similarities from sequence to sequence is that the information obtained from studies with one sequence is applicable, in part, to the understanding of all sequences with similar chemistries. Though there are some quantitative differences between sequences, qualitatively different sequences behave similarly. These similarities have been most useful in the application of our understanding of the basic principles of the pharmacokinetics of antisense drugs to the design of clinical dose regimens. Another advantage of the technology is that there is significant predictability of the pharmacokinetics in laboratory animals to humans. Initial plasma clearance rates scale linearly with body weight [28], and plasma concentrations in monkeys and man are similar after equivalent doses are administered on the basis of body weight, and not surface area. The predictability from sequence to sequence and the ability to extrapolate from animals to man together provide distinct advantages for understanding the pharmacokinetics of the class and for the design of clinical dose regimens. In addition to the cumulative information available for the second-generation platform, another key characteristic of the class that allows for significant flexibility in the design of therapeutic regimens is the long terminal elimination half-life. This improvement over the first-generation
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 207
BASIC PRINCIPLES OF THE PHARMACOKINETICS
207
Antisense drug travel ASOs travel from high concentration to low concentration and from proteins of low affinity to high affinity. low
high
highest
higher
Antisense drug disposition, activity and metabolism Cell surface protein Membrane protein Intracellular protein Plasma protein
mRNA
Cleaved mRNA
Endonuclease
Cleaved ASO Free ASO
Cell
Metabolites
Capillary
Antisense metabolite disposition
Glomerulus Excreted
Only unbound drug or metabolites can be filtered
Metabolites
Free ASO
Kidney
Capillary
Figure 7.14 Cartoon of oligonucleotide distribution, metabolism, and excretion. Top insert: ASOs move down concentration gradients and move from protein to protein based on mass flow and protein-binding affinity. Top panel: ASO circulating in plasma is primarily bound to plasma proteins. Bound or free ASO can interact with cell surface proteins and move down the concentration gradients and to proteins of higher affinity as it makes its way across cell membranes and into the cell where it can hybridize to its cognate mRNA, activate RNase H and/or be cleaved by endonucleases. Cleavage products bind weakly to protein and can be lost from the cell. Bottom panel: ASO or metabolites in circulation that are unbound can be filtered in the kidney and excreted in the urine or bound drug is not readily filtered.
ODNs allows for infrequent dosing. Whereas first-generation ASOs had 20–40-h terminal elimination half-lives, second-generation drugs have 14- to 30-day terminal elimination half-lives. Maintenance of therapeutic concentrations of first-generation drugs required dosing on alternate days. For secondgeneration drugs, therapeutic concentrations can be maintained with doses as infrequent as weekly or
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
208
Page 208
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
monthly, depending on dose and the terminal elimination half-life of the specific sequence. By adjusting dose and dose frequency, it is possible to design regimens that achieve specific concentrations of drug in target organs. 7.4.1
Steady-State Kinetics
Repeated administration of an ASO with a long terminal elimination half-life can result in accumulation in organs and tissues. First-order kinetics dictate that depending on the dose and dose frequency, there will be accumulation of ASO in tissues until a steady state is reached. Animal studies with a second-generation ASO demonstrate that a steady state is obtained in tissues such that no additional accumulation of ASO occurs in kidney, liver, and spleen as dosing is extended from 3 to 9 months (Figure 7.15). For most ASOs, steady-state concentrations of ASO can be predicted on the basis of half-life only, but for some sequences the data are better-fitted assuming first-order kinetics with a saturable or dose-related factor. Drugs with long half-lives require long dosing periods to achieve steady state. Loading regimens have been used to shorten the time to steady state in both clinical trials and in animal studies. Attaining steady state or near steady-state concentrations more quickly than the 3–5 half-lives are useful when exposure needs to be maximized in a short period of time, for example, in a toxicology study or in clinical trials when duration of treatment is limited. In one loading strategy, ASO is given on alternate days for the first week followed by once weekly dosing. In the study results depicted in Figure 7.16, the loading regimen produced renal cortex concentrations of ⬃400 g/g at the end of 8 days. At the end of 13 weeks of treatment the concentration data point attained for renal cortex was ⬃500 g/g. Thus, the loading regimen achieved ⬃80% of the observed steady-state concentrations in cynomolgus monkeys treated with 10 mg/kg/week of ISIS 113715. In this example, the steady-state concentration in the renal cortex could be predicted on the basis of the half-life, the dose, and the frequency. Note that the steady state was attained even though the weekly dose regimen was twice as frequent as would be required by the 14-day half-life. With a half-life of ⬃14 days, accumulation should reach approximately threefold compared to the concentration obtained after a
Tissue concentrations (µg/g)
2000
1500
1000
500
0
3
6 Time
9
Figure 7.15 Concentrations of ISIS 104838 in renal cortex (open cicles), liver (open squares) or spleen (filled diamonds) in monkeys treated with ⬃20 mg/kg/week for 3, 6 or 9 months. Each data point represents the mean of at least four subjects (⫾SD).
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 209
BASIC PRINCIPLES OF THE PHARMACOKINETICS
209
3 mg/kg Simulation Actual measured 113715 concentration
Kidney cortex (µg/g)
600 500 400 300 200 100 0 0
20
40
60 80 Time (days)
100
120
Figure 7.16 Renal accumulations of ISIS 113715 in monkeys treated with 3 mg/kg/week following a loading regiment of alternate day dosing for the first week. One group of monkeys received only the loading regimen and then tissues were assayed by CGE for two monkeys at each of the indicated time points. The data were fitted assuming first-order kinetics and then that model was used to simulate repeated administration at weekly dosing. The data point at 90 days represents the mean (⫾SD) concentration in renal cortex (n ⫽ 6).
single dose.* Comparing the concentration in kidney after day 1 to the concentration after 90 days demonstrates that ISIS 113715 follows first-order kinetics and steady state is attained (Figure 7.16). Because both pharmacology and toxicity are related to tissue concentrations, confirming that second-generation ASOs achieve steady state in predictable ways is useful for setting dose and dose intervals as well as understanding drug safety. It is particularly important for safety because there will not be continuous accumulation of ASO in target tissues like renal cortex with long-term administration of second-generation drugs. 7.4.2
Dose and Schedule
Because the pharmacology with ASOs is dependent on tissue concentrations and it is nearly impossible to collect tissue samples in most clinical trials, we have had to develop surrogates for tissue concentrations. Under equilibrium conditions (defined as ⬎48 h after the last dose), plasma concentrations reflect the exchange between the major organs of accumulation and plasma. Being able to assess equilibrium plasma concentrations has only become possible because of the introduction of a high-sensitivity hybridization-dependent enzyme-linked specific immunoassay [60]. In studies in monkeys, we have demonstrated that equilibrium plasma concentrations (troughs) have a linear relationship to liver and kidney concentrations (see Geary et al., Chapter 11). Like tissue concentrations, with continuous dosing, trough plasma concentrations eventually reach a steady state and remain there (Figure 7.17). The trough (or equilibrium) plasma concentrations obtained at steady state increase linearly with increasing dose, confirming that trough plasma concentrations reflect exposure (Figure 7.18). The use of trough plasma concentrations as a surrogate for tissue concentrations is providing insight into dose and schedule and more informed design of clinical dose regimens. First-order kinetics predict that changing dose interval, for example by administering twice the dose half as frequently should result in similar steady-state concentrations albeit with more variation about the mean. Greater peak to trough variations are acceptable as long as the antisense
*
Assuming first-order kinetics: (concentration ⫽ e⫺t, ⫽ 0.0495/day) and accumulation factor ⫽ 1/e⫺ ⫻ 7 days ⫽ ⬃3.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 210
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Plasma trough concentration ISIS 301012 (ng/mL)
210 20
15
10
5
0 20
30
40
50
60
70
80
90
100
Study days Figure 7.17 Mean plasma trough concentrations (ng/mL) of ISIS 301012 in human subjects (7 days after dose) following 200 mg dose q2w (100 mg/week) for 13 weeks. Plasma samples were analyzed using a hybridization-dependent enzyme-linked immune assay that is specific for the parent drug.
Plasma trough concentration ISIS 301012 (ng/mL)
40
y = 0.147x − 1.2659 R 2= 0.9971
35 30 25 20 15 10 5 0 0
50
100 150 Weekly dose (mg)
200
250
Figure 7.18 Plasma trough concentration (ng/mL) of ISIS 301012 as a function of equivalent weekly dose at the end of 13 weeks treatment in human subjects. Plasma samples collected in ⬃7 days after the last dose were analyzed as described above for Figure 7.16 (mean ⫾ SE, n ⫽ 7 or 8).
activity is maintained at the trough concentration and the peak concentrations are below toxic levels. Clinical trials have been designed to explore the effects of dose and dose frequency. The results obtained with ISIS 301012 in phase 2 clinical trials confirm predictable kinetics and the concentrations in plasma approach steady state (Figure 7.17). Among the variables available in study design is the loading regimen. Whether or not a clinical study uses a loading regimen is dependent on how quickly steady state needs to be achieved which is in turn dependent on how quickly a therapeutic effect is needed. Those variables will vary with the study duration and with the disease indication. Clearly chronic and acute indications will require very different loading regimens. In chronic indications it may be acceptable for it to take weeks or months to achieve steady state, however in acute indications aggressive loading would be more likely used to achieve steady state quickly. Thus, the use of loading or induction regimens will be established for each disease indication or clinical trial.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 211
BASIC PRINCIPLES OF THE PHARMACOKINETICS
7.4.3
211
Relating Exposure and Effect
One of the most important advances that has been made with second-generation drugs comes from combining pharmacokinetic data (either trough plasma concentrations or tissue concentrations) with direct measurements of the molecular target for antisense activity. Using these types of analyses it has been possible to demonstrate concentration response relationships for the reduction in expression of TNF in the synovium of rheumatoid arthritis patients (unpublished observation), reduction in clusterin in the prostates in hormone refractory prostate cancer [61–63] and reductions in circulating apolipoprotein B levels in subjects with elevated cholesterol (Kastalein, in press circulation). These concentration response relationships are relatively consistent from laboratory animals to man. Having plasma as a surrogate for tissue concentrations or by knowing concentrations of drug required at sites of activity is allowing us to design improved dose regimens for critical studies in larger populations (see Chapter 11, this volume for a more complete discussion of pharmacokinetic and pharmacodynamic relationships). 7.4.4
Drug–Drug Interactions
In a typical clinical setting patients are exposed to a multitude of drugs and bioactive foodstuffs. Drug–drug interactions are often the result of competition for binding sites in plasma proteins or competition for drug-metabolizing enzymes. ODNs do not compete with coumadin, valproic acid, asprin, and other commonly used drugs known to be highly protein bound [29] and similar results have been found for second-generation antisense drugs (Isis, unpublished observations). In clinical studies no drug–drug interactions have been observed with first- or second-generation ASOs with cytotoxic oncolytics [64,65], statins (unpublished observations), and orally active antidiabetes drugs [66]. Thus, nonspecific drug–drug interactions do not appear to be common. Drug interactions related to additive or synergistic pharmacology will have to be assessed on a drug by drug basis for each indication, but to date drug interactions based on competition for distribution or metabolism have not been observed in studies designed to detect pharmacokinetic differences. 7.4.5
Remaining Questions
The last remaining question for the use of second-generation ASOs relates to chronic administration and what dose and schedule will be required to maintain activity. First-order kinetics would suggest that maintenance doses would require replenishment of the small fraction of parent drug metabolized and cleared each dosing interval. The amount may vary depending on the sequence and the half-life for the sequence. Preliminary evidence exists that with longer exposure periods there may be deviations from simple first-order kinetics. As we expand our experience to include more chronic exposure studies in laboratory animals and in clinical trials, we will monitor for changes in kinetics with the tools and understanding that we have developed for the platform of secondgeneration antisense drugs. REFERENCES 1. Geary, R. S., Current assessment of PK/PD relationships for antisense therapeutics, World Congress of Pharmacy and Pharmaceutical Sciences, Nice, France, 2002. 2. Geary, R. S., Leeds, J. M., Fitchett, J., Burckin, T., Troung, L., Spainhour, C., Creek, M., and Levin, A. A., Pharmacokinetics and metabolism in mice of a phosphorothioate ASO antisense inhibitor of C-raf-1 kinase expression, Drug Metab. Dispos. 25 (11), 1272, 1997. 3. Geary, R. S., Leeds, J. M., Henry, S. P., Monteith, D. K., and Levin, A. A., Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate ODNs, Anticancer Drug Des. 12 (5), 383, 1997.
CRC_8796_ch007.qxd
212
5/25/2007
7:39 AM
Page 212
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
4. Geary, R. S., Leeds, J. M., Shanahan, W., Glover, J., Pribble, J., Truong, L., Fitchett, J., Burckin, R., Nicklin, P., Philips, J., and Levin, A. A., Sequence independent plasma and tissue pharmacokinetics for 3 antisense phosphorothioate ASOs: mouse to man, in American Association of Pharmaceutical Scientists, Pharm. Research, Plenum Press, Seattle, Washington, 1996, p. S. 5. Geary, R. S., Yu, R. Z., and Levin, A. A., Pharmacokinetics of phosphorothioate antisense ODNs, Curr. Opin. Invest. Drugs 2 (4), 562, 2001. 6. Glover, J. M., Leeds, J. M., Mant, T. G., Amin, D., Kisner, D. L., Zuckerman, J. E., Geary, R. S., Levin, A. A., and Shanahan, W. R., Jr., Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense ODN (ISIS 2302), J. Pharmacol. Exp. Ther. 282 (3), 1173, 1997. 7. Leeds, J. M., Henry, S. P., Geary, R. S., Burckin, T. A., and Levin, A. A., Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys, Antisense Nucl. Acid Drug Dev. 10 (6), 435, 2000. 8. Levin, A. A., A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides, Biochim. Biophys. Acta 1489 (1), 69, 1999. 9. Levin, A. A., Henry, S. P., Bennett, C. F., Cole, D. L., Hardee, G. E., and Srivatsa, G. S., Preclinical development of antisense therapeutics, in Novel Therapeutics from Modern Biotechnology: From Laboratory to Human Testing, 1st ed., Oxender, D. L. and Post, L. E., eds., Springer-Verlag, Heidelberg, Germany, 1998, p. 131. 10. Levin, A. A., Geary, R. S., Leeds, J. M., Monteith, D. K., Yu, R. Z., Templin, M. V., and Henry, S. P., The pharmacokinetics and toxicity of phosphorothioate ASOs, in Biotechnology and Safety Assessment, 2nd ed., Thomas, J. A., ed., Taylor & Francis, Philadelphia, PA, 1998, p. 151. 11. Eckstein, F., Phosphorothioate ODNs: what is their origin and what is unique about them? Antisense Nucl. Acid Drug Dev. 10 (2), 117, 2000. 12. Slim, G. and Gait, M. J., Configurationally defined phosphorothioate-containing oligoribonucleotides in the study of the mechanism of cleavage of hammerhead ribozymes, Nucl. Acids Res. 19 (6), 1183, 1991. 13. Spitzer, S. and Eckstein, F., Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides, Nucl. Acids Res. 16 (24), 11691, 1988. 14. White, A. P., Reeves, K. K., Snyder, E., Farrell, J., Powell, J. W., Mohan, V., and Griffey, R. H., Hydration of single-stranded phosphodiester and phosphorothioate oligodeoxyribonucleotides, Nucl. Acids Res. 24 (16), 3261, 1996. 15. Koziolkiewicz, M., Krakoviak, A., Kwinkowski, M., Boczkowska, M., and Stec, W. J., Stereodifferntiation—the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H, Nucl. Acids Res. 23 (24), 5000, 1995. 16. Brown, D. A., Kang, S. H., Gryaznov, S. M., DeDionisio, L., Heidenreich, O., Sullivan, S., Xu, X., and Nerenberg, M. I., Effect of phosphorothioate modification of ODNs on specific protein binding, J. Biol. Chem. 269 (43), 26801, 1994. 17. Mou, T. C. and Gray, D. M., The high binding affinity of phosphorothioate-modified oligomers for Ff gene 5 protein is moderated by the addition of C-5 propyne or 2⬘-O-methyl modifications, Nucl. Acids Res. 30 (3), 749, 2002. 18. Yu, D., Kandimalla, E. R., Roskey, A., Zhao, Q., Chen, L., Chen, J., and Agrawal, S., Stereo-enriched phosphorothioate ODNs: synthesis, biophysical and biological properties, Bioorg. Med. Chem. 8 (1), 275, 2000. 19. Teplova, M., Minasov, G., Tereshko, V., Inamati, G. B., Cook, P. D., Manoharan, M., and Egli, M., Crystal structure and improved antisense properties of 2⬘-O-(2-methoxyethyl)-RNA, Nat. Struct. Biol. 6 (6), 535, 1999. 20. Geary, R. S., Ushiro-Watanabe, T., Truong, L., Freier, S. M., Lesnik, E. A., Sioufi, N. B., Sasmor, H., Manoharan, M., and Levin, A. A., Pharmacokinetic properties of 2⬘-O-(2-methoxyethyl)-modified ASO analogs in rats, J. Pharmacol. Exp. Ther. 296 (3), 890, 2001. 21. Yu, R. Z., Geary, R. S., and Levin, A. A., Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assessments of antisense oligonucleotides, Curr. Opin. Drug Discov. Dev. 7 (2), 195, 2004. 22. Sewell, L. K., Geary, R. S., Baker, B. F., Glover, J. M., Mant, T. G. K., Yu, R. Z., Tami, J. A., and Dorr, A. F., Phase I trial of ISIS 104838, a 2⬘-methoxyethyl modified antisense oligonucleotides targeting tumor necrosis factor-alpha, J. Pharmacol. Exp. Ther. 303 (3), 1334, 2002.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 213
BASIC PRINCIPLES OF THE PHARMACOKINETICS
213
23. Phillips, J. A., Craig, S. J., Bayley, D., Christian, R. A., Geary, R. S., and Nicklin, P. L., Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate ODN (CGP 69846A) after intravenous and subcutaneous administration, Biochem. Pharmacol. 54 (6), 657, 1997. 24. Templin, M. V., Levin, A. A., Graham, M. J., Aberg, P. M., Axelsson, B. I., Butler, M., Geary, R. S., and Bennett, C. F., Pharmacokinetic and toxicity profile of a phosphorothioate ASO following inhalation delivery to lung in mice, Antisense Nucl. Acid Drug Dev. 10 (5), 359, 2000. 25. Miner, P. B., Jr., Geary, R. S., Matson, J., Chuang, E., Xia, S., Baker, B. F., and Wedel, M. K., Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis, Ailment Pharmacol. Ther. 23 (10), 1427, 2006. 26. Geary, R. S., Teng, C. L., Truong, L., Perry, B., Sinko, P., and Hardee, G. E., First pass hepatic extraction of a partially modified chimeric antisense oligonucleotides in Beagle dogs, in Annual Meeting of the American Association of Pharmaceutical Scientists, Indianapolis, IN, 2000, p. 216. 27. Stavchansky, S., Geary, R. S., and Cho, M., Pharmacokinetics and hepatic first pass effect of an antisense oligonucleotide (ISIS 2302) in rats, in Annual Meeting of the American Association of Pharmaceutical Scientists, Indianapolis, IN, 2000, p. 216. 28. Geary, R. S., Yu, R. Z., Watanabe, T., Henry, S. P., Hardee, G. E., Chappell, A., Matson, J., Sasmor, H., Cummins, L., and Levin, A. A., Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2⬘-O-(2-methoxyethyl) modified antisense oligonucleotides: comparison across species, Drug Metab. Dispos. 31 (11), 1419, 2003. 29. Watanabe, T. A., Geary, R. S., and Levin, A. A., Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302), ASOs 16 (2), 169, 2006. 30. Bijsterbosch, M. K., Rump, E. T., De Vrueh, R. L., Dorland, R., van Veghel, R., Tivel, K. L., Biessen, E. A., van Berkel, T. J., and Manoharan, M., Modulation of plasma protein binding and in vitro liver cell uptake of phosphorothioate ODNs by cholesterol conjugation, Nucl. Acids Res. 28 (14), 2717, 2000. 31. Yu, R. Z., Geary, R. S., Leeds, J. M., Ushiro-Watanabe, T., Moore, M., Fitchett, J., Matson, J., Burckin, T., Templin, M. V., and Levin, A. A., Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate ASO targeting human Ha-ras mRNA in mouse and monkey, J. Pharm. Sci. 90 (2), 182, 2001. 32. Leeds, J. M. and Geary, R. S., Pharmacokinetic properties of phosphorothioate ASOs in humans, in Antisense Research and Applications, 1st ed., Crooke, S. T., ed., Springer, Heidelberg, 1998, p. 217. 33. Nicklin, P. L., Craig, S. J., and Phillips, J. A., Pharmacokinetic properties of phosphorothioates in animals—absorption, distribution, metabolism and elimination, in Antisense Research and Applications, 1st ed., Crooke, S. T., ed., Springer, Berlin, 1998, p. 141. 34. Lorenz, P., Misteli, T., Baker, B. F., Bennett, C. F., and Spector, D. L., Nucleocytoplasmic shuttling: a novel in vitro property of antisense phosphorothioate ODNs, Nucl. Acids Res. 28 (2), 582, 2000. 35. Snyder, R. M., Mirabelli, C. K., and Crooke, S. T., Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions, Biochem. Pharmacol. 35 (6), 923, 1986. 36. Butler, M., Stecker, K., and Bennett, C. F., Cellular distribution of phosphorothioate ODNs in normal rodent tissues, Lab. Invest. 77 (4), 379, 1997. 37. Bijsterbosch, M. K., Manoharan, M., Rump, E. T., De Vrueh, R. L. A., van Veghel, R., Tival, K. L., Biessen, E. A. L., Bennett, F. C., Cook, D. P., and van Berkel, T. J. C., In vitro fate of phosphorothioate antisense ODNs: predominant uptake by scavenger receptors on endothelial cells, Nucl. Acids Res. 25 (16), 3290, 1997. 38. Butler, M., Crooke, R. M., Graham, M. J., Lemonidis, K. M., Lougheed, M., Murray, S. F., Witchell, D., Steinbrecher, U., and Bennett, C. F., Phosphorothioate ODNs distribute similarly in class A scavenger receptor knockout and wild-type mice, J. Pharmacol. Exp. Ther. 292 (2), 489, 2000. 39. Giacomini, K. M. and Sugiyama, Y., Membrane transporters and drug response, in Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th ed., Brunton, L. L., ed., McGraw-Hill, New York, 2006, pp. 41. 40. Peng, B., Andrews, J., Nestorov, I., Brennan, B., Nicklin, P., and Rowland, M., Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate ASO ISIS 1082 in rat, Antisense Nucl. Acid Drug Dev. 11 (1), 15, 2001.
CRC_8796_ch007.qxd
214
5/25/2007
7:39 AM
Page 214
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
41. Graham, M. J., Crooke, S. T., Monteith, D. K., Cooper, S. R., Lemonidis, K. M., Stecker, K. K., Martin, M. J., and Crooke, R. M., In vitro distribution and metabolism of a phosphorothioate ASO within rat liver after intravenous administration, J. Pharmacol. Exp. Ther. 286 (1), 447, 1998. 42. Benimetskaya, L., Tonkinson, J. L., Koziolkiewicz, M., Karwowski, B., Guga, P., Zeltser, R., Stec, W., and Stein, C. A., Binding of phosphorothioate ODNs to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin in P-chirality independent, Nucl. Acids Res. 23 (21), 4239, 1995. 43. Benimetskaya, L., Loike, J. D., Loike, G., Siverstein, S. C., Long, C., Khoury, J. E., Cai, T.-Q., and Stein, C. A., Mac-1 (CD11b/CD18) is an ODN-binding protein, Nat. Med. 3 (4), 414, 1997. 44. Loke, S. L., Stein, C. A., Zhang, X. H., Mori, K., Nakanishi, M., Subasinghe, C., Cohen, J. S., and Neckers, L. M., Characterization of ASO transport into living cells, Proc. Natl. Acad. Sci. USA 86, 3474, 1989. 45. Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkinson, J. L., and Stein, C. A., Phosphorothioate ODNs bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix, J. Biol. Chem. 270, 2620, 1995. 46. Sawai, K., Mahato, R. I., Oka, Y., Takakura, Y., and Hashida, M., Disposition of ASOs in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake, J. Pharmacol. Exp. Ther. 279 (1), 284, 1996. 47. Levin, A. A., Henry, S. P., Monteith, D., and Templin, M., Toxicity of antisense oligonucleotides, in Antisense Drug Technology, Crooke, S. T., ed., Marcel Dekker, New York, 2001, p. 201. 48. Cossum, P. A., Sasmor, H., Dellinger, D., Truong, L., Cummins, L., Owens, S. R., Markham, P. M., Shea, J. P., and Crooke, S. T., Disposition of the 14C-labeled phosphorothioate ASO ISIS 2105 after intravenous administration to rats, J. Pharmacol. Exp. Ther. 267 (3), 1181, 1993. 49. Cossum, P. A., Troung, L., Owens, S. R., Markham, P. M., Shea, J. P., and Crooke, S. T., Pharmacokinetics of a 14C-labeled phosphorothioate ASO, ISIS 2105, after intradermal administration to rats, J. Pharmacol. Exp. Ther. 269 (1), 89, 1994. 50. Crooke, S. T., Graham, M. J., Zuckerman, J. E., Brooks, D., Conklin, B. S., Cummins, L. L., Greig, M. J., Guinosso, C. J., Kornbrust, D., Manoharan, M., Sasmor, H. M., Schleich, T., Tivel, K. L., and Griffey, R. H., Pharmacokinetic properties of several novel ASO analogs in mice, J. Pharmacol. Exp. Ther. 277 (2), 923, 1996. 51. Zinker, B. A., Rondinone, C. M., Trevillyan, J. M., Gum, R. J., Clampit, J. E., Waring, J. F., Xie, N., Wilcox, D., Jacobson, P., Frost, L., Kroeger, P. E., Reilly, R. M., Koterski, S., Opgenorth, T. J., Ulrich, R. G., Crosby, S., Butler, M., Murray, S. F., McKay, R. A., Bhanot, S., Monia, B. P., and Jirousek, M. R., PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice, Proc. Natl. Acad. Sci. USA 99 (17), 1137, 2002. 52. Hua, X. Y., Moore, A., Malkmus, S., Murray, S. F., Dean, N., Yaksh, T. L., and Butler, M., Inhibition of spinal protein kinase C alpha expression by an antisense oligonucleotide attenuates morphine infusion-induced tolerance, Neuroscience 113 (1), 99, 2002. 53. Butler, M., Hayes, C. S., Chappell, A., Murray, S. F., Yaksh, T. L., and Hua, X. Y., Spinal distribution and metabolism of 2⬘-O-(2-methoxyethyl)-modified ASOs after intrathecal administration in rats, Neuroscience 131 (3), 705, 2005. 54. Driver, S. E., Robinson, G. S., Flanagan, J., Shen, W., Smith, L. E. H., Thomas, D. W., and Roberts, P. C., ASO-based inhibition of embryonic gene expression, Nat. Biotechnol. 17, 1184, 1999. 55. Soucy, N. V., Riley, J. P., Templin, M. V., Geary, R., de Peyster, A., and Levin, A. A., Maternal and fetal distribution of a phosphorothioate ASO in rats after intravenous infusion, Birth Defects Res. B Dev. Reprod. Toxicol. 77 (1), 22, 2006. 56. Henry, S. P., Denny, K. H., Templin, M. V., Yu, R. Z., and Levin, A. A., Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice, Birth Defects Res. B Dev. Reprod. Toxicol. 71 (6), 359, 2004. 57. Yu, R. Z., Zhang, H., Geary, R. S., Graham, M., Masarjian, L., Lemonidis, K., Crooke, R., Dean, N. M., and Levin, A. A., Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate ASO targeting Fas mRNA in mice, J. Pharmacol. Exp. Ther. 296 (2), 388, 2001. 58. Wilson, D. M., 3rd, Ape1 abasic endonuclease activity is regulated by magnesium and potassium concentrations and is robust on alternative DNA structures, J. Mol. Biol. 345 (5), 1003, 2005. 59. Gaus, H. J., Owens, S. R., Winniman, M., Cooper, S., and Cummins, L. L., On-line HPLC electrospray mass spectrometry of phosphorothioate ASO metabolites, Anal. Chem. 69 (3), 313, 1997.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 215
BASIC PRINCIPLES OF THE PHARMACOKINETICS
215
60. Yu, R. Z., Baer, B., Chappel, A., Geary, R. S., Chueng, E., and Levin, A. A., Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate ODN in plasma, Anal. Biochem. 304 (1), 19, 2002. 61. Jackson, J. K., Gleave, M. E., Gleave, J., and Burt, H. M., The inhibition of angiogenesis by antisense oligonucleotides to clusterin, Angiogenesis 8 (3), 229, 2005. 62. Gleave, M. and Chi, K. N., Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers, Ann. NY Acad. Sci. 1058, 1, 2005. 63. Gleave, M. and Miyake, H., Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer, World J. Urol. 23 (1), 38, 2005. 64. Adjei, A. A., Dy, G. K., Erlichman, C., Reid, J. M., Sloan, J. A., Pitot, H. C., Alberts, S. R., Goldberg, R. M., Hanson, L. J., Atherton, P. J., Watanabe, T., Geary, R. S., Holmlund, J., and Dorr, F. A., A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer, Clin. Cancer Res. 9 (1), 115, 2003. 65. Villalona-Calero, M. A., Ritch, P., Figueroa, J. A., Otterson, G. A., Belt, R., Dow, E., George, S., Leonardo, J., McCachren, S., Miller, G. L., Modiano, M., Valdivieso, M., Geary, R. S., Oliver, J. W., and Holmlund, J., A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer, Clin. Cancer Res. 10 (18 Pt 1), 6086, 2004. 66. Geary, R. S., Bradley, J. D., Watanabe, T., Kwon, Y., Wedel, M., van Lier, J. J., and Vanvliet, A. A., Lack of pharmacokinetic interaction for ISIS 113715, a 2⬘-O-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone, Clin. Pharmacokinet. 45 (8), 789, 2006. 67. Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. O., Yu, R. Z., Chuang, E., Graham, M. J., and Crooke, R. M. Potent reduction of apolipoprotein B and Low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114 (16), 1729, 2006. 68. Yu. R. Z., Kim, T. W., Hong, A., Watanabe, T. A., Gaus, H. J., and Geary, R. S. Cross species, Pharmacokinetic comparison from mouse to man of a second generation antisense oligonucleotide ISIS 301012, targeting human apolipoprotein 8-100. Drug Metab. Dispos. 35, 460, 2007.
CRC_8796_ch007.qxd
5/25/2007
7:39 AM
Page 216
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 217
CHAPTER
8
Routes and Formulations for Delivery of Antisense Oligonucleotides Gregory E. Hardee, Lloyd G. Tillman, and Richard S. Geary
CONTENTS 8.1 8.2
Introduction .........................................................................................................................217 Systemic Administration .....................................................................................................218 8.2.1 Physical and Chemical Properties ...........................................................................218 8.2.2 Intravenous Infusion ................................................................................................219 8.2.3 Subcutaneous Injection ............................................................................................219 8.3 Local Administration ...........................................................................................................221 8.3.1 Brain ........................................................................................................................221 8.3.2 Ocular ......................................................................................................................221 8.3.3 Topical Delivery ......................................................................................................222 8.3.4 Pulmonary Delivery .................................................................................................223 8.3.4.1 Formulation Considerations .....................................................................223 8.3.4.2 Deposition and Uptake .............................................................................223 8.3.4.3 Demonstration of Pharmacology by the Pulmonary Route .....................224 8.4 Oral and Gastrointestinal Delivery ......................................................................................225 8.4.1 Presystemic Metabolism ..........................................................................................225 8.4.2 Permeability .............................................................................................................227 8.4.3 Systemic Bioavailability ..........................................................................................228 8.4.4 Local GI Uptake ......................................................................................................231 8.5 Conclusions .........................................................................................................................233 References .....................................................................................................................................234
8.1 INTRODUCTION Initial efforts in the creation of antisense therapeutics have focused on fundamental questions such as safety, efficacy, and technology costs, as would be expected for any emerging technology with a potential to create a new therapeutic paradigm. Clinical proof of efficacy has been established with the approval of the first antisense oligonucleotide therapeutic, Vitravene™ (fomivirsen), indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with AIDs [1].
217
CRC_8796_ch008.qxd
218
5/24/2007
22:08
Page 218
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Following this approval, we have seen a dramatic and continuing fall in the cost of goods; it is appropriate that we now address the area of delivery routes and formulations. Advances in this area have the potential to impact oligonucleotide biopharmaceutics and expand the utility of antisense technology. Early research in drug delivery systems focused on a perceived weakness of the technology: cellular uptake. In vitro observations made with phosphorothioate oligodeoxynucleotides led many working in the area to conclude that because of metabolic instability, size and charge, oligonucleotides would not be adequately taken up into the targeted tissues to the extent necessary to exert pharmacological activity. However, an ever expanding body of in vivo animal and clinical data has shown that even simple saline solutions delivered parenterally can lead to significant oligonucleotide uptake and effect. While such simple formulations are efficacious for some therapeutic applications, the development of novel formulations and delivery routes should enable a wider variety of target tissues to be treated through increased efficiency of target-tissue uptake and accumulation. In this chapter, we will address a variety of challenges and opportunities in the delivery of antisense oligonucleotides for a wide range of diseases.
8.2 SYSTEMIC ADMINISTRATION 8.2.1
Physical and Chemical Properties
In the development of any drug product, it is essential that the fundamental physical and chemical properties of the drug molecule and of prototype drug formulations be determined. Such data often dictate the choices considered for dosage form design and subsequent development events. With respect to the inherent properties of the unformulated oligonucleotide, there is sufficient evidence that we may assign common properties for all oligonucleotides for a given class of oligonucleotide chemistry. That is, these data consistently demonstrate that all “firstgeneration” or phosphorothioate oligodeoxynucleotides exhibit similar physiochemical properties. Likewise, newer chemistries appear to have conformity within their defined chemistry, such as for sugar-modified chemistries (e.g., 2-O-methoxyethyl [2-MOE]) or for backbone-modified chemistries (e.g., methylphosphonates). This important feature of class conformity allows estimation of biopharmaceutic and pharmacokinetic parameters across the innumerable nucleotide sequences possible within any single oligonucleotide chemical class. For example, rates of drug release from a dosage form can be estimated from precedent data as well as distribution and elimination estimates even where the biopharmaceutic phenomena are dependent upon biophysical interactions such as protein binding. The exception to this axiom may be in instances where intra- or intermolecular Watson–Crick base pairing occurs. Such base pairing, if significant, may result in a stable secondary structure (if self-complementary) or in a noncovalent polymeric structure consistent with “nearest neighbor” thermodynamic data [2]. Such altered states need to be anticipated if oligonucleotide sequences permit such associations beyond four or five base pairs per 20-mer oligonucleotide. Phosphorothioate oligodeoxynucleotides are synthesized as complex mixtures of diastereomers. In the solid state they are amorphous, electrostatic, hygroscopic solids with low-bulk densities, possessing very high surface areas, and poorly defined melting points. Their good chemical stability allows them to be stored both as lyophilized powders and as concentrated, sterile, aqueous solutions. Stability data demonstrate only minimal change in impurity profile when (1) lyophilized powders are stored at 25°C for more than three years, or (2) sterile solutions are stored refrigerated for more than three years. Oligonucleotides are extremely water-soluble under neutral and basic conditions, consistent with their polyanionic nature. Consequently, drug-product concentrations are often only limited by an increase in solution viscosity at very high concentrations, e.g. 300 mg/ml. Extremes of pH and ionic strength influence the apparent solubility. In acidic environments such as the stomach, ionized
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 219
ROUTES AND FORMULATIONS FOR DELIVERY OF ANTISENSE
219
portions of the molecule are partially neutralized by protonation resulting in a marked decrease in oligonucleotide solubility, an event that can be easily reversed by subsequently elevating the pH. All the physical-chemical characteristics discussed here are important to designing viable, efficacious formulations with acceptable storage and in vivo stability. Each delivery system presents its own formulation challenges, as will be seen in the remainder of this chapter. Phosphorothioate oligonucleotide degradation has been primarily attributed to two mechanisms: desulfurization and acid-catalyzed hydrolysis. Desulfurization of the backbone, observed at elevated temperatures and under intense UV light, leads to (pharmacologically active) oligonucleotides primarily containing one or more phosphate diester linkages where oxygen has replaced sulfur [3]. Note that while such oligonucleotides are pharmacologically active, the accumulation of phosphodiester linkages—particularly if on adjacent or terminal nucleotides—renders the compound more susceptible to metabolism by nucleases. Thus, the presence of numerous phosphodiester linkages may shorten the compound’s in vivo half-life, particularly if the phosphodiesters are located in the central deoxy-gap of the oligonucleotide (e.g., MOE gap-mer oligonucleotides). This gap is between the nuclease-resistant wings of the molecule where 2-O-alkoxyalkane ribonucleosides afford protection from enzymatic cleavage. Indeed, there is evidence that chimeric oligonucleotides containing phosphodiester linkages along with 2-O-alkoxyalkane derivatives improve in vivo activity [4]. Under acidic conditions, a phosphodiester oligonucleotide may be more prone to depurination, resulting in an oligonucleotide containing one or more abasic sites. The loss of bases decreases the base-pair binding affinity to the target mRNA, rendering the oligonucleotide less effective. Also, abasic sites are more susceptible to base-mediated cleavage of the adjacent phosphorothioate linkages. Formulation development must ensure adequate stability and therefore must include analytical techniques for monitoring these attributes. Desulfurization can be monitored by a variety of analytical techniques including, for example, capillary gel electrophoresis, anion-exchange and ion-pair liquid chromatography; however, liquid chromatography coupled to mass spectroscopy is required to monitor other products of which some may be stability limiting. As such, this technique is rapidly becoming the method of choice for assessing oligonucleotide quality and stability. 8.2.2
Intravenous Infusion
Twenty-mer oligonucleotides generally are isotonic (300 mOsm/kg) in solution at concentrations of approximately 150 mg/mL. Simple salt solutions can be used to achieve isotonicity for less concentrated solutions if desired. Additionally, buffering salts can be added as a manufacturing aid and stabilizing agent. These simple solutions have been administered intravenously to mice, monkeys, dogs, pigs, and humans without limitation other than total dose and rate of run-in considerations. 8.2.3
Subcutaneous Injection
Many consider the practical limitation of the subcutaneous route to be a dose volume of approximately one milliliter. Given the high water-solubility of oligonucleotides and that pain of injection studies (using hypertonic salt solutions) that show only slight and transient discomfort up to threefold tonicity, the only limiting factor for subcutaneous dosing is the solution viscosity. Viscosity of oligonucleotide solutions increase exponentially as a function of concentration (Figure 8.1). Not unexpectedly, different sequences have different intermolecular interactions that manifest as significantly different viscosity profiles. This is one of the few sequence-dependent physical-chemical properties noted to date. While it is possible to inject solutions of 100 cPs through a 29-gauge needle, it is very difficult to draw up the dose, or inject with the newer microbore needles (31 gauge) especially if the dosing solution is not equilibrated to room temperature since viscosity is a function of temperature (Figure 8.2). Practical solutions to this limitation include using prefilled syringes, dose withdrawal with a large bore needle, room-temperature storage, and of course limiting the solution concentration.
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 220
220
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
400
Viscosity (cP)
300
200
100
0 0
50
100
150
200
250
300
350
25
30
400
Oligo conc. (mg/mL) Figure 8.1
Effect of oligonucleotide concentration on viscosity.
500 ISIS 104838
Viscosity (cP)
400 ISIS 113715
300 200 100 ISIS 107248
0 0
5
10
15
20
Temperature (°C) Figure 8.2
Effect of temperature (C) on viscosity (cP) for various 200 mg/mL oligonucleotides.
Table 8.1 Systemic Bioavailability by the Subcutaneous Route Is Essentially Complete for a Second-Generation Oligonucleotide, ISIS 104838 Administration Route Monkey IV Subcutaneous IV Subcutaneous Human IV Subcutaneous a b
Dose (mg/kg) 3 4 10 20 2 2.5
Cmax (g/mL)
AUC (gh/mLa)
Plasma BAV (%)
Tissue BAV (%)
33 5.0 92 15.2
46 36 149 364
100 59 100 122
100 96 100 105a
26 5.5
49 49
100 80
NMb NM
Liver. Not measured.
Bioavailability after a subcutaneous injection has been studied extensively in multiple species. While bioavailabilities measured in plasma show nonlinear dose proportionality, the bioavailabilities measured in tissue are essentially complete at all doses. Table 8.1 presents data from monkey
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 221
ROUTES AND FORMULATIONS FOR DELIVERY OF ANTISENSE
221
[5] and man [6] that illustrates apparently low plasma bioavailability at low subcutaneous doses. Since the majority of putative targets for oligonucleotides reside in tissue, it is appropriate to think of subcutaneous dosing as 100% bioavailable. With the potency and biological half-life achieved with the newer generation of oligonucleotides, the subcutaneous route is being advanced in the clinic for a variety of indications.
8.3 LOCAL ADMINISTRATION 8.3.1
Brain
In general, the blood–brain barrier (BBB) is only permeable to lipophilic molecules having a molecular weight less than about 600 Da, while even smaller and electrostatic water-soluble molecules generally can not be transported [7]. This precludes delivery of oligonucleotides to the brain from the systemic circulation without the assistance of specialized drug-delivery systems. Unmodified phosphodiester oligodeoxynucleotides have been directly injected intracerebrally to down-regulate the expression of neurotransmitters in a sequence-specific manner [8]. As expected, phosphodiester oligodeoxynucleotides are rapidly degraded in the brain and while the phosphorothioate oligodeoxynucleotides are more metabolically stable, they are nevertheless rapidly cleared via the cerebrospinal fluid bulk flow. Whitesell et al. demonstrated extensive brain penetration and marked cellular uptake after continuous intracerebral infusions with a mini-osmotic pump [9]. Direct intracerebral administration has been utilized by Sommer et al. [10], to study phosphorothioate oligodeoxynucleotides directed to c-fos and by Mustafa and Dar [11], to down-regulate the adenosine A1 receptor. One report in the literature details the accumulation of systemically administered phosphorothioate oligodeoxynucleotides in implanted subcutaneous and intracranial glioblastoma tumors in mice [12]. A similar phosphorothioate oligonucleotide was shown not to cross the BBB in normal animals [13], so it was hypothesized that the presence of a glioma may sufficiently disrupt the BBB to allow pharmacological concentrations of oligonucleotide to accumulate within the tumor. Accumulation was sufficient in this model to demonstrate antitumor activity. Boado et al. devised delivery systems based on conjugates of streptavidin and the OX26 monoclonal antibody directed to the transferrin receptor as a carrier for the transport of oligonucleotides [14]. These delivery systems were found to transport peptide nucleic acid antisense molecules, but not phosphorothioate oligonucleotides, across the BBB. The authors attributed this difference to preferential binding of phosphorothioate oligonucleotide to plasma protein instead of the antibody complex, which reduced transport. 8.3.2
Ocular
The first approved antisense oligonucleotide therapeutic, Vitravene (fomivirsen) is indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with AIDs [1]. Local treatment is accomplished by intravitreal injection of 50 L of a sterile, aqueous solution with a 30gauge needle. Fomivirsen is cleared from the vitreous of rabbits over the course of 7 to 10 days, by a combination of tissue distribution and metabolism. Following direct intravitreal injection, fomivirsen concentrations were greatest in the retina and iris. Fomivirsen was detectable in retina within hours after injection, and concentrations increased over 3 to 5 days. Metabolism is the primary route of elimination from the eye. Metabolites of fomivirsen are detected in the retina and vitreous in animals. Systemic exposure to fomivirsen following single or repeated intravitreal injections in monkeys was below limits of quantization. In monkeys treated every other week for up to 3 months with fomivirsen, there were isolated instances when fomivirsen’s metabolites were observed in liver, kidney, and plasma at a concentration near the level of detection [15].
CRC_8796_ch008.qxd
5/24/2007
22:08
222
Page 222
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
An alternative to direct intravitreal injection is to use a noninvasive method of oligonucleotide delivery employing iontophoresis. The advantage of using low-current-density iontophoresis is that the oligonucleotide intraocular distribution will allow for therapeutic concentrations to be achieved across a large number of tissues, including the anterior uvea and the cornea as well as neural retinal areas. Voigt et al. [16] evaluated this intraocular oligonucleotide delivery approach in the rat model of endotoxin-induced uveitis, which is characterized by NOSII (nitrous oxide synthase II) up-regulation. Iontophoresis facilitated the penetration of both anti-NOSII oligonucleotide and a control oligonucleotide with scrambled nucleotide sequence across the intraocular tissues of the eyes. Both active and control oligonucleotide were 21-base oligodeoxynucleotides. This biodistribution was demonstrated by histological examination of the fluorescently labeled oligonucleotides and by the down-regulation of NOSII in the iris/ciliary body of the active treated eyes compared to the saline or scrambled oligonucleotide-treated eyes. The application of iontophoresis demonstrates a unique and noninvasive approach to efficiently deliver oligonucleotide into the eye—increasing the likelihood of successful therapy for debilitating eye diseases manifesting posterior segments of the eye. 8.3.3
Topical Delivery
The barrier properties of human skin have long been an area of multidisciplinary research. Skin is one of the most difficult biological barriers to penetrate and traverse, primarily due to the presence of the stratum corneum. The stratum corneum is composed of corneocytes laid in a brick-and-mortar arrangement with layers of lipid. The corneocytes are partially dehydrated, anuclear, metabolically active cells completely filled with bundles of keratin with a thick and insoluble envelope replacing the cell membrane [17]. The primary lipids in the stratum corneum are ceramides, free sterols, free fatty acids, and triglycerides that form lamellar lipid sheets between the corneocytes [18]. These unique structural features of stratum corneum provide an excellent barrier to the penetration of most molecules, particularly, large hydrophilic molecules such as oligonucleotides. To penetrate the stratum corneum barrier, a number of approaches can be pursued. These approaches either alter the oligonucleotide’s physiochemical properties directly, the biophysical properties of the barrier, or provide some other driving force or influence onto both drug and the stratum corneum barrier. Altering the thermodynamic properties of oligonucleotide molecules is possible by either utilizing a hydrophobic counter cation (e.g., benzalkonium) or by chemically modifying the oligonucleotide chemistry to eliminate the anionic backbone charges (e.g., morpholino or PNA oligonucleotide chemistries). These modifications have resulted in increased penetration across isolated hairless mouse skin. This was explained on the basis of greater partitioning into the lipid phase [19]. Alternatively, physically changing the stratum corneum to disrupt its integrity can result in improved skin penetration. There have been a number of creative approaches to decrease the integrity of the skin without overtly causing long-term damage. Some examples of these breaching methods to induce transient openings in the stratum corneum include both ultrasound-induced sonoporation [20] and electroporation [21]. Iontophoresis, which involves application of an electric field across the skin to induce electrochemical transport of charged molecules, has been studied extensively for transdermal delivery of oligonucleotides [22]. Lastly, the use of topical formulations containing permeation enhancers (PEs) offers several advantages in regard to the tailoring of formulation compositions and on the practical ease of application—particularly being able to avoid the use of application devices. Chemical penetration enhancers have recently been studied for increasing transdermal delivery of oligonucleotides or other polar macromolecules [23]. Chemically induced transdermal penetration results from a transient reduction in the barrier properties of the stratum corneum. The reduction may be attributed to a variety of factors such as opening of intercellular junctions due to hydration [24], solubilization of the stratum corneum [25,26], or increased lipid bilayer fluidization [27]. Combining various surfactants and co-solvents can be used to achieve skin penetration, purportedly resulting in therapeutically relevant concentrations of oligonucleotide
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 223
ROUTES AND FORMULATIONS FOR DELIVERY OF ANTISENSE
223
in the viable epidermis and dermis [28]. In summary, it appears feasible to deliver oligonucleotide to the skin using a number of different delivery techniques and formulations. 8.3.4
Pulmonary Delivery
The ability to efficiently deliver oligonucleotides to the lungs makes it possible to treat a number of important diseases. Preclinical data demonstrate delivery to lung tissue by way of intravenous (IV) administration or by the pulmonary route. However, parenteral delivery of oligonucleotides does not lead to substantial lung tissue accumulation, and is therefore not an ideal route for treatment of disease in lung tissue. After a 5-mg/kg IV bolus injection in mice, for example, the concentration in lung tissue has been shown to be less than 2 g/gm [5]. Direct administration to the pulmonary airways through inhalation targets specific cell types not accessible via the parenteral route, increases efficiency of dosing with higher concentrations at much lower administered dose, and results in profound pharmacological response in murine models for asthma (e.g., [29]). The pulmonary route is an increasingly attractive option for local delivery of a wide variety of macromolecules including oligonucleotides. Delivery options include nebulizers, metered dose inhalers, and dry powder inhalers. Any of these pulmonary devices are far less invasive than parenteral administration and, in addition to potentially increasing efficacy, are likely to increase patient compliance.
8.3.4.1 Formulation Considerations Wu-Pong and Byron have contributed a review of the issues associated with the pulmonary delivery of oligonucleotides [30]. Since oligonucleotides are freely soluble and highly hygroscopic, it would be reasonable to assume first-dosage forms will rely upon aerosolization of simple aqueous solutions. Our data suggest that commercially available nebulization devices will generate suitable aerosolizations of oligonucleotide solutions at concentrations of up to 180 mg/mL (Table 8.2) [31]. Ultrasonic and jet nebulizations were found to have essentially no effect on phosphorothioate stability of the oligonucleotide over 40 min, which is longer than typical treatment times (Figure 8.3). Depending on particle size, delivery may primarily be to the upper airways or to the alveoli, where systemic delivery may also be possible [30,32]. Particles with diameters of approximately 5–10 m will generally deposit in the upper airways, while those in the range of approximately 0.5–5 m will reach the alveoli. Smaller particles are often exhaled; larger particles are generally swallowed. Due to the relatively small doses of drug that may conveniently be delivered by aerosolization, this route may be more practical for treatment of the local tissue rather than systemic dosing for oligonucleotides.
8.3.4.2 Deposition and Uptake The local and systemic bioavailability of simple solutions of a second-generation phosphorothioate oligonucleotide (partially modified 2-MOE) in monkeys by direct pulmonary administration was compared to parenteral administration (Table 8.3). Not surprisingly, direct delivery to the lung
Table 8.2 Nebulization of ISIS-2503 Solutions by Healthline Nebulizer Model NEB-3A at 10 mL /min [31] Concentration (mg/mL)
MMADa (m)
100 150 180
1.02 0.77 0.70
a b
Mass mean aerodynamic diameter. Geometric standard deviation.
GSD (m)
% Particles 5 m
Solution Delivery Rate (mg/min)
1.96 2.27 2.29
98.6 98.0 97.8
258 213 198
b
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 224
224
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION Ultrasonic
Jet
% Full length, full PS
100 98 96 94 92 90 0
Figure 8.3
10
20 Time (min)
30
40
Effect of different nebulization methods on phosphorothioate oligonucleotide stability.
Table 8.3 Bioavailability of ISIS 141923 (2 MOE chimera) after pulmonary administration (0.5/mg/kg) Tissue or Biofluid Lung Plasma Peribronchial lymph nodes Liver Kidney cortex a
Concentrationa (g/g or g/mL)
% Bioavailability (Relative to IV)
6.6 (2.5) nd 1.0 (0.6) nd 0.4 (0.1)
1260 1% 0.2 0.1 0.07
Tissues analyzed by LC/MS/MS LLOQ = 0.125 g/g; plasma analyzed by hybridization ELISA–LLOQ = 2 ng/mL.
demonstrated the highest bioavailability to the lung and very little was absorbed systemically. This preferential exposure of the target tissue is ideal for optimization of effect and minimization of offtarget adverse effect. At Isis Pharmaceuticals, Inc., antisense compounds were successfully delivered to cells of the rat lung using simple aqueous formulations aerosolized by commercial nebulization equipment [33]. Single or multiple nose-only administrations led to significant oligonucleotide concentrations in lung tissues and bronchiolar lavage fluid with low or mild toxicity, depending on dose. Using immunohistochemistry, oligonucleotides could be visualized in pneumocytes, vascular endothelium, and alveolar macrophages. Single and multiple exposures differed only in the amount of oligonucleotide present and not the distribution pattern. A similar study in mice determined that the cellular uptake of the phosphorothioate 2-MOE oligonucleotide ISIS 13920 was specific: predominantly into macrophages, and to lesser extent, eosinophils [34]. Cellular uptake was also observed in both tracheal and bronchial epithelium. Furthermore, the use of newer oligonucleotide chemistries, such as the sugar-modified (2-O-methoxyethyl) derivatives that significantly enhance tissue accumulation allows higher steady-state concentrations or less frequent dosing to be achieved, due to their longer tissue elimination half-lives (Table 8.4).
8.3.4.3 Demonstration of Pharmacology by the Pulmonary Route In addition to these studies that characterize deposition and uptake, there are several reports in the literature that demonstrate antisense pharmacology using the pulmonary route. Administration of an aerosolized phosphorothioate oligodeoxynucleotide (first-generation antisense to adenosine A1
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 225
ROUTES AND FORMULATIONS FOR DELIVERY OF ANTISENSE
225
Table 8.4 Comparison of Lung Tissue Exposure 24 hrs after Nose-Only or Intratracheal Administration of ISIS 141923 Species
0.1 mg/kg
0.5 mg/kg
5 mg/kg
50 mg/kg
Lung Tissue t1/2 (days)
Mouse Monkey
0.35 1.0
– 6.6
5.2 –
73 –
4 7
Note: Dose level expressed as the pulmonary dose, i.e., amount estimated to be deposited in lung. Necropsy conducted 24 h after the end of exposure (EOE) or at selected time intervals after exposure. Oligonucleotide concentration data expressed as mean g oligonucleotide/g lung tissue. n 3 to 5 animals.
receptor) desensitized rabbits to subsequent challenge with either adenosine or dust mite allergen. Rabbits treated with the sequence-specific oligonucleotide demonstrated a dose-dependent desensitization, while animals treated with a mismatched sequence control showed no desensitization [35]. Specifically, the authors showed that aerosols created with ordinary nebulizers (which create 80% of droplets 5 m in diameter) effectively reach the bronchial smooth muscle in sufficient quantities to specifically attenuate the target up to 75% [36]. Similar results were found using bradykinin B2 receptor-specific oligonucleotide and a mismatched control [35]. Isis Pharmaceuticals has reported preclinical activity of nebulized 2-MOE ASOs targeting IL-3R, CD86, p38 MAP kinase, and TNF- mRNAs in mouse models of asthma at inhaled doses in the microgram-per-kilogram range [29,37] administered as simple solutions. These ASOs have demonstrated a broad profile of pharmacological activity in acute and chronic models of inhaled allergen challenge in mice. Sequence-specific reductions in targeted protein observed on pulmonary epithelial cells, dendritic cells, macrophages, and eosinophils were seen consistent with the distribution of the ASOs observed by immunohistochemical staining. The literature reviewed here shows that both formulated and unformulated (simple aqueous solution) oligonucleotides can be delivered to the lungs where they subsequently suppress local gene expression, opening a wide variety of diseases to antisense therapy.
8.4 ORAL AND GASTROINTESTINAL DELIVERY Oral and rectal dosage forms are ideal for patient convenience and compliance. For traditional small molecules, these routes have been used for both systemic delivery and delivery to local gastrointestinal (GI) tissues. For 6000 Da, polyanionic, hydrophilic oligonucleotide molecules, a variety of issues must be considered when designing such dosage forms, particularly to enable systemic delivery by the oral route. Among these are chemical instability and precipitation at gastric pH, metabolic instability within the intestinal environment, low intestinal permeability, high protein binding, and first-pass hepatic clearance. These challenges have led many to conclude that effective oral systemic administration of oligonucleotides is not feasible [38]. Indeed, the early reports of oral bioavailability approaching 35% from gavage solutions containing radioactive phosphorothioate oligodeoxynucleotides in rats were consequently determined to be the uptake of degraded forms [39]. The above-mentioned barriers to oral bioavailability of oligonucleotides were delineated by Nicklin et al. [40]. Of these, our experience demonstrates that two stand out as critical: instability in the GI tract and low permeability across the intestinal mucosa. However, progress is being made to address and understand each of these barriers by way of changes to oligonucleotide chemistry and use of appropriate formulations. 8.4.1
Presystemic Metabolism
Natural DNA and RNA are rapidly digested by the ubiquitous nucleases found within the gut. As a consequence, oligonucleotides require stabilization to achieve a reasonable GI residence time
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 226
226
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
to allow absorption to occur. To impart enzyme resistance, modifications can be made to the phosphate backbone, the nucleotide sugar, or both. It has been demonstrated that such modifications need to be incorporated at only a subset of the sites available on the oligonucleotide molecule. Such hybrid structures have demonstrated significantly improved nuclease stability. This was shown by Zhang for both backbone modifications (methylphosphonates) and for sugar-modified (2-O-methyl) oligonucleotides [41,42]. However, care must be taken to ensure that mRNA binding affinity is not impaired by such modifications—particularly, modifications involving an increase in the size of the 2-O-substituent. Therefore, it is not surprising that small 2-O-alkoxyalkyl substituents (i.e., groups related to ethylene glycol) retain or improve upon the RNA binding affinity and have greatly improved nuclease resistance. The 2-MOE derivative was proposed as a promising candidate from this class of derivatives [43] and has since been evaluated for presystemic enzyme stability within the digestive system of the rat. This stability is proportional to the degree of sugar substitution (Figure 8.4). Relative to the unmodified phosphorothioate oligodeoxynucleotides, these data demonstrate the increasing benefit of MOE substituents present as either a hemimer, with MOEs at the 3 termini only; or a gapmer, with MOEs present at both the 3 and 5 termini; and lastly, a full MOE substitution at every sugar location [44]. These derivatives possess promising properties but are still awaiting clinical demonstration of their utility as therapeutic agents. Selection of a specific chemistry for development depends upon a number of criteria, of which nuclease stability is but one. An alternative approach to improving enzyme stability of oligonucleotides is by way of formulations that impose a physical barrier, preventing nuclease from reaching the oligonucleotide cleavage site [45–47]. Examples of such formulations include (1) conventional modified release dosage forms that incorporate the oligonucleotide within the solid matrix of the dosage unit, and (2) oligonucleotides complexed with cationic species formulated through a process referred to as complex coacervation. In addition to enzyme stability, such formulations have been purported to impart additional characteristics favorable to oligonucleotide absorption, including modified delivery (e.g., site-specific or increased retention by bioadhesion), a change in oligonucleotide physicochemical properties (e.g., charge neutralization or lipophilicity), and a change or impact on the absorbing membrane itself (e.g., opening of tight junctions or fluidization of mucosal membrane). These concepts are more fully discussed below.
P=S full 2'-MOE
P=S 2′-MOE gapmer − capped
P=S ODN
P=S 3′-2′-MOE hemimer
% Intact presystemically
120 100 80 60 40 20 0 0
Figure 8.4
5
10
15 Time (h)
20
25
30
Stability of various oligonucleotide chemistries in the rat intestine prior to absorption.
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 227
ROUTES AND FORMULATIONS FOR DELIVERY OF ANTISENSE
8.4.2
227
Permeability
The physicochemical properties of phosphorothioate oligonucleotides present a significant barrier to their GI absorption into the systemic circulation or the lymphatics. These properties include their size (approximately 7 kDa for 20-mers), hydrophilic nature (log Do/w approximating 3.5), and multiple ionization pKas (e.g., unpublished titration data, using a Sirius GlpKa instrument on a 20-mer sequence, noted over 17 pKas for the unmodified oligodeoxynucleotide and over 32 pKas for the MOE hemimer form). While the baseline permeability values for 20-mer oligodeoxynucleotides approximate 2 106 cm/s in the rat small intestine (mucosal-to-serosal), this can be improved by chemistry modifications (Figure 8.5), these values are still far below those of compounds exhibiting high permeability, such as naproxen [48]. The use of formulations can further improve upon this permeability. When formulating oligonucleotide drugs to improve oral bioavailability, the mechanism of oligonucleotide absorption, either paracellular via the epithelial tight junctions or transcellular by direct passage through the lipid membrane bilayer, must be considered. Modeling permeation data using paracellular and transcellular models appropriate for water-soluble, hydrophilic macromolecules suggests that oligonucleotides predominantly traverse the GI epithelium via the paracellular route [49–52]. Therefore, one must select permeation enhancers (PEs) that facilitate paracellular transport in a transient and reversible manner while meeting other formulation criteria including suitable biopharmaceutics, safety considerations, manufacturability, physical and chemical stability, and practicality of the dosage-form configuration (i.e., regarding production costs, dosing regimen, patient compliance, etc.). Initial attempts at selecting PEs have identified certain surfactants, such as bile salts and fatty acids, which appear to facilitate oligonucleotide absorption. The advantages of these components are many in that they are endogenous to foods and body constituents, and the literature is rich with information about the use and exposure of these two classes of compounds [53]. The precise mechanism of action for these PEs are unknown but are believed to involve a disruption of the mucus layer barrier, an increase in the fluidity of the mucosal membrane, and potentially opening the paracellular, tight-junction opening. The mucolytic effect coupled with the increased membrane fluidity
80 × 10 −6 60 × 10 −6 40 × 10 −6
Figure 8.5
P=O full MOE
P=O full MOE
P=S full MOE
P=S 2′-MOE 3′-hemimer
P=S 2′-MOE gapmer
0
P=S ODN
20 × 10 −6 Naproxen
Permeation coefficient (cm/sec)
100 × 10 −6
Effect of oligonucleotide chemistry on permeability in the rat intestine in situ [49].
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 228
228
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
imparted by these excipients appears to allow increased concentrations of oligonucleotide to enter the villi crypt wells. Experimental data suggest that tight junctions at the villi crypts are larger and therefore more permeable than their counterparts at the villi tips [54]. When PE-formulated drug is administered orally to mice, the oligonucleotide can be visualized by immunohistochemistry throughout the brush border areas of the murine ileum [52]. This enhanced intimacy of the oligonucleotide to the absorbing surface should increase its GI residence time and therefore its potential absorption via entry into the paracellular tight junctions. 8.4.3
Systemic Bioavailability
When the previously mentioned formulation (oligonucleotide and penetration enhancer in solution for intrajejunal [IJ] administration) was assembled as a conventional tablet with a one-hour dissolution profile, the plasma concentrations after oral dosing were negligible (data not shown). Upon reformulation to promote immediate dissolution (in less than 15 min), the absolute bioavailability approached 3%, as indicated by the plasma concentration plots in (Figure 8.6). These results, obtained with a rudimentary solid dosage form are ⬃40% that obtained with the IJ dosing. From these results, it may be concluded that the following factors are important for oligonucleotide absorption in the above PE system: coincident presentation of oligonucleotide with the PE components, high concentrations at the absorbing site, and enteric protection to prevent component dilution and oligonucleotide exposure to low pH, which has been associated with rapid degradation. It should be noted that plasma concentrations represent the absorption and distribution of oligonucleotide, but not the true tissue or body elimination. A more relevant metric for pharmacokinetics and bioavailability would be the total tissue levels. This is particularly true for oligonucleotide chemistries that are rapidly cleared from the bloodstream but are accumulated in target tissues or organs. In line with this hypothesis, a study was performed to evaluate plasma pharmacokinetics and tissue distribution of ISIS-2302 and ISIS-15839, a phosphorothioate oligodeoxynucleotide and a MOE hemimer with the same sequence. Pharmacokinetic parameters for each chemical class were assessed in beagle dogs during and following 14-day oral dosing of tablets containing oligonucleotide and PEs in enteric-coated tablets [55]. The in vitro performance of these tablets was such that they remained intact in acid medium, yet rapidly dissolved (⬃15 min) at pH 6.5. In plasma, the 15839 IJ solution (n = 2) 2302 IJ solution (n = 3)
10 Plasma conc. (µg/mL)
2302 oral tablets (n = 6) 15839 oral tablets (n = 4)
8 6 4 2 0 0
30
60
90
120
150
180
Time (min) Figure 8.6
Intact oligonucleotide in dogs after either IJ administration of a solution formulation (open symbols with broken lines, 10 mg/kg) or oral administration of a tablet formulation (filled symbols with solid lines, ⬃15 mg/kg) of two oligonucleotide chemistries. ISIS-2302 (squares) is a phosphorothioate oligodeoxynucleotide; ISIS-15839 (triangles) is a hemimer MOE derivative with the same sequence. Error bars are standard error.
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 229
ROUTES AND FORMULATIONS FOR DELIVERY OF ANTISENSE
229
Table 8.5 Summary of Plasma Oligonucleotide Pharmacokinetics after the First Single 200-mg Oral Dose in a Multiple-Dose Study
AUC (g min/mL) Cmax (g/mL) % Plasma BAV
ISIS 15839
ISIS 2302
91 1.2 1–4%
62 1.1 0.1–3%
Table 8.6 Tissue Oligonucleotide Concentrations and Approximate Bioavailabilities Based on Data Obtained at the End of Two-Week Daily Dosing Study in Dogs Oligonucleotide Chemistry (20-Base Phosphorothioates) ISIS 2302—antisense to ICAM-1 (deoxy) ISIS 15839—antisense to ICAM-1 (hemimer MOE of ISIS 2302) a
Liver Concentration (g/g)
Kidney Cortex Concentration (g/g)
% BAVa
4.9 33
12 109
1.3 5.5
Average bioavailabilities as ratio of final tissue concentrations (oral to IV), dose adjusted.
ISIS 15839 gave approximately 150% the bioavailability found for ISIS 2302 (Table 8.5). However, oligonucleotide tissue concentrations at the end of the study for both liver and kidney cortex were approximately tenfold higher for ISIS 15839 than for ISIS 2302 (Table 8.6). In this multiple dosing study, the distribution of oligonucleotides out of the plasma circulation was very rapid with a distribution half-life of 30–60 min. Therefore, as mentioned earlier, the bioavailability assessments based upon plasma data may be inaccurate or misleading for this class of compounds and this relative range of absolute bioavailabilities. Alternatively, the bioavailability determined from sentinel tissues, such as the kidney and liver, may be a more credible representation of the true systemic exposure since these tissues reflect true elimination kinetics as well as accumulation to steady-state concentrations during chronic dosing. On this basis, our data indicate that bioavailabilities based upon organ concentrations (after oral and IV dosing) would be 50% higher for the kidney and 100% higher for the liver than those calculated by plasma concentrationtime area under the curves (AUC). In consideration of the practical difficulties involved in experimental determinations of organ bioavailability, we have performed simulations of organ accumulation after oral dosing of first-generation phosphorothioate oligodeoxynucleotide versus a MOE gapmer (Figure 8.7). Each simulation is generated assuming a random input metric of 2–15% oral bioavailability (geometric mean 7%) with all other pharmacokinetic parameters consistent for these two chemistries remaining fixed. These simulations indicate that even with variable absorption, long tissue half-lives provide sufficiently improved accumulation, making it feasible to give the newer chemistry MOE gapmer compounds by the oral route. Two studies of oligonucleotide oral administration in human volunteers have been reported in the literature. In the first, the oral absorption of the 2-MOE-modified antisense oligonucleotide, ISIS 104838, was demonstrated in healthy volunteers with an average 9.5% plasma bioavailability across four formulations tested (Figure 8.8). The greatest average performance achieved in this study for a single formulation was 12.0% bioavailability within an individual dose and subject range of 1.96 to 27.5%. This study suggests that oral formulations can be devised that maintain target tissue concentrations associated with inhibition of targeted human mRNA [56]. The second study reports the oral bioavailability (BAV) and pharmacology of these formulations upon repeated oral administration of a second-generation oligonucleotide [57]. In this study, 36 healthy volunteers received an IV loading dose of 200 mg of ISIS 301012 on day 1, after which they received either oral ISIS 301012 or placebo once daily for 30 or 90 days. The oral formulations used in this study utilized a controlled release of the penetration enhancer, sodium caprate, to enhance oligonucleotide bioavailability. Subjects were monitored for plasma (trough) drug levels and serum lipids weekly. Additionally, complete (24-h) plasma pharmacokinetic profiles were
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 230
230
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Predicted conc. (µg/g)
100 80 60 40 20 0 0
Figure 8.7
200
400
600 Time (h)
800
1000
1200
Simulation comparison of tissue oligonucleotide concentrations for a daily oral dosing regimen of 1-month duration of a phosphorothioate oligodeoxynucleotide and a MOE gapmer oligonucleotide at 2 mg/kg using a variable bioavailability input metric randomly generated from 2% to 15% (geometric mean 7%).
A IR minitabs FASTED B 50/50 fast pulsatile FASTED C 50/50 slow pulsatile FASTED D 70/30 fast pulsatile FASTED E 70/30 fast pulsatile FED
3.5
ISIS 104838 conc. in plasma (µg/mL)
3.0
2.5
2.0
1.5
1.0
0.5
0.0 -2
Figure 8.8
0
2
4 6 Time (h)
8
10
12
Mean ISIS 104838 concentration–time profiles in plasma following oral administration of various test formulations. Each data point represents the mean of 6–13 individual measurements and the error bars are standard deviation.
conducted on the first and last oral dosing. A mean oral bioavailability of 6% was observed in this study (Figure 8.9). Maximal pharmacological responses were achieved on days 55 and 69 with a statistically significant decrease of 12–15% apoB and commensurate reductions in LDL-C (p0.005) (Figure 8.10). The oral formulation was generally, well tolerated with mild, intermittent GI symptoms noted. While oral bioavailability was modest, averaging 6%, this study was the first to report significant gene down-regulation and pharmacological activity after oral administration of an antisense oligonucleotide and provides key information for future formulation enhancements.
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 231
ROUTES AND FORMULATIONS FOR DELIVERY OF ANTISENSE
IV 100 mg (n = 6) ORAL 500 mg, Day 3 (n = 24) ORAL 500 mg, Day 43 (n = 24)
100
ISIS 301012 in plasma (µg/mL)
231
10
1
0.1
0.01
0.001 0
5
10 15 Time (h)
20
25
30
Figure 8.9 Mean ISIS 301012 concentration–time profiles in plasma following IV administration (day 1) and oral administrations (days 3 and 43). Each data point represents the mean of 6 or 24 individual measurements and the error bars are standard deviation.
Placebo Oral active 10 5
%Baseline
0 −5 −10 −15 −20
* p < 0.01 ** p < 0.001
*
**
−25 apoB100
LDL-C
Figure 8.10 Day 69 primary endpoints, plasma apoB100 and LDL-C. Mean changes from baseline for placebo and orally treated groups.
8.4.4
Local GI Uptake
Direct delivery of oligonucleotides to GI tissues, by way of oral or rectal dosage forms, may lead to significantly higher local oligonucleotide concentrations than when dosed by the parenteral route [58]. These dosage forms may therefore be effective in delivering oligonucleotides for the
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 232
232
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
treatment of a variety of GI disease indications such as certain malabsorption syndromes, inflammatory conditions, and carcinomas. In support of this local delivery approach are observations in mice (dextran sodium sulfate colitis model) and rats (trinitrobenzene sulfonate [TNBS] colitis model) that locally administered solutions of oligonucleotides accumulate to a greater extent in inflamed GI tissue than in normal tissue [55]. In the rat colitis model, ISIS-2302 in water was administered by IV or intracolonic injection. The oligonucleotide concentration was determined in the colon (Figure 8.11). While there was no significant difference in tissue or plasma concentrations between normal and colitic rats when given oligonucleotide by IV administration, large differences were found between normal and colitic rats for intracolonic administration. Concentrations in the colon, in particular, were considerably higher in the diseased tissue. The data also suggest that diseased tissue may be targeted with simple oral formulations, without the need for PEs. Neurath et al. [58] locally administered a single 150-g dose of the antisense NF-B phosphorothioate oligodeoxynucleotide targeted to mice with TNBS-induced colitis. The oligonucleotide abrogated the clinical and histological signs of colitis more effectively than daily glucocorticoids, suggesting a treatment for Crohn’s disease. Zhang and Agrawal have introduced oligonucleotides into the colon of rats as solutions and suppositories to test stability and uptake [59]. Their work demonstrated the necessity of stabilizing the oligonucleotides to intestinal degradation. A retention enema formulation to treat inflammation of the colon is currently under investigation at Isis Pharmaceuticals, Inc. Absorption into local tissues was achieved in animal enema models using oligonucleotides in an aqueous buffered, viscous formulation. Two hours after a 1-h retention, levels of intact oligonucleotide in healthy tissue were about hundredfold higher than those achieved with an IV injection of an equivalent dose (Table 8.7) [55]. Furthermore, the presence of oligonucleotide was still evident the following day in this single-dose study. A variety of oral dosage forms may be pursued to more conveniently present oligonucleotides for local GI indications. A pharmacokinetic study in dogs shows the feasibility of creating therapeutic levels of drug in the GI tissue by a simple enterically coated solid dosage form. In this study ISIS 13920, a 3-9-8 MOE gapmer, was administered for 5 consecutive days as a 400-mg oral tablet or 200-mg retention enema. GI tissue from the jejunum to the distal colon was analyzed for oligonucleotide concentration either 6 or 24 h after the last dose. The 6-h results are presented in
16 Colon
% dose/whole organ
14 12 10 8 6 4 2 0 0
10
20
30
40
50
Time (h) Figure 8.11 Rat colon tissue oligonucleotide concentrations as a percent of administered radioactive dose for normal rats (filled symbols) or treated with TNBS (open symbols) as a model for colitis. Solid lines represent the IV route and broken lines designate rectal dosing—both at 100 mg/kg of ISIS 2302 with nonexchangeable 3H label.
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 233
ROUTES AND FORMULATIONS FOR DELIVERY OF ANTISENSE
233
Table 8.7 Dog Colon Tissue Biopsy Concentrations of Intact ISIS 2302 Oligonucleotide after Single-Dose IV (2 and 10 mg/kg) or Retention Enema (10 mg/kg) Administrations CGE (g/g)
Formulation (Enemas at 5 mg/mL Oligonucleotide)
3h
24 h
1.5% Hydroxypropylmethylcellulose 1.0% Carrageenan Emulsion with Captex, Labrasol, and Crill 0.5% Tween 80, 0.75% HPMC 5% Sorbitol, 0.75% HPMC IV dosing at 2 mg/kg IV dosing at 10 mg/kg
660 558 224 621 417 2 11
7 3 1 6 1 NA 0.6
Tablets
Enema
400
Tissue concentration (µg/g)
350 300 250 200 150 100 50 0
Jejujum
Mid ileum Term. ileum Prox. colon Mid colon Distal colon Tissues
Figure 8.12 Tissue concentrations of ISIS 13920 6 h after last dose for enterically coated tablets or a 1-h retention enema.
Figure 8.12; from these data it can be seen that the enteric tablet formulation delivered the drug along the GI tract with the highest concentrations appearing in the colon. Importantly, the colon concentrations of intact oligonucleotide approximate those produced by the retention enema (albeit at twice the dose). Colon concentrations of intact drug fell to approximately 1 g/gm of tissue by 24 h for both formulations. Stool analysis accounted for 85–95% of the administered dose in 48 h with greater than 90% of the drug intact. These data suggest that with the use of proper formulations and stable chemistry, local delivery of therapeutic amounts of oligonucleotides is possible using the oral and rectal routes. 8.5 CONCLUSIONS Using fundamental biopharmaceutical principles and guidance from relevant animal models, it is possible to consider new routes of administration that have the potential for increased patient convenience and compliance. To date, antisense oligonucleotide clinical investigations have been limited to the use of local or parenteral administration of simple saline solutions. However, animal
CRC_8796_ch008.qxd
234
5/24/2007
22:08
Page 234
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
models have shown that formulations and delivery routes can be used to alter the tissue distribution of oligonucleotides. By making use of the knowledge gained through these studies, antisense oligonucleotides may be selectively delivered to a variety of target indications that would otherwise not be possible, such as the lung, and colon. Early studies in man have shown it possible to deliver therapeutic doses of oligonucleotides orally. However, to be cost-effective the efficiency of these dosage forms must increase.
REFERENCES 1. De Smet, M.D., Meenken, C., and Van Den Horn, G.J., Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Inflammation, 7(3–4): 189–198, 1999. 2. SantaLucia, J., Jr., A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. Proc. Natl. Acad. Sci. USA, 95: 1460–1465, 1998. 3. Krotz, A.H., Mehta, R.C., and Hardee, G.E., Peroxide-mediated desulfurization of phosphorothioate oligonucleotides and its prevention. J. Pharm. Sci., 94: 341–352, 2005. 4. Altmann, K.-H. et al., Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia, 50: 168–176, 1996. 5. Geary, R.S. et al., Pharmacokinetics of a tumor necrosis factor- phosphorothioate 2-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab. Dispos., 31(11): 1419–1428, 2003. 6. Sewell, K.L. et al., Phase I trial of ISIS 104838, a 2-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-. J. Pharmacol.Exp. Ther., 303(3): 1334–1343, 2002. 7. Pardridge, W.M., Transport of small molecules through the blood-brain barrier: biology and methodology. Adv. Drug Delivery Rev., 15(1–3): 5–36, 1995. 8. Le Corre, S.M. et al., Critical issues in the antisense inhibition of brain gene expression in vivo: experiences targeting the 5-HT1A receptor. Neurochem. Int., 31(3): 349–362, 1997. 9. Whitesell, L. et al., Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc. Nat. Acad. Sci USA, 90(10): 4665–4669, 1993. 10. Sommer, W. et al., The spread and uptake pattern of intracerebrally administered oligonucleotides in nerve and glial cell populations of the rat brain. Antisense Nucleic Acid Drug Dev., 8(2): 75–85, 1998. 11. Mustafa, S.J. and Dar, M.S., Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments. US Patent 5932557, 1999. 12. Yazaki, T. et al., Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol. Pharmacol., 50(2): 236–242, 1996. 13. Crooke, S.T. et al., Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther., 277(2): 923–937, 1996. 14. Boado, R.J., Tsukamoto, H., and Pardridge, W.M., Drug delivery of antisense molecules to the brain for treatment of Alzheimer’s disease and cerebral AIDS. J. Pharm. Sci., 87(11): 1308–1315, 1998. 15. Vitravene™ product insert. 16. Voigt, M. et al., Down-regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis. Biochem. Biophys. Res. Commun., 295: 336–341, 2002. 17. Holbrook, K.A. and Wolf., K., The structure and development of skin, in Dermatology in General Medicine. Fitzpatrick, T.B., Eigen, A.Z., Wolff, K., Freedberg, I.M., and Austen, K.F., eds., McGraw Hill, New York, 97–145, 1993. 18. Lampe, M.A. et al., Human stratum corneum lipids: characterization and regional variations. J. Lipid Res., 24: 120–130, 1983. 19. Lee, Y.M. et al., Effect of benzalkonium chloride on percutaneous absorption of antisense phosphorothioate oligonucleotides. Arch. Phar. Res., 19: 435–440, 1996. 20. Mitragotri, S., Blankschtein, D., and Langer, R., Ultrasound-mediated transdermal protein delivery. Science, 269: 850–853, 1995. 21. Regnier, V., Le Doan, T., and Preat V., Parameters controlling topical delivery of oligonucleotides by electroporation. J. Drug Target., 5: 275–289, 1998.
CRC_8796_ch008.qxd
5/24/2007
22:08
Page 235
ROUTES AND FORMULATIONS FOR DELIVERY OF ANTISENSE
235
22. Banga, A.K. and Prausnitz, M.R., Assessing the potential of skin electroporation for the delivery of protein- and gene-based drugs. Trends Biotechnol., 16: 408–412, 1998. 23. Roberts, M.S. and Walker, M., Water. The most natural penetration enhancer, in Pharmaceutical Skin Penetration Enhancers. Hadgraft J., ed., Marcel Dekker, New York, 1995, 1–30. 24. Catz, P. and Friend, D.R., Mechanism of skin penetration enhancer: Ethyl acetate. Pharm. Res., 6: 108, 1988. 25. Millns, J.L. and Maibach, H.I., Mechanisms of sebum production and delivery in man. Arch. Dermatol. Res., 272: 351–362, 1982. 26. Hadgraft, J. and Williams, D.G., Azone. Mechanism of action and clinical effects, in Pharmaceutical Skin Penetration Enhancers. J. Hadgraft, ed., Marcel Dekker, New York, 1993, 175–197. 27. Michniak, B., In-vitro evaluation of a series of azone analogs as dermal penetration enhancers. Int. J. Pharm., 91: 85–93, 1993. 28. Geary, R.S. et al., Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-RAF-1 kinase expression. Drug Metab. Dispos., 25(11): 1272–1281, 1997. 29. Duan, W. et al., Inhaled p38 Mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am. J. Respir. Crit. Care Med., 171(6): 571–578, 2005. 30. Wu-Pong, S. and Byron, P.R., Airway-to-biophase transfer of inhaled oligonucleotides. Adv. Drug Delivery Rev., 19(1): 47–71, 1996. 31. Deshmukh, H., unpublished results, 2002. 32. Yu, J. and Chien, Y.W., Pulmonary drug delivery: physiologic and mechanistic aspects. Crit. Rev. Ther. Drug Carrier Syst., 14(4): 395–453, 1997. 32. Danahay, H. et al., Distribution of a 20-mer phosphorothioate oligonucleotide, CGP69846A (ISIS 5132), into airway leukocytes and epithelial cells following intratracheal delivery to Brown-Norway rats. Pharm. Res., 16(10): 1542–1549, 1999. 33. Templin, M.V. et al., Pharmacokinetic and toxicity profile of a phosphorothioate oligodeoxynucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev., 10: 359–368, 2000. 34. Hung, E., unpublished observations, 2005. 35. Nyce, J.W. and Metzger, W.J., DNA antisense therapy for asthma in an animal model. Nature (London), 385(6618): 721–725, 1997. 36. Nyce, J.W., Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases. Expert Opin. Invest. Drugs, 6(9): 1149–1156, 1997. 37. Karras, J.G., Geary, R.S., and Gregory, S.A., Inhaled antisense oligonucleotide therapies: inspiration and progress. Drug Discov. Today, in press. 38. Humphrey, M.J., The oral bioavailability of peptides and related drugs, in Delivery Systems for Peptide Drugs. Davis, S.S., Illum, L., and Tomlinson, E., eds., Plenum Press, New York, pp. 139–151, 1986. 39. Agrawal, S. and Zhang, R., Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. Handb. Exp. Pharmacol., 131 (Antisense Research and Application): 525–543, 1998. 40. Nicklin, P.L., Craig, S.J., and Phillips, J.A., Pharmacokinetic properties of phosphorothioates in animals—absorption, distribution, metabolism and elimination. Handb. Exp. Pharmacol., 131(Antisense Research and Application): 141–168, 1998. 41. Zhang, R. et al., In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats. Biochem. Pharmacol., 50(4): 545–556, 1995. 42. Zhang, R. et al., Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleotides phosphorothioate in rats after intravenous administration. J. Pharmacol. Exp. Ther., 278(2): 971–979, 1996. 43. Altmann, K.-H. et al., Second generation of antisense oligonucleotides. From nuclease resistance to biological efficacy in animals. Chimia, 50(4): 168–176, 1996. 44. Bennett, C.F. et al., Antisense oligonucleotide-based therapeutics, in Gene and Cell Therapy: Therapeutic Mechanisms and Strategies. Templeton, N.S., ed., Marcel Dekker, New York, pp. 347–374, 2004. 45. Kolbe, H.V.J. and Boussif, O., Use of a cationic polymer for the preparation of a complex with nucleic acid and related compositions, European Patent Application, EP 987029, 2000. 46. Richardson, S.C.W., Kolbe, H.V.J., and Duncan, R., Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int. J. Pharm., 178(2): 231–243, 1999.
CRC_8796_ch008.qxd
236
5/24/2007
22:08
Page 236
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
47. Zobel, H.P. et al., Evaluation of aminoalkylmethacrylate nanoparticles as colloidal drug carrier systems. Part 2. Characterization of antisense oligonucleotides loaded copolymer nanoparticles. Eur. J. Pharm. Biopharm., 48(1): 1–12, 1999. 48. Khatsenko, O. et al., Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length. Antisense Nucleic Acid Drug Dev, 10(1): 35–44, 2000. 49. Anderberg, E.K., Lindmark, T., and Artursson, P., Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharm. Res., 10(6): 857–864, 1993. 50. Lane, M.E., O’Driscoll, C.M., and Corrigan, O.I., The relationship between rat intestinal permeability and hydrophilic probe size. Pharm. Res., 13(10): 1554–1558, 1996. 51. Soderholm, J.D. et al., Reversible increase in tight junction permeability to macromolecules in rat ileal mucosa in vitro by sodium caprate, a constituent of milk fat. Dig. Dis. Sci., 43(7): 1547–1552, 1998. 52. Teng, C.-L., unpublished results, 1998. 53. Lee, V.H., Yamamoto, A., and Kompella, U.B., Mucosal penetration enhancers of facilitation of peptide and protein drug absorption. Crit. Rev. Ther. Drug Carrier Syst., 8(2): 91–192, 1991. 54. Hollander, D., The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn’s disease. Scand. J. Gastro., 27: 721–726, 1992. 55. Geary, R.S., unpublished results, 2004. 56. Tillman, L.G., Geary, R.S., and Hardee, G.E., Oral delivery of antisense oligonucleotides: plasma bioavailability of ISIS 104838 in man. Accepted for publication, J. Pharm. Sci., 2007. 57. Hardee, G.E. et al., A Phase I Study of Orally Administered ISIS 301012 for the Reduction of ApoB-100 and LDL-cholesterol. Manuscript in preparation, 2006. 58. Neurath, M.F. et al., Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-B abrogates established experimental colitis in mice. Nat. Med. (NY), 2(9): 998–1004, 1996. 59. Zhang, R. and Agrawal, S., Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides, PCT Int. Appl., WO 9840058, 1998.
CRC_8796_ch009.qxd
5/24/2007
22:36
Page 237
CHAPTER
9
Liposomal Formulations for Nucleic Acid Delivery Ian MacLachlan
CONTENTS 9.1 9.2
Liposomes for the Delivery of Nucleic Acid Drugs.............................................................237 Liposome Constituents .........................................................................................................239 9.2.1 Cationic Lipids .........................................................................................................239 9.2.2 The Role of Helper Lipids in Promoting Intracellular Delivery ..............................240 9.2.3 PEG–Lipids...............................................................................................................241 9.2.4 Active Targeting........................................................................................................242 9.3 Methods of Encapsulating Nucleic Acids ............................................................................242 9.3.1 Passive Nucleic Acid Encapsulation.........................................................................243 9.3.2 The Ethanol Drop (SALP) Method of Nucleic Acid Encapsulation........................247 9.3.3 Encapsulation of Nucleic Acid in Ethanol-Destabilized Liposomes .......................247 9.3.4 The Reverse-Phase Evaporation Method of Nucleic Acid Encapsulation ...............248 9.3.5 The Spontaneous Vesicle Formation by Ethanol Dilution (SNALP) Method of Nucleic Acid Encapsulation .....................................................................................249 9.4 Analytical Methods...............................................................................................................251 9.4.1 Measuring Particle Size ............................................................................................251 9.4.2 Zeta Potential............................................................................................................253 9.4.3 Encapsulation............................................................................................................253 9.5 Pharmacology of Liposomal NA..........................................................................................254 9.5.1 Pharmacokinetics and Biodistribution of Liposomal NA Following Systemic Administration ..........................................................................................................254 9.5.2 Toxicity of Liposomal NA Formulations .................................................................256 9.5.3 Immune Stimulation .................................................................................................258 9.5.4 Immunogenicity........................................................................................................259 9.5.5 The Efficacy of Liposomally Formulated NA Drugs...............................................260 References ......................................................................................................................................262 9.1 LIPOSOMES FOR THE DELIVERY OF NUCLEIC ACID DRUGS Liposomes are artificial vesicles made up of one or more bilayers of amphipathic lipid encapsulating an equal number of internal aqueous compartments. They are distinguished on the basis of their size and the number and arrangement of their constituent lipid bilayers (Figure 9.1). 237
CRC_8796_ch009.qxd
238
Figure 9.1
5/24/2007
22:36
Page 238
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Liposomes. Mulilamellar vesicles (MLVs) are large (hundreds of nm in diameter) complex structures containing a series of concentric bilayers separated by narrow aqueous compartments. Large unilamellar vesicles (LUVs) are between 50 and 500 nm in diameter, while the smallest liposomes namely small unilamellar vesicles (SUVs) are ⬍50 nm. LUVs are the preferred systems for delivery of NA drugs. Lipids are drawn roughly to scale.
Multilamellar vesicles (MLVs) are formed by the aqueous hydration of dried lipid films. Typically hundreds of nanometers in diameter, they are large, complex structures containing a series of concentric bilayers separated by narrow aqueous compartments. Simple unilamellar vesicles between 50 and 500 nm in diameter are referred to as large unilamellar vesicles (LUVs) while the smallest liposomes, vesicles smaller than 50 nm in diameter, are small unilamellar vesicles (SUVs). Liposomes have received attention not only for their utility as model membrane systems, but also for use in drug delivery. Typically, liposomes are used as drug carriers, with the solubilized drug encapsulated in the internal aqueous space formed by the liposomal lamellae. Liposomal drug formulations can be used to overcome a drug’s nonideal properties, such as limited solubility, serum stability, circulation half-life, biodistribution, and target tissue selectivity. Experience with conventional small molecule drugs has shown that the drugs that benefit the most from liposomal delivery, are those that are chemically labile, subject to enzymatic degradation and have an intracellular site of action [1]. For this reason, there is considerable interest in exploiting liposomes as carriers of nucleic acids (NAs), either as plasmid vectors for gene therapy applications or to deliver smaller NA species such as antisense oligonucleotides, ribozymes and, more recently, siRNA for the purposes of downregulating target genes. Because of their ability to achieve favorable drug/lipid ratios and their more predictable drug release kinetics LUV are the preferred liposome delivery system for NA drugs. An advantage of liposomal drug delivery is that the pharmacokinetics, biodistribution, and intracellular delivery of the liposome payload are largely determined by the physicochemical properties of the carrier. For example, the biodistribution of a NA entrapped within a small, long circulating liposome is independent of the type of NA, which can be a relatively stable double-stranded plasmid DNA molecule or single-stranded antisense DNA, or one of the more labile ribonucleotide molecules such as ribozymes or a duplex siRNA. This is only true if the liposome is truly acting as a carrier, rather than a mere excipient. Liposomes function as excipients when used to formulate hydrophobic drugs that would otherwise be difficult to administer in aqueous dosage form. Hydrophobic drugs rapidly exchange into lipoproteins or other lipid-rich environments soon after injection, resulting in comparably uncontrolled pharmacology. In the context of NA drug delivery, liposomes are considered excipients if used to enable vialing and aqueous dosing of hydrophobic lipid–NA conjugates [2–5]. (These applications are not considered in this chapter, nor are those that use preformed, cationic lipid-containing vesicles to form “lipoplex” or “oligoplex” systems.)
CRC_8796_ch009.qxd
5/24/2007
22:36
Page 239
LIPOSOMAL FORMULATIONS FOR NUCLEIC ACID DELIVERY
239
An objective inherent in all pharmaceutical development is to minimize the risks associated with treatment while maximizing the benefit to patient health. The most important risk to patients is the toxicity associated with the administration of poorly tolerated compounds, often exacerbated by attempts to increase efficacy by escalating the administered dose. A well-designed liposomal delivery system will be capable of reducing the toxicity and increasing the potency of NA-based drugs by optimizing NA delivery to target tissues. Liposomal NA delivery will be determined by the physical and biochemical properties of the liposome including stability, size, charge, hydrophobicity, interaction with serum proteins, and interaction with nontarget cell surfaces. Ideally, liposomal carriers for NA delivery will have the following properties: (i) they will be safe and well tolerated; (ii) they will have appropriate pharmacokinetic attributes to ensure delivery to intended disease sites; (iii) they will mediate effective intracellular delivery of intact NA; (iv) they will be nonimmunogenic, enabling the use of multidosing treatment regimes; and (v) they will be stable upon manufacture so that large batches can be prepared with uniform, reproducible specifications. In this chapter we discuss the physical makeup, manufacturing methods, and pharmacological considerations specific to liposomal systems for the delivery of NA-based drugs, with emphasis on those that enable systemic delivery of synthetic polynucleotides such as antisense ODN, ribozymes, and siRNA.
9.2 LIPOSOME CONSTITUENTS NA encapsulation was first described in the late 1970s, prior to the development of cationic lipidcontaining lipoplex, using naturally occurring, neutral lipids to encapsulate high-molecular-weight DNA [6–8]. The first reports of low-molecular-weight oligo- or polynucleotide encapsulation similarly used passive techniques to entrap NA in neutral liposomes [9–11]. The advent of cationic lipid-mediated lipofection [12] saw a shift in emphasis away from encapsulated systems in favor of “lipoplex” or “oligoplex” systems. More recently, improvements in formulation technology have allowed for a return to encapsulated systems that contain cationic lipids as a means of facilitating both encapsulation and intracellular delivery. More advanced systems typically contain multiple lipid components, each of which play a role in determining the physical and pharmacological properties of the system as a whole. 9.2.1
Cationic Lipids
Cationic lipids play two roles in liposomal NA formulations. In the first case, they encourage interaction between the lipid bilayer and the negatively charged NA, allowing for the enrichment of NA concentrations over and above that which would be achieved using passive loading in charge neutral liposomes. Cationic lipids allow for encapsulation efficiencies greater than 40% when using coextrusion methods, and greater than 95% when using more sophisticated techniques [13–15]. Cationic lipids also function by providing the liposome with a net positive charge, which in turn enables binding of the NA complex to anionic cell surface molecules. The most abundant anionic cell surface molecules, sulfated proteoglycans and sialic acids, interact with and are responsible for the uptake of cationic liposomes [16–18]. The role of cationic lipids in liposomal uptake presents a dilemma: highly charged systems are rapidly cleared from the blood, thereby limiting accumulation in target tissues. Particles with a neutral charge however, display good biodistribution profiles, but are poorly internalized by cells. This supports the concept of a modular delivery solution, that is, an engineered nanoparticle with individual components fulfilling different functions in the delivery process, and in particular, a system which responds to the microenvironment in a manner that facilitates transfection. Titratable, ionizable lipids are components that allow for the adjustment of the charge on the system by simply changing the pH after encapsulation [19]. At reduced pH when the system is strongly charged, NAs are efficiently encapsulated. When liposomes containing titratable, ionizable lipids are at a pH closer to the pKa of the cationic lipid, such as
CRC_8796_ch009.qxd
240
5/24/2007
22:36
Page 240
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
physiological pH, they become more charge neutral and are able to avoid opsonization by blood components [19]. More recently, the use of novel, pH titratable cationic lipids with distinct physicochemical properties that regulate particle formation, cellular uptake, fusogenicity, and endosomal release of NA drugs have been described [20]. The chemical and biological properties of pH-titratable cationic lipids are influenced by their degree of lipid saturation. In particular, the phase transition properties, as measured using 31P-NMR, are affected. Above the phase transition temperature, Tc, lipids adopt the more highly fusogenic reverse hexagonal HII phase [20–22]. By noting the temperature at which this phase transition occurs, the relative ease with which lipids form the HII phase and become “fusogenic” can be determined. On this basis it has been shown that the fusogenicity of liposomal systems increases as the titratable cationic lipid becomes less saturated. The lipid pKa also correlates with the degree of saturation. pK measurements confirm that saturated lipids carry more residual charge at physiological pH. For this reason, liposomes containing the more highly saturated cationic lipids are taken up more readily by cells in vitro [20]. However, liposomes containing the more fusogenic unsaturated cationic lipids DLinDMA and DLenDMA are more effective at mediating RNA interference in both in vitro cell culture systems and in vivo. The apparently conflicting results between cellular uptake and silencing potency are a reminder that cellular uptake per se is insufficient for effective delivery of NA. Cellular uptake, fusogenicity, and endosomal release are distinct processes, each of which need to be enabled by the delivery vehicle and each of which are profoundly affected by the physicochemical properties of the cationic lipids used. 9.2.2
The Role of Helper Lipids in Promoting Intracellular Delivery
Although we have just shown that cationic lipids may have inherent fusogenic properties of their own, cationic lipids were originally believed to require fusogenic “helper” lipids for efficient NA delivery [23–26]. Fusogenic liposomes facilitate the intracellular delivery of complexed plasmid DNA by fusing with the membranes of the target cell. Fusion may occur at a number of different stages in delivery, either at the plasma membrane, endosome or nuclear envelope. Fusion of first-generation, nonencapsulated lipoplex systems with the plasma membrane is expected to be a particularly inefficient method of introducing NA into the cytosol. Since lipoplex-NA is predominantly attached to the surface of the liposome, lipoplex fusion events resolve with NA, formerly attached to the liposome surface, deposited on the outside surface of the plasma membrane. Encapsulated systems are significantly different from lipoplex in this respect. Upon fusion with either the plasma or endosomal membrane(s), encapsulated carriers deliver their contents directly into the cytosol. Lipids that preferentially form nonbilayer phases, in particular the reverse hexagonal HII phase, such as the unsaturated phosphatidylethanolamine DOPE, promote destabilization of the lipid bilayer and fusion. Similar to fusogenic cationic lipids, decreasing the degree of lipid saturation increases the lipid’s affinity for the fusogenic HII phase [27–32]. However, some cationic lipids can function in the absence of these so-called helper lipids, either alone [24,25] or in the presence of the nonfusogenic lipid cholesterol [33]. This would suggest that either these lipids have properties which promote delivery through a mechanism which does not require membrane fusion, or that their own fusogenic properties are adequate to support delivery. As described above, cationic lipids are readily designed for optimal fusogenicity by controlling lipid saturation. This provides for multiple opportunities for modulating the fusogenicity of a liposomal lipid bilayer [20]. Attempts to address the role of fusogenic lipids in vivo have yielded confounding results. In this regard it is important to distinguish the effect of fusogenic lipids on NA delivery to target tissue from their effect on intracellular delivery. Fusogenic formulations are more likely to interact with the vascular endothelium, blood cells, lipoproteins, and other nontarget systems while in the blood compartment. For this reason there may be an advantage to transiently shield the fusogenic potential of systemic carriers using shielding agents such as polyethylene glycol (PEG).
CRC_8796_ch009.qxd
5/24/2007
22:36
Page 241
LIPOSOMAL FORMULATIONS FOR NUCLEIC ACID DELIVERY
9.2.3
241
PEG–Lipids
An ideal delivery system would be one that is transiently shielded upon administration, facilitating delivery to the target site, yet becomes increasingly charged and fusogenic as it reaches the target cell. PEG lipids partially address this challenge. PEG–lipid conjugates are readily incorporated in liposomal NA formulations. They provide a benefit during the formulation process, stabilizing the nascent particle and contribute to formulation stability by preventing aggregation in the vial [13]. PEG conjugates sterically stabilize liposomes by forming a protective hydrophilic layer that shields the hydrophobic lipid layer. By shielding the liposome’s surface charge they prevent the association of serum proteins and resulting uptake by the reticuloendothelial system when liposomes are administered in vivo [34,35]. In this way, cationic liposome NA formulations are stabilized in a manner analogous to PEGylated liposomal drug formulations that exhibit extended circulation lifetimes [36–41]. Although this approach has been investigated with a view towards improving the stability and pharmacokinetics of lipoplex containing either plasmid DNA [42] or antisense oligonucleotides [43], PEG–lipid-containing lipoplex systems suffer from the heterogeneity and suboptimal pharmacology common to most nonencapsulated NA–cationic lipid complexes. Although PEG–lipid-containing systems are promising with respect to their ability to deliver NA to disease sites, improvements are required to increase their potency. Early PEGylated liposomes for the delivery of small molecule chemotherapeutic drugs utilized stably integrated PEG lipids such as PEG-DSPE [39]. These systems are designed to function as carriers that facilitate the accumulation of active drug compound at disseminated disease sites. The drug is released at the cell surface at a “leakage rate” determined by the liposomal bilayer composition. NA-based drugs differ in this respect in that they require effective intracellular delivery, hence the use of the cationic and fusogenic lipids described earlier. PEGylated systems typically exhibit relatively low-transfection efficiencies. This is mainly due to the ability of the PEG coating to inhibit cell association and uptake [23,44,45]. Ideally, PEG–lipid conjugates would have the ability to dissociate from the carrier and transform it from a stable, stealthy particle to a transfection-competent entity at the target site. Various strategies have been applied to this problem. A number of investigators have explored the use of chemically labile PEG–lipid conjugates [46–52], in particular those that are “pH sensitive.” Typically, these systems invoke a chemically labile linkage between the lipid and PEG moieties that reacts via acid-catalyzed hydrolysis to destabilize the liposomes by removal of the sterically stabilizing PEG layer. Although this approach results in improved performance both in vitro and in vivo, it may be regarded as suboptimal for two reasons. First, pH-sensitive PEG lipids are designed to be rapidly hydrolyzed in the reduced pH environment encountered within the endosome, but since PEG lipids are known to inhibit cellular uptake, a prerequisite to endosomal localization and hydrolysis, their use actually limits the amount of material delivered to the endosome [53]. Second, the incorporation of pH-sensitive or otherwise chemically labile lipids results in a truncation of formulation shelf life relative to systems that use more stable PEG–lipids. An alternative to the use of acid-labile PEG–lipids involves the use of chemically stable, yet diffusible PEG lipids. The concept of diffusible PEG lipids arose from the observation that the length of the PEG lipid anchor has an influence on PEG lipid retention and the stability and circulation lifetime of empty lipid vesicles [54]. It has been found that by modulating the alkyl chain length of the PEG lipid anchor [55–59], the pharmacology of encapsulated NA can be controlled or “programmed” in a predictable manner. Upon formulation, the liposome contains a full complement of PEG in steady-state equilibrium with the contents of the vial. In the blood compartment, this equilibrium shifts and the PEG–lipid conjugate is free to dissociate from the particle over time, revealing a positively charged and increasingly fusogenic lipid bilayer that transforms the particle into a transfection-competent entity. Diffusible PEG lipids differing in the length of the their lipid anchors have been incorporated into liposomal systems containing plasmid DNA (SPLP) [13,55], antisense oligonucleotides (PFV, SALP) [19,56,60], and siRNA (SNALP) [14,15,61]. This approach may help to resolve the two conflicting demands imposed upon NA carriers. First, the carrier must be stable and circulate long
CRC_8796_ch009.qxd
5/24/2007
22:36
242
Page 242
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
enough to facilitate accumulation at disease sites. Second, the carrier must be capable of interacting with target cells to facilitate intracellular delivery. 9.2.4
Active Targeting
Active targeting refers to processes that aim to increase the accumulation, retention or internalization of a drug through the use of cell-specific ligands. This is to be distinguished from the passive “disease site targeting” or the “enhanced permeability and retention” (EPR) effect, which results in the accumulation of appropriately designed carriers in target sites such as tumor tissue. Active targeting has been successfully applied to liposomal small molecule drug formulations and generally has the effect of improving the therapeutic index of the liposomal drug when measured in preclinical studies. NA delivery systems stand to benefit from targeting in two ways, first through improving the accumulation and binding of formulations to target cells and second by facilitating intracellular delivery through endocytosis. The perceived benefits of active targeting have encouraged numerous investigators in this area and targeting of NA formulations has been achieved through the use of molecules as diverse as antibodies directed against cell surface proteins [62–65], protein ligands of cell surface receptors [66–69], vitamins [70–72], and glycolipids [73,74]. The earliest reports of targeted liposomal formulations of encapsulated NA were attempts to improve the intracellular delivery characteristics of charge neutral liposomes encapsulating either synthetic antisense DNA [63,65] or in vitro transcribed antisense RNA [64]. The results of these studies were encouraging, suggesting a significant benefit associated with the use of targeted systems. Although these in vitro studies effectively demonstrated the potential advantage of targeting at the level of intracellular delivery, they were unable to address important pharmacological considerations such as those that influence accumulation at disease sites. It is unlikely that addition of targeting ligands to delivery systems that are rapidly removed from the circulation will result in delivery exceeding that achieved by systems that display passive disease site targeting. For this reason many investigators have pursued approaches involving the addition of targeting ligands to sterically stabilized and charge shielded systems, such as those containing PEG lipids [71,72,75–77]. This approach has been advanced, in part, by the development of the so-called postinsertion technique [78]. Postinsertion allows for the insertion of ligand–PEG–lipid conjugates into preformed liposomes containing encapsulated NA. This represents a significant improvement on earlier approaches in which ligands were chemically coupled to preformed liposomes, an approach limited by suboptimal coupling efficiencies, or where ligand–lipid conjugates were incorporated in the first stages of the formulation process, an approach limited by the resulting negative impact on NA encapsulation efficiency and subsequent suboptimal presentation of the targeting ligand. A number of reports suggest that it is possible to design encapsulated systems containing targeting ligands that retain extended circulation lifetimes and passive disease site targeting the following systemic administration. It remains to be seen if the benefits of active targeting outweigh the increased cost, manufacturing complexity and immunogenicity that often accompanies the use of such technology.
9.3 METHODS OF ENCAPSULATING NUCLEIC ACIDS To capitalize on the pharmacology of liposomal drug carriers it is necessary to completely entrap NA within the contents of a liposome. In this regard it is important to distinguish first-generation “lipoplex” or “oligoplex” systems from those that truly encapsulate their NA payload. Lipoplex are electrostatic complexes formed by mixing preformed cationic lipid-containing vesicles with NA [12,79,80]. The result is a heterogenous, metastable aggregate that is effective when used to transfect cells in culture but has relatively poor performance in vivo. Upon systemic administration, lipoplex systems are rapidly cleared from the blood, accumulating in the capillary bed of first-pass organs such as the lung.
CRC_8796_ch009.qxd
5/24/2007
22:36
Page 243
LIPOSOMAL FORMULATIONS FOR NUCLEIC ACID DELIVERY
243
Lipoplex are effectively taken up by the cells of the innate immune system, contributing to their profound toxicities and off-target effects. These side effects may manifest as “efficacy” in antitumor or antiinfective applications, confounding data interpretation and encouraging the acceptance of false-positive results. For these reasons, an abundance of caution is encouraged when initiating in vivo studies that use liposomes to deliver NA. Of particular importance is the use of appropriate analytical methodology, described in Section 9.4, to properly characterize lipid-based systems prior to and during use. 9.3.1
Passive Nucleic Acid Encapsulation
Liposomal encapsulation of small molecule drugs may be achieved by either “passive” or “active” loading. Unlike small molecule drugs, NAs are not readily packaged in preformed liposomes using pH gradients or other similar active loading techniques. This is predominantly due to the large size and hydrophilic nature of NA, which conspire to prevent them from crossing intact lipid bilayers. For this reason, much of the work on NA encapsulation has utilized passive loading technology. Passive encapsulation typically involves the preparation of a “lipid film,” the lipidic residue that remains after evaporation of the organic phase of a lipid solution (Figure 9.2). Rehydration of the
Lipid solution in solvent
Nucleic acid solution in buffer
Dried lipid film
Lipid hydration with nucleic acid solution
MLV formation by freeze/thaw (5−10×)
MLV extrusion (10×)
LUV collection
Free nucleic acid removal
Sample concentration
Sterile filtration Figure 9.2
Passive method of NA encapsulation. Passive encapsulation utilizes a dried lipid film prepared by evaporating the organic phase of a lipid solution. The resulting lipid film is rehydrated in an aqueous solution of NA in buffer, forming MLV. Multiple freeze-thaw cycles increase the extent of NA encapsulation within the MLV bilayers. The vesicles are then extruded through polycarbonate filters producing LUV.
CRC_8796_ch009.qxd
244
5/24/2007
22:36
Page 244
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
lipid film in aqueous media, typically buffer containing NA, followed by vigorous mixing, results in the formation of MLV. This is followed by multiple cycles of freezing and thawing to increase the extent to which the NA solute is entrapped by the MLV bilayers. The MLV preparation is then subjected to multiple rounds of extrusion through polycarbonate filters to produce LUV (Figure 9.2 and Figure 9.3) [81]. The size of the LUV is determined by the size of the filter pores. This process suffers from a number of limitations. When used to encapsulate NA, the efficiency of passive encapsulation is generally quite low, ranging from 3 to 45%, depending on the composition of the lipid bilayer and other factors (Table 9.1). The low encapsulation efficiency, consequently, necessitates the incorporation of a postencapsulation separation step such as dialysis, size exclusion chromatography or ultrafiltration to remove nonencapsulated NA. In an effort to improve the efficiency of encapsulation, excess lipid is often incorporated in the formulation process, resulting in low NA/lipid ratios which ultimately impact toxicity and cost of goods. Finally, the extrusion process is inherently difficult to scale. Preparation of large batches requires the use of custom-built extruders to accommodate large filters. The probability of filter tears, resulting in batch failure, increases as the size and cost of the batch increases. In spite of these process limitations, extrusion-based methods for liposome preparation have been successfully adopted by many laboratories, presumably because the technology is readily accessible to the casual investigator. Furthermore, significant progress has been made adapting or enhancing extrusion-based processes for the liposomal formulation of NA-based drugs. These include the use of cationic and anionic lipids [82,83], ionizable cationic lipids [19,84], PEG lipids [85], and detergent or organic solvents such as ethanol [19,60] to control bilayer assembly.
Figure 9.3
The Lipex™ thermobarrel extruder for the preparation of uniformly sized liposomes by extrusion. An MLV or other vesicle preparation is introduced to the top of the extruder and the extruder is pressurized with nitrogen, forcing the MLV through a polycarbonate filter of defined pore size. The resulting LUVs are collected via the outlet port at the bottom of the device. Extrusion is repeated, typically for a total of 10 passes. The unit permits thermostatic operation by virtue of the thermobarrel, which can be coupled to a circulating water bath. (Photo courtesy Northern Lipids Inc., Vancouver, Canada, http://www.northernlipids.com.)
Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive Passive
Passive Passive Passive Passive Passive Passive Passive Passive Passive
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
29 30 31 32 33 34 35 36 37
Formulation Method DOPE:Chol:Oleic Acid:Palmitoyl-CD4 DPPC:CH:SPDP-PE EPC:Chol:DMPG;EPC:DMPG DOPE:Chol:Oleic Acid DPPC:Chol:SPDP-PE PC:Chol:PS EPC:Chol⫾Folate-PEG-DSPE PC:Chol DOPE:Chol:Oleic Acid:Palmitoyl-CD4 DDAB:PC:Chol PC:Chol:PS HVJ liposome: PC:Chol: DC-Chol DOGS:DOPE HVJ liposome HVJ liposome:Chol:PC:PS DSPC:Chol EPC:Chol:Folate-PEG-DSPE DPPC:Chol:DPPS or DPPA HVJ liposome: PS:PC:Chol HVJ liposome: PC:DOPE: Sph:PS:Chol DPPE:Cetyltrimethyl ammonium bromide HVJ liposome DOPE:CHEMS or SPC PC40:Chol:PEG-DSPE:DOTAP EPC:Chol HVJ liposome: PS: PC:Chol DPPC:DMPG HVJ liposome: PE-DTP:PS:PC:Chol immunoliposomes CHEMS:DOPE or conventional SPC liposomes DDAB:EPC:Chol HVJ liposome: PS:PC:Chol PE:CHEMS:LLO Folate liposomes: EPC:Chol:DSPE-PEG-Pteroate PE:CHEMS:LLO Thiocationic lipid: oleic acid:Vitamin D HVJ liposome: PS:PC:Chol DSPC:Chol:CPL
Lipid Composition
Table 9.1 Liposomal Formulations of Oligo- and Polynucleotide Drugs
ODN ODN ODN Various ODN ODN ODN ODN
ODN ODN ODN ODN ODN ODN ODN ODN ODN ODN ODN Ribozyme ODN ODN Plasmid/ODN RNA Aptamer ODN ODN pDNA ODN ODN TFD, ODN ODN ODN ODN ODN ODN ODN
⬍10 3 ⬍2 10 2–3 ⬍10 30–40 ⬍10 ⬍10 ⬎90 ⬍10 60 88 ND 10–75 ND 15–20 24–32 ND ND 10 ND ⬃16 80–100 10–15 ND 43.5⫾ 4 ND
LIPOSOMAL FORMULATIONS FOR NUCLEIC ACID DELIVERY (Continued)
[176] [177] [178] [179] [72] [180] [181] [182] [183]
[153] [63] [154] [155] [65] [156] [85] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [92] [167] [168] [169] [170] [171] [93] [172] [173] [174] [175]
Reference
22:36
Up to 20 ⬎85 ND 7–15 ND 10–30 ND 2–5 ND
Payload
Encapsulation (%)
5/24/2007
250–300 467.2⫾72.0 ND 240–370 90–110 90–100 ND ND 130
220⫾55 ⬃200 460⫾200 170 100–140 ND 100–140 110⫾40 220⫾55 ⬍2000 ND ND 100–150 ND ND 50–65 ND 50–70 ND ND ND ND 200–300 ⬍200 110⫹30 ND 316–562 400–500
Size (nm)
CRC_8796_ch009.qxd Page 245
245
(Continued)
Passive Passive Passive Passive Passive Ethanol drop—SALP Ethanol drop—SALP Ethanol drop—SALP Ethanol drop—SALP Ethanol drop—SALP Ethanol drop—SALP Ethanol drop—SALP Ethanol drop—SALP Ethanol drop—SALP Reverse-phase evaporation Reverse-phase evaporation Reverse-phase evaporation Reverse-phase evaporation Reverse-phase evaporation Reverse-phase evaporation Reverse-phase evaporation
Reverse-phase evaporation Reverse-phase evaporation Reverse-phase evaporation Ethanol-destabilized liposomes Ethanol dilution—SNALP Ethanol dilution—SNALP Ethanol dilution—SNALP Ethanol dilution—SNALP Ethanol dilution—SNALP Ethanol dilution—SNALP
59 60 61 62 63 64 65 66 67 68
100 ND 880 ND 50–200 110⫾30 100–120 110⫾30 100–120 ⬃130 ⬃130 100–200 80–90 100–150 188 70–120 ND 150–190 ⬎200 ⬍200 110–130
EPC:DPPC:Chol DOPC: Tween 20 PC:DMPA:Chol HVJ liposome: EPC:ESM:Chol:DC-Chol EPC:Chol:PEG-PE: DOTAP PC:Chol:DODAP:PEG-Cer-C14 or -C20 DOPE:Chol:DODAC:PEG-Ceramides DSPC:Chol:DODAP:PEG-Cer-C14 DOPE:Chol:DODAC:PEG-C er-C14 DODAP:DSPC:Chol: PEG-Cer-C14 DODAP:DSPC:Chol:PEG-Cer-C14 EPC:Chol:DODAP DC-Chol:EPC:PEG-DSPE DC-Chol:EPC:PEG-DSPE, Transferrin-PEG-DSPE “Charge-neutralized liposome” HSPC:DSPE-PEG:DOTAP:DSPE-PEG-MAL:Chol CHEMS:DOPE, CHEMS:DOPE:PEG-PE HSPC:Chol:PEG-DSPE PE:CHEMS:Chol DPPC:DPPG:Chol DODAC:DOPE:PEG-DSPE:PEG:DMPE HSPC:DSPE-PEG:DOTAP:Rho-PE: DSPE-PEG-Maleimide DOTAP:Chol:HSPC: PEG-DSPE or MAL-PEG-DSPE DODAP:Chol:PC:PEG-DSPE DOTAP, POPC,CHOL, MPB-PE, PEG-DSPE DSPC:Chol:PEG-Cer-C14:DOTAP DSPC:Chol:PEG-C-DMA:various cationic lipids DSPC:Chol:PEG-C-DMA:DLinDMA or DODMA DSPC:Chol:PEG-C-DMA:DLinDMA DSPC:Chol:PEG-C-DMA:DLinDMA DSPC:Chol:PEG-C-DMA:DLinDMA DSPC:Chol:PEG-C-DMA: DLinDMA ODN ODN ODN ODN/Plasmid siRNA siRNA siRNA siRNA siRNA siRNA
ODN siRNA ODN, siRNA ODN siRNA ODN ODN ODN ODN ODN ODN ODN ODN ODN ODN ODN ODN ODN ODN ODN ODN
Payload
[200] [201] [202] [60] [20] [127] [14] [143] [15] [61]
[184] [185] [186] [187] [188] [19] [56] [189] [190] [191] [192] [193] [194] [195] [76] [75] [196] [77] [197] [198] [199]
Reference
22:36
90–95 80–100 ⬎90 90 67–85 90–95 93⫾3 90–95 92–97 90–95
ND 65 ND ND ND 50–80 43–57 ND 43–57 ND ND 57–85 70–80 70–80 85–95 80–90 ND 80–100 10–14 ⬎95 90
Encapsulation (%)
5/24/2007
100–140 150–200 ⬍180 70–120 132–182 100–130 140⫾12 100–130 73–83 71–84
Size (nm)
Lipid Composition
246
38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58
Formulation Method
Table 9.1
CRC_8796_ch009.qxd Page 246
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
CRC_8796_ch009.qxd
5/24/2007
22:36
Page 247
LIPOSOMAL FORMULATIONS FOR NUCLEIC ACID DELIVERY
9.3.2
247
The Ethanol Drop (SALP) Method of Nucleic Acid Encapsulation
Stabilized antisense-lipid particles (SALPs) were developed as a means of improving both the limited efficiency of passive NA encapsulation and the pharmacology of the resulting particles. SALPs are prepared by dropwise addition or injection of an ethanolic lipid solution to an aqueous solution of NA, followed by extrusion through polycarbonate filters [19] (Figure 9.4). By utilizing an ionizable aminolipid at an acidic pH, where the aminolipid is fully charged, highly efficient (up to 70%) encapsulation may be achieved. Furthermore, the use of an ionizable lipid facilitates adjustment of the total charge of the system by simply changing the pH after the encapsulation step. In this manner, antisense oligonucleotides may be encapsulated in lipidic systems at NA/lipid ratios as high as 0.25 (w/w) [19]. At the higher NA/lipid ratios novel small multilamellar vesicles (SMLVs) are formed, consisting of numerous (typically 6–9) lamellae arranged concentrically around a dense core. At lower drug to lipid ratios more typical LUVs or capped-LUVs are formed. 9.3.3
Encapsulation of Nucleic Acid in Ethanol-Destabilized Liposomes
An alternative to the SALP method uses ethanol-destabilized cationic liposomes [60,86] (Figure 9.5). This method requires empty liposome formation by extrusion prior to addition of NA. Once cationic liposomes of the desired size have been prepared, they are destabilized by the addition of ethanol to 40% v/v. Destabilization of preformed vesicles requires the controlled addition of ethanol to a rapidly mixing aqueous suspension of vesicles, to avoid formation of localized areas of high ethanol concentration (⬎ 50% v/v) that promote the fusion and conversion of liposomes into large lipid structures. The addition of NA to ethanol-destabilized liposomes must also be accomplished carefully, in a dropwise manner, to avoid aggregation of the resulting particle suspension. The required extrusion step and the sensitive nature of both the vesicle destabilization
Lipid solution in ethanol
Nucleic acid solution in buffer
Dropwise addition while mixing NA solution
Vesicle formation
Vesicle sizing by extrusion (10×)
Sample concentration
Free nucleic acid and ethanol removal
Sterile filtration
Figure 9.4
Ethanol drop (SALP) method of NA encapsulation. The ethanol drop or SALP method involves the dropwise addition of an ethanolic solution of lipid to an aqueous solution of NA, resulting in the formation of MLV. Vesicles are then sized by extrusion through polycarbonate filters. This method allows for the encapsulation of antisense oligonucleotides with up to 70% efficiency. Either SMLV or LUV can be prepared using this process, depending on the starting NA/lipid ratio.
CRC_8796_ch009.qxd
5/24/2007
22:36
Page 248
248
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
Lipid solution in solvent
Dried lipid film
Lipid hydration in buffer MLV formation by freeze/thaw (5−10×)
MLV extrusion (10×)
LUV collection
Nucleic acid solution in buffer
LUV destabilized in ethanol
Nucleic acid encapsulation
Free nucleic acid and ethanol removal
Sample concentration
Sterile filtration Figure 9.5
Encapsulation of NA in ethanol destablized liposomes. A dried lipid film is rehydrated in buffer, resulting in the formation of MLV. Multiple freeze-thaw cycles follow, and the empty vesicles are then extruded through polycarbonate filters, producing LUV. The LUVs are then destabilized by the controlled addition of ethanol to the rapidly mixing aqueous suspension of vesicles. NA solution is added to the destabilized liposomes in a drop wise manner resulting in encapsulation.
and NA addition represent process challenges that must be overcome prior to adopting this method for the reproducible preparation of encapsulated NA at a scale suitable for clinical evaluation. 9.3.4
The Reverse-Phase Evaporation Method of Nucleic Acid Encapsulation
Reverse-phase evaporation, an effective means of preventing the aggregation of charged liposomes, has previously been used to encapsulate plasmid DNA [87–91] and more recently antisense oligonucleotides [75,92]. The coated cationic liposomes (CCL) developed by Allen et al. utilize a reverse-phase evaporation procedure to accomplish NA encapsulation [75,76,93]. The CCL process is comprised of two stages (Figure 9.6). In the first, hydrophobic cationic lipid–NA seed particles are formed. In the second, the cationic particles are coated with neutral lipids and vesicles are formed by reverse-phase evaporation. The formation of the cationic lipid–NA intermediate is performed by combining two immiscible fluids, an organic solution of cationic lipid in chloroform and an aqueous solution of NA. Addition of methanol results in the generation of a Bligh–Dyer
CRC_8796_ch009.qxd
5/24/2007
22:36
Page 249
LIPOSOMAL FORMULATIONS FOR NUCLEIC ACID DELIVERY
Cationic lipid solution in chloroform
249
Nucleic acid solution in buffer
Methanol
Biphasic intermediate
Chloroform & water
Bligh−Dyer monophase
Neutral & PEG lipids
Phase separation & recovery
Sonication of organic phase
Gel formation by rotary evaporation
Rehydration
Figure 9.6
Reverse-phase evaporation method of NA encapsulation. The combination of cationic lipid solution in chloroform, and aqueous NA solution in the first step of the reverse-phase evaporation method results in the formation of hydrophobic cationic lipid–NA seed particles. Methanol is added, producing a Bligh–Dyer monophase. Upon reconstitution with excess chloroform and water, the hydrophilic NA is drawn into the organic phase along with the cationic lipid. Neutral lipids are then added, and the organic phase is sonicated and subsequently evaporated to a gel phase. The rehydration step results in NA encapsulated in lipid vesicles ranging from 300 to 600 nm in size.
monophase [94]. When the two-phase system is reconstituted by the addition of excess chloroform and water, the hydrophilic NA is drawn into the organic phase in association with the cationic lipid. Neutral lipids are added and the organic phase is sonicated prior to evaporation to a gel phase. Rehydration results in formation of 300–600 nm vesicles encapsulating NA. Sizing is accomplished via extrusion and unencapsulated NA is removed by size exclusion chromatography. 9.3.5
The Spontaneous Vesicle Formation by Ethanol Dilution (SNALP) Method of Nucleic Acid Encapsulation
The previously described formulation methods rely on the incorporation of an extrusion step to facilitate preparation of small, monodisperse liposomes. The stable nucleic acid lipid particle (SNALP) method was developed specifically as an alternative to these extrusion-based methods [13]. Originally conceived as an alternative to a detergent dialysis method used to encapsulate plasmid DNA, the method has subsequently been adapted to the encapsulation of smaller NA payloads. The detergent dialysis method of plasmid encapsulation involves the simultaneous solubilization of hydrophobic (cationic and helper lipid) and hydrophilic (PEG lipid and plasmid DNA) components in a single detergent-containing phase [55,57]. Particle formation occurs spontaneously upon removal of the detergent by dialysis. This technique results in the formation of small (⬃100 nm diameter) stabilized plasmid
CRC_8796_ch009.qxd
5/24/2007
22:36
Page 250
250
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
lipid particles (SPLPs) containing one plasmid per vesicle in combination with optimized plasmid trapping efficiencies approaching 70%. Although SPLP show considerable potential as systemic gene transfer agents [55,95,96], the detergent dialysis manufacturing method suffers from a number of limitations. Detergent dialysis is exquisitely sensitive to minor changes in the ionic strength of the formulation buffer. Changes as small as 10 mM result in a dramatic decrease in encapsulation efficiency [55,57]. Even when SPLPs are formed under ideal conditions the detergent dialysis method results in the formation of large numbers of empty vesicles that require separation from SPLP by gradient ultracentrifugation. The detergent dialysis process is also difficult to scale to the size required to support preclinical and clinical development of the technology. Finally, detergent dialysis is very inefficient when used to encapsulate smaller NA species such as siRNA duplexes or antisense DNA oligonucleotides. For these reasons, alternative methods of preparing SPLP were explored and a more simple, robust, and fully scalable method for the encapsulation of plasmid DNA has been developed. This method, termed “stepwise ethanol dilution,” produces SPLP with the same desirable properties as those prepared by detergent dialysis [13]. Lipid vesicles encapsulating plasmid DNA are formed instantaneously by mixing lipids dissolved in ethanol with an aqueous solution of DNA in a controlled, stepwise manner (Figure 9.7). Combining DNA and lipid flow streams result in rapid dilution of ethanol below the concentration required to support lipid solubility. Using this method, vesicles are prepared with particle sizes ⬍150 nm and DNA encapsulation efficiencies as high as 95%. When the method is adapted to the encapsulation of smaller NA species, vesicle sizes as low as 45 nm are readily obtained and encapsulation efficiencies of 95% are routine. The term SNALP, is used to differentiate from particles prepared using the SALP and SPLP methods, and to denote the more generally applicable methodology which can be applied to any charged NA species. The ability of the ethanol dilution method to rapidly prepare liposomes of desirable size and encapsulate NA with high efficiency is thought to result from the precise control of the conditions
Nucleic acid solution in buffer
Lipid solution in ethanol
Spontaneous vesicle formation by mixing
Vesicle stabilization by dilution
Sample concentration
Ethanol removal
Sterile filtration Figure 9.7
Ethanol dilution (SNALP) method of NA encapsulation. The ethanol dilution or SNALP method involves in-line mixing of lipids dissolved in ethanol with nucleic acid dissolved in buffer, resulting in the spontaneous formation of lipid vesicles. As the solutions are mixed, ethanol is diluted below the concentration required to maintain lipid solubility, resulting in vesicle stabilization. Controlled particle sizes from 40 to 150 nm, and encapsulation efficiencies of up to 95% are routinely observed. No extrusion steps are required.
CRC_8796_ch009.qxd
5/24/2007
22:36
Page 251
LIPOSOMAL FORMULATIONS FOR NUCLEIC ACID DELIVERY
251
under which the lipids enter the aqueous environment, self-arrange into lipid bilayer fragments, and then form liposomes. By analogy, similar parameters have been shown to be critical for SPLP formation and plasmid encapsulation when using detergent dialysis [95,97]. Ionic strength, cationic lipid, and PEG lipid content must be optimized to maximize plasmid entrapment and minimize aggregation or the formation of empty vesicles [97]. The first stage of dilution is proposed to result in the formation of macromolecular intermediates, possibly lamellar lipid sheets or micelles. NA is recruited to these bilayer fragments by electrostatic attraction. If the cationic lipid content is too low, the plasmid fails to associate with these intermediates, favoring the formation of empty vesicles. If the cationic lipid concentration is too high, the surface charge on the lipid intermediate attracts excess NA, leading to the formation of polydisperse aggregates. At optimal cationic lipid concentrations, NA is proposed to associate with the lipid intermediates in such a way as to reduce the net positive charge on the lipid surface. Association of additional lipid leads to the formation of vesicles containing encapsulated NA. Similar to detergent dialysis, SNALP formation by ethanol dilution is optimized by balancing ionic strength, cationic lipid, and PEG lipid content. However, the ethanol dilution method appears much more robust than detergent dialysis, with good results achieved through a wide range of formulation conditions. In summary, a variety of techniques are available for encapsulating NA into lipid-based systems. Stepwise ethanol dilution, the SNALP approach, generates small (diameter ⬍100 nm), well-defined, stable systems with high encapsulation efficiencies (⬎95%) and a broad range of NA/lipid ratios (⬎0.1 w/w) that exhibit the extended circulation lifetimes required to achieve preferential accumulation at target sites such as solid tumors or liver. Among the various methods for encapsulating NA, stepwise ethanol dilution most adequately satisfies demands related to scalability and reproducibility.
9.4 ANALYTICAL METHODS An important adjunct to any method of preparing liposomes for NA delivery is the characterization of the resulting system using appropriate analytical methodology. The critical measurements are those that determine the size and monodispersity of the particle preparation, the degree of NA encapsulation, and the particles’ surface charge. Since each of these attributes has the potential to affect the pharmacology of a liposomal NA delivery system and each has the potential to change over time, it is critical to develop an understanding of each system’s properties and their stability by monitoring each of these parameters using the appropriate methodology. 9.4.1
Measuring Particle Size
Two methods are commonly used to determine the size of a liposome preparation. The first is direct visualization using scanning or transmission electron microscopy. The second is an indirect method, dynamic light scattering, also referred to as quasi-elastic light scattering (QELS) or photon correlation spectroscopy (PCS). Dynamic light scattering measures the size of liposomes suspended in a liquid. A colloidal liposome preparation is in a state of random movement due to Brownian motion. The speed of any given particle is inversely proportional to its size and smaller liposomes move more quickly than their larger counterparts. When a suspension of liposomes is illuminated with a laser, the movement, and therefore the size of the liposomes, can be measured by analyzing the rate at which the light intensity fluctuates as a result of light scatter. It is important to understand that depending on which method is used to measure the size of a liposome preparation, one can, and will, generate different results. Examination of liposomes under an electron microscope provides a two-dimensional image. Generally, we assume that the ideal liposome is spherical, while in reality, especially on an electron microscope grid, there is infinite number of diameters that can be measured. If the maximum length is used as the diameter, then the
CRC_8796_ch009.qxd
5/24/2007
252
22:36
Page 252
ANTISENSE DRUG TECHNOLOGY, SECOND EDITION
particle is assumed to be a sphere of this maximum dimension. Using the minimum diameter will obviously produce a different result for the particle size. The situation becomes more complex when we consider the problem of describing a liposome preparation that consists of one or more populations of particles with different sizes. If we imagine a photograph taken with an electron microscope of a liposome preparation consisting of three spheres of diameters 50, 100 and 150 nm, how do we determine and express the aver